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Abstract 
 
Age-related macular degeneration (AMD) and inherited macular diseases (IMD) are retinal 
disorders that can cause blindness through atrophy of the retinal pigment epithelium (RPE) or 
choroidal neovascularisation (CNV). RPE transplantation in severe forms of neovascular AMD 
has been performed with promising short-term outcomes. However, this approach has not been 
evaluated in atrophic types of AMD or IMD. Furthermore, the long-term outcomes of 
photoreceptors cell function rescue by RPE reconstruction in neovascular AMD is unknown. 
Current surgical techniques are complex with associated high complication rates. Therefore, 
other treatment approaches to reconstruct the RPE are required. 
This thesis aims to examine whether long-term photoreceptor cell function rescue can 
be achieved through RPE reconstruction by investigating the outcomes of autologous RPE 
transplantation or full macular translocation in AMD and IMD. A further aim is to determine 
the feasibility of a new approach to reconstruct the RPE using human embryonic stem cell 
(hESC). 
A prospective study of autologous RPE-choroid grafts in 9 patients with atrophic 
macular disease secondary to AMD or IMD demonstrated that submacular RPE graft can 
support retinal function and fixation. However, there was a high surgical and post-operative 
complication rates and the overall visual acuity and reading ability declined. Long-term follow-
up demonstrated that the graft can maintain retinal function for over 2 years in some patients.  
A retrospective review of long-term outcomes following autologous RPE-choroid grafts 
and full macular translocation in 12 and 40 patients with neovascular AMD, respectively, 
showed that rescue of retinal function beyond 2 years is possible. A visual acuity of 6/12 was 
achieved and maintained for over 2 years in 8% and 15% of patients who had patch graft and 
translocation, respectively. However, overall visual acuity outcomes were limited by delayed 
post-operative complications such as recurrent CNV and cystoid macular oedema. 
A prospective porcine experiment showed that subretinal implant of hESC derived-RPE 
was feasible and human donor cell can survive in vivo for up to 6 weeks. However, there was 
significant loss of the hESC-RPE which may have occurred intra-operatively or during the first 
2 weeks post-operatively. Macrophages were noted at the site of the graft suggesting some 
inflammatory and immunological responses to the human cells, polyester substrate or surgical 
trauma. 
The work in this thesis has provided the proof of principle that reconstruction of the 
RPE can maintain retinal function in atrophic and neovascular macular diseases over the long-
term. A novel approach using hESC-RPE on an artificial substrate may be a more feasible and 
safer alternative to current clinical techniques of RPE reconstruction.  
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The retina is a layer of neural tissue that lines the posterior segment of the eye. The 
macula is that central portion of the retina which provides high contrast visual acuity 
(VA), colour discrimination and reading ability. Diseases of the retina are the most 
common causes of childhood and adult visual loss in the developed countries (Klein et 
al. 1995; Attebo et al. 1996; Klaver et al. 1998; Krumpaszky et al. 1999; Munoz et al. 
2000; Apte et al. 2001; Dimitrov et al. 2003). Among these blinding retinal disorders, 
the most common is age-related macular degeneration (AMD) which peaks in the 8th 
and 9th decade (Klaver et al. 1998) and contributes to more than half of blindness 
registration (Yong et al. 2006). In contrast, inherited dystrophy of the retina or macula 
is less common with a prevalence of 1 in 4,000 (Hamel 2006; Michaelides et al. 2003). 
However, they can lead to blindness during the 2nd or 3rd decade of life. Although the 
advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has significantly 
reduced the impact of neovascular complications of AMD on visual loss (Brown et al. 
2006; Kaiser 2006) and may become useful in certain retinal dystrophies (Querques et 
al. 2008), there are currently no treatment for the dry or atrophic form of these macular 
diseases. 
 
1.1 Natual history of atrophic macular disease 
 
Visual loss in AMD can be due to geographic atrophy (GA) or choroidal 
neovascularisation (CNV). Although CNV may regress spontaneously or following a 
course of anti-VEGF therapy (Brown et al. 2006), chorioretinal atrophy may continue  
unabated to cover the entire posterior pole over 5 to 10 years (Sarks et al. 2006). At the 
end stage of dry degeneration, there is often a large central scotoma with loss of reading 
ability and impaired visual acuity (VA) ranging from 6/60 to counting fingers (CF) by 
using eccentric fixation (Shih et al. 2006; Wong et al. 2008).  
Inherited retinal or macular dystrophy usually presents symmetrically and 
bilaterally. Patients often had a history of progressive loss of central, peripheral, colour, 
or night vision or any combinations of the above in the first 2 decades of life. Although 
VA can be variable at the end stage  of macular dystrophy, many of these patients are 
affected by central or paracentral scotomata which often have significant impact on 
activities of daily living such as reading (Rotenstreich et al. 2003; Mori et al. 2001). In 
contrast, end stage retinal dystrophy often has very poor vision with only perception of 
motion or light due to loss of both central and peripheral visual fields (Hamel 2006).  
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The similarities in the natural histories of both atrophic AMD and some forms of 
inherited retinal degenerations are also mirrored by the loss of the retinal pigment 
epithelium (RPE), choriocapillaris and photoreceptor cells that characterise these 
conditions. These structures are interdependent and they constitute a functional unit that 
provides the transducing interface for visual perception (Strauss 2005).  
 
1.2 Retinal pigment epithelium and macular disease 
 
The RPE is a neuroepithelium-derived, cellular monolayer that lies on Bruch’s 
membrane (BM) between the photoreceptor outer-segments and the choriocapillaris. 
Optimal functioning of these layers is critical to sight (Custer and Bok 1975). 
Furthermore, the survival of the photoreceptor cell is dependent on the RPE and vice 
versa. The functions and characteristics of the RPE have been reviewed and 
documented extensively (Marmour and Wolfensberger 1998; Strauss 2005; Bharti et al. 
2006). More recently, with the increased understanding of the molecular and cellular 
mechanisms of disease processes, most importantly inflammation and 
neovascularisation, the concept of healthy RPE as a therapeutic cell has emerged. The 
RPE forms the outer blood-retinal barrier and may play an important role in maintaining 
the relative immune privileged status of the subretinal space (Streilein et al. 2002). In 
terms of angiogenesis related factors, both pigment epithelial derived factor (PEDF) and 
VEGF are secreted by the RPE (Tanihara et al. 1997; Witmer et al. 2003; Zhao et al. 
2006; Cai et al. 2006). The extra-cellular matrix, which can have an anti-angiogenic 
function, is also secreted by the RPE. This central importance of RPE to normal retinal 
structure and function explains the rationale and attraction of using RPE transplantation 
in the treatment of several types of retinal and macular dystrophies or degenerations. 
RPE dysfunction can be the primary defect in inherited retinal and macular 
dystrophies. Examples of specific RPE disorders are the monogenic dystrophies that 
include those arising from mutations in lecithin retinol acyltransferase (LRAT) 
(Thompson et al. 2001; Ruiz et al. 2001), RPE65 (Veske et al. 1999; Gu et al. 1997), 
cellular retinaldehyde-binding protein (CRALBP) (Maw et al. 1997), merTK (D'Cruz et 
al. 2000; Gal et al. 2000; Duncan et al. 2003; Tschernutter et al. 2006) or bestrophin 
(Sun et al. 2002; Marmorstein et al. 2000). Treatment of some of these dystrophies such 
as RPE65, CRALBP and the merTK dystrophies may well be achieved by gene therapy 
rather than cell transplantation (Vollrath et al. 2001; Acland et al. 2001; Acland et al. 
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2005; Tschernutter et al. 2005; Pang et al. 2006; Bainbridge et al. 2008; Maguire et al. 
2008). Others however, such as Best’s disease, where there is structural loss and 
damage to the RPE, will require repopulation of the cell layers with unaffected RPE 
cells. Although there are few primary RPE dystrophies there are many more 
photoreceptor dystrophies that lead to secondary RPE atrophy and dysfunctions. The 
observation of RPE atrophy in primary photoreceptor disorders shows that RPE 
transplantation may have a broader role than for treatment of diseases which have 
primary RPE dysfunction. 
Possibly more important in visual morbidity is the role of the RPE in complex 
diseases such as AMD (Rymer and Wildsoet 2005; Nowak 2006). The RPE can be 
involved in both the active disease such as the inflammatory response or in the balance 
of factors that modulate eye growth and CNV formation (Tanihara et al. 1997; Witmer 
et al. 2003; Rymer and Wildsoet 2005; Zhao et al. 2006; Cai et al. 2006). Alternatively, 
the loss of RPE may be the manifestation of the degenerative aspect such as in 
geographic atrophy (GA) secondary to AMD. As such, RPE transplantation can 
theoretically be used in specific well-defined photoreceptor and RPE disease as well as 
more global multifactorial diseases involving the outer retina and choroid. 
Reconstruction of the submacular RPE has been performed in animal disease 
models and human clinical trials. Current surgical approach used to reconstruct RPE in 
neovascular AMD include full macular translocation (Machemer and Steinhorst 1993; 
Eckardt et al. 1999) and autologous RPE-choroid graft (van Meurs and Van Den Biesen 
2003). Short-term outcomes of translocation surgery have provided the proof of 
principal that visual function can be rescued by RPE transplantation (Toth et al. 2004; 
Mruthyunjaya et al. 2004). This is because rotation of the fovea to a region with 
healthier RPE is in effect a type of RPE transplantation. Although macular translocation 
has been carried out in patients with GA or adult foveomacular vitelliform dystrophy, 
the outcomes have been disappointing (Cahill et al. 2005a; Eckardt et al. 2004). It is not 
known if autologous RPE-choroid may be a better alternative to translocation in 
atrophic macular disease. Furthermore, the long-term outcomes of translocation and 
patch grafts are unknown. Given the surgical complexity of the current surgical 
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1.3 Aims of the thesis 
 
The aims of this thesis are:  
 
(1) To examine and describe the feasibility and safety of autologous equatorial RPE-
choroid transplantation in atrophic macular diseases and the short and long term visual 
function and graft survival. 
 
(2) To describe the long-term visual function and structural outcomes of autologous 
equatorial RPE-choroid transplantation and full macular translocation in neovascular 
AMD, and to compare the outcomes of the first 12 cases from each of these two 
techniques. 
 
(3) To examine and describe the feasibility, safety and survival of hESC-RPE patch 
transplantation into the subretinal space of the normal pig eye and to investigate the 
immunological reaction to subretinal xenograft. 
 
1.4 Overview of the thesis 
 
Following on from this introduction, chapter 2 provides the background to RPE 
transplantation by reviewing the literatures on reconstruction of RPE in animal models 
and human trials. For both animal and human studies, the sources of donor cells are 
listed, surgical techniques are described and the structural, functional and 
immunological outcomes are summarised and discussed. 
Chapter 3 outlines the materials and methods used for the clinical studies 
(chapters 4 and 5) and animal experiments (chapter 6).  
Chapter 4 describes a prospective study of autologous RPE-choroid graft in 
atrophic macular disease. The primary outcome measure of the trial was to evaluate 
whether equatorial RPE-choroid can be harvested and delivered to the submacular space 
in patients with atrophic macular disease. The secondary outcome measure is intra- and 
post-operative complications. The exploratory outcome measures are VA, contrast 
sensitivity, reading ability, fixation stability, microperimetry, electrophysiology, quality 
of life questionnaire responses, features on fundus autofluorescence and optical 
coherence tomography and graft perfusion on fluoresceine and indocyanine green 
angiographies. 
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Chapter 5 describes a retrospective study of patients with neovascular AMD 
who have undergone full macular translocation or autologoure RPE-choroid patch graft. 
Since most of these patients had follow-up for over 2 years, the information will provide 
an insight into the ability of autologous RPE in maintaining foveal function. The 
primary outcome measure is the change in VA from pre-operative to the most recent 
follow-up visit. The secondary outcome measure is the rate of delayed post-operative 
complications. Microperimetry results are also examined to provide structure-function 
correlation as an exploratory analysis. The outcomes of the 12 patients who received 
autologous RPE-choroid graft are also compared and contrasted with the first 12 
patients who had undergone full macular translocation. 
Chapter 6 describes a series of human-to-porcine xenograft experiments which 
examined the feasibility and safety of subretinal hESC-RPE transplantation. The pig eye 
is chosen as a model because of its anatomical resemblance to the human eye. RPE 
derived from hESC is used as the donor cell because these can be pre-made as a 
monolayer on a polyester substrate without the need to harvest autologous cells. In 
theory, the surgical technique of subretinal grafting a pre-made patch is much less 
complex than either full macular translocation or autologous RPE-choroid graft, and can 
be performed by any ophthalmologist trained in vitreoretinal surgery. The main 
outcome measures of the experiment are the success rate of grafting and post-operative 
complication rates. Survival of donor cell and immunological or inflammatory reaction 
are determined by immunohistochemistry and electron microscopy. 
As chapters 4, 5 and 6 deal with different types of surgical techniques and 
clinical indications, a brief introduction including review of the literature relevant to 
that chapter is provided at the beginning of the chapter. Methodology specific to the 
study or experiment are described within the relevant chapter. The results are then 
discussed within the context of prior literature. The findings described in these chapters 
and their significances are then brought together in the final concluding chapter 7. 
 
 






Chapter 2 Background 
Background 
 Page 24  
 
2.1 History of RPE transplantation 
 
It is now over 20 years since the earliest works carried out in RPE transplantation were 
first published (Gouras et al. 1983; Gouras et al. 1985; Li and Turner 1988b; Lane et al. 
1989). The potential for RPE transplantation in the treatment of retinal and macular 
diseases based on the published literature will be examined. The role of RPE 
transplantation in the context of other treatments such as gene therapy (Bainbridge et al. 
2008; Maguire et al. 2008), anti-VEGF agents (Brown et al. 2006; Rosenfeld et al. 
2006; Gragoudas et al. 2004), photodynamic therpya (PDT) (Michels and Schmidt-
Erfurth 2001), angiostatic steroids (Russell et al. 2007), and the retinal prostheses 
(Terasawa et al. 2006; Yanai et al. 2007) will be put into perspective. The extensive 
literature on proof of principle in animal RPE transplantation will be explored first 
followed by a review of the clinical trials of RPE transplantation or translocation.  
 
2.2 Animal experiments on RPE transplantation 
 
Prior to transplantation of the RPE into animal models, it was necessary to isolate and 
characterise the donor RPE. The human RPE was isolated from Bruch’s membrane 
(BM), maintained in culture and its morphologic and metabolic features characterised in 
detail during the early 1980s (Flood et al. 1980; Boulton et al. 1982; Hu et al. 1982).  
By the late 1980s, RPE transplantation to the subretinal space had been reported by a 
few laboratories (Gouras et al. 1989; Sheedlo et al. 1989a; Lane et al. 1989). These and 
subsequent animal RPE transplantation studies examined five critical issues that are 
most relevant to clinical application: 
 
1. What is the most suitable source of RPE for transplantation?  
 
2. What is the best technique to harvest, prepare and deliver the RPE graft?  
 
3. Will the donor RPE adhere to Bruch’s membrane or its equivalent substrate?  
 
4. Will the donor RPE with or without substrate evoke immunological rejection? 
 
5. What are the effects of donor RPE on retina, visual function and choroid? 
 
6. What is the long term outcome of RPE transplantation?  
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2.2.1 Source of donor cells 
 
The various cell sources for RPE or RPE-analogous cell transplantation are tabulated 
(see Tables 2.1 and 2.2). Relevant details of each are discussed within the review of 
animal experiments and human trials to follow. The table is not exhaustive but aims to 
illustrate the wide variety of cell types that have been examined for RPE transplantation 
and the associated literature. In contrast to experience in human RPE transplantation, 
the most compelling animal experiments that showed visual function rescue used 
xenogeneic cell sources. The ideal donor RPE will have the following features; (1) 
readily available and continuous source of cell supply, (2) ease of handling during 
delivery to the subretinal space, (3) adherence to the BM or its substrate, (4) ability to 
evade immunological rejection, (5) able to perform all the physiological functions of the 
macular RPE and (6) survival for the life time of the host.  
 
2.2.2 Transplantation techniques 
 
The steps of any transplantation procedure must include harvesting of donor tissue or 
cells, may require ex vivo modification and ultimately surgical delivery into the host. 
Each of these steps is discussed separately below. 
 
2.2.2.1 Donor cell harvesting 
In early experiments of RPE allograft or xenograft, isolation of donor cells involved 
trypsin digestion of RPE cells from an enucleated eyecup. Dissected or debrided RPE 
cells were collected as sheets or suspension and finally concentrated by centrifuge 
(Flood et al. 1980; Mayerson et al. 1985). To harvest a monolayer of RPE, Tezel et al. 
(1997) and Ho et al. (1997) have described techniques of using dispase to separate RPE 
cells from its basement membrane, embedding the monolayer on gelatine with 
subsequent storage at 4ºC or maintenance in culture.  
 In autologous RPE grafts, harvesting and implantation of the RPE were 
performed in the same eye at the same operation. Autograft harvesting techniques were 
first reported in human trials before they were investigated in animal models. 
Techniques of translocating RPE from one part to another part of the same eye have 
been described in pigs (Lane et al. 1989; Maaijwee et al. 2007b) and rabbits 
(Wongpichedchai et al. 1992; Phillips et al. 2003; Hu et al. 2008). The harvesting 
procedures described by Lane et al. (1989) and Wongpichedchai et al. (1992) were 
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based on a technique described by Peyman et al. (1975) for biopsy of sclero-chorio-
retinal tissue in human. Similarly, the harvesting techniques described by Phillips et al. 
(2003) and Maaijwee et al. (2007b) in animal models were based on surgical procedures 
first reported in human; the autologous peripheral RPE cell suspension (Binder et al. 
2002) and the autologous equatorial RPE-choroid grafts (van Meurs and Van Den 
Biesen 2003), respectively.  
 Techniques of harvesting RPE-analogous cells such as iris pigment epithelium, 
Schwann cell, marrow stromal cells, umbilical/placental stem cells, neural or retinal 
progenitor cells and embryonic stem (ES) cells can be found in the literatures listed in 
Tables 2.1 and 2.2. The generation of non-human primate stem cells through genomic 
reprogramming using somatic cell nuclear transfer (Byrne et al. 2007) and human 
induced pluripotent stem (iPS) cell line through viral transfection of master 
transcriptional regulators (Yu et al. 2007; Takahashi et al. 2007) have opened a new 
horizon for regenerative medicine as these can potentially provide autologous source of 
donor  cells without the need to harvest the cells from the target tissue. In this thesis, the 
use of human ES cells derived RPE (hESC-RPE) as donor cells will be examined in a 
pig model (see chapter 7). 
 
2.2.2.2 Ex vivo modification 
Several ex vivo modification of the RPE donor cells in animal experiments have been 
described and these included cell labelling, genetic modification, immortalisation and 
tissue engineering.  
Donor RPE can be tracked with various markers incorporated into the cells prior 
to implantation. These include India ink (He et al. 1993), carbon particles (el Dirini et 
al. 1992), nuclear fluorescent dye (Wongpichedchai et al. 1992), tritiated thymidine 
(Gouras et al. 1985; 1992), 5-bromo-2-deoxyuridine (Ye et al. 1998; Gabrielian et al. 
1999b; Lund et al. 2001a) (see Figure 2.1) and carboxyfluorescein diacetate 
succinimidyl ester (Cong et al. 2008). 
Table 2.1 Use of human RPE and non-RPE cells for subretinal transplantation 
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Genes introduced into the donor RPE prior to transplantation have been shown 
to be expressed in the subretinal space (Osusky et al. 1995; Dunaief et al. 1995; Lai et 
al. 1999; Lai et al. 2000; Saigo et al. 2004; Abe et al. 2005). This can also be useful for 
tracking the fate of donor cells through expression of reporter gene products such as 
beta-galactosidase (Osusky et al. 1995; Dunaief et al. 1995) and green fluorescent 
protein (Lai et al. 1999; 2000; Hansen et al. 2003; Saigo et al. 2004; Abe et al. 2005). 
The advantages and disadvantages of these markers have been reviewed previously 
(Lund et al. 2001b). A more clinically relevant benefit of ex vivo genetic modification 
is the ability to insert genes for adhesion molecules receptors (integrin α and β), growth 
factors (BDGF or bFGF) or cytokines (TGF-β2 or interleukin-10) which may enhance 
cell adhesion, promote photoreceptor rescue and reduce immunogenicity of the donor 
cells (Fang et al. 2009; Saigo et al. 2004; Enzmann et al. 2001a).  
 
 
Figure 2.1 Bromodine-deoxyuridine labelled human cells in rat subretinal space  
Persistence of transplanted hRPE7 cells can be tracked at 5 months after transplantation. 
(a) Cresyl violet staining showing retinal histology and presence of RPE cells associated 
with rescue of the outer nuclear layer. (b) Bromodine-deoxyuridine (BrdU) labelled 
hRPE7 cells incorporated into the RPE layer, marked with asterix, stained with anti-
BrdU antibodies (Courtesy of Professor Pete Coffey). GC; ganglion cell, INL; inner 
nuclear layer, ONL; outer nuclear layer, RPE; retinal pigment epithelium.  
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Spontaneously immortalised RPE cell line such as D407 and ARPE-19 may also 
be useful in providing consistent and readily available cell source for animal 
experimentation (Davis et al. 1995; Dunn et al. 1996; 1998). However, there is recent 
evidence to suggest that ARPE-19 may not be optimal as it does not express merTK 
which is critical for photoreceptor outer segment phagocytosis (Vugler et al. 2008). 
More recently, ex vivo bioengineering of cells on an extracellular matrix has 
been explored to enable delivery of RPE as a sheet rather than cell suspension. The 
rationale for using natural or artificial extracellular matrix support for delivery of RPE 
is that RPE attaches poorly to the host BM when it is damaged or absent following 
surgical extraction of CNV (Del Priore and Tezel 1998; Castellarin et al. 1998; Tezel et 
al. 1999) and the surface on which the RPE is cultured has marked impact on the 
growth and differentiation of the RPE (Campochiaro and Hackett 1993; Song and Lui 
1990). Several coated or uncoated, biological or synthetic, substrates have been 
developed to mimic the function of BM and enable surgical handling of the RPE patch 
graft. Some of the supports that have been tried were derived from biological sources, 
allowing RPE to achieve a very good level of differentiation and a few of these were 
also well tolerated in the subretinal space. These biological substrates include lens 
capsule (Nicolini et al. 2000; Lee et al. 2002; Turowski et al. 2004), Descemet 
membrane (Thumann et al. 1997), Amniotic membrane (Capeans et al. 2003), collagen 
sheet (Bhatt et al. 1994; Thumann et al. 2009) and fibrinogen (Oganesian et al. 1999). 
To increase the stiffness and ease of handling of the graft, different groups have tried 
gelatine encasement of the RPE monolayer (Del Priore et al. 2003a; 2003b) or the lens 
capsule substrate itself (Kiilgaard et al. 2002), and ultraviolet cross-linking of the 
substrate (Bhatt et al. 1994). Among these, fibrinogen was found to be particularly 
inflammatory while other substrates were reported to be well tolerated in the short-term. 
However, stiff cross-linked collagen substrate did not allow RPE graft to conform to the 
shape of subretinal space (Bhatt et al. 1994). In contrast, gelatine encased anterior lens 
capsule was still too floppy and did not prevent curling of the substrate in the subretinal 
space (Kiilgaard et al. 2002). Other artificial membranes used for RPE delivery include 
polyether urethanes like Tecoflex® and Pellethane® which were found to support the 
growth of ARPE-19 cells to confluence and as a monolayer when the substrates were 
air/gas plasma treated (Williams et al. 2005). A similar result with good phagocytosis 
function of the RPE was achieved with Polydimethylsiloxane when air/ammonia gas 
treated (Krishna et al. 2007). Biodegradables have also been tried and include polylacto-
co-glycolic acid and (Hadlock et al. 1999; Giordano et al. 1997) poly lactic acid 
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(Thomson et al. 1996). Ultimately, whatever substrate is used must meet all the 
following conditions: (1) surgically easy to handle and transplant, (2) support 
reasonable differentiation of the RPE monolayer, (3) to be compatible with the host 
immune and visual system and ultimately for human use; (4) available as clinical-grade 
product. During the course of work for this thesis, our group has found a non-
biodegradable substrate based on polyester. This material has been found to be easy to 
handle surgically and is able to support differentiation and growth of hESC-RPE as a 
monolayer. Chapter 6 of this thesis will also examine how well pigs can tolerate 
subretinal implant of this polyester substrate. 
 
2.2.2.3 Delivery techniques 
The first report of RPE transplantation described an open-sky technique where cultured, 
3H-thymidine-labeled, human RPE cells were transplanted on to denuded Bruch’s 
membrane in owl monkeys without attempt to reattach the retina (Gouras et al. 1983; 
Gouras et al. 1985). Although donor RPE cells were seen attached to Bruch’s 
membrane, the difficulty in reattachment of the retina was a major disadvantage of this 
technique. 
 Subsequent to the open sky technique, two types of closed-eye techniques of 
allogeneic RPE transplantation were developed to enable reattachment of the retina. The 
internal approach involved a pars plana entry with or without vitrectomy followed by a 
trans-retinal delivery of the cells with a pipette through a small retinotomy. This 
approach has been used for RPE graft in rabbits (Lopez et al. 1987; Brittis et al. 1987), 
rats (Gouras et al. 1989), pigs (Lane et al. 1989), cats (Wang et al. 2001), dogs 
(Verdugo et al. 2001) and monkeys (Sheng et al. 1995). The external approach involves 
dissection of the posterior or dorsal sclera and trans-sclero-choroidal injection of RPE 
cells into the subretinal space, thus avoiding vitrectomy and retinotomy (see Figure 
2.2). This later technique has been used for RPE graft in rats (Li and Turner 1988b), 
rabbits (Wongpichedchai et al. 1992) and mice (Jiang et al. 1994). Wongpichedchai et 
al. (1992) describes a comparison of these two approaches in rabbit eyes. Although the 
external technique is most commonly used in small animal experiments, the internal 
approach is more appropriate in human RPE transplantation with current vitrectomy 
system. Nevertheless, the very large lens in the small rodent eye and the small vitreous 
cavity necessitate external approach in small animal models. 
  
 
Figure 2.2 Trans-sclero-chroidal injection of RPE cells  
(a) A diagram outlining the overall process of RPE transplantation in rat using the 
external approach. (b) The optic nerve head (arrow) as seen through operating 
microscope. (c) A photograph showing a transcleral incision (arrow) after localised 
conjunctival peritomy. (d) A localised retinal detachment (arrow) after subretinal 
injection of RPE cells (Courtesy of Dr David Keegan). 
  
 
Adding to the variety of approaches to access the subretinal space and RPE 
harvesting techniques is the different instrumentation for delivery of RPE cell 
suspension or sheet into the subretinal space. Blunt tipped needle (Li and Turner 1988a; 
1988b) and glass cannula (Lopez et al. 1987; Lopez et al. 1989) have been used for 
delivering dissociated RPE cells or small patches of RPE sheet (Gouras et al. 1994; 
Berglin et al. 1997). Electronically motorised injector (Wongpichedchai et al. 1992) or 
manually controlled oil-hydraulic microinjection pump (Weichel et al. 2002) have been 
developed to allow controlled, slow and steady injection of the RPE cell suspension into 
the subretinal space. 
Larger RPE patch grafts can be introduced into the eye and inserted into the 
subretinal space by using an explant injector where the carrier platform can be shielded 
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by an advancing protective flexible plastic cannula (Thumann et al. 2006). The design 
of the platform is similar to the aspiration-reflux spatula used by van Meurs in 
autologous RPE-choroid patch graft (Maaijwee et al. 2007b). In both instruments, 
opening(s) on the platform is connected to a syringe that allows direct control of 
attachment and release of the graft on the platform or spatula through aspiration and 
reflux at the plunger respectively. Alternatively, subretinal forceps could also be used to 
hold and insert the patch graft (Hu et al. 2008). Coupling of a motorised vibrator to the 
subretinal forceps has been shown to facilitate smooth release of the graft (Maaijwee et 
al. 2008b). 
 Once the graft is delivered into the subretinal space, survival of transplanted 
RPE depends on (1) donor cell attachment to BM and by implication, an adequate BM 
or equivalent substrate and (2) evasion of immune rejection and induction of immune 
deviation. These major obstacles to successful transplantation will be addressed 
separately in the next 2 subsections. 
 
2.2.3 Donor RPE attachment and integration 
 
It is widely accepted that RPE cells must attach to a suitable substrate in order to avoid 
apoptosis (Tezel and Del Priore 1997; Tezel et al. 2004) or more specifically anoikis. 
The term, anoikis, refers to apoptosis triggered in response to lack of extracellular 
matrix binding. In other words, RPE cells are anchorage dependant. In the following 
sections, the effects of healthy, injured and diseased BM on the survival of RPE cell 
suspensions are discussed. The ability of transplanted substrate to support survival of 
RPE in autologous and allogeneic grafts will also be reviewed. 
 
2.2.3.1 Donor RPE cell suspension adhesion on Bruch’s membrane 
In order for donor RPE cells to survive, they need to adhere to healthy BM within 
minutes or hours of subretinal transplantation. In the early animal experiments of RPE 
transplantation, exposure of the BM was initially achieved by hydraulic or mechanical 
debridement of the RPE cells. It was noted that during surgical detachment of the retina, 
patches of RPE were lifted off BM due to strong adhesion of the apical RPE to neural 
retina and BM was incompletely exposed. Therefore, EDTA wash was also used during 
bleb detachment to facilitate separation of the RPE basal plasma membrane from the 
RPE basement membrane layer of the BM (Wongpichedchai et al. 1992). In most 
animal experiments, the investigators have tried to preserve the BM by hydraulically 
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removing the RPE cells to ensure exposure of the RPE basement membrane. In vitro 
studies showed that this basal lamina layer of the Bruch’s membrane provides the best 
substrate for RPE cell adhesions (Del Priore and Tezel 1998). Donor RPE cells can 
attach to undamaged BM within two hours of delivery (Gouras et al. 1985). These 
donor RPE cells can form tight junctions with adjacent cells, basal infoldings and apical 
processes that interdigitate with the outer segments of photoreceptors cells (Yamaguchi 
et al. 1992).  
However, in current clinical indications of RPE transplantation, there may be 
pre-existing injury or age-related changes in the BM. An ex vivo system consisting of 
human BM explant has been developed for study of RPE adhesion to different layers of 
BM (Tezel et al. 1999). These types of studies have shown that age-related changes in 
the inner collagenous layer of Bruch’s membrane can inhibit RPE cell repopulation of 
BM (Tezel et al. 2004), and indeed, aged submacular BM does not seem to support 
uncultured RPE attachment and differentiation altogether (Zarbin 2003). An in vivo 
rabbit study demonstrated that autologous RPE cell in suspension may adhere to BM 
damaged by a blunt, bent-tipped 30 g metal cannula and rescue outer retina and 
choriocapillaris at 30 days (Phillips et al. 2003). However, this method of injury to BM 
does not re-create the clinical scenario where BM and choriocapillaris are severely 
damaged during removal of CNV. Given the absence of basal lamina in choroidal 
stroma, it is unlikely that RPE cell suspension will adhere to choroidal bed in GA or 
after CNV excision and reproduce the BM and choriocapillaris from de novo. 
Therefore, it is likely that reconstruction of the BM and choriocapillaris is as important 
as replacement of RPE cells if ‘maculoplasty’ is to be successful in neovascular AMD 
and GA (Del Priore et al. 2006). This requirement has led to the development and use of 
RPE-substrate grafts. 
  
2.2.3.2 Use of substrate to enhance RPE adhesion and monolayer formation 
A few studies have used rabbits and pigs to investigate the fate of donor cells when 
biological or artificial substrates were incorporated into the RPE graft. Bhatt and 
colleagues (1994) examined the effect of cross-linking collagen substrate on surgical 
handling and attachment of donor RPE in a rabbit xenotransplantation model. They 
found a monolayer of donor human fetal RPE remaining in the subretinal space despite 
absorption of the noncross-linked collagenous support. In contrast, when cross-linked 
collagen was used as a substrate, the donor cells were dispersed in the subretinal space, 
forming multiple layers on the substrate at 6 weeks. Using 3-dimensional carrier 
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systems, Oganesian et al. (1999) and Rezei et al. (2000) observed lateral migration of 
the donor human fetal RPE xenograft away from the spheroid or microsphere depot at 1 
month postoperatively. Histology demonstrated intraretinal migration of the RPE when 
cross-linked fibrinogen carrier system was used (Oganesian et al. 1999). After 1 month, 
the donor human fetal RPE and the poly (DL-lactide-co-glycolide) polymer spheroid 
succumb to immunological rejection (Rezai et al. 2000). In a porcine model, Nicolini et 
al. (2000) showed survival of RPE on the anterior lens capsule that was allotransplanted 
with a confluent porcine RPE layer. Although they were not able to distinguish host 
from donor RPE, it appears that the capsule was able to support growth of the RPE in 
the subretinal space for 2 weeks. Del Priore et al. (2004) showed presence of donor cells 
by using Barr-body stain after allotransplantation of RPE into porcine subretinal space 
as a sheet encased in gelatine. These donor cells were seen at 4, 9 and 17 days as well as 
1 and 3 months postoperatively. The authors hypothesised that the graft became folded 
in the subretinal space and donor cells adjacent to the RPE survived by attachment to 
the host BM and those which were on the inner portion of the graft degenerated and 
were phagocytosed by subretinal macrophage (Del Priore et al. 2004).  
The use of autologous macular or equatorial RPE-choroid as the donor graft 
ensures that the RPE is transplanted as a monolayer and avoids the issue of rejection 
(Peyman et al. 1991; Stanga et al. 2002; van Meurs and Van Den Biesen 2003). 
However, the thick choroidal substrate requires vascularisation and perfusion to 
maintain the survival of the donor RPE and overlying photoreceptor cells.  When these 
RPE-choroid patch grafts were translocated to mechanically debrided BM in pig and 
rabbit models, they were successfully revascularised from the underlying choroid by 
vertical bridging vessels (Maaijwee et al. 2007b; Hu et al. 2008). Interestingly, these 
vertical vessels can even grow through an intact BM as demonstrated by 
revascularisation of an inverted graft (Maaijwee et al. 2007b). These vascularised patch 
grafts supported survival of the donor RPE for up to 3 months. Since the graft was 
vascularised by 1 week, it is likely that inosculation (simple connection between the 
existing recipient choroidal bed and donor choroid patch vasculatures) plays a role in 
early graft perfusion. It remains to be determined if choroidal patch revascularisation 
involves vasculogenesis and angiogenesis as seen in skin grafts (Capla et al. 2006). 
More importantly, macular cone and rod photoreceptors may not survive during this 
period of outer retinal ischaemia when the choroid is undergoing vascular remodelling. 
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2.2.4 Immunology and rejection 
 
The survival of donor cells does not only depend on graft integration, allogeneic and 
xenogeneic donor cells will also need to evade immune rejection by if they are to suvive 
in the subretinal space. The subretinal space exhibit features of immune-privileged sites, 
characterised by the ability of foreign tissue to survive and induction of systemic 
immune deviation towards the foreign antigens expressed in the subretinal space 
(Streilein et al. 2002). Furthermore, there is evidence to suggest that the RPE (i.e. the 
donor tissue) may also be immune-privileged at different levels (Farrokh-Siar et al. 
1999; Rezai et al. 1999; Rezai et al. 1997; Zamiri et al. 2004). The surgical procedure 
itself may trigger non-specific inflammatory response and the various chemokines and 
cytokines released during this initial response may undermine the immune-privileged 
features of the donor RPE. As with all differentiated cells, RPE constitutionally express 
class I major histocompatibility complex (MHC) antigens.  However, class II MHC 
antigens and mRNA of various chemokines (e.g. RANTES and MCP-1), cytokines (e.g. 
interleukins 6, 8 and 15) and cytokine receptors may be induced after exposure to 
interferon-γ and tumour necrosis factor-α (Hollborn et al. 2000; Enzmann et al. 2001b; 
Hollborn et al. 2001). In the following sections, the immunological reactions to RPE 
grafts in different animal models or combinations of donor-host discordance will be 
discussed separately as they may have different levels of immune privilege and 
immunogenic potentials. 
  
2.2.4.1 RPE grafts into mice and rats hosts 
The extent of immune privilege in the subretinal space of transgenic mice models has 
been investigated previously (Wenkel and Streilein 1998). Both cell-associated and 
soluble antigens injected into the subretinal space can actively suppress systemic 
delayed-type hypersensitivity (DTH) reaction, confirmed by adoptive transfer assay of 
splenocytes (Wenkel and Streilein 1998). Such immune deviation was abolished when 
the RPE was damaged by sodium iodate (Wenkel and Streilein 1998). This suggests that 
submacular space is unlikely to retain its immune privilege after RPE transplantation 
given that the host RPE can be damaged by the disease process or the surgery itself. 
Furthermore, despite evidence of persistence of immune deviation (failure to acquire 
DTH) to P815 tumour cells and soluble antigens in the subretinal space, the subretinal 
tumour graft was eliminated by an unknown mechanism after 2 weeks (Wenkel et al. 
1999). This observation implies that the rejection process in subretinal space was not 
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induced by the T-cells that mediate donor-specific DTH (Wenkel et al. 1999). Unlike 
the anterior chamber, immune deviation induced by subretinal placement of antigen 
does not lead to immune privilege in the subretinal space. Although mice have been 
used for immunological studies, most transplantation experiments have been performed 
in rats. Below is a summary of previous works that have investigated immune reaction 
to allogeneic and xenogeneic RPE grafts into rat subretinal space. 
 RPE allograft can survive for up to 12 months in the RCS rats without 
immunosuppression (Li and Turner 1991). Donor RPE from Sprague-Dawley rats 
sustained outer nuclear layer for 6 months before age-related donor cell loss lead to 
gradual decline in the rescue effect (Li and Turner 1991). In contrast, Zhang and Bok 
(1998) demonstrated slow decline, during the first 2 months, in the ability of donor RPE 
allograft to rescue photoreceptors when there is mismatch in major histocompatibility 
complex (MHC) II or both MHC I and II between the recipient and the donor rats. The 
decline in rescue was accelerated when the host rat was challenged with donor spleen 
cells (Zhang and Bok 1998). Despite the lack of lymphocytes, Zhang and Bok (1998) 
concluded that systemic immunity to subretinal RPE allograft was the cause of delayed 
loss of RPE function. 
 Cow, pig and human donor RPEs have also been xenotransplanted into rat eyes. 
Although cryopreserved bovine RPE was not rejected in rat subretinal space at 3 months 
(Durlu and Tamai 1997), fresh porcine RPE was rejected by 2 months after grafting 
(Grisanti et al. 2002). The rejection process was accompanied by loss of outer nuclear 
layer thickness and infiltration of pigment-loaded, ED1-positive cells. These were 
probably resident macrophages from within the retina (Grisanti et al. 2002). 
Interestingly, there was no lymphocytic infiltration and the same graft was rejected 
when placed in subcutaneous tissue by a DTH response. Abe et al. (1999) demonstrated 
increased expression of interleukin 1 and 6 by xenografting cultured human RPE into 
rats. However, it is still not known what role these interleukins may play in immune 
rejection. Spontaneously immortalised human RPE cell line, ARPE-19 have also been 
shown to maintain outer nuclear layer and cortical visual function beyond 6 months in 
immunosuppressed RCS rats (Coffey et al. 2002). Inner retinal changes in the natural 
history of RCS rats have also been arrest for up to 10 months of age by early xenograft 
of ARPE-19 cells (Wang et al. 2005b). However, McGill et al. (2004) found that 
despite rescue of spatial vision in RCS rats by ARPE-19 cells, there is still gradual 
decline in vision which may be due to intrinsic properties of the graft or immune 
rejection. More recently, Wang et al. (2005b) demonstrated that ARPE-19 cells were 
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rapidly lost in the subretinal space of immunosuppressed RCS rats with only one fifth of 
the cells injected detectable in the subretinal space at 2 weeks. By 28 weeks, only 0.2% 
of the cells remained in the subretinal space. The mismatch between the declining 
number of grafted ARPE-19 cell and the persistence of anatomical and functional rescue 
raised the possibility that diffusible factors may be primarily responsible for the action 
of transplanted RPE  (Wang et al. 2005b). Furthermore, degree of visual rescue cannot 
be used as a measure of graft survival. 
 
2.2.4.2 RPE grafts into rabbits and cats hosts 
Rabbit models have also been used extensively to study immune rejection of RPE 
grafts. Activated and non-activated RPE allograft from pigmented to albino New 
Zealand rabbits are both associated with increased level of interleukin 6 in the vitreous 
during the first 2 weeks (Enzmann et al. 2000). Although the relationship between 
interleukin 6 and RPE graft rejection is unknown, serum interleukin 6 levels have been 
measured for identifying early local inflammatory reactions after liver transplantation 
(Kunz et al. 1998).  Crafoord et al. (1999) showed that the RPE allograft rejection at 6 
months in New Zealand white rabbits was characterised by dispersion of the melanin 
pigment in the subretinal space and throughout the neuroretina, phagocytosis of pigment 
by macrophage, Muller glial cells and host RPE, absence of lymphocyte, loss of the 
adjacent photoreceptor outer and inner segments, and reduced thickness of outer nuclear 
layer. Immunosuppression of these rabbits with cyclosporine did not prevent or reduce 
this inflammatory response (Crafoord et al. 2000). A more rapid rejection of porcine 
fetal RPE xenograft in rabbits was described by Del Priore et al. (2003a) with around 
10% of the grafted cells detectable at 12 weeks even with triple immunosuppression 
using prednisone, cyclosporine-A and azathioprine. Similar to allograft rejection, 
porcine xenograft elicited a macrophage response in the absence of lymphocytes. There 
was also no vascular leakage on fluorescein angiography during rejection. Human fetal 
RPE xenograft transplanted as a monolayer sheet (Sheng et al. 1995) or cell suspension 
(He et al. 1993; Gabrielian et al. 1999b; Lai et al. 1999) into rabbits also induced 
macrophage migration within 1 to 3 months. Gabrielian et al. (1999b) demonstrated 
initial retinal glial cell response within the first 2 weeks at the site of human fetal 
xenograft and around the retinotomy. By 3 weeks, donor cell number has significantly 
reduced and by 4 weeks, both retina and choroid were involved in inflammatory 
response dominated by macrophages. In green fluorescent protein (GFP)-labelled 
human RPE xenograft to rabbits, local immunosuppression with intravitreal 
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cyclosporine delayed rejection (Lai et al. 2000). The use of intravitreal tacrolimus 
resulted in survival of cultured adult human RPE xenograft in rabbits for up to 1 year 
(Wang et al. 2002). Human fetal RPE on collagen, fibrinogen or biodegradable polymer 
as substrates induced choroidal inflammatory response when xenografted into rabbits. 
(Bhatt et al. 1994; Oganesian et al. 1999; Rezai et al. 2000). A short-term follow up 
study (7 days) in feline RPE allograft did not reveal any rejection (Wang et al. 2004). 
 
2.2.4.3 RPE grafts into pigs and monkeys hosts 
Porcine RPE allograft induced infiltration of macrophage in the subretinal space of non-
immunosuppressed pigs by 9 days but the graft was not rejected at 3 months (Del Priore 
et al. 2004). The authors suggested that these macrophages migrated into the subretinal 
space to clear the cell debris from degenerated RPE which did not have the opportunity 
to attach to the BM. Human fetal RPE xenograft to non-immunosuppressed monkeys 
have revealed 30% to 60% rate of rejection depending on the site of graft (Berglin et al. 
1997). Interestingly, foveal grafts were rejected more often than extramacular grafts and 
rejection occurred in one subretinal location and not in another of the same or 
contralateral eye (Berglin et al. 1997).  
 
2.2.4.4 Approaches to reduce immune rejection 
The role of the host immune system in limiting the success of allogeneic or xenogeneic 
transplants cannot be overemphasized and graft rejection remains a major obstacle to 
successful RPE transplantation. Modification of the donor cell to reduce its 
immunogenicity and immune modulation of the host animal may minimise graft loss 
due to rejection. Factors that may influence rejection includes histocompatibility 
matching (Zhang and Bok 1998), culture and cryopreservation of donor cells (Durlu and 
Tamai 1997; Valtink et al. 1999a), cytokine-induced immune activation of the donor 
RPE (Kohen et al. 1997; Enzmann et al. 2000), donor RPE cell transfection with genes 
expressing immunosuppressive cytokines (Enzmann et al. 2001b), graft tissue 
architecture as a monolayer sheet or a cell suspension (Wenkel and Streilein 2000), type 
of substrate used to support the tissue (Bhatt et al. 1994; Gabrielian et al. 1999a; Rezai 
et al. 2000; Kiilgaard et al. 2002), break down in blood-retinal barrier due to disease 
and surgery (Wenkel and Streilein 1998), local or systemic immunosuppression 
(Crafoord et al. 1999; Lai et al. 2000; Lund et al. 2001a; Wang et al. 2002; Del Priore et 
al. 2003a) and donor-specific challenge (Jiang et al. 1994). 
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2.2.5 The effect of RPE transplant on retina and choroid 
 
The aim of RPE transplantation is to retard or restore visual loss. This is primarily 
achieved through restoration of photoreceptor cell function although there may be 
indirect beneficial effect through choroidal and retinal circulations. The Royal College 
of Surgeons (RCS) rat, an animal model of RPE dystrophy (Mullen and Lavail 1976), 
has been used extensively for in vivo experiments to demonstrate the prove of principle 
and mechanism of visual rescue in RPE transplantation. This dystrophic strain of rat has 
a recessive defect in the merTK gene (D'Cruz et al. 2000) which results in failure of 
RPE to phagocytose shed rod outer segments (Bok and Hall 1971). The consequences of 
this mutation include accumulation of subretinal debris, death of rod and later cone 
photoreceptor cells, secondary inner retinal degeneration, retinal vascular changes and 
central adaptive modulation in neural circuit. Each of these secondary changes has been 
shown to be prevented or reversed by RPE transplantation in the RCS rat (see Figure 
2.3) (Li and Turner 1988a; Seaton et al. 1994; Lund et al. 2001a; Coffey et al. 2002; 
Wang et al. 2005a).  
 
2.2.4.1 Photoreceptor cell rescue 
The first subretinal RPE grafts in RCS rats demonstrated preservation of the thickness 
of the outer nuclear layer, outer plexiform layer, and outer and inner segments of the 
photoreceptors (Li and Turner 1988a). Further more, the outer segment debris zone was 
reduced with increased number of phagosomes in the transplanted RPE cells (Li and 
Turner 1988a; Lopez et al. 1989). These rescued photoreceptor cells regenerated outer 
segments at normal rate (Lavail et al. 1992; Lin et al. 1996), expressed visual pigment, 
membrane Na+/K+ ATPase (Sheedlo et al. 1989b) and two synaptic components in the 
plexiform layers (Sheedlo et al. 1993a) and the outer segments were surrounded by the 
interphotoreceptor matrix (Lavail et al. 1992). Similar but much more transient 
photoreceptor rescue was seen after subretinal injection of saline (Silverman and 
Hughes 1990; Li and Turner 1991; Faktorovich et al. 1990).  
Despite histological evidence of rescued photoreceptors with the necessary 
components for phototransduction, initial attempts at full-field electroretinography 
(ERG) failed to detect any corneal or vitreal responses to light stimulus after RPE graft 
(Gouras et al. 1989; Yamamoto et al. 1993). These findings may be due to inadequate 
number of grafted RPE cells and hence rescued photoreceptors to generate a full field 
response. A later study was able to demonstrate corneal ERG response in RCS rats that 
had received RPE graft as small sheets in a larger area of subretinal space (Jiang and 
Hamasaki 1994). Corneal ERG after RPE transplantation in RCS rats has since been 
reported by another group (Sauve et al. 2004; Pinilla et al. 2005; Sauve et al. 2006). 
These reports demonstrated a correlation between b-wave amplitude and field area 
rescued (Sauve et al. 2004), and the relationship between cone/rod ratio in the b-wave 
and the number of cone rescued (Pinilla et al. 2005).  Light- and dark-adaptation study 
of collicular sensitivity demonstrated that only the cone threshold was prevented from 
deterioration after RPE graft (Girman et al. 2005).  
The disparity between anatomical (Coffey et al. 2002) and functional (Girman et 
al. 2005) rod rescue raises intriguing questions regarding photoreceptor-donor RPE 
interaction (see below). One explanation for the lack of rod rescue is that cones are able 
to depend on Muller cells to recycle visual pigments (Mata et al. 2002) and hence are 
less dependent on RPE function (Girman et al. 2005). 
Figure 2.3 Photoreceptor resuce in the RCS rat model 
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2.2.4.2 Visual pathway rescue 
The function of the post photoreceptor visual pathway after RPE transplantation has 
been evaluated by electrophysiological and psychophysical measurements. Intraretinal 
and ganglion cell electrode recording by Yamamoto et al. (1993) demonstrated evidence 
of activity in bipolar and ganglion cells in response to light in the region of retina 
adjacent to the graft. Relative retinal sensitivity in the area of graft preservation has also 
been examined by electrode recording of single- and multi-unit receptive fields over the 
surface of the superior colliculus of RCS rats that received subretinal RPE allograft The 
central to peripheral field loss in RCS rats was shown to be limited by subretinal RPE 
allograft (Sauve et al. 1998) and xenograft from immortalised human RPE cell lines 
(Lund et al. 2001a; Sauve et al. 2002). Electrophysiological preservation of central 
visual pathway by RPE xenograft has been correlated with changes in retinal 
morphology (i.e. outer nuclear layer rescue, see Figure 2.4) and full-field ERG in the 
RCS rats (Lund et al. 2001a; Sauve et al. 2002; Sauve et al. 2004). In RCS rats that 
received spontaneously or trans-genetically modified human RPE xenograft with 
extended life span, single-unit electrophysiological responses to light stimuli have also 
been recorded in the primary visual cortex, area 17 (Coffey et al. 2002). The ability of 
these neurons in tuning into a range of specific stimulus parameters such as orientation, 
direction of movement, contrast sensitivity, spatial and temporal frequencies and 
complex centre-surround interactions, similar to those found in the normal rats, 
confirms the ability of human RPE to restore complex visual function in RCS rats 
(Coffey et al. 2002; Girman et al. 2003). 
Non-invasive psychophysical testing, ranging from simple visual reflexes to 
complex visual tasks, have been used to assess the integrity of the visual system after 
RPE graft. Whiteley et al. (1996) demonstrated some but incomplete preservation of 
pupillary light reflexes. By using a water escape paradigm, Little et al. (1998) 
demonstrated that RCS rats that received human fetal RPE had shorter swimming 
pathway and time, implying an ability to see and use light as a clue for finding the 
escape platform. Visual acuity testing by optokinetic head-tracking to moving stripes 
and two-choice pattern discrimination test of vertical and horizontal stripes has also 
demonstrated the ability of immortalised RPE xenograft in preserving cortical visual 
functions for long durations (Lund et al. 2001a; Coffey et al. 2002) (see Figure 2.5).  
Using the visual water task under high luminance to measure grating acuity, (McGill et 
al. 2004) have also demonstrated the ability of ARPE19 subretinal graft in preserving 
cone mediated vision in these RCS rats.  
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2.2.4.3 Effects on retinal and choroidal vasculature 
The effects of RPE grafts extend beyond retinal and visual pathways. Seaton and 
colleagues (1992) demonstrated that implanted RPE cells can maintain the density and 
architecture of the deep retinal vasculature. Further more, in animals that had lost 
photoreceptors already, RPE graft not only prevented but also induced involution of 
retinal neovascularisation (Seaton et al. 1994). In a rabbit model of RPE autograft, Majji 
and De Juan E Jr (2000) demonstrated the ability of autotransplanted RPE suspension in 
maintaining choriocapillaris as well as photoreceptors. It was concluded that formation 
of a monolayer on healthy Bruch’s membrane was essential for maintaining the 
differentiated state of RPE and preserving adjacent choriocapillaris and photoreceptors. 
 
2.2.4.4 Mechanisms of retinal function rescue 
Although the mechanism of photoreceptor rescue by donor RPE is unknown, evidence 
points toward two types of interaction: (1) direct contact between RPE and 
photoreceptors or (2) indirect interaction through diffusible factors released by donor 
RPE. Electron microscopic studies suggested cell contact as a requirement for 
photoreceptor rescue (Lavail et al. 1992). Reduced outer segment debris zone in RCS 
rats correlated with increased phagocytic activity of the donor RPE (Li and Turner 
1988a; Gouras et al. 1989). On the other hand, evidence of rescue extending beyond the 
grafted area (Lin et al. 1996; Sauve et al. 2002), photoreceptor rescue by basic 
fibroblast growth factor (bFGF) (Faktorovich et al. 1990), intravitreal RPE graft 
(Castillo, Jr. et al. 1997) and Schwann cell grafts (Lawrence et al. 2000; Wang et al. 
2005b) suggest that diffusible factors such as ciliary neurotrophic factor (CNTF), glial 
cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor 
(BDNF) or bFGF, may be involved in cell rescue.  
 Variables that have been shown to positively affect the rescue of photoreceptors 
following RPE allograft transplantation include younger donor age (Sheedlo et al. 
1993b), higher number of donor cells and fresh rather than cultured cells (Li and Turner 
1991). Durlu and Tamai (1997) demonstrated photoreceptor rescue in RCS rats 
receiving cryopreserved bovine RPE xenograft. Fresh human fetal (Little et al. 1996), 
juvenile or adult (Castillo, Jr. et al. 1997) RPE as a xenograft has been shown to support 
photoreceptor survival and visual function (Little et al. 1998). Both spontaneously 
immortalised RPE and genetically modified RPE with extended lifespan have the ability 
to restore visual field and cortical visual function (Lund et al. 2001a). Although efficacy 
of xenogeneic RPE grafts has been well documented, there has been no study which 




Figure 2.4 Functional rescue after RPE graft in the RCS rat  
A comparison of retinal sensitivity and histological maps following ARPE-19 
transplantation in a dystrophic RCS rat. The figure shows (a) the retinal sensitivity map 
from electrode recording at the superior colliculus and (b) the corresponding outer 
nuclear layer cell count in the retina. The grey scale coding indicates the corresponding 
retinal and superior collicular areas. The highest sensitivity correlates to the area of 




Figure 2.5 Optokinetic reflex testing in rats  
A diagram showing the various aspects of visual acuity testing based on the optokinetic 
reflex. A rotating drum is used with three different square-wave grating frequencies. 
The animal is placed inside the rotating drum which stimulates head turning in the test 
animal. The highest frequency grating that stimulates head turning indicates the visual 
acuity (Courtesy of Professor Pete Coffey). 
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 Genes introduced into the donor RPE prior to transplantation have been shown 
to be expressed in the subretinal space (Osusky et al. 1995; Dunaief et al. 1995; Lai et 
al. 1999; Lai et al. 2000; Saigo et al. 2004; Abe et al. 2005). For example, Abe and 
colleagues (2005) demonstrated that BDNF-transfected RPE grafts resulted in 
significant photoreceptor rescue in both grafted and non-grafted areas. Genetically 
transduced donor RPE may serve as a vehicle for genetic therapy in addition to cellular 
therapy in retinal degeneration (Ogata et al. 1999).  
 
 
2.2.6 Long-term outcomes 
 
Animal experiments of RPE graft have not consistently demonstrated sustained rescue 
of photoreceptors and visual function. Delayed decline in visual function after RPE 
graft may be due to a combination of three mechanisms: (1) changes in the post-
photoreceptor visual pathway independent of photoreceptor rescue, (2) photoreceptor 
dysfunction or degeneration independent of RPE graft function or survival, and (3) 
dysfunction or loss of donor RPE cells.  
 Progressive degenerative and reactive changes in the bipolar, horizontal, 
amacrine, ganglion and Muller glial cells, neuronal migration and retinal 
neovascularisation were prevented and reversed by RPE graft in RCS rats for 9 months 
(Wang et al. 2005a). Further down stream, cortically mediated vision and visual 
responsiveness in the superior colliculus have remained comparable to normal controls 
even when RPE graft did not restore the complete complement of photoreceptors in 
RCS rats (Sauve et al. 2002; Coffey et al. 2002). Also, delayed loss of photoreceptor 
has not been reported to occur when the donor RPE remains present in RCS rats. These 
findings suggest that donor RPE loss is the major cause of late-onset visual loss.  
 As discussed in Section 2.2.4, immunological rejection of RPE xenograft may 
occur in rat and rabbit models within weeks. However, photoreceptor rescue in rats was 
found in areas without donor RPE and was extended for long durations even when a 
minority of donor cells survived (see Figure 2.1). The mechanism for this may be 
related to the indirect rescue effect described in section 2.2.5. However, ultimately, 
retinal function will decline as the entire population of donor cells are lost to rejection. 
Currently, immune response poses a major obstacle to the long-term survival of the 
donor RPE. 
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2.2.7 Summary of animal experiments 
 
The preceding literature review has provided evidence that RPE transplantation can 
rescue retinal function based on the structural and functional outcomes in the RCS rat. 
However, many questions remain. Although the superiority of phenotypic features of 
stem cell derived RPE over immortalised RPE cell lines has been shown in vitro, we do 
not know if this can be translated into its ability to rescue photoreceptor in vivo. 
Furthermore, despite demonstration of proof of principle using subretinal injection of 
RPE cell suspension in rat eye; this delivery technique is not clinically useful due to 
absence of healthy BM in various retinal diseases. Further studies in feasibility and 
safety of RPE patch graft delivery are required as there is currently only 1 study using 
patch graft in a large animal model (Del Priore et al. 2004). 
 
2.3 Human Trials in RPE Transplantation 
 
Since the first case report of human homologous and autologous RPE transplantation for 
the treatment of neovascular AMD (Peyman et al. 1991), several other techniques of 
RPE translocation or transplantation have been published (see Table 2.3). The major 
milestones in the development of the techniques of human RPE transplantation are 
summarised in the timeline in Figure 2.6. Most of the human trials have involved 
patients with neovascular AMD since there is evidence to support that loss of the RPE 
occurs during and after excision of CNV (Del Priore et al. 2006); these are the 
demonstration of RPE cells on surgically removed CNV (Lopez et al. 1991; 
Grossniklaus et al. 1994; Nasir et al. 1997), the failure of spontaneous RPE 
repopulation to resurface the excision bed adequately (Hsu et al. 1995; Rosa et al. 1996) 
and enlarging RPE defect months after surgical excision of CNV (MacLaren and 
Aylward 2005). The corollary of this, that RPE reconstruction under the macula restores 
vision, has also been shown. The most compelling evidence is from the data on clinical 
outcome following macular translocation. 
 
2.3.1 Proof of principle 
Although macular translocation with 360º retinotomy for neovascular AMD (Machemer 
and Steinhorst 1993) is not strictly RPE transplantation, it is functionally similar; by 
virtue of moving the neural retina, the RPE-choroid that comes to lie under the fovea is 
different and can be viewed as essentially transplanted. There is now an extensive 
literature showing reversal of VA loss, restoration of reading ability and improvement 
in health-related quality of life (QOL) within 1 year following translocation surgery in 
neovascular AMD (Pertile and Claes 2002; Lai et al. 2002; Aisenbrey et al. 2002; 
Mruthyunjaya et al. 2004; Fujikado et al. 2002; Toth et al. 2004; Cahill et al. 2005b) 
and in myopic CNV (Fujikado et al. 2001; Sawa et al. 2008). However, visual rescue in 
the long-term may not be sustained  (Aisenbrey et al. 2007; Baer et al. 2008). Despite 
the uncertain long-term outcome, translocation still represents a gold standard of retinal 
rescue to which RPE transplant needs to be compared to. This review of human RPE 
transplantation will (1) indentify the source of donor RPE used, (2) explore the key 
issues in case selection, (3) describe the various surgical techniques (see Table 2.3), (4) 
discuss general issues of post-operative care and complication, and (5) summarise the 
outcomes of RPE graft, i.e. graft survival and visual function. 
 
2.3.2 Source of donor cells  
Both allogeneic and autologous RPE cells have been used in human transplantation. 
Early studies of allogeneic adult or fetal RPE graft had  poor functional outcome due to 
graft rejection and fibrosis despite immunosuppression (Peyman et al. 1991; Algvere et 
al. 1999; Weisz et al. 1999). However, Tezel and colleagues showed that allogeneic 
adult RPE sheet encased in gelatine survived for 12 months when triple 
immunosuppression was given for 6 months post-operatively (Tezel et al. 2007). 
 
 
Figure 2.6 RPE transplantation surgical techniques  
This figure shows a timeline (from year 1980 to 2010) showing the development of 
human RPE transplantation techniques in relation to the first submacular surgery 
reported in 1988.  In the early 1990’s, allogeneic RPE grafts were used and later, 
throughout early 2000’s, various techniques of autologous RPE grafts were described. 
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Table 2.3 Publications of allgeneic and autologous RPE transplantation in human  







Peyman et al. (1991) 
Del Priore et al. (2001), Tezel et al. (2007)* 









Algvere et al. (1994; 1996; 1997; 1999)* 
Weisz et al. (1999) 
5, 5, 5, 7 
0 






Peyman et al. (1991) 
Stanga et al. (2002), MacLaren et al. (2005)* 
Yepez and Arevalo (2003) 












Binder et al. (2002; 2004) 
van Meurs et al. (2004) 













van Meurs and Van Den Biesen (2003) 
Maaijwee et al. (2007a; 2008a; 2008c; 2008d)* 
Bindewald et al. (2004) 
Joussen et al. (2006) 
Heussen et al. (2008) 
Joeres et al. (2008) 
Treumer et al. (2007a; 2007b)* 
MacLaren et al. (2007) 
Joussen et al. (2007), Caramoay et al. (2010)* 
Chen et al. (2008) 
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patch graft with 
peripheral 180º 
retinotomy 
van Meurs (2005) 
Petersen et al. (2008) 
Ma et al. (2009)  
Gibran et al. (2009) 
Cereda et al. (2010) 













NR; not reported 
*same senior author, possibly the same patients with longer follow-up 
 
The use of autologous RPE for maculoplasty avoids the issue of immune 
rejection. However, this approach is based on the assumption that the RPE away from 
the lesion is healthy and unaffected by the macular disease process. However, 
psychophysical, histological and epidemiological observations suggest that pathology of 
neovascular AMD may extend beyond the macula (Brown et al. 1986; Green and Enger 
1993; Knudtson et al. 2004). More recently, the association between AMD and systemic 
complement factor dysfunction provides further evidence that disease process in AMD 
may be more widespread (Scholl et al. 2008). A more obvious concern for donor RPE 
health is in the treatment of atrophic macular disease. Studies have found frequent 
peripheral reticular degeneration of the RPE in patients with atrophic AMD (Lewis et 
al. 1985; Sunness et al. 1999b). Furthermore, patients with IMD may also have full 
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field ERG abnormality, suggesting generalised photoreceptor cell dysfunction (i.e. a 
retinal dystrophy with macular involvement) and abnormal peripheral RPE 
(Michaelides et al. 2005). This raises the question of whether autologous macular, 
paramacular or even equatorial RPE should be used as a source of donor cells for 
maculoplasty in eyes affected by AMD and IMD. Several long term studies which 
examined donor RPE function following the use of macular, paramacular and equatorial 
sources of RPE may provide clues on whether autologous sources are suitable. 
MacLaren et al. (2005) reported long-term survival of macular RPE-choroid 
graft in 4 patients although they had loss of fixation and autofluorescence signal over 
the grafts after 5 years. Although the authors concluded that delayed loss of 
photoreceptors may account for the poor long term outcome, RPE dysfunction cannot 
be excluded. This is a likely possibility since the donor RPE is from the macular region, 
the site of pathology in AMD.  Van Meurs and Van Den Biesen (2003) described a 
modified technique in which equatorial RPE-choroid was used to reconstruct 
submacular RPE defect. The same group reported slightly higher rate of vision 
stabilization and improvement after RPE graft in the 11 patients who were followed for 
4 years (Maaijwee et al. 2007a). Reports of long-term outcomes after macular 
translocation, which uses paramacular RPE, are conflicting. Baer et al. (2008) reported 
no de novo drusen, atrophy or de novo CNV under the translocated fovea after 2 years 
in 56 patients. Aisenbrey et al. (2007) showed visual decline from de novo GA under 
the translocated fovea in 25 of 90 patients after a mean follow up of 38 months. Another 
complicating issue is that atrophic retina may also induce atrophy of the underlying 
RPE as shown in long term outcomes of macular translocation for the treatment of GA 
(Cahill et al. 2005a). Therefore, it remains to be determined if paramacular and 
equatorial RPE are equally capable of maintaining macular photoreceptor cell function. 
This issue will be explored further in Chapter 5 of this thesis where the long term 
outcome of autologous RPE-choroid patch graft is compared to that of macular 
translocation in neovascular AMD. 
 The enthusiasm of allogeneic RPE grafts in the last decade has been overtaken 
by the promising long term outcomes of autologous RPE grafts. However, the technique 
of translocating autologous equatorial RPE-choroid patch to the macula has not gained 
widespread acceptance. One limitation of this approach is the complex surgical steps 
required in harvesting equatorial RPE. The use of immortalised RPE cell lines (such as 
ARPE19 or D407) or RPE derived from stem cells (such as ES or iPS cells) will avoid 
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this extra surgical step. However, these cell sources have not yet been used in human 
clinical trials.  
 
2.3.3 Patient selection for RPE transplantation  
RPE transplantation has been performed in both neovascular and atrophic macular 
diseases and the key issues in case selection will be discussed separately for each 
indication. However, for both, the health of equatorial or peripheral retina-RPE-choroid 
will also need to be considered when planning autologous RPE graft. 
 
2.3.3.1. Neovascular macular disease 
As stated earlier, the vast majority of RPE transplantation in human has been performed 
for the purpose of restoration of RPE-Bruch’s membrane-choriocapillaris complex 
defect created by surgical removal of CNV in AMD. As these grafts were performed at 
a time when the only treatment available were laser photocoagulation and PDT, 
common inclusion criteria used were large subfoveal occult or minimally classic CNV, 
pigment epithelial detachment (PED), RPE rip (Maaijwee et al. 2008a), large 
submacular haemorrhage (Gibran et al. 2009), retinal angiomatous proliferation (RAP) 
(Krebs et al. 2008) or any lesions that failed to respond to PDT or laser. Even with the 
promising result from the use of anti-VEGF agents in neovascular AMD (Gragoudas et 
al. 2004; Brown et al. 2006; Rosenfeld et al. 2006; Brown et al. 2009), surgical removal 
of CNV and RPE transplantation remains an option for patients who are loosing vision 
despite anti-VEGF therapy or have AMD lesion subtypes that makes them ineligible for 
receiving anti-VEGF therapy. To date, only 1 case of CNV secondary to presumed 
ocular histoplasmosis syndrome has received RPE transplantation following CNV 
removal (van Meurs et al. 2004). Preoperative factors that may influence patient 
selection include duration of symptoms, foveal function, lesion size and subtypes and 
status of the donor RPE in the same eye in autologous grafts (see above). 
From the 2 largest series of RPE transplantation using autologous equatorial 
RPE-choroid grafts, visual outcome was found to be unrelated to duration of disease and 
baseline VA (Joussen et al. 2006; Maaijwee et al. 2007a). This may be due to error in 
patient recollection of the duration of symptom, poor relationship between VA and 
potential photoreceptor cell reserve and lack of power from the small sample size in 
these series. In contrast, shorter symptom duration, better pre-operative fixation stability 
have been shown to predict favourable outcome in patients undergoing macular 
translocation (Fujii et al. 2002b; Uppal et al. 2007). Since RPE graft is similar to 
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macular translocation in that both are rescue procedures, most clinicians would presume 
that once foveal photoreceptor cells are lost as indicated by the presence of subfoveal 
RPE atrophy or disciform scar, RPE transplantation would not be beneficial in restoring 
high quality central vision unless it is combined with photoreceptor cell replacement.  
The 2 large series of autologous RPE-choroid grafts, however, found that lesion 
subtypes may predict visual outcome. Joussen and colleagues (2006) reported that 
classic, occult and massive subretinal haemorrhage tends to have better visual outcome 
than vascularised PED or RAP lesions. In contrast, Maaijwee and colleagues showed 
that patients with predominantly classic and occult lesions had significantly better 
postoperative VA at 1 year than those with minimally classic or hemorrhagic (≥50% 
blood) lesions. This lack of consistency may be due to inadequate power from the small 
sample size and other confounding factors such as health of equatorial RPE-choroid and 
intraoperative trauma (Maaijwee et al. 2008c). In theory, classic CNV with recent visual 
decline would imply healthier and greater reserve of foveal photoreceptors for rescue by 
RPE transplantation and hence better outcome. 
Two other lesion subtypes of neovascular AMD may also need to be identified 
during case selection as they will have impact on surgical approach. CNV 
membranectomy in RAP may lead to macular hole and haemorrhage due to strong 
adhesion between the retina and CNV tissue due to the retino-choroidal anastomotic 
vessel (Shimada et al. 2005; MacLaren et al. 2007; Krebs et al. 2008). Idiopathic 
polypoidal choroidal vasculopathy (IPCV) may not be suitable for autologous RPE-
choroid graft because equatorial choroid may also be affected by the subRPE and intra-
choroidal vascular abnormalities (Yannuzzi et al. 1998). 
 
2.3.3.2. Atrophic macular disease 
Atrophic macular disease is a heterogeneous group of disorder which can be inherited, 
acquired or both. The most common cause is AMD whereas in younger patients, either 
retinal or macular dystrophy may result in macular dysfunction and subsequent atrophy 
(Holder 2001). Regardless of underlying aetiology, most atrophic macular diseases are 
characterised by bilateral progressive and irreversible central visual loss. Although their 
presentations can be asymmetrical, with loss of vision in one eye followed by the 
second eye many months or years later, the ultimate VA tends to be similar in both eyes. 
The exact pathophysiology of GA in AMD and IMD are unknown. However, in a subset 
of dystrophies, linkage to several genes expressed in the photoreceptor cells suggest a 
possible sequence of event: abnormal outer segments and their interaction with retinal 
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pigment epithelial (RPE) cells leading to RPE cell death with subsequent 
choriocapillaris atrophy and photoreceptor cell loss (Kaplan et al. 1993; Allikmets et al. 
1997; Hoyng et al. 1996; Felbor et al. 1997). In some of these patients, the macular 
lesion may resemble GA secondary to AMD, where photoreceptor cell loss is also 
thought to be due to either primary RPE cell death or impaired choroidal perfusion 
(Sakamoto et al. 1995; Friedman et al. 1995; McLeod et al. 2002).  
There is currently no effective treatment for patients with atrophic macular 
disease although allogeneic and autologous RPE transplantation have been performed in 
atrophic AMD (Gouras and Algvere 1996; Algvere et al. 1999; Joussen et al. 2006; 
2007) and macular translocation, which in principal is a form of RPE reconstitution, has 
been performed in a patient with adult vitelliform macular dystrophy with limited 
improvement in reading ability postoperatively (Eckardt et al. 2004). Optimal timing for 
intervention in atrophic macular disease remains controverial because: (1) progression is 
slow, (2) endpoint is difficult to define, (3) there is an unknown risk to benefit ratio of 
the procedure and (4) late stage diseases may not benefit from a photoreceptor rescue 
approach. Previous trials of RPE transplantation for atrophic AMD have used VA 
(Algvere et al. 1997) or loss of reading (newspaper print size) ability (Joussen et al. 
2007) as inclusion/exclusion criteria. Using VA as an end point, Joussen and colleagues 
(2007) reported high rate of VA loss despite survival of the graft.  
As there is lack of literature regarding RPE transplantation in atrophic macular 
diseases, this thesis will examine, in a clinical trial, the use of autologous equatorial 
RPE-choroid graft in these conditions. In particular, microperimetry outcomes will be 
used to determine if grafted RPE is able to maintain retinal function.  
 
2.3.4 Surgical techniques 
Autologous RPE transplantation requires a more complex procedure than allogeneic 
RPE graft due to the extra surgical steps in harvesting donor cells within the same eye. 
The following sections will review the current surgical techniques, beginning with 
general issues in donor cell harvesting and preparation of the submacular space. Then 
the specific details of allogeneic and autologous RPE grafting techniques will be 
discussed separately.  
 
2.3.4.1. Donor cell and submacular space preparation 
Allogeneic RPE grafts harvested from both human adult and fetus have been delivered 
as sheet, or microaggregate in patients with neovascular or atrophic AMD. Peyman 
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(1991) described harvesting technique of donor RPE sheet from a fresh adult globe 
enucleated for severe eye trauma. RPE allograft has also been harvested as sheets from 
fetus of 13 to 20 weeks of gestation by dissection and maintained in tissue culture for 2-
7 days (Algvere et al. 1994; Gouras et al. 1994). Fresh fetal RPE in the form of 
microaggregate in suspension (Gouras and Algvere 1996; Algvere et al. 1997) or sheet 
in small fragments (Castillo, Jr. et al. 1995; Weisz et al. 1999)  also been prepared and 
transplanted into patients with AMD. Adult cadaveric (death to enucleation time of 7.5 
hours) RPE has been harvested, treated with dispase, encased in porcine gelatin matrix 
on its basal surface for transplantation within 24 hours of gelatin solidification (Tezel et 
al. 1997; Del Priore et al. 2001). Over 99% of the RPE cells on the gelatin matrix were 
confirmed to be viable with a calcein and ethidium homodimer based assay (Del Priore 
et al. 2001). In contrast, cultured, HLA-typed, cadaveric RPE that have been stored 
through cryopreservation, have also been transplanted (Valtink et al. 1999a). At least 
461 cell cultures have been prepared and 116 fully typed and well-differentiated cell 
cultures are stored in the cell bank set up by Valtink et al. (1999a).  
In order to harvest autologous cells for RPE transplantation, it is important to 
have access to the donor cells by ensuring good visibility and clearance of vitreous gel 
around the harvesting site. Visibility can be optimised by removing any lenticular or 
vitreous opacity. Phacoemulsification and intraocular lens implant can be performed at 
the time of RPE transplantation (Binder et al. 2002; 2004). Chandelier or infusion line 
light sources allow bimanual manipulation of the graft. Separation of the posterior 
hyaloid from retina often needs to be induced in eyes with AMD (van Meurs 2005). The 
peripheral vitreous base may need to be thoroughly shaved to minimise the impact of 
anterior proliferative vitreoretinopathy (PVR). Peeling of epiretinal membrane and 
internal limiting membrane prior to membrane extraction have also been reported. This 
may prevent posterior PVR (or epiretinal membrane) and re-opening of the retinotomy. 
Four techniques of autologous RPE transplantation have been described (see Figure 
2.6): submacular RPE-choroid pedicled flap rotation (Peyman et al. 1991), submacular 
RPE-choroid free graft transposition (Stanga et al. 2001a), submacular injection of 
suspension of RPE cells from the peripheral fundus (Binder et al. 2002), and 
translocation of equatorial RPE-choroid patch graft to submacular space (van Meurs and 
Van Den Biesen 2003).  
The technique of submacular CNV removal is based on that described by 
Thomas and Kaplan (1991) and Thomas et al. (1994). Variations of this technique of 
CNV removal have also been described to allow easier access to the submacular space. 
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Peyman and co-workers (1991) described submacular CNV removal with RPE 
transplantation through a 250-degree (8 to 9-clock-hour) arc retinotomy just outside the 
temporal arcades. Following membrane removal, 1 patient received autologous pedicled 
RPE flap rotation and another had allogeneic RPE patch transplantation. Yepez and 
Arevalo (2003) described a technique involving inferior 140-degree (4 to 5-clock-hour) 
peripheral retinotomy for access to submacular RPE. van Meurs (2005) advocated a 
temporal 10 clock-hour retinotomy at the ora serrata (flap-over approach) for removal of 
massive subretinal haemorrhage which extends to the equator.  
 
2.3.4.2 Allogeneic RPE transplantation 
Delivery techniques described for homologous RPE graft usually require a small pipette 
for injection of the graft through a small or even self-sealing retinotomy. The size and 
location of RPE allograft delivered by injection is determined by the area of induced 
macula detachment. Allogeneic RPE cells have been transplanted to subfoveal (Algvere 
et al. 1997) or extramacular regions (Weisz et al. 1999). The advantage in delivery of 
the graft as a suspension is that the procedure is relatively easy to perform. However, 
efflux of RPE cells into the vitreous cavity, non-adherence to Bruch’s membrane, 
incorrect apical-basal orientation and failure to form a monolayer are significant 
disadvantages of this delivery technique. Small patches of RPE can be delivered into the 
eye, as semi-rolled up sheet within a micropipette or cannula, through the retinotomy to 
subfoveal or extrafoveal locations (Weisz et al. 1999; Algvere et al. 1994; Gouras and 
Algvere 1996). Both fetal RPE sheets and adult gelatin encased RPE patches 
spontaneously unfold in the subretinal space (Algvere et al. 1994; Del Priore et al. 
2001). Monolayer sheets of organised, correctly orientated RPE may improve graft 
viability and survival. However, due to folding and contraction of the graft, multi-
layering with incorrect orientation of the RPE can still occur in the subretinal space 
even when it is grafted as a monolayer.  
Except for the large retinotomy used by Peyman et al. (1991), none of the 
allogeneic RPE graft performed had laser to the macular retinotomy. Weisz et al. (1999) 
did not use any endotamponade, Del Priore et al. (2001) used air tamponade, Algvere et 
al. (1994; 1997) used gas (SF6 or C3F8) or silicon oil (5,700 centistokes) tamponade and 
Peyman et al. (1991) used silicon oil (12,500 centistokes) together with an encircling 
band and 360-degree peripheral laser.  
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2.3.4.3 Autologous RPE transplantation 
The 4 approaches to autologous RPE-choroid graft will be described separately. The 
earliest attempts used macular RPE-choroid as a rotation flap or free graft (Peyman et 
al. 1991; Stanga et al. 2001b).  
Through the macular retinotomy for removal of the membrane, a macular RPE-
choroid flap or graft can be created using a vertical scissors. A large extramacular 
retinotomy used by Peyman (1991) allowed easier access to submacular RPE enabling a 
large RPE-choroid flap to be fashioned and repositioned under the fovea. Similarly, 
Yepez and Arevalo (2003) described a technique for easier assess to submacular RPE-
choroid graft transposition via a large inferior retinotomy with perfluorocarbon assisted 
retinal detachment. Through a standard macula retinotomy, Stanga et al. (2001a) 
reported the use of vertical scissors to cut a triangular patch of RPE and choroid from 
the edge of the membrane excision bed and repositioned it centrally to a subfoveal 
location, all in one continuous procedure operating in the submacular space. This 
technique was successful in maintaining the correct orientation of the graft (RPE facing 
up) in seven out of eight patients. In the first patient of this series (Stanga et al. 2001a), 
the RPE-choroid pedicle flap was not rotated far enough to a subfoveal location. In 
contrast, Angunawela et al. (2005) reported successful subfoveal placement of a RPE-
choroid pedicle flap that remained vascularised after 4 years. Heavy liquid has been 
used (Stanga 2001) to stabilise the RPE-choroid graft and to expel subretinal fluid 
through the retinotomy. Endotamponade with silicone oil has been described (Peyman 
et al. 1991; Stanga et al. 2001a; Yepez and Arevalo 2003).  
Two techniques of harvesting suspension of RPE cells from the peripheral 
fundus have been described (Binder et al. 2002; Binder et al. 2004; van Meurs et al. 
2004). Binder et al. (2002; 2004) described a technique of using a subretinal pic to 
create a retinotomy nasal to the optic disc and induce a nasal retinal detachment by 
subretinal infusion of Ringer’s or balanced salt solution (BSS) plus. A bent, blunt 20 G 
vitreoretinal cannula was then inserted in the subretinal space to mobilize RPE cells 
over an area of 2 to 4 disk diameters. The freed, dissociated, RPE cells were aspirated 
by an assistant who controlled the microsyringe connected to the cannula. Instead of 
retinotomy, van Meurs et al. (2004) harvested peripheral RPE through an inferior 
retinectomy. Three weeks preoperatively, argon green laser photocoagulation 
retinopexy was performed to isolate the inferior peripheral retina. Following lensectomy 
(if phakic), vitrectomy and inferior retinectomy, a modified bent 21 gauge aspiration 
cannula with an 8-O nylon loop was used to simultaneously scrap RPE off the Bruch’s 
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membrane and aspirate the free RPE cells. Once removed from the eye, the RPE was 
either re-injected, unmodified, back into submacular space (Binder et al. 2002), or 
centrifuged with (van Meurs et al. 2004) or without (Binder et al. 2004) autologous 
serum, diluted with BSS plus solution (Binder et al. 2004), and then re-injected into the 
submacular space. Cell counts and viability testing were performed on the samples to 
assess if further harvesting was needed and the quality of harvested RPE cells. Poly-L-
lysine was injected in the submacular space by van Meurs et al. (2004) to promote 
adhesion of the RPE cells to Bruch’s membrane. Lowering of bottle height (Binder et 
al. 2002) and perfluorocarbon bubble (Binder et al. 2004; van Meurs et al. 2004) were 
used to reduce reflux during submacular injection of the RPE cell suspension. The 
retinotomies (Binder et al. 2004) and the retinectomy (van Meurs et al. 2004), if needed, 
received further laser. Air, gas or silicone oil endotamponade were used and patients 
were instructed to posture supine for 24 hours (van Meurs et al. 2004) or 1 hour 
followed by prone positioning (Binder et al. 2002; 2004) for a few days. 
The technique of harvesting RPE-choroid patch graft from the equator followed 
by submacular insertion as initially described by van Meurs and van den Biesen (2003) 
has being used by several European groups. Briefly, following complete vitrectomy, a 
donor site is selected in the superior midperiphery, avoiding the vortex veins. Heavy 
retinochoroidal burns (chalky white), using endodiathermy (van Meurs and Van Den 
Biesen 2003; Joussen et al. 2006), diode laser (MacLaren et al. 2007) or green Nd:YAG 
laser (Treumer et al. 2007a), are placed around a 1.5 x 2 mm circle (Treumer et al. 
2007a) or a 2-3 mm square (van Meurs and Van Den Biesen 2003; Joussen et al. 2006; 
MacLaren et al. 2007) to mark the donor site of RPE-choroid patch graft and to prevent 
choroidal haemorrhage (Treumer et al. 2007a). A patch of retina-RPE-choroid within 
the diathermy or laser mark is then cut out and separated from the sclera. Treumer et al. 
(2007a) reported removal of the retina before harvesting of the RPE-partial thickness 
choroid patch. Several approaches to choroid patch harvesting have been described. van 
Meurs (2005) makes an initial full thickness choroid incision and use a long spatula to 
sweep under the patch prior to cutting the rest of the graft. This releases any attachment 
between the choroid and sclera allowing clean release of the full-thickness RPE-choroid 
graft from the sclera when it is cut around. An alternative method is to cut around the 
graft with vertical scissors and then release the graft from sclera with horizontal, 
serrated curved scissors. Once the patch is harvested, the retina may spontaneously 
detach or peeled with a forceps. Since the RPE-choroid patch has a tendency to roll up 
into a half cylinder with RPE on its convex side, parallel to the limbus, bimanual 
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technique is usually required to load the graft onto a customised aspirating-reflux 
spatula (DORC Surgical Instruments, Netherlands) or grasp the graft with a partially 
closing subretinal forceps. Treumer et al. (2007a) reported that curling of the patch may 
be reduced by preparing a round rather than square RPE-choroid patch. The graft is then 
inserted through the retinotomy. Once the entire graft is submacular, heavy liquid is 
injected over the macula to flatten the detachment. The surgical assistant then pushes 
the plunger of the aspirating-reflux spatula to release the grip on the graft. As the 
macula collapse on the graft, the spatula or forceps are withdrawn. Major drawbacks of 
the current technique in RPE-choroid graft delivery are (1) damage to RPE as the graft 
is inserted through the retinotomy, (2) premature collapse of the macula before the graft 
is advanced to subfoveal location, (3) entanglement between the choroid side of the 
graft and the spatula or forceps preventing smooth release of the graft and (4) folding of 
the graft after its release in the submacular space. Some of these issues have been 
addressed by creating larger retinotomy along the temporal raphe, use of modified 
aspirating-reflux spatula with separate subretinal infusion cannula to inflate the 
subretinal space and attaching a vibrating device to the subretinal forceps (Maaijwee et 
al. 2008b). A clinical illustration of the anatomical outcomes of this technique can be 
seen in Figure 2.7. 
van Meurs (2005) described a modification of the equatorial patch graft 
technique where a temporal 180º peripheral retinotomy was created instead of a small 
paramacular retinotomy. The aim was to facilitate removal of extensive submacular 
haemorrhage and enable harvesting of a larger equatorial RPE-choroid graft. Further 
reports using similar technique have been published recently (Petersen et al. 2008; 
Gibran et al. 2009; Ma et al. 2009; Degenring et al. 2010). Briefly, the technique 
involved the following steps: (1) creating a 180º temporal retinotomy, (2) flapping the 
nasal retina over the disc to expose submacular RPE, (3) removal of submacular tissue 
and blood clot, (4) harvesting of a large temporal equatorial/paramacular RPE-choroid 
patch graft, (5) transposition of the patch graft to cover the submacular RPE defect, (6) 
stabilisation of the graft on the submacular defect and (7) reattach the temporal retina. 
This technique avoids the disadvantages of a small macular retinotomy which are: 
limited access to remove large clots, greater trauma during insertion of the patch graft, 
damage to potential eccentric fixation locus, and posterior PVR. However, there are also 
several drawbacks of this approach including: prolonged surgical time, increased 
surgical trauma related to inducing a large temporal retinal detachment, technical 
difficulty in keeping the temporal retina folded over the disc, need for heavy liquid to 
facilitate translocation of the large patch graft and high risk of post-operative retinal 
detachment due to the extensive retinotomy.  
 
 
Figure 2.7 Equatorial autologous RPE-choroid graft: OCT 
(A, B) Colour fundus photographs and (C, D) Stratus optical coherence tomography 
(OCT) scans of a patient with large haemorrhagic pigment epithelial detachment with 
subretinal fluid (*) before and after autologous retinal pigment epithelium (RPE) -
choroid patch graft. The yellow arrow shows the location and direction of the OCT scan 
and the white arrow points to the optic nerve head. 
 
2.3.4.4 Ex vivo donor RPE assessment and modification 
Except for transposition of macular RPE-choroid patch (Stanga et al. 2002), all other 
techniques of RPE transplantation provide opportunity for ex vivo examination of the 
graft and genetic modification. Results of cell count and viability examination have 
been reported by Binder et al. (2002; 2004) and van Meurs et al. (2004) in autologous 
RPE suspension graft. Ex vivo genetic modification by a self-inactivating lentiviral 
vector can be performed within 30 minutes of immersion of the graft in vector 
suspension, within the time frame of submacular surgery. The infective potential of the 
transduced graft can also be eliminated by the washing procedure described by 
MacLaren et al. (2007).  
 
 
2.3.5 Intra-operative complication 
No intra-operative complications were reported in any of the reported RPE allograft 
cases except for iatrogenic retinal break (Tezel et al. 2007). This may reflect the ease of 
subretinal delivery of cells through a micropipette. In Stanga’s series of submacular 
RPE-choroid flap rotation and graft transposition (2001a), two had unsuccessful 
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grafting. In one patient the flap was non-subfoveal and in another, the graft was placed 
up side down. van Meurs et al. (2004) reported 2 cases of reflux of RPE graft from the 
retinotomy despite the use of perfluorocarbon bubble to tamponade. In the same series, 
one patient required silicone oil for post-operative tamponade as the preoperative barrier 
laser was ineffective in preventing extension of induced inferior retinal detachment. 
Other intra-operative complications following autologous equatorial RPE-choroid graft 
included partly folded graft and inadequate positioning of patches (van Meurs et al. 
2006; Maaijwee et al. 2007a), failure to release graft from forceps inversion of graft 
(Joussen et al. 2006; Maaijwee et al. 2007a), loss of graft through sclerostomy 
(Maaijwee et al. 2007a), damage to papillomacular bundle (Maaijwee et al. 2007a), 
subretinal haemorrhages from donor and recipient choroidal beds (Joussen et al. 2006; 
Maaijwee et al. 2007a), strong CNV-retina adhesions (Joussen et al. 2006; Maaijwee et 
al. 2007a; MacLaren et al. 2007) and iatrogenic peripheral retinal break (Joussen et al. 
2006). 
 
2.3.6 Post-operative course and complication  
The post-operative care of patients receiving autologous grafts is similar to that of any 
vitreoretinal surgery. However, immunosuppression is required when allogeneic grafts 
are used. Phakic eyes filled with silicone oil will require a second procedure with or 
without cataract extraction. The main vision threatening complications following 
autologous or allogeneic grafts are intraocular haemorrhage, retinal detachment (RD) 
with or without proliferative vitreoretinopathy (PVR) and disease recurrence (i.e. CNV 
or GA). Increasingly, optical coherence tomography (OCT) and fundus 
autofluorescence (AF) have been used to monitor the status of retina and RPE following 
transplant. Structural and functional outcomes related to the graft and retina will be 
discussed in subsequent sections. 
 
2.3.6.1 General postoperative management 
Following fetal or adult allogeneic RPE graft, immunosuppression with a short course 
of oral steroid (60 mg per day of prednisolone for 1-2 weeks), within 2 weeks of graft 
(Algvere et al. 1994), or a 6-month course of cyclosporine and azathioprine with or 
without systemic steroid (Del Priore et al. 2001; Tezel et al. 2007) have been used. 
However, allogeneic RPE graft in GA has been performed without the use of post-
operative immunosuppressant (Algvere et al. 1997; Algvere et al. 1999; Weisz et al. 
1999). Tezel et al. (2007) described the frequent systemic work up, including blood 
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count, hepatic and renal function and serum drug levels, required in patients receiving 
triple immunosuppresion.  
Eyes with silicon oil endotamponade generally had oil removed, at the earliest, 2 
months following the procedure unless RD occurred. In elderly phakic patients, cataract 
formation was common following vitrectomy. This is can be addressed at the time of 
RPE transplantation by performing phaco-vitrectomy with (Binder et al. 2002; 2004) or 
without implant (van Meurs 2005) or alternatively, at the time of silicone oil removal. 
Post-operative acute intraocular pressure rise related to steroid response or pupillary 
block have also been reported (Binder et al. 2002; 2004; Tezel et al. 2007; Maaijwee et 
al. 2007a). 
 
2.3.6.2 Intraocular haemorrhage 
Early (< 6 months) and late (> 6 months) post-operative intraocular haemorrhage after 
RPE transplantation are common. Early post-operative subretinal haemorrhage, within 
the first 3-6 months, was reported in 50%, 43%, 25%, 11% and 8% of the case series by 
Heussen et al. (2008), Joussen et al. (2006), MacLaren et al. (2007) and Maaijwee et al. 
(2007a) and Joussen et al. (2007) respectively. However, Stanga et al. (2002) and 
Treumer et al. (2007a) and did not report occurrence of early subretinal haemorrhage. 
Joussen et al. (2006) reported that early post-operative haemorrhage was more common 
in patients taking anti-platelet agents or after removal of an occult membrane, and less 
common if Densiron® was used for tamponade. Maaijwee et al. (2007a) reported that 6 
of the 9 patients with early post-operative haemorrhage were on anticoagulant. 
Subretinal haemorrhage may be found between the graft and the choroidal bed or the 
graft and the neuroretina or both. Visual loss from early subretinal haemorrhage may 
not be reversible as a result of several pathological processes: toxicity of the blood to 
overlying neuroretina (MacLaren et al. 2007), graft failure from absence of 
revascularization, subretinal fibrosis (Binder et al. 2002), or fibrous encapsulation of the 
graft (Joussen et al. 2006). Although small amount of subretinal haemorrhage can be 
managed conservatively, massive subretinal haemorrhage may require clot evacuation 
and re-grafting of the RPE choroid patch (Joussen et al. 2006). Regardless of whether 
the patch is re-grafted or reperfused, visual prognosis remains poor after large early 
post-operative subretinal haemorrhage (Joussen et al. 2006). Suprachoroidal  and 
vitreous cavity haemorrhage have been reported (Binder et al. 2004; Joussen et al. 
2006; Maaijwee et al. 2007a). Despite vitreous washout and drainage of suprachoroidal 
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haemorrhage in one case, severe pre- and sub-retinal fibrosis developed (Joussen et al. 
2006). 
Spontaneously resolving late post-operative subretinal haemorrhage, unrelated to 
recurrent CNV, has been reported (van Meurs and Van Den Biesen 2003; MacLaren et 
al. 2007). Although fluorescein and ICG angiographies may help to rule out CNV, it 
may be difficult to interpret these due to coexisting progressive RPE staining and 
cystoid macular oedema.  
 
2.3.6.3 Retinal detachment and proliferative vitreoretinopathy 
Post-operative RD following graft usually occurs within 6 months. The rate of RD after 
RPE graft is variable depending on the surgical technique and complexity.  Although 
allogeneic RPE cell suspension grafts were not complicated by RD, probably because of 
the use of small retinotomy and micropipette to inject the cells (Algvere et al. 1999; 
Weisz et al. 1999), 1 of 5 patients developed RD after fetal allogeneic patch graft 
(Algvere et al. 1994). However, RD developed in 3 of 12 patients (25%) who received 
adult allogeneic RPE patch graft and one of these progressed to inoperable PVR (Tezel 
et al. 2007). One of the 9 patients (11%) who received submacular RPE-choroid graft 
developed RD (Stanga et al. 2002). Four of the 39 (10%) patients who received RPE 
suspension graft developed RD secondary to reopening of the retinotomy (Binder et al. 
2004). The van Meurs and van Den Biesen’s (2003) technique, however, had variable 
RD rates ranging from 8 to 42% (Joussen et al. 2006; Joussen et al. 2007; Treumer et 
al. 2007a; Maaijwee et al. 2007a; MacLaren et al. 2007; Heussen et al. 2008). 
Detachments following autologous equatorial RPE-choroid graft were usually 
attributable to PVR and tractional re-opening of the retinotomies. 
The development of PVR following patch grafts may be related to the release of 
RPE cells into the vitreous during donor cell harvesting, insertion of the graft through a 
small macular retinotomy, manipulation of the graft in the submacular space and later, 
continued release of RPE from the residual RPE or choroid bed at the donor site post-
operatively. The risk of RD via reopening of the macular retinotomy may be increased 
by traumatic enlargement of retinotomy, persistent submacular fluid and poor 
chorioretinal adhesion around the retinotomy due to RPE atrophy and lack of barrier 
laser (MacLaren et al. 2007). On the other hand, the risk of RD via reopening of the 
donor site may be increased by larger and more posterior donor retinectomy (close to 
vascular arcade) as preretinal membranes tend to start in the macular region. Anteriorly 
located donor site may also be susceptible to reopening as vitreous base contraction may 
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occur from anterior PVR. In view of these possible mechanisms of PVR, there several 
modifications of the surgical technique have been suggested. 
The ideal location of donor site should be half way in between the superior 
arcade and the posterior edge of the superior vitreous base, i.e. the equator. Choice of 
the size of the donor graft is a balance between, (1) the number of RPE cells and the 
surface area of the choroid to form vascular connection in a large donor patch, and (2) 
ease of submacular insertion of the graft and lesser risk of PVR (smaller retinectomy 
and retinotomy) from a smaller donor patch. Thorough removal of dispersed intravitreal 
RPE cells may reduce the rate of PVR. A relatively low rate (8%) of RD, reported by 
Maaijwee et al. (2007a) in a case series of 84 patients was thought to be related to the 
use of superior rather than inferior harvesting site and painstaking removal of hyaloid 
facilitated by the use of chandelier illumination and triamcinolone staining. Yepez and 
Arevalo (2003) reported the use of heparin and 5-fluoro-uracil (Asaria et al. 2001) as 
prophylactic measure against PVR. Interestingly, short-term tamponade did not seem to 
increase the rate of RD as it occurred in only 7 of 23 (30%) eyes with SF6 versus 10 of 
22 (45%) eyes with silicon oil tamponade in the series reported by Joussen and 
colleagues (Joussen et al. 2006).  
Macular pucker or pre-retinal membrane (ERM) was also common (17 to 24%) 
after RPE transplantation (van Meurs et al. 2004; Joussen et al. 2006; Treumer et al. 
2007a). The mechanism of ERM formation is probably similar to that of PVR and 
relates to the paramacular retinotomy. Previous reports described peeling of ERM +/- 
ILM at the the time when silicon oil was removed or subsequent revision surgery 
(Joussen et al. 2006; Maaijwee et al. 2007a). However, these studies did not describe 
the impact of peeling on patients’ the visual symptoms. 
 
2.3.6.4 Persistence and recurrence of disease 
In addition to early haemorrhage and RD, visual loss may also occur due to disease 
persistence and recurrence. In neovascular AMD, incomplete removal of the CNV 
complex leads to persistent residual CNV which is usually seen within the first 1-3 
months. Recurrent CNV may occur through a defect in RPE, especially when this is 
located near the fovea and this usually manifest after 3-6 months. These are common 
after submacular surgery. Following laser photocoagulation or surgical removal of 
subfoveal CNV from AMD, persistent or recurrent CNV may be seen in around 50% of 
patients during the first 2-3 years (MPS Group 1994b; Hawkins et al. 2004). Even with 
full or limited macular translocation, recurrent CNV can still occur in 25 to 35% within 
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the first 1-2 years respectively (Baer et al. 2008; Fujii et al. 2002a). In atrophic macular 
disease, development of RPE atrophy or even CNV over the recipient site may be 
considered as disease recurrence. 
Algvere and colleague (1999) reported CNV at recipient sites between 1 and 2 
years following allogeneic fetal RPE transplant in 3 of 5 patients with GA receiving 
small patch grafts. Tezel et al. (2007) attributed the development of fibrosis and 
haemorrhage around the graft in 2 patients, within 1 month after discontinuation of 
immunosuppression, to immune rejection rather than recurrent CNV. It may also be 
possible that the late leakage, haemorrhage and fibrosis are due to recurrent CNV. For 
autologous RPE suspension, 2 cases (5%) of recurrent CNV were reported in Binder’s 
(Binder et al. 2004) prospective series of 39 patients at 3 and 12 months. However, 
recurrence was not reported in her earlier pilot study of 14 patients over 2 years (Binder 
et al. 2002) nor in van Meurs’s (2004) case series of 8 patients over 3 to 16 months of 
follow up. Recurrent CNV was not reported in case series of autologous equatorial 
RPE-choroid graft with short term follow up (MacLaren et al. 2007; Joussen et al. 
2006; Joussen et al. 2007). However, Joussen et al. (2006) described early development 
of fibrosis and haemorrhage around the patch graft in 19 of 45 (42%) eyes. Heussen et 
al. (2008) reported recurrent CNV in 11 of 30 (37%) patients between 6 and 12 months 
following autologous RPE-choroid graft and Treumer et al. (2007a) reported 1of 10 
(10%) patients with recurrent CNV after patch graft for atrophic AMD. In the largest 
series of patch graft, Maaijwee et al. (2007a) reported recurrent CNV in 11 of 85 
patients (13%) after 2-27 months.  Despite treatment with either laser photocoagulation 
or intravitreal anti-VEGF agent, most patients had visual decline (Maaijwee et al. 
2007a; Heussen et al. 2008). The mechanism of visual loss is unclear since subfoveal 
growth of the recurrent CNV is usually prevented by the patch graft (Heussen et al. 
2008). Although recurrence of GA has not been reported following autologous 
equatorial RPE-choroid patch graft at 6-12 months, longer term follow up is required 
since recurrent GA following translocation occurred late (Cahill et al. 2005a; Khurana 
et al. 2005).  
 
 
2.3.6.5 Other ocular and systemic complications  
Post-operative serous macular detachment and cystoid macular oedema unrelated to 
CNV has also been reported (van Meurs and Van Den Biesen 2003; Joussen et al. 2006; 
Joeres et al. 2008). In a case series of 29 patients, Joeres et al. (2008) found that 14 eyes 
had normal retinal structure preoperatively on time-domain OCT. Among these, 7 
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retained normal appearance but the rest became oedematous (2), atrophic (2), or both 
atrophic and oedematous (2), and 1 developed a macular hole. Retinal oedema over 
graft may be related to traction from ERM, delayed donor RPE dysfunction or 
perifoveal capillary incompetence. Other ocular complications reported include macular 
hole, optic atrophy, glaucoma, vein occlusion and artery occlusion (Maaijwee et al. 
2007a; Joussen et al. 2007; Joeres et al. 2008).  
Systemic complication may occur in the setting of immunosuppression. One 
patient died from congestive cardiac failure at 114 days after allogeneic RPE patch graft 
(Del Priore et al. 2001). Three of 12 patients receiving immunosuppression after 
allogeneic grafts had to discontinue their medications due to adverse reactions rior to 6 
months (Tezel et al. 2007). One patient in MacLaren’s (2007) series had post-operative 
acute myocardial infarct which required intensive care unit admission. This was thought 
to be related to the anaesthesia for the procedure itself. 
 
2.3.7 Graft survival and function 
Short term survival of donor RPE depends on how the cells were delivered. As cell 
suspension, the RPE will need to attach to a suitable basement membrane to prevent 
apoptosis (Tezel and Del Priore 1997). Autologous RPE-choroid patch graft, however, 
requires establishment of choroidal perfusion through vascular re-connection with 
adjacent or underlying choroid at the recipient site. Longer term survival of donor RPE 
largely depends on their sources. Allogeneic graft faces the barrier of immunological 
rejection within the first 6 months whereas autologous equatorial RPE may not be able 
to support foveal cone functions for long durations. Furthermore, delayed patch graft 
ischaemia may lead to late visual loss. The study of donor RPE survival and integration 
during the first months after grafting has been facilitated by the use of silicone oil as 
tamponade. Graft survival, structure and perfusion have been studied directly using AF 
imaging, OCT and high-speed ICG angiography, and indirectly through mapping of the 
preferred retinal locus for fixation and microperimetry. The following sections will 
address RPE survival in allogeneic grafts, autologous cell suspension grafts and 
autologous RPE-choroid patch grafts respectively. 
 
 
2.3.7.1 Allogeneic RPE suspension and patch grafts 
As discussed above, a short course of oral steroid (Algvere et al. 1994), or a 6-month 
course of cyclosporine and azathioprine with or without systemic steroid (Del Priore et 
al. 2001; Tezel et al. 2007) have been used for immunosuppression in patients receiving 
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allogeneic grafts. RPE allograft survival after delivery as cell suspension is difficult to 
evaluate. Algvere et al. (1994) have reported increased pigmentation in the macular 
region as a sign of cell adherence and growth. Although no specific features on 
autofluorescence imaging or angiography have suggested RPE suspension graft 
survival, improvement in retinal sensitivity on microperimetry may reflect rescued 
photoreceptor by viable donor RPE (Weisz et al. 1999). However, given the poor 
adhesion of uncultured adult, fetal and immortalised RPE cell lines to aged or damaged 
human BM (Zarbin 2003; Del Priore and Tezel 1998; Tezel et al. 2004), it is unlikely 
that cell suspension graft would have survived (see below). On the other hand, fetal and 
adult allogeneic RPE patch grafts appear to survive while the patient was 
immunosuppressed (Algvere et al. 1994; Tezel et al. 2007). There has been no OCT 
study of the structure allogeneic grafts. 
Immune rejection is a significant barrier to long-term graft survival in allograft. 
It was proposed that the loss of immune privilege in the subretinal space following 
membrane removal was the cause of patch allograft rejection in all 7 patients with 
neovascular AMD in the study by Algvere et al. (1999). Interestingly, these grafts 
maintained visual function during the first month. Between 1 and 3 months, macular 
oedema, fluorescein leakage and graft depigmentation occurred, followed by 
progression to fibrous encapsulation after 3 months (Algvere et al. 1994). In contrast, 
extrafoveal fetal RPE patch allografts in GA were not rejected after 30 months with the 
exception of one case which was rejected within 6 months. In this patient, the graft was 
placed adjacent to the retinotomy; a site of damaged blood retinal barrier. Subfoveal 
fetal RPE allograft as a cell suspension in atrophic AMD was rejected after 12 months. 
Similarly, in 2 patients with RPE rip, the fetal RPE suspension allograft was also 
rejected within 6 months. Algvere et al. (1999) concluded that rejection is common but 
not inevitable and the risk factors for rejection include CNV removal, larger number of 
cells transplanted and proximity of transplant to fovea or retinotomy. As described 
previously, 2 of 12 patients from Tezel and colleagues’ series (2007) developed fibrosis 
and haemorrhage around the graft within 1 month of discontinuing immunosuppression. 
The authors attributed this to graft rejection given the temporal relationship.  
Other evidence of immune activation is the presence of autoreactive 
lymphocytes (against retinal antigens) in a patient who received RPE allograft. 
However, it was not possible to determine if the surgical procedure or the 
transplantation was the cause (Weisz et al. 1999). Histological examination of the eye at 
2 – 3 months after adult allogeneic RPE patch graft did not demonstrate excessive 
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inflammatory cell infiltrate (Del Priore et al. 2001). As the mechanism of RPE allograft 
rejection is unknown, current immunosuppressive regime will only be empirical until 
the mechanism of RPE rejection is understood.  
 
2.3.7.2 Autologous RPE suspension and patch grafts 
Survival of autologous RPE suspension on damaged BM after subretinal injection has 
been difficult to demonstrate. Binder and colleagues (Binder et al. 2004; Krebs et al. 
2008) were unable to provide evidence of cell survival following autologous RPE 
suspension graft although they showed visual improvement in some patients. Although 
the authors suggested the use of an in vivo donor RPE marker to determine if these RPE 
cells survived, absence of donor RPE will not be a unexpected given previous ex vivo 
experiments have demonstrated poor adhesion of uncultured adult, fetal and 
immortalised RPE cell lines to aged or damaged human BM (Zarbin 2003; Del Priore 
and Tezel 1998; Tezel et al. 2004). Since cells are unlikely to have survived on 
damaged BM, the Long-term survival of submacular injection of peripheral RPE cell 
suspension becomes unlikely.  
Early survival and function of RPE-choroid patch grafts depends on minimal 
surgical trauma to the RPE during harvesting and delivery and early perfusion of the 
graft. Factors that may impact on late equatorial RPE-choroid graft function include; 
size of the patch, ability of equatorial RPE cell to maintain foveal cones, primary 
photoreceptor cell dysfunction and delayed graft ischaemia. 
Surgical trauma to donor RPE may occur during harvesting of donor RPE, 
loading of the graft on instruments, insertion through retinotomy and release of the graft 
and withdrawal of instruments. Electron microscopic examination of the RPE-choroid 
donor patch demonstrated intact Bruch’s membrane but patchy loss of RPE or RPE cells 
with avulsed apical membrane (MacLaren et al. 2007). Placement of folded or even 
inverted graft significantly reduces the ability of the patch graft in supporting 
photoreceptor cells (Stanga et al. 2002; van Meurs et al. 2006; Joussen et al. 2006). 
Further evidence of the importance of surgical trauma in relation to outcome was 
provided by Maaijwee and colleagues (Maaijwee et al. 2008c). 
Graft perfusion has been detected as early as 1 week to as late as 4 months after 
patch graft using either early frames of FFA or high-speed ICG angiography (Joussen et 
al. 2006; Treumer et al. 2007a; Maaijwee et al. 2008d). It has also been shown that 
reconnection of vascular channels between the patch and the recipient choroidal bed can 
occur at the edge of the graft (see Figure 2.8). Joussen et al. (2006), on the other hand, 
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reported that the patch is perfused from the underlying choroid. Serial ICG angiography 
demonstrated initial reconnection of vascular channels and later remodelling of the 
RPE-choroid patch vasculature (Joussen et al. 2006). It is not known if there is ingrowth 
of underlying or adjacent choroidal vessels into the patch graft and recruitment of 
marrow-derived endothelial progenitor cells, similar to that found in skin graft 
integration (Capla et al. 2006). The process from initial connection to complete graft 
revascularisation may take up to 3 weeks (Joussen et al. 2006).  
Failure of the graft to revascularise can be due to (1) separation of the graft from 
adjacent or underlying choroid by haemorrhage or (2) absence of choroid vessels around 
the graft. Absence of medium sized choroidal vessels may occur in areas affected by 
GA or following excision of CNV, previous repeated photodynamic therapy or possibly 
previous repeated anti-VEGF therapy. It is now generally accepted that a pedicle of 
choroid is not necessary for RPE-choroid patch survival as was suggested by Yepez and 
Arevalo (2003). With time, ischaemic RPE-choroid graft becomes encased in fibrous 
tissue. If the patch was only partially vascularised, the avascular portion of the graft 
may undergo fibrosis. The reported rates of failure to revascularise ranged from 6 to 
11% (van Meurs 2005; Joussen et al. 2006; MacLaren et al. 2007; Treumer et al. 2007a; 
Maaijwee et al. 2008d). In Joussen’s series (2006), 4 patients with failed graft 
vascularisation received a second RPE choroid patch, and 1 of these remained non-
perfused. Revascularisation rate in patients with GA is similar to those in patients with 
neovascular AMD with only 2 of 12 patients demonstrated incomplete or absence of 
graft perfusion (Joussen et al. 2007). These 2 patients did not have intentional damage 
to BM prior to insertion of the grafts. Once perfused, the patch remained vascularised 
during the entire follow up period except for one case reported by Joussen et al. (2006) 
where patch perfusion had reduced at 6 months in a patient with GA. It is important to 
note that presence of vascularisation or autofluorescence signal do not always correlated 
with visual function (Joussen et al. 2006). Furthermore, a non-perfused graft (and 
presumably, dying RPE cells) may retain autofluorescence signal (derived from 
peripheral photoreceptors) for as long as 6 weeks after transplantation (Joussen et al. 
2006; Treumer et al. 2007a). Conversely, a vascularised graft may also loose its 
autofluorescence signal years later due to possible delayed photoreceptor (MacLaren et 
al. 2005) or RPE cell death. 
Long-term equatorial RPE-choroid graft survival has not been well 
characterised. Although there has been no study which correlated equatorial RPE cell 
function to outcome, it has been assumed that patients with peripheral degenerative 
changes and those with full-field ERG abnormality may not benefit from autologous 
RPE-choroid patch graft. Following submacular RPE-choroid flap rotation or graft 
reposition, Stanga et al. (2002) noted development of fibrosis around the graft and lack 
of visual improvement after 10 months. Although they attributed these to primary graft 
failure from poor revascularization, long term (4-5 years) follow up on 4 of the 9 
patients revealed that the grafts were in fact perfused. MacLaren et al. (2005) concluded 
that the failure of visual improvement and progressive visual loss may in fact be due to 
a primary progressive photoreceptor cell death rather than primary or secondary graft 
failure. It was proposed that the insult of surgery or continuation of natural history of 
the disease led to progressive photoreceptor cell loss. Joeres et al. (2008) used OCT To 
study the structure graft in 29 patients and found a trend that eyes with thinner grafts 
had better VA than those with thicker grafts at 6 months. Also, despite the significant 
undulation of the graft surface, most patient did not complain of metamorphopsia 
(Joeres et al. 2008). 
 
 
Figure 2.8 Equatorial autologous RPE graft: angiography  
Colour fundus photographs and indocyanine green angiographies (a, c) before and (b, d) 
after autologous RPE-choroid patch graft, showing intrinsic vascular filling pattern 
(white arrow) within the graft which is significantly different from the corresponding 
region (yellow outline) in the preoperative angiogram (yellow arrow), suggesting 
perfusion of the transplanted choroid. 
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2.3.8 Retinal structure and functional rescue  
There is clinical evidence to suggest that the removal of the RPE-CNV complex and 
reconstruction of the RPE and sub-RPE defect with healthy donor RPE can restore 
retinal structure and function. Restoration of retinal structure has been reported using 
optical coherence tomography (OCT) in trials of autologous RPE-choroid patch graft 
(MacLaren et al. 2005; 2007; Joeres et al. 2008). Various measures of retinal function 
including distance visual acuity (VA), reading ability, microperimetry and 
electrophysiology have been used to demonstrate reversal of visual loss or stabilisation 
of vision. The following sections will examine each outcome measure in relation to 
natural history and outcomes following different techniques of surgery for neovascular 
and atrophic macular diseases. 
 
2.3.8.1 Retinal structure 
OCT is an indispensible tool in the management of neovascular AMD as it allows 
detailed visualisation of pathology within the choroid, sub-RPE space, sub-retinal space, 
retina and vitreoretinal interface. Although there is no natural history data on OCT 
outcomes in untreated AMD, histological studies and clinical examinations of end stage 
AMD or disciform scars suggest that retinal thickness is likely to reduce due to loss of 
outer nuclear layer. Interestingly, subretinal fluid and serous pigment epithelium 
detachment may also spontaneously resolve.  
 Several studies have demonstrated restoration of foveal contour and resolution 
of intraretinal oedema or subretinal fluid following autologous RPE-choroid graft 
(MacLaren et al. 2005; Maaijwee et al. 2007a; MacLaren et al. 2007). In case series of 
29 patients, Joeres et al. (2008) found 14 patients with macular oedema preoperatively. 
Following autologous equatorial RPE-choroid graft, 4 had normal retinal structure. The 
remaining 10 eyes had persistent oedema alone (3), atrophy (2), mixture of atrophy and 
oedema (4) or developed a macular hole (1). They also found that normalisation of 
retinal structure did not always correlate with improved VA.  
 Data on OCT outcomes following RPE graft is scarce. Interpretation of current 
evidence is complicated by the possibility of missed pathology in time-domain OCT 
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2.3.8.2 Visual acuity 
The most commonly used measure of visual function outcome is the best-corrected 
distance VA. Measurements on the Snellen and the Early Treatment Diabetic 
Retinopathy Study (ETDRS) charts have been converted into logarithm of minimal 
angle of resolution (logMAR) for reporting outcomes. However, mean change in VA 
and proportion with VA gain or loss across different studies are not comparable due to 
differences in assigning logMAR values to VA measurements when the ETDRS chart 
could not be read from 1 metre. The following paragraphs will summarise the natural 
history in neovascular and atrophic macular diseases, and in these context, review the 
VA outcomes following allogeneic and autologous RPE grafts. 
Results from the untreated controlled arms of clinical trials, such as the macular 
photocoagulation study (MPS) and submacular surgery trials (SST), and meta-analysis 
have provided data on the natural course of VA for over 3 years in patients with 
subfoveal CNV (MPS Group 1994a; Hawkins et al. 2004; Wong et al. 2008). It is 
apparent from these reports that VA outcome in neovascular AMD may be dependent 
on the duration of symptom, and location, size and composition of the CNV. Other 
features such as serous or haemorrhagic PED, RPE rip and subretinal haemorrhage may 
also significantly alter the natural course of VA (Braunstein and Gass 1979; Avery et al. 
1996). In eyes with subfoveal CNV, those with classic only features tend to have a 
worse presenting vision and a more rapid decline in VA during the first 2 years than 
those with occult only CNV. In the meta-analysis by Wong and colleagues (2008), the 
mean VA loss in neovascular AMD was 1 line at 3 months, 3 lines at 1 year and 4 lines 
at 2 years from a baseline of 0.64 logMAR (~6/24 Snellen). One study showed that VA 
continues to decline even at 4 years with a mean loss of over 6 lines in either classic 
only or occult only eyes (Maguire 1999). However, there is limited information on the 
natural history of patients presenting with very poor initial VA (< 3/60) since these 
patients are usually excluded from randomised trials of new therapy. The VA outcome 
in this group of patients may also be dependent on the duration of visual loss and other 
parameters such as fixation pattern (see below). This is highly relevant to surgical trials 
because many patients in the initial cohort who underwent subfoveal CNV removal with 
RPE graft were not eligible for conventional therapy due to poor VA as a result of 
disciform scar, RPE rip or large submacular haemorrhage. 
The natural history of VA change in GA has been reported by Sunness et al. 
(1997). Although doubling of visual angle can occurred in 20-50% of eyes over 2 years, 
a later study demonstrated that improvement in VA also occurred in the worse seeing 
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eye when the better seeing eye lost vision (Sunness et al. 1997; 2000) Therefore, one 
should be cautious when interpreting VA outcomes in uncontrolled case series. 
Furthermore, VA outcomes should be interpreted in conjunction with other measures of 
visual function such as fixation locus and stability (see below). 
There is some evidence that allogeneic graft can support fixation although only 
for short duration. The first reported allogeneic RPE graft, described by Peyman et al. 
(1991), had counting fingers (CF) vision at 2 feet, pre- and post-operatively due to 
fibrous encapsulation of the graft from presumed graft rejection. In Algvere and 
Gouras’ (1994; 1997; 1999) series of 5 patients with neovascular AMD, mean VA 
declined 0.96 to 1.26 logMAR at 3 months. Although fixation on the patch was shown 
in 2 patients on microperimetry at 1 month, visual loss occurred between 1 and 3 
months, coinciding with development of graft failure. In the same series, an overall VA 
loss also occurred in the 9 patients with atrophic AMD who received allogeneic fetal 
RPE grafts either as cell suspension or monolayer sheet (Algvere et al. 1999). Severe 
visual loss occurred in 3 of these 9 patients due to development of CNV 1-2 years after 
the graft. In the series by Tezel et al. (2007), mean VA declined from 0.84 to 1.00 
logMAR over 12 months following adult allogeneic RPE graft although this was not 
statistically significant. The absence of VA benefit was also supported by the lack of 
fixation over graft in any of the 12 patients post-operatively.  
Amongst the various techniques of autologous RPE graft, the most compelling 
evidence of VA rescue came from case series on the use of equatorial RPE-choroid as 
autograft. The earlier techniques of autologous RPE grafts had disappointing VA 
outcomes. Peyman et al. (1991) demonstrated doubling of visual angle with VA 
improved from CF at 5 feet to 3/60 although fixation was on the graft was not reported. 
In Stanga’s series (2002) of 9 patients with submacular RPE-choroid autograft, VA did 
not improve, with pre-operative VA ranging from CF to 6/30 and post-operative VA 
ranging from hand motions (HM) to 6/30 after 1-2 years.  Furthermore, in those with 
uncomplicated postoperative course loss of fixation and VA occurred over time 
(MacLaren et al. 2005). At 4-5 years, only one patient had stable VA whereas the 
remaining 3 patients had further loss. This was thought to be due to continuing 
photoreceptor death rather than graft RPE dysfunction (MacLaren et al. 2005). 
Binder et al. (2002; 2004) demonstrated, in 2 prospective studies, that VA can 
improve after autologous RPE cell suspension transplants. In the feasibility and safety 
pilot study, she reported improvement of 2 or more lines in 8 of the 14 eyes (57%) after 
12 months of follow up (Binder et al. 2002). In this group of patients, most were 
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primary CNV (13), most had mixed classic and occult (10, remaining 2 had classic only 
an 2 had occult only), all had angiographic growth of lesion 3-9 months previously, 
substantial visual decline and baseline VA ranging from CF to 6/15 (6 out 14 had VA ≤ 
6/60). The initial sizes of the lesions ranged between 1.02 and 8.24 mm in maximum 
diameter (mean = 4.59 mm). To further evaluate functional benefit of RPE suspension 
transplant, Binder et al. (2004) performed RPE grafts in 39 eyes and compared the 
outcomes of these with 14 eyes that had undergone CNV removal alone. This group of 
patient is different from those in the pilot study in that most had occult membrane with 
minimal classic areas (50 out of 53; 94%). The baseline VA range was not reported. The 
initial size of the lesions ranged from 3.1 to 10.1 mm (median = 6.0 mm). Similar to the 
pilot study, VA improved 2 or more lines in 21 of the 39 eyes (54%) at 12 months. In 
the control group, mean VA improved during the first 6 months and then deteriorated by 
12 months. Overall, the net change was a gain of 1 line in the control group and 2 lines 
in the transplanted group. In a larger series of 68 patients (28 had RAP lesion) using the 
same technique, Krebs et al. (2008) reported no significant change in mean VA (from 
1.02 to 1.06 logMAR) at 12 months. van Meurs et al. (2004), however, was unable to 
demonstrate a visual benefit from a his technique of cell suspension transplant in 8 
patients with pre-operative VA ranging from CF to 6/120 due to minimally classic CNV 
larger than 2 disc diameters, with or without submacular blood. Post-operative VA 
ranged from HM to 6/120 after 3 to 16 months of follow up.  Because of the severe 
complications encountered and only modest visual gain in those without complication, 
the authors have abandoned this technique in favour of autologous equatorial RPE-
choroid graft (van Meurs and Van Den Biesen 2003). 
In the original description of autologous equatorial RPE-choroid graft, van 
Meurs and van Den Biesen (2003) reported that 67% had gained 3 or more lines from a 
baseline mean VA of 1.10 logMAR. At longer follow of 12-24 months, 8 of 18 (44%) 
patients maintained this improvement (van Meurs 2005). All these patients had 
minimally classic subfoveal lesions larger than 1 disc diameter with or without 
submacular blood. In a report of the long-term outcome by the same group, at 36 and 48 
months, 4 of 24 (17%) and 2 of 11  (18%) patients had VA of 6/24 or better (Maaijwee 
et al. 2007a). However, these encouraging results have not been reproduced by other 
groups. Joussen et al. (2006) reported an overall visual decline, with only 7% of the 45 
patients had VA gain of 3 lines or more. The mean (range) baseline VA in this cohort 
was 0.85 (0.3-1.6) logMAR and the mean lesion size was 4.2 mm excluding the 3 
lesions larger than 10 mm (Joussen et al. 2006). The majority had PED (16) or occult 
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only lesions (14). Post-operatively, the mean (range) VA declined by three and a half 
lines to 1.2 logMAR (0.4 logMAR to PL). Significant proportion of patients (31%) had 
severe visual loss immediately after surgery. By 6 months, 20% and 18% had VA of CF 
or worse and 6/24 or better, respectively. Overall, 7% of eyes had 3 or more lines of 
gain in VA. Smaller case series of this technique in patients with neovascular AMD 
reported a wide range of rates of 3 line VA gain over 6-12 months varying from 17 to 
70% (Fawzy et al. 2006; Treumer et al. 2007a; MacLaren et al. 2007; Heussen et al. 
2008). However, if patients who had post-operative complication were excluded from 
analysis, the mean change in VA would have been a gain of 2-3 lines. The proportions 
of the types of lesion treated were different between the three groups of investigators. 
Treumer et al. (2007a) reported outcomes in patients with massive submacular 
haemorrhage (5), large occult only CNV (3), PED (1) and geographic atrophy (1).  Pre-
operative mean (range) VA was 1.4 (0.7-1.8) logMAR. Fawzy et al. (2006) reported 
outcomes in patients with massive submacular haemorrhage (5), occult only CNV (11), 
classic only CNV (2), mixed CNV (1) PED (4) and rupture of RPE (2). Pre-operative 
VA ranged from 0.3 to 1.4 logMAR. Heussen et al. (2008) included eyes with classic 
CNV (1), mixed CNV (1), RAP lesion (1, RPE rip (2), massive submacular 
haemorrhage (5) ), occult CNV (7) and the majority had PED (13). The mean baseline 
VA was 0.8 logMAR. MacLaren et al. (2007) reported outcomes in patients with occult 
CNV (10) with or without haemorrhagic PED, serous PED or RPE rip, minimally 
classic (1) and large classic CNV (1) not responding to previous PDT or too large for re-
treatment. Their pre-operative VA ranged between 6/15 and 4/60 (mean of 0.82 
logMAR). 
 In summary, there is good evidence that VA can improve in neovascular AMD 
treated with CNV removal and RPE graft. However, it is difficult to compare results 
from different case series due to varied case mix and different methods of VA 
assessment. Without a control group, these studies were unable to conclude that RPE 
transplantation could improve visual outcome. 
 
2.3.8.3 Reading ability 
Reading ability is quantified by near acuity, critical print size and maximum reading 
speed. Near acuity is more commonly measured with charts that require word rather 
than letter recognition. This accounts, in part, the disparity between the near and 
distance acuity reported by Lovie-Kitchin and Bailey (1981). Reading speed increases 
as the print size enlarge until the critical print size is reached where the speed reaches a 
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maximum (Legge et al. 1985b). Many factors can influence the maximum reading 
speed, including contrast threshold (Legge et al. 1992; Crossland et al. 2005b), size of 
scotoma (Sunness et al. 1996; Ergun et al. 2003), location of eccentric fixation in 
relation to the scotoma (Rayner et al. 1980; Fine and Rubin 1999; Nilsson et al. 2003; 
Sunness and Applegate 2005) and fixation stability (Crossland et al. 2004a). Reading 
ability following RPE graft has been assessed by using the Jaeger chart (Binder et al. 
2002; 2004), Radner reading chart  (Joussen et al. 2006; Kirchhof et al. 2006) or the 
Pepper reading test (Tezel et al. 2007). Reading speed and acuity have also been used to 
document visual outcomes following macular translocation surgery (Eckardt et al. 1999; 
Fujikado et al. 2002; Abdel-Meguid et al. 2003; Mruthyunjaya et al. 2004; Toth et al. 
2004) 
Although the natural course of reading ability in neovascular AMD has been 
reported in the untreated controls of clinical trials such as the MPS group (Crossland et 
al. 2004a; MPS Group 1994c), TAP and VIP study groups (Bressler 2001; 
Blumenkranz et al. 2002; Bressler et al. 2004b; Pieramici et al. 2006), and the SST 
research group (Bressler et al. 2004a; Hawkins et al. 2004), they are not comparable 
due to different methodologies. In atrophic AMD, Sunness and Applegate (2005) 
reported that 74% of patients continued to loose speed of reading as GA enlarges over 
time after 4 years. The VA range of these patients at entry was between 6/24 and 6/60. 
Currently, there is only anecdotal evidence that demonstrates restoration of 
reading ability by RPE graft. Reading speed did not improve after allogeneic RPE graft 
(Tezel et al. 2007). Using autologous RPE cell suspension transplant, 7 of the 14 
patients achieved reading acuity of Jager 1 to 10 print size where as only 3 could read 
the chart pre-operatively (Binder et al. 2002). However, this result was not reproduced 
in a larger prospective study of 39 patients where only 10% had reading acuity in the 
same range post-operatively (Binder et al. 2004). In Joussen’s series (2006) of 
autologous equatorial RPE-choroid graft, 31 of 45 had reading ability pre-operatively 
but only 13 (7%) were able to read post-operatively. However, a trend was noted for 
patients without intra-operative or post-operative complications and those with mixed 
classic and occult CNV to have better postoperative reading acuity. Heussen et al. 
(2008) reported improvement in Radnar reading test in some patients between 6 and 12 
months but interpretation of reading ability outcome is difficult due incomplete data set 
during follow up. In a group of 12 patients with GA, Joussen et al. (2007) demonstrated 
gain of reading ability in 2 of 3 patients and loss of reading ability in 3 of 9 patients 
after autologous equatorial RPE-choroid graft.  
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In summary, it is not clear from most reports whether the gain in reading ability 
is clinically meaningful. Even if the improvement is beyond the test-retest variability of 
reading test, it is important to determine if the change is due to rescue of function by the 
transplanted RPE or to central adaptation and eccentric fixation. Despite the 
uncertainties, recovery of reading ability in some of these patients may become the main 
drive for further development and refinement of the technique of RPE transplantation. 
 
2.3.8.4 Microperimetry and visual field 
From the above discussion, it is apparent that the reported VA and reading ability 
outcomes have not been convincing in demonstrating rescue of retinal function by RPE 
transplantation. This is because loss of retinal sensitivity within fovea leads to 
development of central scotoma and shifting of fixation from the centre of fovea to one 
or more extrafoveal loci where retinal sensitivity still remains (Fujii et al. 2003; 
Crossland et al. 2004a). Such eccentric locus (or loci) of fixation can sometimes supoort 
reasonable distance acuity and reading ability. Although the shift in the preferred retinal 
locus can lead to loss of fixation stability and reduced re-fixation accuracy (Schuchard 
2005), adaptation and training can also improve VA and reading ability independent of 
graft function (Nilsson et al. 2003).  
Macular sensitivity, preferred retinal locus and fixation pattern can be studied by 
conventional automated perimeter or microperimetry through the Rodenstock scanning 
laser ophthalmoscope (SLO) (Mainster et al. 1982; Timberlake et al. 1982) or the Nidek 
MP1 (Midena et al. 2004). The SLO microperimetry is no longer in production and the 
Nidek MP1 has been shown to produce comparable result when compared with SLO 
(Rohrschneider et al. 2005) and conventional automated perimetry (Springer et al. 
2005). Macular sensitivity has been studied using the 10-2 perimetry (Stanga et al. 
2001a; Binder et al. 2004), the SLO microperimeter (Algvere et al. 1994; Algvere et al. 
1999; Weisz et al. 1999; Joussen et al. 2006; Joussen et al. 2007; Heussen et al. 2008) 
and the Nidek MP1 (van Meurs 2005; Treumer et al. 2007a; Treumer et al. 2007b; 
Maaijwee et al. 2007a; MacLaren et al. 2007). Fixation locus and stability have been 
evaluated by fixation target of OCT (van Meurs and Van Den Biesen 2003), fixation rod 
(van Meurs and Van Den Biesen 2003), Foerster cross (Joussen et al. 2006), cross-
pattern fixation target or single-point flashing light in the Zeiss confocal laser scanning 
ophthalmoscope (Stanga et al. 2001a), Rodenstock SLO fundus perimetry (Algvere et 
al. 1994; Weisz et al. 1999; Joussen et al. 2006; Kirchhof et al. 2006) and the Nidek 
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Micro Perimetry 1 (van Meurs 2005; Treumer et al. 2007b; Treumer et al. 2007a; 
Maaijwee et al. 2007a; MacLaren et al. 2007). 
Retrospective studies using microperimetry to document natural history in 
neovascular AMD have been reported by Fujii et al. (2003) and  Midena et al. (2004). 
Prospective studies on development of macular scotoma, eccentric fixation and loss of 
fixation stability in neovascular and atrophic AMD have also been reported by Fujii et 
al (2003), Crossland et al. (2004a; 2005a) and Sunness et al. (1996; 2005). These 
studies demonstrated enlargement of scotoma and shift in fixation locus. In general, the 
pattern of enlargement is unpredictable although in GA, pattern of junctional AF signal 
may predict loss of retinal sensitivity (Scholl et al. 2004). Although the topographical 
variation in retinal sensitivity may be informative, there is no data on the test-retest 
variability of microperimetry to aid interpretation of change in sensitivity or fixation 
stability over time.  
Algvere et al. (1994) demonstrated that foveal fixation was supported by 
allogeneic RPE patch until the onset of graft rejection between 1 and 3 months in 
neovascular AMD. Four of 5 eyes had retinal function over the patch at 1 month but this 
was lost due to rejection. When graft rejection was not seen, as in those with geographic 
atrophy or severe RPE degeneration, there was no change in fixation after 
transplantation. In atrophic AMD, retinal sensitivity did not change over the RPE 
allograft (Algvere et al. 1999). Interestingly, Weisz et al. (1999) reported “spotty” 
perception of SLO microperimetry stimulus at 8 months over transplanted area that 
previously had no perception of the stimulus.  
Although 7 of the 9 patients in Stanga’s series had fixation on the patch at 12 to 
32 months following submacular RPE-choroid translocation (Stanga et al. 2002), 
MacLaren et al. (2005) reported that all 4 patients examined at 5 to 6 years after the 
graft had lost foveal fixation. Central retinal sensitivity was present when tested by 10-2 
perimetry within the first year of graft (Stanga et al. 2002). Binder et al. (2002) reported 
3 of the 18 (17%) patients gaining foveal fixation at 12 or more months in her pilot 
study of autologous RPE cell suspension transplant. In her second report on the same 
technique, Binder et al. (2004) found no difference in mean defect on central 10-degree 
static threshold perimetry between those who received and those who did not receive 
RPE transplantation. In van Meurs’ series of cell suspension transplant (2004), 3 
patients had fixation within the edge of CNV extraction bed and 3 had fixation outside 
the CNV extraction bed. 
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The first report of autologous equatorial RPE-choroid patch graft demonstrated 
fixation over the patch graft at 7-14 months after transplantation in 4 out of the 6 (67%) 
patients (van Meurs and Van Den Biesen 2003).  At 12 – 24 months, 12 of the 18 (67%) 
patients still had fixation over the graft (van Meurs 2005). In a larger series of 84 eyes, 
62 (74%) had fixation on the graft as assessed by slit lamp biomicroscopy at follow up 
between 1 and 4 years. Joussen et al. (2006) and Treumer et al. (2007a) however, 
reported lower rates of post-operative foveal fixation, 42% (8 out of 19) and 50% (5 out 
of 10), at 6 and 12 months respectively. Joussen et al. (2006) reported that eyes with 
stable fixation preoperatively were more likely to maintain stable fixation after surgery 
and a weak correlation exist between visual acuity, fixation locus and stability. Heussen 
et al. (2008) reported that only 3 of 11 eyes with poor VA (<6/60) had fixation on the 
patch but did not state the locus of fixation in those with good VA. Both MacLaren et 
al. (2007) and Joussen et al. (2007) reported that fixation on the patch was possible for 
1 or more year but the rate of achieving fixation over the graft was not given. It is 
difficult to compare the fixation outcomes between these studies since preoperative 
fixation behaviour was not characterised fully and different techniques of measuring 
fixation were used.  
Joussen et al. (2006) demonstrated that the retina overlying the graft was able to 
detect light stimuli. Areas of retina overlying fibrosis or haemorrhage had a relative or 
absolute scotoma. Retina overlying a CNV of greater than 1 mm2, areas of RPE atrophy 
or no AF signal had absolute scotoma. Treumer et al. (2007a) demonstrated that if 
retinal sensitivity over the patch graft was not present within 3 months of grafting, it 
was not achieved during the 6 to 12 months of follow up. Further more, MacLaren et al. 
(2007) reported that topographic variability in retinal sensitivity in the area overlying 
the graft may be accounted for, in part, by the extent of graft choroid perfusion. In 
geographic atrophy, patch graft did not improve sensitivity of the retina that was 
overlying on atrophic RPE (Joussen et al. 2007). Figure 2.9 shows that both AF and 
graft perfusion are necessary but not sufficient for restoration of retinal sensitivity. 
Comparison with pre-operative microperimetry is critical in determining if absence of 
sensitivity over graft was due to surgical trauma or pre-existing pathology.  
In summary, there is compelling evidence that RPE patch graft is able to support 
foveal cone function to maintain stable fixation in some patients. However, there has 
been no report, as yet, which demonstrated that RPE graft can improve or restore retinal 
sensitivity over an area of absolute scotoma present pre-operatively (Joussen et al. 
2006).  




VA, reading ability and microperimetry are psychophysical tests which are prone to 
variability due to learning and fatigue. Electrodiagnostic tests are objective and are able 
to study, in isolation, photopic or scotopic, inner or outer retinal, and localised macular 
or generalised retinal responses to light. Full-field ERG is not useful in assessing 
localised macular function rescue by RPE graft since full-field response can be normal 
even in eyes with severe macular damage. Multifocal ERG allows assessment of 
macular function by recording focal ERG signals simultaneously at multiple retinal loci 
within the macula over a brief period of time (Sutter and Tran 1992). Pattern ERG, an 
older technique, provides information on the macular retina as a whole but does not 
provide topographic information on variation in retinal function within the macula. 
These modalities have been used in the setting of AMD in early detection, monitoring 
of treatment and predicting visual outcomes (Feigl et al. 2005; Obata et al. 2006; Neveu 
et al. 2006). There is limited prospective data on the change in multifocal or pattern 
ERG with exudative or atrophic AMD (Neveu et al. 2006). Current models of 
multifocal ERG system can be combined with an SLO for continuous monitoring of 
fixation and allow accurate overlay of individual response traces on fundus image. This 
will enable spatial correlation between electrophysiological responses and retinal 
pathology to be made (Jurklies et al. 2002; Kondo et al. 1997; Poloschek et al. 2003; 
Bellmann et al. 2004; Glybina and Frank 2006).   
Currently, there is only 1 prospective study of RPE transplantation which 
examined the electrophysiology outcome. Binder et al. (2004) demonstrated higher 
mean a-wave and b-wave amplitudes in the multifocal ERG wave forms in the 
transplanted group than the control group after 12 months. During the first 3 months, 
increased amplitudes were attributed to reduction of macular oedema and metabolic or 
trophic support from the transplanted RPE. The control group demonstrated progressive 
deterioration of the amplitude during the 12 months follow up period.  
The use of video-monitored multifocal ERG in patients undergoing RPE graft 
may enable correlation, in multiple areas of the graft, between choroidal flow, AF 




Figure 2.9 Equatorial autologous RPE graft: microperimetry 
A postoperative case of autologous equatorial RPE-choroid transplantation (yellow 
outline) in a patient with inherited macular disease. (a) Microperimetry using Nidek 
MP1 showing retinal sensitivity map over the graft. Red open squares denote no vision. 
Colour scale squares with numbers denote increasing sensitivity based on decibel scale 
in label c. (b) Autofluorescence image showing areas of homogenous autofluorescence 
within the graft. Areas with retinal sensitivity on microperimetry are outlined. (c) A 
close up of microperimetry result showing sensitivity at the fovea. (d) Choriocapillary 
perfusion on fluorescein angiography within the graft.  
 
 
2.3.8.6 Other measures of outcome 
Other measures of visual functions include contrast sensitivity (CS), chromatic 
sensitivity and Vernier- or hyper-acuity. Tezel et al. (2007) reported no improvement in 
CS following allogeneic RPE graft. Joussen et al. (2006) reported that all patients had 
improvement of distortion following autologous equatorial RPE-choroid graft. Quality 
of life (QOL) questionnaire has also been used to measure outcome following RPE 
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graft. Unlike macular translocation (Cahill et al. 2005b), vision-specific QOL as 
measured by the National Eye Institute Visual Function Questionnaire (NEI-VFQ) after 
autologous equatorial RPE-choroid graft has not been shown to correlate with VA 
outcomes (Heussen et al. 2006). 
 
2.3.9 Summary of human trials  
In summary, human trials of autologous RPE grafts in neovascular AMD have 
demonstrated retinal function rescue with encouraging long-term outcomes. There is 
limited clinical data on allogeneic RPE grafts due to lack of availability of adult and 
fetal RPE cell sources and inability to prevent allograft rejection. However, several 
issues regarding autologous grafts remain unanswered. Can autologous equatorial RPE-
choroid graft be performed safely in atrophic macular disease? How do we reliably 
measure and monitor long-term retinal function rescue by RPE transplantation in 
atrophic macular disease if VA does not reflect disease progression or graft function? In 
neovascular AMD, it is still not clear how translocation of the RPE compares to 
translocation of the the fovea in their long-term visual outcomes. Despite the promising 
visual outcomes at 1 year from each type of apparoch, do we know if paramacular and 
equatoridal RPE-choroid can maintain foveal function beyond 2 years? 
 
2.4 Aims and Hypotheses 
The aim of this thesis was to investigate the outcomes of autologous RPE 
transplantation in AMD and IMD in order to provide proof of principal of short- and 
long-term photoreceptor cell function rescue. These data will be used for the purpose of 
proposing a novel surgical technique of hESC derived-RPE transplantation. 
The overall hypothesis of this thesis is that autologous RPE transplantation by 
either RPE-choroid graft or macular translocation can maintain retinal function for over 
2 years in patients with atrophic or neovascular macular disease.  
 
The clinical studies were designed to specifically investigate the following hypotheses: 
1. Autologous RPE-choroid graft can support retinal function at 1 year and 
maintain this for at least 2 years in atrophic AMD and IMD. 
2. Autologous RPE choroid graft and full macular translocation can support retinal 
function for at least 2 years in neovascular AMD. 
3. Human ESC derived-RPE transplantation is a simpler and safer alternative 
technique of reconstructing RPE than the current surgical approaches.  






Chapter 3 Materials and Methods 
Materials and Methods 
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3.1 Clinical studies and design 
The methodology described below refers to two prospective pilot studies (Chapter 4) 
and two retrospective case series (Chapter 5).  
The atrophic macular disease studies (Chapter 4) consist of 2 prospective 
single-centre, single-surgeon clinical trials approved by the hospital Research 
Governance and the Local Research Ethics Committees (Appendices 2 and 3). The 
design and conduct of these studies followed the tenets of the Declaration of Helsinki. 
Informed consent was obtained from each patient after the experimental nature of the 
study had been explained. 
The neovascular macular disease studies (Chapter 5) were retrospective case-
series approved by the hospital Research Governance (Appendices 4, 5 and 6). The 
tenets of the Declaration of Helsinki were followed. All patients gave informed consent 
for these procedures to be carried out as part of previous clinical trials approved by the 
Local Research Ethics Committee or as routine care. 
 
3.1.1 Patient selection 
Inclusion and exclusion criteria for the prospective and retrospective study are listed 
below. 
  
3.1.1.1 Atrophic macular disease study 
For the atrophic disease study, patients with macular atrophy due to AMD or IMD were 
included.  
In the atrophic IMD study the inclusion criteria were: (1) A diagnosis of 
inherited macular or retinal dystrophy with macular involvement, (2) VA of 6/36 (0.8 
logMAR) or less in the study eye, (3) recent visual acuity of 6/12 or better within past 
12 months in treatable eye, (4) over 25 years old, (5)  fit for surgery and able to consent 
to surgery, and (6) fundus AF imaging and full-field ERG results suggestive of a 
localised macular disorder (i.e. normal mid-peripheral autofluorescence and presence of 
rod and cone full-field ERG responses).  
For the atrophic AMD study the inclusion criteria were: (1) A diagnosis of dry 
AMD, (2) VA of 6/24 (0.6 logMAR) or less in the study eye, (3) evidence of recent loss 
of reading ability in the past 12 months in the study eye, (4) Over 50 years old, (5) fit 
for surgery and able to consent to surgery, (6) FAF imaging and full-field ERG results 
suggestive of a localised macular disorder.  
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For both studies, the exclusion criteria are: (1) inability to give informed 
consent, (2) inability to complete follow-up programme, (3) unfit for local or general 
anaesthetic, (4) inability to complete follow-up programme and (5) any other concurrent 
corneal, retinal or neurological pathology affecting central vision. 
 
3.1.1.2 Neovascular macular disease study 
All patients with neovascular AMD who had undergone surgery with the intention of 
macular translocation or autologous RPE-choroid patch graft from January 2003 to 
December 2008 at Moorfields Eye Hospital were eligible. None of these patients were 
eligible to receive photodynamic therapy (available from September 2003) or 
intravitreal anti-VEGF agent (available in the NHS from August 2008) according the 
National Institute of Clinical Excellence (NICE) guidelines. The first 12 cases from 
each group were chosen for comparison as the casese are matched in terms of surgical 
learning curves.  
 
3.1.2 Surgical procedures 
The surgical technique of autologous equatorial RPE-choroid patch graft in atrophic 
macular disease, and autologous RPE equatorial RPE-choroid patch graft and full 
macular translocation in neovascular macular disease are described below. 
 
3.1.2.1 Autologous equatorial RPE-choroid patch graft in atrophic macular disease 
For atrophic macular disease, the technique is similar to that described by van Meurs 
and van den Biesen (2003) for neovascular AMD with the exception of the need to 
removal of CNV. All 9 patch grafts were carried out by Mr L. Da Cruz of Moorfields 
Eye Hospital.  
A 3 port pars plana vitrectomy was performed followed by macular detachment 
through 1 or more punctuate retinotomies. Endodiathermy was applied to delineate a 3- 
to 4-mm circular region in the superior equatorial retina, which was subsequently cut 
out as a full-thickness RPE-choroid patch graft after removal of the overlying sensory 
retina by peeling (see Figure 3.1). The graft was gripped on the choroidal surface with a 
customised aspirating cannula designed by van Meurs (DORC Surgical Instruments, 
Zuidland, The Netherlands). A 5-ml syringe attached to the end of the cannula was used 
to create a sufficiently strong vacuum aspiration force to hold the graft. The graft was 
slid through the macular retinotomy into the subfoveal space. Gentle reflux of the 
syringe released the graft once in position. A 3- to 4-mm diameter perfluoro-n-carbon 
heavy liquid bubble (Perfluoron, Alcon Laboratories Inc., Fort Worth, Texas, USA) was 
used to hold the graft during 2 to 4 further manipulations to ensure the graft unfolds 
correctly at a subfoveal position. Retinopexy was not applied to the macular retinotomy 
and the eye was filled with 1300 centi-stoke silicone oil (Oxane, Bausch and Lomb, 
Rochester, U.S.A.).  
 
 
Figure 3.1 Autologous RPE-choroid patch graft in atrophic disease  
Following pars plana vitrectomy, (A) the macular is detached (blue arrow) using a 
subretinal cannula. (C) The superior equatorial region is marked by endodiathermy and 
(D) full-thickness retina-choroid patch is cut out using a segmentation scissors (white 
arrow head). (E) The patch is loaded onto a specialised aspiration-reflux spatula (white 
arrow) and (E) the surplus retina (yellow arrow) is peeled and discarded. The RPE-
choroid patch graft has a tendency to curl around the spatula due to its elasticity. (F) 
The patch graft (green arrow) is then inserted through an enlarged retinotomy into the 
submacular space.  
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After a minimum of 2 months, patients underwent phacoemulsification cataract 
surgery combined with silicone oil removal, performed by Mr L. Da Cruz, the author or 
one of the vitreoretinal fellows at Moorfields Eye Hospital. 
 
3.1.2.2 Autologous equatorial RPE-choroid patch graft in neovascular macular disease 
For neovascular disease, the surgical technique of patch graft was similar to that 
described by van Meurs and Van Den Biesen (2003). Of the 12 patch grafts, 3 were 
performed by Mr G. W. Aylward and 9 were performed by Mr L. Da Cruz.  
Briefly, after a complete 3 port pars plana vitrectomy, a superior equatorial 
donor site was chosen and delineated with contiguous argon laser photocoagulation. The 
CNV was removed through a superonasal or superotemporal macular retinotomy. The 
graft was cut out with vertical scissors and the overlying retina peeled with forceps. 
Using a custom made aspirating-reflux spatula (DORC, Netherlands), the graft was 
inserted into the submacular space and manipulated to a subfoveal location. The bleb 
retinal detachment was then flattened with perfluoro-n-octane heavy liquid (Perfluoron, 
Alcon Laboratories Inc., Fort Worth, Texas, USA) and exchanged for silicone oil.  
After a minimum of 2 months, patients underwent phacoemulsification cataract 
surgery combined with silicone oil removal. These were performed by Mr L. Da Cruz, 
Mr G. W. Aylward or one of the vitreoretinal fellows at Moorfields Eye Hospital. 
 
3.1.2.3 Full macular translocation in neovascular macular disease 
For macular translocation in neovascular AMD, the surgical technique was similar to 
that described previously (Eckardt et al. 1999; Toth and Freedman 2001). All 
translocations were performed by a single surgeon (Mr L. Da Cruz, Moorfields Eye 
Hospital).  
A phacoemulsification with intraocular lens (IOL) implant was performed; 
followed by vitrectomy, detachment of the posterior hyaloid and vitreous base shaving. 
Retinal detachment was induced using a flexible dual bore 41-gauge cannula 
(1270.0.100, Synergetics, St Louis, Missouri, USA) and extended to total detachment 
by 2 or 3 air-fluid exchanges. After creating a 360º retinotomy with the vitreous cutter, 
the temporal retina was flapped over the disc nasally, using Eckardt’s ring-end forceps 
(1286-QM, DORC, Netherlands) to allow removal of the CNV and any subretinal 
blood. A small bubble of perfluoro-n-octane heavy liquid (Perfluoron, Alcon 
Laboratories Inc., Fort Worth, Texas, USA) was then placed onto the disc to flatten the 
posterior pole. The Tano stiff diamond dusted membrane scraper (20.07. Synergetics, St 
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Louis, Missouri, USA) was used to grip the retinal surface and rotate the fovea away 
from the RPE defect. The entire vitreous cavity was filled with perfluorocarbon liquid 
followed by 360º endolaser retinopexy. The perfuorocarbon liquid was then directly 
exchanged for silicone, using a technique similar to that described by Li and Wong 
(2007).  
Two months after translocation. Counter-rotation surgery was performed (Mr J. 
Lee or J. Acheson, Moorfields Eye Hospital) in combination with removal of silicone 
oil (Vitreoretinal Fellow, including myself in some cases) if the retina was flat. Counter-
rotation involved 3 or 4 muscles depending on the angle of incyclotorsion. For excyclo-
rotation of the globe, the superior oblique was disinserted, the medial rectus was 
repositioned inferiorly, the inferior oblique was advanced to the superior edge of lateral 
rectus and the lateral rectus was repositioned superiorly.  
 
3.1.2.4 Management of post-operative complications and follow-up schedule 
Re-operation including repair of retinal detachment, removal of residual silicone oil, 
surgical iridotomy for pupil block and cataract extraction were performed by Mr L. Da 
Cruz. Proliferative vitreoretinopathy with retinal break was treated by membrane 
peeling, with or without retinectomy and gas or oil tamponade (Mr Lyndon Da Cruz).  
Intravitreal injections of anti-VEGF agents or steroid for treatment of macular oedema 
or recurrent CNV were performed by the retina fellows at Moorfields Eye Hospital. 
For both the prospective and retrospective studies, all patients had a 6 and 12 
month evaluation. The primary endpoint was at 6 months. Thereafter, patients were 
routinely followed 4 to 6 monthly. The 6 to 12 month outcomes have been published 
previously for the first 27 and 12 patients who underwent full macular translocation and 
RPE-choroid patch graft for neovascular AMD, respectively (MacLaren et al. 2007; 
Uppal et al. 2007).  
 
3.1.3 Outcome measures and follow-up schedule 
 
3.1.3.1 Atrophic macular disease study 
For the prospective trials, the primary outcome measure was surgical feasibility, i.e. 
the proportion of patients in whom submacular placement of the autologous RPE-
choroid graft was achieved.  Secondary outcome measures were intra-operative and 
post-operative complication rates, and macular function and structure.  
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Post-operative complication was assessed on slit-lamp examination including 
applanation tonometry and fundus biomicroscopy. Any pathology detected was further 
investigated and documented with various imaging modalities (see below). 
Functional outcomes were measured using 3 types of clinical tests: 
psychophysical tests, electrophysiological recordings and questionnaires-based 
assessment (see Table 3.1). The main functional outcome measure was best-corrected 
distance VA. Other psychophysical measures included CS, reading ability and 
microperimetry (to provide information on fixation characteristics and retinal 
sensitivity). Objective assessment using electrophysiological techniques included full-
field ERG, pattern ERG and multifocal ERG. Questionnaire used in the pilot study 
assessed visual function or general health related quality of life.  
Detailed macular structure assessments were based on OCT scans, fundus AF 
image, and fundus photographs and angiographies in addition to fundus biomicroscopy. 
These imaging modalities complement fundus examination to provide further 
information on the status of outer retinal structures (in particular, outer nuclear layers 
and photoreceptor inner and outer segments), the presence of RPE and choroidal 
perfusion (see Table 3.2). 
For the two clinical trials, functional and structural outcomes were assessed at 
baseline and again at 6 months post-operatively. If silicone oil was still in-situ at 6 
months, formal assessment was delayed until 3 months after removal of oil. Quality of 
life questionnaire was administered at baseline and repeated after 12 months 
postoperatively. 
 
Table 3.1 Functional outcome measures in atrophic macular disease study 
Psychophysical tests Electrophysiological tests QOL Questionnaires 
Letter chart 
     Visual acuity 
     Contrast sensitivity 
     Reading ability 
Microperimetry 
     Fixation locus 
     Fixation stability 
     Retinal sensitivitiy 
Macular responses 
     Pattern ERG 
     Multifocal ERG 
Global retinal responses 
     Full-field ERG 
Visual function-related 




     RAND 36-Item Health 
SurveyTM   
ERG; electroretinogram, RAND; Research and Development Corporation, QOL; quality of life 
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Table 3.2 Structural outcome measures in atrophic macular disease study 
Photoreceptor cells Retinal pigment epithelium Choroidal and retinal 
vasculature and perfusion 
Optical coherence tomography  
(OPL, ONL, and HRB) 
Fundus examination 
Fundus autofluorescence 
Optical coherence tomography 
(HRB) 
Fundus biomicroscopy 
Indocyanine green angiography 
 Fluorescein angiography 
 
HRB; highly reflective band, ONL; outer nuclear layer, OPL; outer plexiform layer 
 
3.1.3.2 Neovascular macular disease study 
For the retrospective studies, the primary outcome measure was the mean change in 
VA of the operated eye from pre-operative to the most recent follow-up visit. 
Secondary outcome measures included the proportions of patients who gained 3 lines 
of VA (0.3 logMAR) or more, the median VA and proportions of patients who achieved 
a VA (logMAR) of 0.30, 0.70 or 1.00 or better (Snellen VA of 6/12, 6/30 or 6/60 or 
better) at the 1 year and the most recent visits.  
Exploratory analyses were also conducted in a subset of patients to identify the 
causes of delayed visual loss and examine structure-function correlation in detail. These 
include:  
 
1. The rate and causes of visual loss (> 0.2 logMAR decline in VA) after 1 year in 
those patients who achieved a VA of 1.00 logMAR or better.  
2. The change in fixation stability and retinal sensitivity on serial microperimetry 
in the subset of patients with good VA outcomes or fixation on the patch graft. 
The retinal sensitivity change was examined in conjunction with features on 
serial fundus AF and OCT images.  
3. A comparison of the difference in the change in VA at 1, 2 3 and 4 years 
between the first 12 patients from the macular translocation cohort and the 12 
patients from the autologous RPE-choroid graft cohorts, respectively. 
4. A comparison of microperimetry and macular AF from the 3 best cases (those 
with the best VA) of the 12 patients in each cohort as described above. 
 
For structural outcome, all pre- and post-operative clinical documentation, 
fundus photographs, fundus angiographies, OCT and fundus AF images were reviewed 
to determine the occurrence of postoperative complications such as retinal detachment, 
intraocular haemorrhage, macular oedema, recurrent CNV and RPE atrophy.  
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3.1.4 Visual acuity and contrast sensitivity tests 
All patients underwent refraction by optometrists at Moorfields Eye Hospital. Refracted 
VA and CS were measured by either the author or one of the hospital optometrists. 
Best-corrected distance VA was measured using a standardised protocol on the back 
illuminated ETDRS charts 1 and 2 (Lighthouse Low Vision Product, New York, NY, 
USA) for right and left eyes, respectively, starting at 4 metres (Ferris, III et al. 1982). 
The charts were mounted on a light box with an average luminance of 150 cd/m2. With 
the appropriate refractive correction in place for the study eye and occlusion of the 
fellow eye, the patient was instructed to read from the top of the chart and stopped only 
if 4 or more mistakes were made in a line. If less than 15 letters were read at 4 metres, 
the patient was moved forward to read at 1 metre from the chart after adding +0.75 D to 
the spherical prescription. The patient was stopped from read further when 6 lines were 
read at 1 metre. To calculate the letter score at 1 metre, 30 was added to the number of 
letters read at 4 meters. However, if less than 15 letters were read at 4 meters, letter 
scores from 4 metres was added the letter score from 1 metre (stopping at 6 lines). 
Table 3.3 shows how letter score was converted to the logMAR unit (Holladay 2004). 
For patients who could not see any letter from 1 metre, but could only count fingers or 
only perceive hand motions at 30 cm, VA was assigned 1.98 or 2.28 logMAR 
respectively as recommended by Lange and colleagues (2009).  
CS was measured using a standardised protocol on the wall mounted Pelli-
Robson contrast sensitivity charts (Clement Clarke Inc., Columbia, OH, USA) at 1 
metre with chart luminance of 80-120 cd/m2 (Pelli et al. 1988). The right eye was tested 
followed by the left eye on charts 1 and 2 respectively with +0.75D added to the 
spherical prescription. The patient was asked to name each letter on the chart starting 
with the high contrast letters on the upper left-hand corner. The test was stopped when 
the patient failed to correctly identify 2 or more letters correctly in a triplet. The letter-
by-letter scoring was used to minimise test-retest variability (Elliott et al. 1990). Letter 
score was converted to logCS by assigning 0.05 logCS to each letter read except for the 
first line.  
For retrospectively studies, some of the VA measurements were performed on 
the Snellen chart from 6 metres in the vitreoretinal clinic. Snellen VA fractions were 
converted to their equivalent measures in logMAR (see Table 3.3). 
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Table 3.3 Conversion between Snellen fraction and logMAR 
ETDRS Letters at 1 metre Snellen Fractions at 6 metres logMAR 
85 6/6 0.00 
76 6/9 0.18 
70 6/12 0.30 
61 6/18 0.48 
55 6/24 0.60 
46 6/36 0.78 
35 6/60 1.00 
20 3/60 1.30 
11 2/60 1.48 
0 1/60 1.80 
0 CF 1.98* 
0 HM 2.28* 
CF; counting fingers at 2 feet, ETDRS; early treatment for diabetic retinopathy study, HM; hand 
motions, logMAR; logarithim of minimum angle of resolution, NPL; no perception of light.  
*LogMAR equivalents for counting finger vision and hand motion perception were based on the 
results from the study by Lange et al. (2009) 
 
3.1.5 Reading ability test 
Reading ability was measured using the MNRead acuity charts (Lighthouse Low Vision 
Product, USA) at 25 centimetres (Legge et al. 1989). All reading tests were carried out 
by the author. The patient wore distance correction with a +4.00 D added to the trial 
frame and occluder to the fellow eye. Testing was performed in a well lit room with 
chart luminance of 100 cd/m2 and the patient seated. Patients were instructed to read the 
sentence aloud as each sentence was uncovered. A stop watch was used to record the 
time taken to read each sentence. Words which were read incorrectly were marked. RA 
is a measure of the smallest print that can be read. The following formula (3.1) was used 
to calculate RA when the chart was read from 25 cm: 
 
 RA = 1.6 – (sentences x 0.1) + (errors x 0.01) (3.1) 
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Reading rate increases as the print size increase from RA (Legge et al. 1985a; Legge et 
al. 1985b). However, when the critical print size (CPS) is reached, the reading rate 
remains constant at around the maximum reading speed (MRS).  The reading speed 
(RS) in words per minute for each sentence can be calculated from the formula (3.2):  
 
 RS = 60 x (10 – errors) / (time in seconds) (3.2) 
 
In the presence of a plateau of RS, the MRS is defined as the mean of 3 highest reading 
speeds at the plateau and CPS is defined as the smallest print size that supports at least 
90% of the MRS.  
 
3.1.6 Microperimetry 
Microperimetry and fixation test were performed by the author using the Nidek MP 1 
(NAVIS software version 1.7.2; Nidek Technologies, Padova, Italy) microperimeter 
(Midena et al. 2004). This technique allows quantitative and qualitative assessments of 
retinal sensitivity and fixation characteristics and examination of their relationships with 
specific fundus structures. It is, therefore, a subjective test of retinal function but also 
allows direct structure-function correlation. 
The Nidek MP 1 allows the operator to view the fundus on the computer 
monitor as it is imaged in real time by an infrared (IR) fundus camera (768 x 576 pixels 
resolution; 45° field of view). Fixation target and stimuli are projected on to a liquid 
crystal display within the instrument for the subject to see. The operator can also view 
the stimulus and fixation target as part of the retinal image on the computer monitor. 
Background luminance is set on 4 apostilb (1.27 cd/m2). Stimulus intensity may be 
varied in 1 dB (0.1 log) step scale from 0 to 20, where 0 dB represents the brightest 
luminance of 400 apostilb (127 cd/m2). MP1 also provides an automated tracking 
system to compensate for any eye movement.  
At the beginning of each examination, an infrared retinal image is captured and 
frozen to allow retinal areas with high contrast to be chosen for tracking. This reference 
landmark is tracked every 40 ms (25 Hz). The stimulus position on the display is then 
corrected according to the actual location of the fundus to allow sensitivity threshold 
testing at the same retinal locus during the microperimetry examination. A CCD colour 
camera within MP1 also enables acquisition of digital colour retinography (1392 x 1040 
pixels resolution; 45° field of view; Xenon flash) at the end of the examination. Both 
the microperimetry map and fixation scatter plot can be overlaid onto this colour fundus 
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image through automated or manual registration of two reference retinal landmarks. 
Fundus AF image, angiography and reconstructed en-face image from OCT scans can 
also be imported into the software for overlay of microperimetry data. 
Slit lamp examination, and fundus photography and angiography were avoided 
prior to microperimetry examination. In all patients, pupils were dilated with one drop 
each of tropicamide 1% and phenylephrine 2.5%. The non-tested eye was patched 
during the test and the room light was switched off to avoid glare. Fixation and retinal 
sensitivity testing procedures are outlined below. 
 
3.1.6.1 Fixation test 
In general, a red or white cross spanning 2º was used as the fixation target during 
fixation test. The patient was instructed to look for a cross target and remain looking at 
the centre of target while position of the fundus was tracked for 30 seconds. Fixation 
analysis considers three aspects: (1) stability, (2) eccentricity from the center of fovea 
and (3) number of preferred retinal locus.  
Stability can be quantified by calculation of the bivariate contour ellipse area 
(BCEA) as proposed by Steinman (1965) or by the proportion of fixation points within 
a set distance from the gravitational center of all fixation points as proposed by Fujii et 
al. (2003)  
The BCEA method is based on the assumption that eye movements during 
fixation generate a bivariate normal distribution in x and y axis (coronal plane). This 
area corresponds to a preset proportion of the region on retinal surface where the patient 
uses to fixate on the center of the target. Equation 3.3 is used to calculate the area: 
 
 BCEA = 2kπσHσv(1 – ρ 2)1/2 (3.3) 
 
where σH is the standard deviation of point location in the x axis, σv is the standard 
deviation of point location over the y axis and ρ is the product-moment correlation of 
these two position components. The constant, k, is related to the preset proportion of the 
retinal region used for fixation, P, by equation 3.4: 
 
 P = 1 – e-k (3.4) 
 
Similar to previous studies, fixation stability was calculated with P = 0.68 (k = 1.14). 
The BCEA is expressed in minarc2. Although global BCEA has been widely used, it 
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validity has been questioned due to non-Gaussian distribution of the fixation loci and 
closely located multiple PRL (Timberlake et al. 1982; Crossland et al. 2004b; Reinhard 
et al. 2007; Tarita-Nistor et al. 2008).  
The second method of quantifying fixation stability was originally described by 
Fujii et al. (2003); eyes with more than 75% of the fixation points located within the 2° 
diameter circle are classified as having stable fixation. If less than 75% of the fixation 
points are located within 2° diameter circle, but more than 75% of the fixation points 
are located within 4° diameter circle, they are classified as having relatively unstable 
fixation. If less than 75% of fixation points are located within 4° diameter circle, the 
fixation pattern is described as being unstable. 
In patients with macular scotoma involving the fovea, they adapt by using non-
foveal retina for fixation and reading. This alternative eccentric position on the retina is 
called preferred retinal locus or PRL (Timberlake et al. 1987). A classification of 
eccentricity of PRL (also used by Nidek MP1) is one that has been described by Fujii et 
al. (2003) Predominantly central fixation is defined by more than 50% of fixation points 
within the 2º diameter centered at the fovea. Eyes with poor central fixation had more 
than 25% but less than 50% of the fixation points within the central 2º diameter whereas 
those with predominant eccentric fixation had less than 25% of the preferred fixation 
within the same region. The location of fovea is often difficult to identify. However, 
using spectral domain OCT and fundus overlay, the centre of fovea can be estimated 
based on the surface contour and internal retinal structures of the OCT scan and then 
marked on the colour fundus image. Once this image is imported into the NAVIS 
software and registered with the fixation map, the eccentricity of PRL can be classified. 
Change in location of PRL can be measured by comparing the fixation map 
across visits using the onboard NAVIS software. PRL may shift due to disease 
progression, natural adaptation or fixation training (Crossland et al. 2005a; Deruaz et al. 
2006; Tarita-Nistor et al. 2008). Many patients develop more than 1 PRL used for 
different lighting conditions, target size, visual tasks and other unknown factors (Lei 
and Schuchard 1997; Duret et al. 1999; Crossland et al. 2004b; 2005a; Reinhard et al. 
2007; Sullivan et al. 2008). PRLs which are far from each other can be seen readily on 
the fixation scatter plot.   
 
3.1.6.2 Retinal sensitivity test 
For microperimetry, 4-2 strategy was used as recommended by Convento and Barbaro 
(2007) to reduce testing time. The stimulus size was set at either Goldman III (area of 4 
 Page 94  
 
mm2, diameter of 26 min arc or 0.4 degrees) or V (area of 64 mm2, diameter of 104 min 
arc or 1.6 degrees) and the duration at 200 ms. Two types of test grids were used. To 
test retinal sensitivity over the graft specifically, the polygon setting was chosen to 
allow manual selection of the test region and density of the test grid. To measure the 
overall macular function, standardised test grids covering the central 20º were used; 
either the 68-loci grid similar to the 10-2 program of Humphrey automated perimeter or 
the 76-loci grid (macula 20º) available with the software. The “activate pre-test” and 
“eccentric pattern” options were selected to enable appropriate starting threshold as 
determined by 4 pre-selected test loci in each quadrant and manual centering of the 
testing grid. In eyes with unstable and eccentric fixation, the algorithm recommended by 
Sunness et al., was used for predicting the location of foveal center (1999a). The 
refinement and recheck option were not used.  
The Nidek MP1 onboard software provides an analysis output after the operator 
determines the location of the fovea (see Figure 3.2). Absolute retinal sensitivity is 
displayed for the individual 68 test loci and as an average for the central 20º; mean or 
macular sensitivity. The software also compares the absolute sensitivity to a normative 
database derived from 180 healthy volunteers stratified into 6 age groups to calculate 
the deviation (in dB) from normal (Convento and Barbaro 2007). The local deviation 
from normal is shown in the local defect map and the average deviation for the central 
20º, mean or macular deviation is also displayed. Loci with sensitivity within 2 standard 
deviations (SD) were classified as normal. Those between 2 and 3 SD, between 3 SD 
and 0 dB seen, and 0 dB not seen, were categorised as ‘suspect’, ‘relative scotoma’ and 
‘dense scotoma’ respectively. The local defect map also provides colour-coded 




Figure 3.2 Normal microperimetry examination printout 
This is a normal microperimetry in a 31 year old subject. The printout displays (A) the 
retinal sensitivity map, (B) the local defect map, (C) the mean sensitivity and mean 
defect in decibel (dB), (D) the colour coded sensitivity map, (E) summary statistics of 
fixation performance during microperimetry, (F) fixation loci plot in relation to fundus 
image, (G) fixation loci plot in relation to gravitational centre of all loci and (H) 
graphical display of fixation stability. 
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3.1.7 Electrophysiology 
The electroretinogram (ERG) waveforms are generated by the retina in response to a 
light stimulus. The various types of ERG responses are determined by the vector 
summation of the electrical currents, arising from synaptic junctions and ion channels of 
the photoreceptor cells, the various neuronal cells and the Műller cells, relative to the 
position of the recording electrodes. The ERG, therefore, allows objective measurement 
of various aspects of retinal function. 
Electrophysiological testing was performed by the department of 
electrophysiology at Moorfields Eye Hospital. Results were interpreted by Professor 
Graham Holder, Dr Anthony Robson and Dr Magella Neveu from the same department. 
The pattern ERG (PERG), multifocal ERG (mfERG) and full-field ERG were recorded 
under conditions which incorporated the international standards and guidelines 
published by the International Society of Clinical Electrophysiology of Vision (ISCEV) 
(Bach et al. 2000; Marmor et al. 2003; Marmor et al. 2004; Holder et al. 2007; Hood et 
al. 2008). First, the PERG was recorded with the patient optimally refracted. The 
patient’s eyes were then dilated for the recording of the full-field and multifocal ERGs. 
The responses were recorded binocularly using gold foil corneal electrodes referenced 
to surface electrodes at the ipsilateral outer canthi. The ground electrode was positioned 
on the forehead.  
 
3.1.7.1 Pattern ERG 
The PERG response is recorded to a reversing black and white checkerboard pattern 
stimulus. This is projected onto central retina without net change in stimulus luminance 
(see Figure 3.3A). PERG is clinically useful to objectively (1) distinguish optic nerve 
from macular dysfunction and (2) detect and quantify the severity of macular 
involvement in generalised retinal dysfunction (Holder 2001).  
The PERG was evoked by a high contrast checkerboard reversal pattern (check 
size of 45 minarc) covering a field of 15° x 11°, at a rate of 4.5 reversals per second, 
with 98% contrast and a mean luminance of > 80 cd/m2. The amplifier gain was set to 
200 x 103 and band pass filtered (1-100 Hz). The patient was asked to fixate on a red 
central fixation target and fixation was monitored using CCTV (closed circuit 
television). The PERG waveform was analysed in terms of the amplitude of the P50 and 
N95 components and the latency of the P50 component. The P50 component was of 
particular interest in assessment of patients receiving RPE transplant as it is partly 
driven by elements distal to the ganglion cells (Holder 2001). 
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3.1.7.2 Full-field ERG 
The full-field ERG is a mass response of the retina to a lumance stimulus. Under dark 
adapted (scotopic) condition, a bright flash stimulus generates an ERG waveform which 
consists of an early negative wave (the a-wave) which is largely generated from the rod 
photoreceptor cells (Breton et al. 1994; Hood and Birch 1993b) and a later but larger 
positive wave (the b-wave) which arises from post-phototransduction activity (Knapp 
and Schiller 1984). A dim flash stimulus in scotopic condition generates the “rod 
specific ERG” which screens for rod system dysfunction (see Figure 3.3B). A bright 
flash stimulus is required to generate the “bright flash ERG” which consists of an a-
wave and a b-wave and this measures function of the photoreceptor cells (a-wave) and 
inner retina (b-wave). Under light adapted (photopic) conditions the rod system is 
suppressed and cone system function is assessed using a 30 Hz flicker stimulus (30 Hz 
flicker ERG) and a 2 Hz stimulus (single flash photopic ERG). These ERG responses 
are generated primarily by the ON- and OFF- bipolar cells (Bush and Sieving 1996). 
Similar to the bright flash ERG, the b-wave of the single flash photopic ERG is 
generated from the inner retina (Heynen and van Norren 1985; Bush and Sieving 1994). 
However, the a-wave component of the bright flash ERG has a small contribution from 
the cone photoreceptor cells as well as the cone OFF-bipolar cells (Bush and Sieving 
1994; Hood and Birch 1993a).  
For full-field ERG testing, the patients’ pupils were dilated with phenylephrine 
2.5% and tropicamide 1% and the patient was dark adapted for 20 minutes. An extended 
ERG protocol was recorded which incorporated the ISCEV standards: (1) the rod-
specific ERG response to a dim white flash, (2) the bright flash ERG response to a 
standard white flash, and after 10 minutes of light adaptation to a rod-suppressing 
background illumination, (3) the 30Hz flicker ERG and (4) the single flash photopic 
ERG. At Moorfields Eye Hospital, responses to flash intensities other than those 
specified by ISCEV standards were also recorded (see Table 3.4). The amplifier gain 
was set to 2 x 103 or 5 x 103 and band pass filtered (0.5 to 3,000 Hz). The sampling 
interval was 0.5 ms and analysis time was 200 ms (100 ms for photopic ERGs). The 
patient was asked to look straight ahead, refrain from blinking and keep their lids wide 
open. The ERG components were analysed in terms of the amplitudes of the a-wave and 
b-wave as well as the implicit time of these components measured from the onset of the 
flash.  
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Full-field ERG was performed to detect subclinical pathology in the peripheral 
and equatorial retina. To ensure that autologous equatorial RPE is relatively healthy, we 
excluded patients with severe generalised retinal dysfunction. Furthermore, the ERG is 
used to objectively assess the effects of surgery on cone and rod system function in 




Table 3.4 Summary of electrophysiological testing protocol 






Dark adapt for 20 minutes 
  1 white 0.0010 2 
  2 white 0.0022 2 
Rod response 3 white 0.0120 5 
  4 red 0.20 2 
  5 red 0.30 2 
  6 white 0.14 10 
  7 white 0.50 10 
  8 white 1.30 10 
Maximal 9 white 3.00 15 
  10 white 4.43 15 
Bright flash 11 white 11.5 20 
Light adapt for 10 minutes 
(background light at 25 cd/m2) 
Cone flicker 12 white 3.0  
Single flash 13 white 3.0  
cd; candela, ERG; electroretinography, ISCEV; International Society of Clinical 
Electrophysiology of Vision, m; metre, s; second 
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3.1.7.3 Multifocal ERG 
The mfERG is an array of localised cone-driven ERG signals that are recorded under 
photopic conditions (see Figure 3.3C). The responses are a mathematical extraction of 
local signals derived from the correlation between a pseudo-random sequence of 
flashing hexagonal elements (see Figure 3.3C) and the continuous ERG response 
recorded at the cornea (Sutter and Tran 1992). Although the waveform of the mfERG 
response (first-order kernel) resembles the conventional ERG, the peaks are designated 
by n1 and p1 instead of the a-wave and b-wave (Hood et al. 2008).    
The mfERG was recorded and analysed using the RETIscan System version 3.1 
(Roland Consult, Wiesbaden, Germany) with the patient fully dilated and a +3.00 D 
lens was added to the patient’s refraction (if present) for recording. The stimulus used 
consisted of an array of 61 flashing hexagons, displayed on a computer monitor, 
covering a visual field of 56.9°, at a viewing distance of 33 cm. Patients were asked to 
fixate on the centre of a large cross-hair fixation target which was centred on the central 
hexagon. Patients who could not see the fixation target clearly were asked to maintain 
fixation on the assumed centre of the cross-hair. Patient fixation was monitored by 
direct observation. The stimulus-distortion factor was set to 4 to compensate for 
differences in cone density across the retina, from centre to periphery. The amplifier 
gain was set to 100 x 103 or 200 x 103, and band-pass filtered (5–300 Hz). Eight trials 
were recorded for each mfERG session, and the average recording time for each trial 
was between 1 and 2 minutes. The total duration of a recording session was 
approximately 20 minutes or less. These techniques are similar to those used in previous 
studies (Bellmann et al. 2004; Neveu et al. 2006). Quantitative analyses were performed 
with the RETIscan system software. The n1 and p1 components of the first-order 
kernels were considered for mfERG evaluation (Hood and Zhang 2000). The 61 local 
mfERG responses were grouped into 5 concentric ring groups (see Figure 3.3E) of 
equal eccentricity centred on the fovea. These groups were defined as follows: ring 1 
(central hexagon), from 0° to 2.1° eccentricity; ring 2, from 1.4° to 6.7° eccentricity; 
ring 3, from 5.7° to 12.0° eccentricity; ring 4, from 9.5° to 19.8° eccentricity; ring 5, 
from 15.1° to 28.5° eccentricity. For each ring group, the traces were averaged and the 
peak amplitude and the implicit time of p1 and n1 from each ring were analysed. 
Results of peak amplitude and implicit time were compared with normative values 
ranging between the 5th and the 95th percentiles. Information gained from mfERG was 
used to complement microperimetry results by objectively quantifying retinal function 
rescue in RPE transplantation. 
 
 
Figure 3.3 Normal PERG, full-field ERG and mfERG waveforms.  
Schematic diagrams of (A) pattern electroretinography (PERG) and bright flash ERG 
waveforms. PERG response consists of the P50 and N95. The P50 is generated from 
both the ganglion cells and cells distal to them in the central retina whereas the N95 is 
predominantly generated from the ganglion cells. The bright flash ERG response 
consists of the a-wave and b-wave. The a-wave is generated from photoreceptor cells 
and the b-wave is generated in the inner retina. (B) Composite of waveforms showing 
PERG and 4 types of full-field ERG recordings as recommend by the International 
Society of Clinical Electrophysiology of Vision (ISCEV). Under scotopic condition, the 
rod specific and bright flash ERG are recorded and under photopic conditions, the 30Hz 
flicker and single flash ERGs are recorded. (C) The mfERG stimulus pattern with 61 
white and black elements. (D) First-order kernels were extracted for each locus. (E) The 
5 concentric ring groups used for analysis. The n1 and p1 waves are cone pathway 
responses. The peak amplitude and the peak times are analysed for each ring group. 
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3.1.8 Quality of life questionnaire 
To provide additional information on outcomes of surgical intervention, patients’ 
perception of quality of vision (QOV) and health-related QOL were also assessed using 
the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) and 
the RAND 36-Item Health Survey (version 1.0). Both of these were administered by the 
author or the research co-ordinator, before and approximately 1 year after surgery. 
The NEI VFQ-25, a vision-targeted measure of QOL, consists of 25 of the 51 
questions in the previous longer version of the questionnaire (Mangione et al. 1998; 
Mangione et al. 2001). The answer for each item was converted to a score ranging from 
0 to 100 and the scores from item(s) that contribute to each of the 12 subscales were 
averaged to give the subscale scores. These 12 subscales can be grouped into 3 
categories. The first category is a general health subscale (1 item) that was not used 
because the RAND 36-Item Health Survey was also administered to all patients. The 
second category contains 5 subscales that address patients’ perception of their QOV, 
including (1) general vision (1 item), (2) difficulty with distance tasks (3 items), (3) 
difficulty with near tasks (3 items), (4) peripheral vision (1 item), and (5) colour vision 
(1 item) subscales. The remaining 6 subscales; (1) dependency (3 items), (2) role 
limitations (2 items), (3) mental health (4 items), (4) social function (2 items), (5) 
driving (2 items), and (6) ocular pain (2 items) subscales are incorporated into the third 
category which assess patients’ perception of vision specific QOL. Reliability and 
validity of the NEI VFQ-25 has been reported (Mangione et al. 2001).  
The RAND 36-Item Health Survey (version 1.0), a measure of general health 
QOL, consists of the 36 questions identical to the Medical Outcome Study 36-Item 
Short-Form Health Survey (Ware, Jr. and Sherbourne 1992) but has a different scoring 
method (Hays et al. 1993). The answer for each item was converted to a score ranging 
from 0 to 100 and the scores from items that contribute to each of the 8 subscales were 
averaged to give the subscale scores. These 8 subscales are: (1) physical functioning (10 
items), (2) role limitations due to physical health (4 items), (3) role limitations due to 
emotional problems (3 items), (4) energy/fatigue (4 items), (5) emotional well-being (5 
items), (6) social function (2 items),  (7) pain (2 items), and (8) general health (5 items). 
Included in the questions is also a single item that provides indication of patient’s 
perception of change in health during the previous 12 months. Reliability and validity of 
the RAND 36-Item Health Survey has been reported (Bousquet et al. 1994). 
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3.1.9 Fundus confocal scanning laser ophthalmoscopy 
Fundus AF was captured by using a scanning laser ophthalmoscope – the Heidelberg 
Retina Angiograph II (HRA II) or the Spectralis OCT+HRA (Heidelberg Engineering 
GmbH, Dossenheim, Germany). These were performed by the author or one of the 
medical photographers at Moorfields Eye Hospital. A series of 5 to 15 images over a 
30º or 45º fields were acquired and then aligned and averaged with the image analysis 
software provided with HRA II (Heidelberg Eye Explorer, Heidelberg Engineering 
GmbH, Dossenheim, Germany). Fundus AF images were descriptively analysed for 
distribution, pattern and intensity of AF signals in the macular region. Low and high AF 
signals were interpreted in conjunction with clinical features and findings on OCT and 
fundus angiography (Schmitz-Valckenberg et al. 2008). A normal AF image is shown in 
Figure 3.4. Note the lack of AF signal over the disc and blocking of AF signals by 
haemoglobin within the retinal vasculature and macular xanthophylls at the foveal 
centre. 
 
3.1.10 Optical coherence tomography 
Both time- and spectral-domain optical coherence tomography (OCT) were used 
during the course of the studies (see Figure 3.4). These were performed by the author or 
one the medical photographers at Moorfields Eye Hospital. For the time-domain Stratus 
OCT™, software version 4.0 (Carl Zeiss Meditec, Inc., Dublin, CA, USA), the 6 radial-
line scan protocol was used to obtain 6 mm B-scans consisting of 512 A scans each, 
centred at the fovea. Three types of spectral-domain OCT instruments were used during 
the study. For SOCT Copernicus, software version 1.35 (Optopol Technology Sp. z o.o., 
Zawiercie, Poland), a raster-line scan protocol was used to cover an area of 6 x 6 mm 
(120 x 530 axial scans, vertical x horizontal). For Topcon 3D-OCT 1000, software 
version 2.12 (Topcon, Tokyo, Japan), a raster-line scan protocol was also used to cover 
an area of 6 x 6 mm (512 x 126 axial scans, vertical x horizontal). Centre point foveal 
thickness was measured manually using the caliper provided by the on-board software. 
A subset of patients also had simultaneous fundus AF imaging and SD-OCT scanning 
using Spectralis®. Integrated eye tracking capability (TruTrack™) within the 
Spectralis® enables pixel to pixel registration between the fundus AF image and the 
SD-OCT line-scan that was acquired simultaneously. To enhance signal to noise ratio, 
30 to 100 single-line OCT frames were averaged during simultaneous fundus AF and 
SD-OCT imaging. In each eye, several OCT line-scans through separate regions with 
increased AF were obtained to examine the retinal architectural correlates to regions of 
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abnormal AF signals. The 3 highly reflective bands (see Figure 3.4) in the outer retina 
were interpreted as suggested by Drexler and colleagues (2001; 2003) 
Presence of epiretinal membrane, intraretinal cysts, retinal thickening, retinal 
atrophy (loss of outer plexiform layer and the interface between inner and outer segment 
of the photoreceptor cell layer), subretinal fluid, RPE layer irregularity or thickening 
and full-thickness macular hole were recorded. 
 
3.1.11 Digital fundus photography and anigiography 
Digital colour photography, and fluorescein and indocyanine green (ICG) angiography 
(TRC-50 IA/IMAGEnet H1024 system, Topcon, Tokyo, Japan) were performed by the 
medical photographers at Moorfields Eye Hospital. Five ml of 2g/ml sodium fluorescein 
and 5 ml of 5mg/ml ICG were injected intravenously for fundus angiographies. Early 
fluorescein images were examined for choriocapillaris flush. Early ICG images were 
examined for intrinsic vascular pattern within the graft. Late ICG images were 
examined for leakage from choroidal polyps and/or associated branching vascular 
network. Baseline lesion characteristic and size in disc area were graded by an 
independent masked observer (Dr PJ Patel, Moorfields Eye Hospital) according to the 
MPS criteria (MPS Group 1991).  
 
 
Figure 3.4 Non-invasive fundus imaging  
(A) Colour fundus photograph, (B) Fundus autofluorescence image, (C) time domain 
optical coherence tomography (OCT) scan and (D) spectral domain OCT scan through 
the foveal centre (white arrows pointing towards the foveal dip) of the right eye of a 
healthy 32 year old subject. Reduced autofluorescence signal at the foveal centre 
(yellow arrow, B) is due to absoption of excitation light by the macular xanthophylls. 
The faint reflective line and the 3 highly reflective bands (bottom left insert) at the level 
of outer retina represent the external limiting membrane (ELM), the interface of inner 
and outer segment of photoreceptor layer (band 1), the interdigitation between the tips 
of the outer segments and the apical microvilli of the pigment epithelium (band 2) and 
the retinal pigment epithelium (band 3). Anterior to the ELM is the hyporeflective outer 
nuclear layer.  
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3.2 Animal experiment and design 
 
The pig was chosen as the recipient for RPE transplantation because the anatomy and 
physiology of the pig eye is similar to that of the human eye. The pig eye has a large 
vitreous cavity relative to the lens, thus allowing the use of modern vitrectomy surgical 
approach. The pig retina is holangiotic with a specialised region, area centralis, dorsal to 
the disc which is devoid of large blood vessels and contains high density of cones 
(Gerke Jr et al. 1995; Chandler et al. 1999). Furthermore, full-field and mfERG of the 
pig eye have been characterised (Rosolen et al. 1999; Kyhn M.V. et al. 2007) and the 
distribution of the 2 types of cones has been reported (Hendrickson and Hicks 2002). 
Recent works in porcine cell mediated immune system (Gerner et al. 2008; Piriou-
Guzylack and Salmon 2008) and pharmacology of cyclopsorine (Cibulskyte et al. 2005; 
2007a; 2007b) may also enhance our interpretation of the outcomes of subretinal 
xenotransplantation. The pathophysiological changes following bleb retinal detachment 
(Jackson et al. 2003; Lewis et al. 2005; Iandiev et al. 2006; Hollborn et al. 2008), RPE 
debridement (Del Priore et al. 1995; Kiilgaard et al. 2007) and choroidal 
neovascularisation (Kiilgaard et al. 2005; Lassota et al. 2006; 2007; 2008) in pigs have 
been studied extensively. The availability of porcine model of retinitis pigmentosa 
(Petters et al. 1997; Tso et al. 1997) will also facilitate proof of principal experiments of 
retinal cell replacement therapy in a large animal model.  
Seven to 9 week old female domestic pigs were used. The left eyes were 
operated and the right eyes served as controls with the exception of 1 pig which had 
bilateral surgery. A series of 4 experimentes were carried out as summarised in Table 
3.5.  
 
3.2.1 Home Office approval 
This study was reviewed and approved by the Animals (Scientific Procedures) 
Inspectorate of the UK Home Office Animals Scientific Procedures Division in 
November 2007 (565-07: cellular therapy for eye disease).  The abstract can be found 
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All procedures were performed by personal licence holders, in accordance with the 
Animals (Scientific Procedures) Act 1986.  
 
Table 3.5 Summary of pig experiments 




Purpose Dates of surgery 
1 3 Yes Surgical feasibility December, 13-14th 2007 
2 6 Yes/No Long term survival April, 3rd-4th 2008 
3 7 Yes/No Short term survival and 
immunology 
November, 12-13th 2008 
4 5 No Control study and 
immunology 
December, 4th 2008 
 
 
3.2.2 Human embryonic stem cell lines 
Once removed from cryopreservation, hESC line (Shef-1), from Sheffield University, 
was maintained for up to 74 passages with media changes every 2 days. This cell line 
was maintained in flasks coated with 0.1% gelatine and seeded with mitomycin C-
inactivated CF-1 mouse embryonic fibroblast (MEF) feeders as described previously 
(Draper and Andrews 2002). Cells were maintained in basic hESC medium: high 
glucose (4.8g/L) KnockOutTM Dulbecco’s modified Eagle’s medium (KnockOutTM D-
MEM, Invitrogen) with 20% KnockOutTM serum replacement (KnockOutTM SR, 
Invitrogen), 1% non-essential amino acid solution, 1mM L-Glutamine (Invitrogen), 
4ng/ml human bFGF (Invitrogen) and 0.1mM β-mercaptoethanol (Sigma). Cells were 
split regularly (1:4) in order to maintain colonies of undifferentiated hESCs, This was 
assessed by staining for stem cell markers such as the stage-specific embryonic 
antigens; globo-series glycolipids (SSEA-3 and SSEA-4) and the keratin sulphate-
related antigens (TRA-1-60 and TRA-1-81), as described previously (Adewumi et al. 
2007). Routine screening at the University of Sheffield confirmed the hESCs used in the 
present study (Shef-1) to be karyotypically normal (46, XY). Cell culture and feeding 
were performed by the senior research staff members at Professor Pete Coffey’s 
laboratory at the UCL Institute of Ophthalmology. 
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3.2.3 Derivation of RPE from hESC 
The generation of RPE from hESC has been described previously (Vugler et al. 2008) 
and was performed by the senior research staff members at Professor Pete Coffye’s 
laboratory at the UCL Institute of Ophthalmology.  
Briefly, hESC-RPE were reliably formed when hESC colonies were allowed to 
become superconfluent on a MEF density of 6 x 103 (experiment 1 and 2) or 9 
(experiment 3 and 4) x 103 per cm2. When the individual colonies grew to confluence 
(approximately 10 days post-passage) the medium was changed daily using basic hESC 
medium minus bFGF. After 1-2 weeks of the daily feeding regime, pigmented foci can 
be observed in the superconfluent hESC culture. These pigmented foci were excised 
mechanically using the tip of a glass Pasteur pipette and a microsurgical crescent blade. 
This approach was only possible when individual pigmented focus was greater than 1 
mm in size. During this procedure, the surrounding non-pigmented material was 
dissected away meticulously to avoid harvesting undifferentiated cells and thus risk of 
tumour formation. 
For the patch grafts used in pigs 2, 4, 5, 6, 7 and 8, the pigmented blob of cells 
were transferred onto the substrate directly as a “blob” for further expansion (see 
below). For pig 9, the pigmented cells were washed with dissociation solution 
containing trypsin and then re-seeded onto the substrate for further differentiation (see 
below). For the remaining 8 pigs (11 to 17 and 22), the pigmented cells isolated from 
the flask were placed in a culture dish coated with growth factor reduced Matrigel™ 
(BD Biosciences, diluted 1:30, coated at 37ºC for 30 minutes using 200 μl / cm2). A 
total of 10 pigmented foci were placed in each dish and the hESC-RPE was allowed to 
expand on Matrigel for up to 35 days (5 weeks) in basic hES cell medium minus bFGF 
(media changes every 2-3 days). These cells were also washed with dissociation 
solution containing trypsin and then re-seeded onto the substrate for further 
differentiation (see below). 
 
3.2.4 Creation of hESC-RPE monolayer on a substrate 
The artificial substrate for delivery of hESC-RPE as a monolayer is a type of polyester 
with pre-specified porosity and thickness. The substrate was first coated with growth 
factor reduced Matrigel™ (BD Biosciences, diluted 1:30, coated at 37ºC for 30 minutes 
using 200 μl / cm2). To avoid growth of hESC-RPE on both sides of the substrate, the 
polycarbonate membrane within the 6.5 mm Transwell® Insert (Corning®, Acton, MA, 
USA) was cut out and replaced by the substrate by gluing it onto the insert using a low 
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viscosity silicone elastomer sealant (Kwik-Cast™ & Kwik-Sil™, World Precision 
Instruments, Inc., FL. USA). The “blob” or dissociated hESC-RPE harvested from the 
flask (with MEF feeders) or the dish (coated with Matrigel™) was then re-seeded onto 
the substrate within the insert at a density of approximately 300 – 400 x 103 cells/cm2. 
After 4 weeks, these cells achieved full differentiation and were sufficiently adherent to 
the substrate for use in the porcine transplantation studies. The hESC-RPE monolayer 
on the substrate within the modified Transwell Insert was then transferred at 37ºC to the 
operating theatre on the day of surgery.  
 
3.2.5 Preoperative medication and anaesthesia 
All pigs were pre-medicated with intramuscular injection of 1.5 ml (1 mg/kg) of 
xylazine (Rompun, Bayer, UK), 1.5 ml (5 mg/kg) of ketamine (Vetalar; Parke Davis 
Ltd, Gwent, UK) and 4 mg/kg of carbrofen (Pfizer). Following endotracheal intubation, 
general anaesthesia was maintained by artificial ventilation with isoflurane 2.5 - 3% 
(Aerrane, Baxter Health Care Ltd, Berkshire, UK) in combination with 2L/min of NO2 
and 5L/min of oxygen. The stroke volume (400ml/stroke) and respiratory frequency 
(20/min) were kept constant during the experiment. Oxygen saturation, pulse rate and 
rectal temperature were monitored. Venous blood was then taken from the jugular vein 
prior under general anaesthesia. All drug administration and anaesthesia were 
performed by the research assistants or manager at the Northwick Park Institute of 
Medical Research (NPIMR). 
The pupil was dilated with 3 drops of 1% cyclopentolate and 3 drops of 2.5% 
phenylephrine (Minims™; Chauvin Pharmaceuticals Ltd, Romford, UK).  Prophylactic 
intramuscular ampicillin LA (Intervet UK Ltd, Milton Keynes, UK), 5.75 ml, was given 
prior to surgery. 
 
3.2.6 Surgical procedure 
The periorbital skin was cleaned with povidone iodine 10% (Videne, Ecolab Ltd, Leeds, 
UK) and a sterile drape (BD Visitec™ Visidrape™, Alcon Laboratories Inc., Fort 
Worth, Texas, USA) was placed around the surgical field. Lateral canthotomy was 
performed after clamping the lateral canthus with a straight artery forceps. Self retaining 
retractors were used as lid speculum. Localised peritomies and 3 sclerostomies at 2 mm 
from the limbus were made (see Figure 3.5). The pig underwent a three-port pars plana 
vitrectomy using the 20-gauge system (Accurus, Alcon Laboratories Inc., Fort Worth, 
Texas, USA) and an indirect wide-angle viewing sytem (Oculus BIOM 3m, Oculus 
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Optikgerate GmbH, Wetzlar, Germany). Posterior vitreous detachment was induced and 
extended up to the major retinal vessels. Then, a localised bleb retinal detachment was 
created by injecting compound sodium lactate (Hartmann’s solution, Baxtor Healthcare 
Ltd, Thetford, Norfolk, UK) under the nasal retina near the visual streak by using a dual 
bore 41-gauge cannula (1270.0.100, Synergetics, St Louis, Missouri, USA). The 
retinotomy was enlarged with disposable 20-gauge vertical scissors (707.25, DORC, 
Netherlands). The sclerostomy for delivery of the graft was also enlarged with the MVR 
blade whilst the graft was prepared.  
The hESC-RPE on the substrate was cut out from the insert and laid on a sterile 
surface ensuring the monolayer of cells was facing up. A customised membrane punch 
(see Figure 3.6) was then used to cut a 1 x 3 mm patch graft with rounded edges (see 
Figure 3.6). Under dissecting microscope, the graft was grasped along the long edge 
using disposable mini-end-grasping forceps (Alcon Grieshaber AG, Switzerland) ready 
for delivery. This was performed by Dr Ahmado, PhD student at Professor Peter 
Coffey’s laboratory. 
Prior to insertion of the graft into the eye, the infusion line was pinched to 
temporarily stop the outflow fluid jet stream through the sclerostomy while the graft 
was inserted into the eye. Once inside the globe, the graft was first engaged at the 
retinotomy and nudged into the subretinal space with the forceps (see Figure 3.5). Once 
the graft was stable within the bled detachment, fluid-to-air exchange was performed 
using disposable 20-gauage back-flush instrument (1281-AD, DORC, Netherlands) to 
aspirate the subretinal fluid and reattach the retina under air. The sclerostomies were 
closed with 7-0 coated polyglactin 910 sutures (Vicryl W 9561, Ethicon, Livinigton, 
Scotland, UK). One drop each of chloramphenicol 0.5% and atropine sulphate 1% 
(Minims™; Chauvin Pharmaceuticals Ltd, Romford, UK) one 1 cm of betamethasone 
eye ointment (Betnesol, UCB Pharma Ltd, Slough, UK) was applied to the conjunctival 
sac at the end. All surgical procedures were performed by Mr Lyndon Da Cruz and 
assisted by the author. Equipments and instruments required for vitrectomy surgery and 
wide-angle viewing system at NPIMR were partly arranged by the author. 
 
3.2.7 Postoperative care and termination  
Selected pigs (see chapter 7) were given oral cyclosporine (650 mg per day) 
starting 24 hours before surgical procedure. In these animals, oral immunosuppression 
with cyclosporine was given for a maximum of 2 weeks postoperatively. All pigs 
received topical dexamethasone 0.1% (Maxidex, Alcon Laboratories Inc., Fort Worth, 
Texas, USA) and chloramphenicol 0.5% (Minims™; Chauvin Pharmaceuticals Ltd, 
Romford, UK) 4 times a day and then tapered over 4 weeks. Cycloplegia was achieved 
with cyclopentolate 1 % (Minims™; Chauvin Pharmaceuticals Ltd, Romford, UK) 
twice a day for 1 week. All drops were administered by the staff at NPIMR and 
documented in a drug chart.  
 
Figure 3.5 Porcine pars plana vitrectomy and RPE patch transplantation 
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All pigs underwent postoperative examination by the author. The pigs were 
sedated with 1.5 ml (1 mg/kg) of xylazine (Rompun, Bayer, UK), 1.5 ml (5 mg/kg) of 
ketamine (Vetalar; Parke Davis Ltd, Gwent, UK) and isoflurane (2-3%) via a mask. At 
1 week, intraocular pressure was measured with an applanation tonometer (Tono-Pen® 
XL, Reichert, Inc. Depew, NY, USA). External eye and retina were examined using 
indirect fundoscopy (Heine Sigma 100, Heine Optotechnik, Herrsching, Germany) 
through a 20 D lens and dilated pupils under sedation.  
All pigs also had blood taken prior to termination at 2 days, 7 days, 14 days, 4 
weeks and 6 weeks. Following phlebotomy and examination, the pigs were euthanised 
using 20ml of pentobarbital sodium (Abbott Laboratories, North Chicago, IL, USA). 
The left eye of all 22 pigs were enucleated after termination at 1-2 hours, 2 days, 7 days, 
14 days, 4 weeks and 6 weeks after surgery. The non-operated fellow eyes were also 
enucleated in some pigs to serve as a control. In one animal, splenectomy was also 
performed for control of CD4 antibody. 
 
3.2.8 Tissue preparation 
The enucleated globes were punctured at the peripheral cornea to allow penetration of 
4% paraformaldehyde in 0.1 M phosphate buffer. Within 3 hours of enucleation, the 
cornea, lens and vitreous were removed and the remaining posterior eye-cup was 
photographed before and after 2-3 times of wash with PBS. The posterior eye-cup was 
then cut into halves. In 10 of 22 eyes, the globe was cut so that the patch graft was also 
cut in half using a cryostat blade. For pig 11, each eye was bisected so that each 
contains a whole patch. Pigs 18 and 19 had bisection of the globe so that each of the 2 
eye-cup fragments contained the area of control bleb detachment without the patch. The 
segments were immediately processed for either light microscopy (immuno-
histochemistry) or electron microscopy. 
The eye-cup fragments containing the whole or half of the patch were marked 
and left in 30% sucrose/PBS overnight at 4ºC for immunohistochemistry. For the 10 
other segments containing half or whole of a patch, 1% paraformaldehyde and 3% 
glutaraldehyde in 0.08M cacodylate buffer (Karnowsky solution) were used to fix the 
tissue for 72 hours. 
For immunohistochemistry, the tissue was transferred from sucrose to be 
embedded in optimal cutting temperature (OCT) media (Tissue Tek®, VWR, 
Leicestershire, UK) in dry ice/acetone slurry and stored at -80ºC. The eye cup fragments 
were sectioned at 14 μm on a cryostat (Leica CM1850, Leica Microsystems Nussloch 
GmbH, Nußloch, Germany) and mounted on charged glass slides (VWR, Lutterworth, 
Leicestershire, UK). These were dried for at least an hour in a cool current of air before 
wrapping in foil and stored at -80 oC.  
For electron microscopy, the tissues were post-fixed in 1% osmium tetroxide in 
cacodylate buffer, dehydrated in a graded series of alcohols and epoxypropane prior to 
embedding in Araldite CY212 resin (Agar Scientific, Standsted, UK) for six hours 
without rotation (to minimise dissociation of the patch from the retina and choroid) and 
then cured overnight in a 60˚C oven. Semi-thin (1μm) sections for light microscopy and 
ultra-thin (70nm) sections for transmission electron microscopy (TEM) were cut using a 
Reichert-Jung Ultracut E microtome (Leica Microsystems Nussloch GmbH, Nußloch, 
Germany), fitted with a diamond knife. All tissue cutting and sections were performed 




Figure 3.6 Preparation of hESC-RPE patch graft  
(A) Human embryonic stem cell derived retinal pigment epithelium (hESC-RPE) 
monolayer is re-seeded onto a polyester membrane in a 96 well. (B) A customised 
punch is used to create a 1x3 mm size graft. (C) The 1x3 mm patch graft is cut out by 
the punch with the help of a hammer. (D) The remaining polyester patch contains a 
monolayer of hESC-RPE except where the forceps was used to grasp the membrane 
(yellow arrow) and a rim surrounding the defect in the membrane where the patch graft 
was cut out (white arrow). 
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Sections were blocked in 0.3% triton in PBS plus 5% donkey serum (Jackson 
ImmunoResearch) for 1h before overnight incubation at room temperature in a 
humidified chamber, in primary antibodies (see Table 3.6) diluted in 0.3% triton X-
100/PBS plus 1% donkey serum. After washing, sections were incubated at room 
temperature in appropriate fluorescent donkey secondary antibodies (FITC and TRITC, 
pre-adsorbed to various species, Jackson ImmunoResearch) diluted 1:200 in PBS plus 
2% donkey serum. Cell nuclei were visualised with DAPI (4’6-diamindino-2-
phenylindole dihydrochloride, Sigma; 1:5,000, Sigma Chemical Co., Poole, Dorset, 
UK) followed by washing in PBS and mounting in Vectashield (Vector Laboratories 
Ltd., Peterborough, UK). Immunologically stained sections were examined using the 
Zeiss confocal microscope and LSM Image Browser software. Immunohistochemical 
staining and titration of antibody concentration were performed by Dr Jean Lawrence 
from Professor Peter Coffey’s research group. Images were taken by Drs Jean Lawrence 
and Anthony Vugler from the same research group. Images were collated by the author 
for further analysis. An example of normal porcine retina on cresyl violet stain is shown 
in Figure 3.7.   
 Positive and negative controls were also performed. Figure 3.8 shows positive 
controls for T (CD4 and CD8) and B (CD79) lymphocyte antibodies using spleen 
harvested from one of the animals. Macrophage antibody stained cells with large 
pigment clumps. These cells did not stain for human markers or RPE specific cell 
markers. Negative controls with no primary antibodies demonstrated only 
autofluorescent macrophages. There was prominent non-specific background staining 
when anti-rabbit secondary antibodies were used with anti-CD3 and anti-GFAP primary 
antibodies. 
 
3.2.10 Electron microscopy 
Semi-thin sections were stained with alcoholic toluidine blue. Ultra-thin sections were 
contrasted by sequential staining with saturated uranyl acetate in 50% ethanol followed 
by lead citrate and viewed and photographed in a TEM (JEOL 1010 TEM, JEOL Ltd., 
Tokyo, Japan) operating at 80kV. The electron micrographs were taken by Dr Jean 
Lawrence from Professor Peter Coffey’s research group. Images were collated by the 
author for analysis. 
 




Figure 3.8 Positive controls for T and B cells markers  
Immunohistochemistry demonstrated (A) CD8-positive (B) CD4-positive and (C) 
CD79-positive cells within the porcine spleen when stained with fluorescent (FITC) 
donkey anti-mouse antibodies.   
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Table 3.6 Antibodies used for staining target cells. 
Antibody Target Raised in Source Dilution 
TRA-1-85 Human Oka blood group 
antigen  
Mouse Prof Peter Andrews, 
Sheffield 
1:10 
PCNA Human nucleus Mouse Chemicon/Millipore 1:500 
GFAP Reactive astrocytes and 
Muller cells 
Rabbit DAKO 1:500 
CRALBP RPE/Muller cells Mouse Thermo Scientific 1:1000 
Bestrophin RPE Mouse Chemicon/Millipore 1:1000 
RPE65 RPE Mouse Chemicon/Millipore 1:500 
Pmel17 RPE: immature 
melanosomes 
Mouse DAKO 1:100 
Ki67 Proliferating cells Rabbit Vector 1:2000 
Ki67 Proliferating cells Mouse DAKO 1:50 
Macrophage 
antibody  
Pig and other species 
Macrophages 
Mouse Abcam 1:100 
CD79a Pig B cells Mouse AbD Serotec 1:100 
Pig CD8a Pig T cells: Cytotoxic T 
cells including NK 
Mouse Thermo Scientific 1:10 
Pig CD4a Pig T cells: CD4 T helper Mouse AbD Serotec 1:10 
CD3 Pig T cells Rabbit Sigma Aldrich 1:1000 
CD; cluster of differentiation, CRALBP; cellular retinaldehyde binding protein,  GFAP; glial 
fibrillary activation protein, PCNA; proliferating cell nucleus antigen, Pmel 17, premlanosome 
17; RPE65, retinal pigment epithelium specific protein 65kDa; SLA; swine leukocyte antigen, 
TRA-1-85, specific epitope on the protein basigin/CD147.   
 
 






Chapter 4 Autologous RPE Transplantation in Atrophic Macular 
Disease 
Autologous RPE Transplantation in 
Atrophic Macular Disease 




There is currently no effective treatment for patients with acquired or inherited atrophic 
macular disease. These conditions are characterised by progressive decline in macular 
function that often spares the fovea (and hence maintaining normal VA) until late in the 
disease process. Although their presentations are often asymmetrical, with sequential 
loss of VA separated by many months or years, VA in each eye tends to become equally 
impaired as paracentral scotomata expand and coalesce to form a ring, and then later, a 
large central scotoma.  
The exact pathophysiology of macular RPE atrophy in IMD and AMD is not yet 
fully elucidated. However, the characteristic RPE atrophy and linkage to genes 
expressed in the photoreceptor cells in IMD suggest a possible sequence of event: 
abnormal outer segments and their interaction with RPE leading to RPE cell death with 
subsequent choriocapillaris atrophy and photoreceptor cell loss (Kaplan et al. 1993; 
Allikmets et al. 1997; Hoyng et al. 1996; Felbor et al. 1997). In some of these patients, 
the macular lesion resembles GA of AMD, where photoreceptor cell loss is also thought 
to be due to either primary RPE cell death or impaired choroidal perfusion (Sakamoto et 
al. 1995; Friedman et al. 1995; McLeod et al. 2002). Histological study of eyes with 
GA of AMD also showed intact inner retinal structures despite extensive loss of outer 
nuclear layer and RPE (Kim et al. 2002). These observations suggest that preservation 
of the outer retina using RPE transplantation may restore or maintain visual function 
because there is no primary inner retinal degeneration. The proof of principal for this 
approach comes from studies on the anatomical and functional outcomes of RPE 
transplantation in the RCS rat model and full macular translocation in neovascular 




In this chapter, the results of 2 clinical trials examining the use of autologous equatorial 
RPE-choroid patch graft in patients with atrophic IMD and AMD, respectively, are 
presented to answer the following questions: 
 
1.  What is the recruitment rate and what are the reasons for screening failures for 
entry into the trials of autologous equatorial RPE-choroid patch graft in atrophic 
IMD or AMD? 
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2.  Is it feasible and safe to perform autologous equatorial RPE-choroid patch graft 
in patients with atrophic IMD or AMD? 
 
3.  What are the functional and structural outcomes following autologous equatorial 
RPE-choroid patch graft in patients with late stage atrophic IMD or AMD? 
 
4.3 Specific Methodology 
 
4.3.1 Genotyping of dystrophy patients 
In addition to the investigations outlined under Section 3.1, IMD patients recruited to 
this study were offered the opportunity for genetic testing. Four of the 5 patients agreed 
to genotyping and their bloods were taken after counselling. Samples were sent for 
genetic analysis at the regional molecular genetics laboratory, Manchester, UK. 
Screening for Sorsby fundus dystrophy (SFD) was carried out by bi-directional 
sequencing of the exon 5 and intron 4/exon 5 splice acceptor site of the tissue inhibitor 
of metalloproteinases-3 (TIMP-3) gene. Peripherin/RDS gene abnormalities were sought 
using bi-directional sequencing of the entire coding sequence of rhodopsin including 
intron/exon boundaries. Further samples were also sent to Asper Biotech, Tartu, Estonia 
to look for variations in ABCA4 using an arrayed primer extension genotyping array 
chip. 
 
4.3.2 Data collection and statistical analysis 
Data were collated and analysed by the author. All patients referred for consideration of 
autologous RPE-choroid patch graft were recorded in a log book. The reasons for not 
meeting eligibility, as documented in the medical charts, were noted.  
Baseline demographic and clinical features, intraoperative course and 
postoperative complications were tabulated. Functional outcomes including VA, CS and 
reading ability at baseline, 6, 12, 18 and 24 months were presented in graphs and tables 
where available. Results of microperimetry tests (fixation characteristics and retinal 
sensitivity), electrophysiological studies and questionnaires (NEI VFQ-25 and the 
RAND 36-Item Health Survey) before and after surgery were described in figures, 
tables and Appendix 7. OCT features of the choroid, patch graft and the overlying 
neuroretina were described. Pre- and postoperative fundus AF images and 
angiographies were analysed.  
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Structure-function correlations were explored qualitatively by importing fundus 
AF, colour photographs and angiographies, captured within a 3 month window of the 
microperimetry test, into the NAVIS software provided by the Nidek MP1. Co-
registration or overlay of microperimetry maps onto these images allowed correlation 
between function (retinal sensitivity or fixation loci/stability) and structure (perfusion, 




4.4.1 Recruitment rate and screening failures 
A total of 23 patients with IMD were referred for consideration of autologous RPE-
choroid graft between August 2005 and April 2008 (33 months period, referral rate of 
~8 per year). Full-field ERG demonstrated generalised retinal dysfunction in 7 and the 
remaining 16 only had macular dysfunction as revealed by the PERG. At the time of 
referral, 19 had results of genetic testing. Of these, 5 had peripherin/RDS mutations, 6 
had disease-associated ABCA4 sequence variants and the remaining 8 had no mutations 
detected.  
Five patients (22% of referral) were enrolled into the study (4 with macular 
dystrophy and 1 with retinal dystrophy). The remaining 18 patients had Snellen VA that 
was better than 6/36 and therefore were not eligible despite large areas of parafoveal 
atrophy. Although Snellen VA was worse than 6/36 in the enrolled IMD cohort, 3 of the 
5 patients had better BCVA when the ETDRS chart was used (see Table 4.1). 
Functionally, these patients were considered to be worse than 6/36 because they only 
had a very small central island of vision detected on microperimetry.  
 A total of 9 patients with GA secondary to AMD were referred for consideration 
of autologous RPE-choroid graft between April 2007 and December 2007 (9 month 
period, referral rate of ~12 per year). Of these, 4 patients (44% of referral) were enrolled 
and 5 were not eligible due to relatively good VA in 4 patients and lack of recent 
decline in vision in 1 patient.  
 
4.4.2 Baseline patient features 
All 5 patients in the IMD group had evidence of intact subfoveal RPE on angiography 
and fundus AF imaging, and fixation at the fovea on slit lamp examination. However, 
only 2 of 4 patients with preoperative microperimetry demonstrated ability to use the 
fovea for the fixation task. The remaining 2 patients used non-foveal retinal loci for 
fixation. In contrast, all 4 patients with atrophic AMD had subfoveal GA and therefore, 
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they were fixating eccentrically; placing the preferred retinal locus nasal (patients 6-8) 
or temporal to the GA (patient 9) in their right eyes. 
Patient 2 had a family history of retinal dystrophy suggestive of dominant 
inheritance. He had an R172W mutation in the peripherin/RDS gene associated with 
normal implicit time but reduced cone amplitude, similar to that described previously in 
a large cohort of patients with RDS dystrophy (Downes et al. 1999). He also had the 
characteristic peripapillary atrophy and increased, speckled, fundus AF pattern 
surrounding the area of atrophy (Downes et al. 1999). Patients 1 and 5 had 
autofluorescent basal laminar drusen. They had no history of renal disease and renal 
functions were normal. Patient 7 had calcified drusen within the area of GA. None of 
the patients had yellow subretinal flecks typically seen in Stargardt disease and fundus 
flavimaculatus, or yellow submacular vitelliform lesions characteristic of Best disease 
or adult vitelliform macular dystrophy. Other demographic and clinical data at baseline 
are summarised in Tables 4.1 and 4.2. 
 





Sex Side Duration of 
visual loss 
(months) 
VA in study 
eye (logMAR) 
VA in fellow 
eye (logMAR) 
1 52 M R 6 0.76 1.10 
2 45 M L 3 0.44 1.00 
3 41 M L 6 0.32 0.78 
4 45 M R 12 0.84 0.78 
5 66 F L 6 0.60 1.00 
6 51 M R 36-48 1.64 0.90 
7 89 F R 12-24 0.94 2.28 
8 68 F R 12-24 0.70 1.40 
9 74 M R 12 0.80 0.68 
F, female; L, left; logMAR, logarithm of minimum angle of resolution; M, male; R, right; VA, 
visual acuity. 
 
Table 4.2 RPE graft in atrophic disease: Baseline clinical features 
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4.4.3 Feasibility and safety outcomes 
The key surgical steps for autologous patch graft are: (1) induction of posterior vitreous 
detachment and vitrectomy, (2) creation of bleb detachment and retinotomy in the 
macular region, (3) preparation of the autologous RPE-choroid patch graft from the 
superior equatorial region, (4) transfer and delivery of the autologous patch graft from 
the donor site to the submacular space and (5) sealing of the retinotomy / retinal break, 
and closure of the sclerostomies / peritomies.  
 Standard technique of pars plana vitrectomy and induction of vitreous 
detachment were able to be carried out in all patients. Two patients had intraoperative 
entry site retinal breaks. Bleb detachment in the macular region required several 
punctate retinotomies in most patients due to strong adherence between retina and RPE 
in the areas of RPE atrophy. One patient developed a full-thickness macular defect 
during bleb detachment. It was possible to harvest autologous RPE-choroid patch grafts 
from the superior equatorial region in all 9 patients. However, the patch graft had a 
tendency to contract and wrap around the spatula after removal of the overlying retina. 
Delivery of the patch graft required enlargement of the retinotomy in all patients. 
Submacular release of the patch graft from the spatula was unreliable. In one patient, 
reflux of air bubbles into the submacular space during release of the graft caused 
subretinal haemorrhage. In other patients, re-insertion of the patch graft was necessary 
due to failure of the spatula to release the graft in the submacular space. Because of its 
elasticity, the patch graft tended to form an elongated shape with folded edges when 
released in the submacular space. Contraction of the graft also led to wrinkled 
appearance on the surface of the RPE-choroid patch. Most patients had 2 or more 
subretinal manipulations of the patch graft in an attempt to unfold its edges without 
success. All 9 patients received silicone oil tamponade. A list of intra-operative 
complications for each patient can be found in Table 4.3. 
Postoperative complications included retinal detachment, raised intraocular 
pressure, cataract and neovascularisation. Three patients (33%) developed retinal 
detachment prior to removal of silicone oil. A total of 6 detachment repair procedures 
were performed (1 patient had 1, 1 patient had 2 and 1 patient had 3). The retina was flat 
in all patients without silicone oil tamponade at the most recent follow-up visit. High 
intraocular pressure was found in 2 patients within the 1st week which was controlled 
medically. Cataract developed in 4 (patients 1, 5, 8 and 9) of 7 phakic patients and they 
were extracted at the time of oil removal (3 patients) or after 2 years (1 patient). Some 
degree of epiretinal membrane was present in all patients although 3 of these caused 
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significant retinal traction and macular pucker. One patient required 1 additional 
operation to extract residual oil bubble after the initial removal of oil surgery. In 2 
patients, the macular retinotomy used for insertion of the patch graft remained open.  
Patient 2 developed a stable intraretinal neovascularisation on the nasal border 
of the graft that was not associated with subretinal fluid, exudates or haemorrhage 
during the 24 months of follow-up (see Figure 4.1). Extensive subretinal fibrosis 
developed in patient 9 due to intra-operative submacular haemorrhage. Two patients 
developed choroidal neovascularisation (see Figure 4.1). One of these is currently 
receiving intravitreal ranibizumab.  
Two patients who had re-operations for PVR retinal detachment also developed 
recurrent ocular pain due to scleritis. Their symptoms were controlled with a course of 
oral non-steroidal anti-inflammatory drugs. One patient (patient 6) developed iris 
neovascularisation at 16 months, related to anterior retinal ischaemia secondary to 
extensive retinectomy. This patient currently remains on aqueous suppressant for raised 
IOP. A list of postoperative complications can be found in Table 4.3. 
 
4.4.4 Functional outcomes 
Functional assessments consist of psychophysical measurements of retinal functions 
(i.e. VA, CS, reading ability, and microperimetry), electrophysiological testing and 
questionnaires regarding quality of life and vision.  
The median VA (logMAR) declined from 0.76 at baseline to 1.34 and 1.08 at 6 
and 12 months, respectively (Friedman test, p = 0.003). The mean (SD) change in VA 
(logMAR) was +0.59 (0.37) and +0.30 (0.37) at 6 and 12 months, respectively. The 
median CS (logCS) declined from 1.05 at baseline to 0.75 and then returned to 1.05 at 6 
and 12 months, respectively (Friedman test, p = 0.081). VA and CS outcome are shown 
in Tables 4.4, 4.5 and 4.6 and as box plots in Figure 4.2. 
At baseline, 2 of 9 patients were unable to read the largest print text (1.5 
logMAR) on the MNRead chart. These 2 patients (patients 1 and 5, see Figure 4.3) 
gained reading ability postoperatively but only one had subjective improvement. Of the 
remaining 7 patients, severe decline in reading acuity (>0.8 logMAR loss) was found in 
4 patients at 6-12 months. Figure 4.3 illustrates the reading speed profile at various text 
sizes pre- and post-operatively in all 9 patients. Reading speed profiles for 2 patients 
with early IMD and early AMD were also included in Figure 4.3 for comparison.  
 
Table 4.3 RPE graft in atrophic disease: Surgical complications 
 
 
 Page 124  
 
 
Figure 4.1 RPE graft in atrophic disease: Neovascular complications 
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Fixation on the patch graft was found in 2 patients (see Figure 4.4 and 4.5). 
One of these developed an alternative locus of fixation when tested again at 16 months. 
The other patient developed fixation on the graft at 29 months because the alternative 
fixation locus (outside the graft) was affected by the development of CNV. In the other 
6 patients, the grafts were placed under the preferred retinal loci but the patch grafts 
were unable to support fixation (see Figures 4.4, 4.5 and 4.6). In 1 patient, the graft 
was misplaced (away from fixation locus) due to intra-operative complication and the 
fixation locus remained unchanged.  
 Preoperative microperimetry was available for comparison in 8 patients. 
Accurate follow-up post-operative microperimetry was not possible due to distortion of 
retinal vascular landmarks and significant image registration error at the time of the 
follow-up microperimetry.  A common feature in the pre-operative microperimetry was 
the presence of dense central scotoma surrounded by a rim of reduced retinal sensitivity 
or a central island of vision surrounded by a ring scotoma. Patient 1 was unable to have 
pre-operative microperimetry. Post-operatively, there was retinal sensitivity present 
over the inferotemporal portion of his graft and at the fovea (located adjacent to the 
inferior edge of the graft, Figure 4.7). The sensitivity over the inferotemporal region of 
the graft and at the fovea was maintained above 10 dB (with Goldmann V target) when 
re-examined at 38 months. Patient 5 had retinal sensitivity over the superior half of the 
graft at 9 months which was maintained at 29 months (see Figure 4.7). Patients 6 and 8 
had retinal sensitivity over the temporal portion of the graft. Some retinal sensitivity 
was also detected over the graft in patients 2, 3 and 4 but none was detected over the 
grafts in patients 7 and 9. In the 8 patients with pre-operative microperimetry, it was 
noted that the area of dense scotoma enlarged following graft. Table 4.7 summarises the 
findings of microperimetry.  
Electrophysiological studies, including pattern ERG, full-field ERG and 
mfERG, were performed in all patients pre-operatively. A summary of the results of 
patter ERG and full-field ERG are shown in Appendix 7 and Table 4.8. Overall, 
surgical procedure induced both cone and rod system dysfunction with cone system 
more severely affected than rod system. This was shown in the more marked delay and 
reduction of amplitude in the 30 Hz flicker as well as some reduction in the b-wave 
amplitude of rod-specific ERG. Peak time delay and reduction in the a-wave amplitudes 
of the bright flash and photopic ERGs suggest dysfunction at the level of photoreceptor 
cells. Multifocal ERG also showed deterioration particularly in rings 3 to 5. In 2 of 3 
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patients with a second postoperative electrodiagnostic test, there was evidence of partial 
recovery of peripheral cone function on full-field and mfERG.  
The NEI VFQ-25 and the RAND 36-Item Health Survey questionnaires were 
completed by 8 of 9 patients before and after surgery. The median score and medium 
change in scores for each subscales in the categories of quality of vision (5 subscales), 
vision specific QOL and general health QOL (8 subscales) are shown in Tables 4.9 and 
4.10 for IMD and AMD respectively. In these cohorts, reduction in peripheral and 
colour vision subscale scores were noted. Interestingly, despite loss of visual function, 
there was improvement in the mental health and role dependency subscales scores in the 





Figure 4.2 RPE graft in atrophic disease: VA outcomes at 1 and 2 years 
Bar charts showing the mean visual acuity (VA) letter scores with standard error for 
mean before and at 6, 12, 18 and 24 months after patch graft. (A) VA in patients with 
dry age-related macular degeneration (AMD) showed slight decline which was not 
statistically significant (p = 0.065, Friedman test). (B) VA in patients with inherited 
macular dystrophy (IMD) showed statistically significant decline at 6 to 24 months (p = 
0.014, Friedman test).  
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Table 4.4 RPE graft in atrophic disease: VA, CS and Reading outcomes 
 
 Page 128  
 Table 4.5 RPE graft in atrophic disease: Visual acuity outcomes 
VA (logMAR) Patient 
Number Baseline  6 months 12 months 18 months 24 months 
1 0.76 1.10 1.10 0.96 1.00 
2 0.44 1.40 1.32 1.36 1.40 
3 0.32 1.34 1.08 N/A N/A 
4 0.84 1.00 1.06 1.04 1.04 
5 0.60 1.12 1.12 1.02 0.92 
6 1.64 1.98 1.54 1.56 1.98 
7 0.94 1.46 1.06 N/A N/A 
8 0.70 0.92 0.90 0.92 N/A 
9 0.80 1.98 0.58 2.28 N/A 
logMAR, logarithm of minimum angle of resolution; N/A, not available; VA, visual acuity. 
 
 
Table 4.6 RPE graft in atrophic disease: Contrast sensitivity outcomes 
CS (logCS) Patient 
Number Baseline  6 months 12 months 18 months 24 months 
1 1.20 1.05 0.75 N/A N/A 
2 0.60 0.15 0.90 N/A N/A 
3 1.65 0.90 1.20 N/A N/A 
4 1.50 1.05 1.20 N/A N/A 
5 1.25 0.75 1.35 N/A N/A 
6 0.00 0.00 0.00 N/A N/A 
7 1.05 0.75 0.75 N/A N/A 
8 0.75 1.35 1.35 N/A N/A 
9 0.90 0.00 N/A N/A N/A 
CS, contrast sensitivity; logCS, logarithm of contrast sensitivity; N/A, not available. 
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Figure 4.3 RPE graft in atrophic disease: Reading outcomes at 1 year 
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Figure 4.4 RPE graft in atrophic disease: Fixation in patients 1 - 3 
Pre- and post-operative fixation tests in patients 1, 2 and 3. (A, B, microperimetry not 
available at baseline) Patient 1 was fixating at the fovea pre- and postoperatively. (C, D) 
Patient 2 lost foveal fixation despite placement of graft under the fovea. (E, F) The 
preoperative eccentric fixation locus in patient 3 was displaced nasally by the insertion 
of the patch graft.  
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Figure 4.5 RPE graft in atrophic disease: Fixation in patients 4 - 6 
Pre- and post-operative fixation tests in patients 4, 5 and 6. (A, B) The preoperative 
eccentric fixation locus in patient 4 was displaced superiorly by the insertion of the 
patch graft. (C, D) Patient 5 lost foveal fixation but established eccentric fixation on the 
patch graft at 29 months. (E, F) The preoperative eccentric fixation locus in patient 6 
was displaced nasally by the insertion of the patch graft.  
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Figure 4.6 RPE graft in atrophic disease: Fixation in patients 7 - 9 
Pre- and post-operative fixation tests in patients 7, 8 and 9. (A, B) The preoperative 
eccentric fixation locus in patient 7 was displaced nasally by the insertion of the patch 
graft. (C, D) The preoperative eccentric fixation locus in patient 8 was displaced nasally 
by the insertion of the patch graft. (E, F) Patient 9 remained fixating at a similar 
eccentric locus after misplacement of patch graft. 
 
 Page 133  
Figure 4.7 RPE graft in atrophic IMD: Microperimetry in patients 1 and 5 
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Figure 4.8 RPE graft in atrophic AMD: Microperimetry in patients 6 and 8 
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Table 4.7 RPE graft in atrophic disease: Retinal sensitivity over graft 
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Table 4.8 RPE graft in atrophic disease: Summary of pattern and full-field ERG  
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 Table 4.9 RPE graft in atrophic IMD: NEI VFQ-25 and RAND 36-Item Health 
Survey 









NEI VFQ-25 Composite score 62.5 (56, 69) 59.5 (33, 65) -3 (-27, 0) 
Quality of vision (NEI VFQ-25) 
    General vision 50 (40, 60) 30 (20, 60) -10 (-40, 0) 
    Difficulty with near tasks 42 (25, 50) 29 (25, 42) -4.5 (-25, 0) 
    Difficulty with distance tasks 46 (42, 50) 50 (33, 58) +4 (-17, +16) 
    Peripheral vision 100 (75, 100) 75, (25, 100) -12.5 (-75, 0) 
    Colour vision 87.5 (50, 100) 62.5 (50. 75) -12.5 (-50, 0) 
Vision specific QOL (NEI VFQ-25) 
    Dependency 62.5 (50, 83) 62.5 (25, 92) +4 (-33, +9) 
    Role limitations 50 (50, 63) 50 (0, 75) -6.5 (-50, +25) 
    Mental health 41 (13, 81) 63 (19, 94) +22 (-19, +38) 
    Social function 50 (50, 63) 44 (25, 75) -6 (-25, +12) 
    Driving 0 (0, 67) 0 (0, 0) 0, (-67, 0) 
    Ocular pain 94 (75, 100) 94 (63, 100) +6 (-37, +13) 
General health QOL (RAND 36 Item) 
    Physical functioning 90 (90, 100) 97.5 (80, 100) +2.5 (-10, +10) 
    Physical health 100 (25, 100) 87.5 (0, 100) -12.5 (-25, 0) 
    Mental health 90 (80, 96) 88 (72, 100) +2 (-16, +4) 
    Energy/fatigue 72.5 (55, 85) 62.5 (60, 85) -12.5 (-20, +30) 
    Emotinal well being 100 (100, 100) 100 (0, 100) 0 (-100, 0) 
    Social functioning 100 (62.5, 100) 100 (37.5, 100) 0 (-25, 0) 
    Pain 100 (100, 100) 85 (67.5, 100) -15 (-32.5, 0) 
    General health 82.5 (80, 90) 65 (60, 70) -17.5 (-30, -10) 




 Page 138  
 Table 4.10 RPE graft in atrophic AMD: NEI VFQ-25 and RAND 36-Item Health 
Survey 









NEI VFQ-25 Composite score 35 (16,51) 25.5 (12, 53) -2 (-19, +2) 
Quality of vision (NEI VFQ-25) 
    General vision 30 (20, 40) 30 (20, 60) 0 (-20, +40) 
    Difficulty with near tasks 21 (0, 33) 16.5 (0, 33) 0 (-9, 0) 
    Difficulty with distance tasks 8 (8, 58) 8 (0, 25) -4 (-33, 0) 
    Peripheral vision 87.5 (25, 100) 50 (0, 75) -37.5 (-75, +25) 
    Colour vision 37.5 (0, 100) 12.5 (0, 100) -12.5 (-25, 0) 
Vision specific QOL (NEI VFQ-25) 
    Dependency 4 (0, 42) 4 (0, 50) +4 (-8, +8) 
    Role limitations 12.5 (0, 25) 25 (0, 50) +12.5 (-25, +50) 
    Mental health 12.5 (0, 63) 15.5 (0, 50) -3.5 (-19, +19) 
    Social function 31.5 (25, 38) 31.5 (0, 50) -0.5 (-25, +13) 
    Driving 0 (0, 0) 0 (0, 0) 0 (0, 0) 
    Ocular pain 75.5 (50, 100) 81.5 (13, 88) -12.5 (-37, +25) 
General health QOL (RAND 36 Item) 
    Physical functioning 67.5 (40, 95) 17.5 (5, 85) -40 (-70, +5) 
    Physical health 50 (25, 100) 0 (0, 50) -37.5 (-100, 0) 
    Mental health 88 (60, 96) 52 (48, 64) -36 (-48, +4) 
    Energy/fatigue 70 (40, 70) 37.5 (15, 50) -32.5 (-55, +10) 
    Emotinal well being 66.7 (0, 100) 0 (0, 0) -66.7 (-100, 0) 
    Social functioning 100 (75, 100) 18.8 (0, 100) -81.3 (-100, +25) 
    Pain 60 (20, 70) 22.5 (10, 60) -28.8 (-47.5, 0) 
    General health 80 (60, 85) 72.5 (60, 85) -5 (-15, +10) 
NEI VFQ-25; National Eye Institute-25 Item Visual function questionnaire, QOL; quality of 
life. 
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 4.4.5 Structural outcomes 
Structural assessments consist of angiography to demonstrate graft vascularisation and 
perfusion, fundus AF imaging to indirectly detect RPE-photoreceptor cell interaction, 
and OCT to visualise retinal and choroidal structures.  
Two of the 9 patients declined further angiographies postoperatively since they 
developed severe nausea and vomiting during fluorescein dye injection preoperatively. 
The remaining 7 patients demonstrated early hyperfluorescence (fluorescein) and 
distinct intrinsic vascular patterns (indocyanine green) within the patch graft (see 
Figure 4.9). The 2 patients who developed postoperative CNV demonstrated increasing 
intensity and area of hyperfluorescence in the region of the CNV lesions. 
Fundus AF imaging was performed in all patients although the qualities of the 
images varied considerably. AF signal was present over all 9 grafts to varying degrees 
with patients 4 and 9 demonstrating the least graft AF intensity. The remaining 7 grafts 
had homogenous pattern of AF signals over a small portion of the patch (see Figures 
4.9, 4.10 and 4.11). Heterogeneous linear pattern of AF signal in the remaining portion 
of the patch grafts corresponded to the pigmentary changes and wrinkling of the graft 
surface. The region surrounding the graft showed variable increased and decreased AF 
signals. Reduced AF signal was associated with RPE atrophy, subretinal fibrosis, or 
masking by pigmentary hyperplasia and thick epiretinal membrane (see Figures 4.11B 
and 4.12B). Increased AF signal was found at the junctional zone surrounding RPE 
atrophy and at the sites of macular retinotomies that remained open (see Figures 4.11D 
and 4.12F).  
OCT scan was performed in all patients pre- and postoperatively. The majority 
of scans had motion artefacts and segmentation errors even with the new generation 
spectral-domain OCT scanner. Although artefacts precluded accurate registration 
between the fundus image and the OCT scans, most scan sets had adequate B scan 
quality to allow qualitative analysis of the inner and outer retinal structures.  A feature 
common to all patient was the prominent irregular elevation of the highly reflective 
band that represents the wrinkled RPE layer of the patch graft. In some scans, 
hyporeflective circular structures within the choroid of the patch graft could be seen 
(SOCT Copernicus and Spectralis HRA+OCT). The retina over the graft had varied 
appearance (see Figure 4.13). Cystic changes were frequently seen within the retina 
over the graft regardless of retinal thickness (see Figure 4.13). In some patients, cysts 
were associated with retinal thinning while in others, there was associated retinal 
thickening or oedema. Using the Spectralis OCT, it was possible to visualise outer 
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 nuclear layer over some portions of the patch graft suggesting rescue of the 
photoreceptor cells by the autologous RPE graft (see Figure 4.13). 
 
4.4.6 Structure-function correlation 
Retinal sensitivity was generally found over the part of the graft closest to the 
retinotomy. This portion of the graft also tended to have better choriocapillaris 
perfusion and more uniform AF signal (see Figure 4.14). However, these features were 
not sufficient to predict function. Raster B scans from spectral-domain OCT showed 
intact outer retinal structures in areas with retinal sensitivity on microperimetry (see 
Figure 4.14). However, outer retinal structure was not always easy to distinguish 





Figure 4.9 RPE graft in atrophic disease: graft perfusion 
Fundus photographs and angiographies of patient 6 (A-C) at baseline and (D-F) at 5 
months postoperatively. (B, E) Early phase fluorescein angiography showed 
choriocapillaris perfusion in the temporal portion of the graft. (C) Indocyanine green 
angiography showed distinct choroidal vascular pattern within the graft, different from 
the receipient choroidal bed. (F)The graft choroidal vessels are also most prominent at 
its temporal portion.  
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Figure 4.10 RPE grafts in atrophic disease: autofluorescence in patients 1 -3  
Fundus autofluoresence (AF) images before and after autologous RPE-choroid graft in 
(A, B) patients 1, (C, D) patient 2 and (E, F) patient 3. Graft AF signal is present over 
all 3 grafts. Note that there is RPE atrophy (dark areas) in the regions where the macular 
retinotomies were created in each of the 3 patients.  
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Figure 4.11 RPE grafts in atrophic disease: autofluorescence in patients 4 -6  
Fundus autofluoresence (AF) images before and after autologous RPE-choroid graft in 
(A, B) patients 4, (C, D) patient 5 and (E. F) patient 6. (B) In patient 4, graft AF signal 
is weak and the small area without AF signal inferotemporal to the graft is due to 
masking by epiretinal membrane. (D, F) AF is present over the region of the graft in 
patients 5 and 6. (D) There is a round area of increased AF superior to the graft in 
patient 5 corresponding to the macular retinotomy that did not close postoperatively.  
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Figure 4.12 RPE grafts in atrophic disease: autofluorescence in patients 7 -9  
Fundus autofluoresence (AF) images before and after autologous RPE-choroid graft in 
(A, B) patients 7, (C, D) patient 8 and (E, F) patient 9. Graft AF signal is weak in 
patient 7 (B) due to masking by thick epiretinal membrane. (D, F) AF is present over 
graft in patients 8 but is only very faint in patient 9, temporal to the pre-existing 
geographic atrophy. (F) There is a round area of increased AF signal superotemporal to 
the graft in patient 9 corresponding to the region of macular retinotomy that did not 
close postoperatively.  
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Figure 4.13 RPE grafts in atrophic disease: variation in retinal structure  
(A) Preoperative optical coherence tomography (OCT) images of patient 9 showed 
outer retinal atrophy typically seen in atrophic macular diseases. (B) At 1 week, 
choroidal vessels could be visualised as circular hyporeflective areas within the graft 
choroidal tissue in patient 8. (C) Retinal thickening and epiretinal membrane associated 
with oedematous cystic changes over the graft in patient 7 at 11 months. (D) Retinal 
atrophy and epiretinal embmrane associated with atrophic cystic change in patient 1 at 
38 months. (E) Retinal oedema adjacent to foveal atrophy over the graft in patient 2 at 
24 months. (F) OCT scan of the authors’s right eye showing normal retinal structures.  
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Figure 4.14 RPE grafts in atrophic disease: structure-function correlation  
(A) Microperimetry map in patient 1 demonstrates retinal sensitivity over the temporal 
portion of the graft at 45 months. (B) Microperimetry map in patient 5 demonstrates 
retinal sensitivity over the superior portion of the graft at 26 months. (C, D) Spectralis 
optical coherence tomography (OCT, through the green lines) with fundus 
autofluorescence imaging in the region with retinal sensitivity over the graft allows 
structure-function correlation. (E, F) OCT shows rescue of outer nuclear layer by the 
RPE patch graft. Segments of the OCT scan were enlarged to illustrate that all layers of 
the retina were preserved over the patch graft (boxes X and Z) as compared with regions 
unaffected by RPE atrophy (boxes X and Y). Abbreviations: GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. 
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 4.5 Discussion 
 
These results demonstrated that autologous RPE-choroid patch graft can be performed 
in patients with atrophic macular diseases. However, there was significant intra- and 
postoperative complications which contributed to an overall loss of central visual 
function following graft. Nevertheless, microperimetry demonstrated retinal sensitivity 
supported by autologous RPE graft in 7 of the 9 patients. In 2 of these patients, the 
natural preferred retinal loci were over the patch, implying good quality of retinal 
function supported by the graft.  
Although this is a preliminary study and consists of only 9 patients, the 
extensive data collected can be used to guide the design of possible future trials 
exploring novel therapies in atrophic macular disease. The results and implications for 
future clinical trials will be discussed in the following 4 sections: (1) recruitment and 
eligibility criteria, (2) feasibility and safety outcomes, (3) functional assessments and 
(3) structural assessments.  
 
4.5.1 Recruitment and eligibility criteria  
The aim of the exclusion/inclusion criteria was to identify patients who have noted 
recent decline in visual function so that patch graft may prevent visual loss prior to 
photoreceptor cell death.  
Over the course of the atrophic disease study, 32 patients were referred for 
consideration of RPE patch graft because they had subjective decline in vision. Nine 
(28%) were enrolled into the study and the remaining 23 were excluded because their 
VA were better than the entry criteria. There were 2 important issues arising from the 
use of VA to determine disease progression. First, there’s significant disagreement 
between Snellen and ETDRS VA measurement. Second, VA tends to remain stable 
despite progression of atrophic disease and subjective decline in visual function.  
Falkenstein et al. (2008) reported that VA measured on Snellen charts was on 
average 2 lines worse than that measured with the ETDRS charts. In a subset of 30 
patients who had Snellen VA of 6/60, the corresponding mean ETDRS VA was 0.68 
logMAR (~6/30); a discrepancy of around 3 lines. Therefore, the author’s observation 
of mismatch between Snellen and ETDRS VA in patients with atrophic macular disease 
is consistent with the study by Falkenstein et al (2008). Such discrepancy may be 
related to the non-standardised testing method and conditions (i.e. variable testing 
distance and reduced or non-uniform Snellen chart luminance). Another reason for the 
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 discrepancy between Snellen and ETDRS VA may be related to the small island of 
central vision in some patients with atrophic macular disease. In the ETDRS chart, there 
are 5 letters per row. In contrast, there are only 1, 2 and 3 letters on the 6/60, 6/36 and 
6/24 lines respectively. A patient with a small central island of vision may not be able to 
locate these larger letters on a Snellen chart and yet is more likely to find at least 1 of 
the 5 letters on the ETDRS chart with equivalent letter size. The ETDRS chart has now 
been accepted as a standard for all clinical trials. The author has therefore collaborated 
in further studies during the course of this Thesis to validate the test-retest variability of 
VA measured on the ETDRS chart using standardised protocol in a cohort of AMD 
patients during the course of this thesis (Patel et al. 2008). 
Some of the patients who were not eligible for transplantation were monitored 
by the author over a course of 1-2 years. It was noted that the majority of these patients 
had subjective decline in visual performance that was not reflected in any change in 
VA. Further examination of their FAF images showed definite enlargement of RPE 
atrophy. A retrospective review (see Appendix 1) of serial microperimetry in 9 of these 
patients with stable VA but enlarging RPE atrophy on FAF imaging showed statistically 
significant decline in the mean retinal sensitivity in the loci adjacent to dense scotoma 
(defined as loci where brightest stimulus was not detected) over 6-12 months (Chen et 
al. 2010). During the same time interval, there was no significant decline in mean 
retinal sensitivity or fixation stability. At the same time, a separate study also described 
a similar method of analysing serial microperimetry using peri-lesional sensitivity 
change to detect disease progression over 2 years (Meleth et al. 2010). Future cell 
transplantation studies may need to consider the use of serial microperimetry rather than 
VA to identify those patients with the most rapid functional decline.   
In retrospect, it becomes apparent that by setting the VA cut off at 6/36 and 6/24 
for the IMD and AMD cohorts respectively, this study was only able to recruit patients 
with advanced disease; characterised by extensive loss of photoreceptor cells. Future 
trials investigating novel rescue therapies in atrophic diseases will need to consider the 
limitation of using reduced VA as entry criterion. However, this restriction is difficult to 
overcome especially if the novel therapy has potential risk to sight. The recent reports of 
high predictive values of certain fundus AF patterns around atrophic regions in dry 
AMD may help to identify high risk patients earlier in the disease process and therefore 
enable earlier experimental intervention (Holz et al. 2007). In future studies, other 
measures of disease progression, such as increase in dense scotoma size, decline in peri-
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 lesional retinal sensitivity or loss of cone using microperimetry or AOSLO, should be 
documented to help with patient selection in RPE transplantation.  
 
4.5.2 Feasibility and safety outcomes 
It is uncommon for patients with GA or IMD to undergo vitrectomy surgery. Although 
macular translocation has been performed on a handful of such patients, submacular 
surgery in eyes with atrophic macula has not been described previously. Therefore, 
feasibility and safety of submacular surgery in these patients were considered as 
important outcome measures.  
 
4.5.2.1 Feasibility of patch graft technique in atrophic disease 
The first and the last of the 5 surgical steps in autologous RPE-choroid patch graft can 
be considered to be standard components of most vitrectomies. Separation of the 
posterior hyaloid was achieved in all 9 patients. The need for multiple exchanges of 
intraocular instruments through the sclerostomy explains the high rate of entry site 
breaks (22%). Retinopexy of entry site breaks and donor site retinotomy were 
necessary. However, it was chosen not to perform retinopexy around the macular 
retinotomies because of extensive pre-existing RPE atrophy in the macular region and 
high likelihood of spontaneous closure under oil tamponade.  
Several punctate retinotomies were required to create separation between 
atrophic retina and Bruch’s membrane due to strong chorioretinal adhesion in regions of 
RPE atrophy. One patient developed a macular hole during bleb detachment due to 
severe foveal atrophy. Similar difficulty in bleb detachment has been described 
previously in patients with GA (Joussen et al. 2007). It is anticipated that bleb 
detachment will be easier to achieve in patients enrolled into future studies that recruit 
subjects with early disease and no RPE atrophy.  
Preparation of the autologous RPE-choroid patch was possible in all patients. 
This step is associated with significant risk of bleeding especially when intraocular 
pressure drops during exchange of instruments. Frequent exchange was necessary 
because of the need for 2 types of scissors to cut out the RPE-choroid patch, a spatula to 
hold or grip the graft and a pair of forceps to remove the surplus retina. Timing of 
removing surplus retina had impact on the stability of the graft over the spatula. Early 
removal of the surplus retina tended to allow the graft to contract and its edge to curl 
around the spatula. Delaying removal of the retina until the graft is loaded on the spatula 
may prevent excessive curling but can lead to choroidal bleed and intraocular fluid 
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 current within the vitreous cavity during exchange of instruments. Both peeling of the 
surplus retina and intraocular fluid current can potentially damage the RPE on the patch 
graft (MacLaren et al. 2007). Such trauma could be avoided if a readily available RPE 
patch graft was pre-loaded on a protective delivery device. Another problem of 
harvesting autologous RPE patch is the continued release of RPE from the donor site. 
This may lead to formation of PVR membrane adjacent to the donor site, leading to 
tractional opening of the donor site retinotomy and hence retinal detachment (as seen in 
patient 2). Furthermore, inferior PVR membrane may develop leading to inferior 
tractional detachment, retinal shortening and the need for extensive inferior retinectomy 
to reattach the retina (as seen in patient 6). During the course of this study, fresh surplus 
retina was kept with each patient’s consent for further studies. We examined the 
histology of retina from patients in inherited dystrophy (Wickham et al. 2009) and used 
retina from patients with AMD as a bio-assay for assessing function of stem cell derived 
RPE in vivo (Carr et al. 2009a).  
The most difficult step of this technique was the delivery of the patch graft into 
the submacular space. Once the macular retinotomy is made, enlargement was required 
to enable insertion of the graft. The enlarged retinotomies closed in all except 2 patients. 
One of these went on to develop recurrent retinal detachments due to failure to close the 
retinotomy. The location and size of the retinotomy may have impact on patient’s 
choice of eccentric fixation and the amount of frictional trauma to the RPE. 
Furthermore, to minimise photoreceptor cells loss, laser retinopexy around the 
retinotomy was not performed and the bleb detachment was kept inflated whilst the 
graft was pushed into the subretinal space. Although the aspirating-reflux spatula 
designed by van Meurs (2003) was able to grip the graft, the main short-comings of this 
device was its inability to release the graft reliably.  The elasticity of the choroid also 
led to folding of the edges of the graft around the elongated shaped spatula resulting in 
an effectively smaller graft. The under surface of the spatula also caused RPE loss at the 
site of graft insertion and may lead to choroidal trauma and bleed.  
The approach to RPE-choroid graft delivery has been modified since the initial 
description in 2003. Van Meurs described the use of large temporal raphe linear 
retinotomy to avoid damage to the superior paramacular region (IOVS 2008;49:E-
Abstract 4904). This may be beneficial in patients without foveal function due to 
inherited macular disease as they tend displace the central scotoma to the superior visual 
field, i.e. placing the preferred retinal loci superior to the region of atrophy (Sunness et 
al. 1996). However, for the right eyes of patients with GA from AMD, this approach 
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 may not be suitable since the majority of patients tends to displace the central scotoma 
to the right of fixation in the visual field space and hence placing the preferred retinal 
loci near the temporal raphe (Sunness et al. 1996). Petersen et al. (2008) described the 
use of temporal 180º retinotomy near the ora to enable direct translocation of 
paramacular or equatorial RPE-choroid patch graft. Although this may avoid retinotomy 
related frictional damage to the graft surface, the technique is more complex with a 
greater risk of PVR. To facilitate release of the patch graft, Maaijwee and colleague 
(Maaijwee et al. 2008b) described the use of an electric vibrator (from a mobile phone) 
attached to subretinal forceps and more recently Knulst et al. (2009) described a micro-
scale thermal tissue gripper that enables reliable release of tissue in fluid phase. 
However, it has yet to be shown that these instruments lead to better surgical and 
functional outcomes.  
 
4.5.2.2 Post-operative complications 
The post-operative complications seen following RPE-choroid graft in this group of 
patients are similar to those described previously in patients with neovascular AMD 
(Joussen et al. 2006; MacLaren et al. 2007).  
Intra-operative and continued post-operative release of RPE cells from the mid-
peripheral RPE donor site into the vitreous cavity may contribute to the formation of 
PVR membrane and ERM leading to donor site break, opening of the donor macular 
retinotomy, retinal detachment and macular pucker. Retinal detachment occurred in 3 of 
9 patients. These were related to retinal break near the donor site, inferior PVR and re-
opening of macular retinotomy, respectively. The high rate of detachment is comparable 
to that reported by Joussen and colleagues (2007) in which 5 of the 12 patients had post-
operative retinal detachment. The high rate of detachment was the main reason for 
termination of the clinical trial before enrolment of 10 patients from each arm of the 
trial.  
 CNV developed in 2 patients and confirmed on angiography at 11 and 26 
months respectively. Both of these patients were at risk because they were greater than 
50 years of age and one of these also had contralateral neovascular AMD. The patch 
graft prevented centripetal growth of the CNV. However, in patient 5, there was 
subretinal fluid extending from temporal edge of the graft, around the inferior edge and 
to the nasal border of the graft. In this patient, development of CNV led to a shift in 
eccentric fixation from outside the graft to directly over the patch.  
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  Complications after routine posterior segment surgery such as cataract, residual 
oil and glaucoma were also seen. Unfortunately, 2 patients developed post-operative 
scleritis which may be related to the multiple procedures required for retinal detachment 
repair. It is not know if prolonged exposure of the bare internal scleral surface (at the 
donor site) to intraocular silicone oil may also predispose the eye to recurrent scleritis.  
 
4.5.3 Functional assessments 
The purpose of RPE transplantation is to prevent further degeneration of the outer 
retina. Functionally, this can be shown by demonstrating stability of visual acuity, 
reading ability, retinal sensitivity, ERG responses and score in questionnaires exploring 
quality of life. Each of these outcome measures, alone, is unable to provide a complete 
picture of the status of retinal and visual function. However, most clinical trials have 
chosen VA as a primary endpoint. As discussed previously, VA may not be a suitable 
primary endpoint for treatment trials involving patients with atrophic macular disease 
just as VA is not considered as appropriate primary outcome measure in studies of 
glaucoma treatment. In both diseases, the aims of the therapy are to prevent loss of VA. 
This tends to occur late in the disease process. In the following paragraphs, limitations 
of each of the endpoint measure will be discussed. 
 
4.5.3.1 Acuity, contrast sensitivity and reading tests 
Distance VA declined in all patients after graft although the overall decline tended to be 
greater in those with IMD. The decline in VA at 6 month was followed by slight 
improvement at 12 months. This remained stable for up to 2 to 3 years after the graft. 
The partial recovery of VA loss at 6 months may be explained by adaptation to another 
preferred retinal locus (see next section). Similarly, there was a general trend for 
reduction in CS although this was reversed by 12 months. 
Reading ability improved in 2 and declined in 7 patients. Interestingly, 
improvement in near visual function was found to be greater than distance VA 
following macular translocation (Eckardt et al. 1999; Fujikado et al. 2002; 
Mruthyunjaya et al. 2004). This discordance was attributed to reduction of the scotoma 
size. Improvement in reading ability and decline in distance VA in patient 5 may be 
explained by the enlargement of visual span as fixation shifts from the small foveal 
central island to the edge of central scotoma (Sunness et al. 1997). Alternatively, this 
patient’s poor reading performance pre-operatively may be due to factors related to 
perceptual span, eye movement or motivation (Robbins and McMurray 1988; Bullimore 
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 and Bailey 1995). Another possibility is the greater test-retest variability in reading 
assessment using the MNRead charts in patients with macular diseas compared to those 
without (Subramanian and Pardhan 2009). 
Despite the overall loss of acuity and reading ability, this study has been 
successful in demonstrating the proof of principal in RPE transplantation. This paradox 
can be understood when VA outcome is examined in conjunction with microperimetry 
findings. 
 
4.5.3.2 Microperimetry tests 
Microperimetry demonstrated convincing evidence that RPE graft can rescue retinal 
function. The patch graft supported retinal sensitivity in 7 patients. Two of these also 
used the patch to support fixation. These findings suggest that VA may not be a suitable 
primary endpoint in trials involving atrophic disease. The 2 patients with no sensitivity 
over graft had severe epiretinal membrane and graft fibrosis, respectively.  
In some of these 7 patients, the area of highest sensitivity was near the edge of 
the graft. This may be an artefact due to tracking error or stray light from reflection of 
the light stimulus. However, correlation between preserved photoreceptor cell layer on 
OCT and retinal sensitivity in the same region provides evidence that the intact outer 
retinal structures supported the edge of the graft may be contributing to function. 
Although photoreceptor cells were rescued over the patch graft, these regions were not 
chosen as the preferred retinal locus for fixation in all patients. Several reasons may 
explain this observation: (1) retinal sensitivity was not as high as other retinal loci 
(outside the graft) which can potentially provide a better VA or CS, (2) quality of vision 
supported by graft may be poor due to metamorphopsia arising from irregular graft 
surface and, (3) the region of retinal function rescue by the graft did not have the 
horizontal span for reading task. It is important to note that all patients had large central 
or paracentral scotoma and therefore had no photoreceptor cells to rescue in large 
portions of the macular region even before the graft. 
Comparison between pre and postoperative microperimetry maps was not 
possible because of widespread distortion in retinal vasculature landmarks induced by 
grafting. However, it was the impression of the author that the size of scotoma appeared 
to have enlarged after patch graft. Quantification of the change in scotoma size was not 
possible because the preoperative microperimetry testing grids used were too small for 
comparison with postoperative microperimetry maps. Enlarged scotoma may be related 
to a combination of (1) mechanical or photic injury during submacular surgery, (2) 
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 ischaemic or hypoxic injury during the 1st week after surgery while the graft was not yet 
vascularised and (3) natural history of atrophic disease progression. 
Follow-up microperimetry at 2-3 years in selected patients showed an overall 
decline in retinal sensitivity over the patch. In view of the small sample size, lack of a 
control group and the potential test-retest variability of retinal sensitivity measurements 
in patients with macular disease, it is difficult to interpret these findings. 
Future studies using microperimetry as a trial end point will benefit from 
improvement in the onboard NAVIS software and testing strategies of the Nidek MP1. 
Shortening of testing time may improve reliability. An increase in the range of stimulus 
brightness (from 20 to 40 dB) will allow more precise mapping of the absolute scotoma. 
The ability to import pre-captured fundus image which has already being co-registered 
with OCT to identify the foveal centre will enable more accurate centralisation of 
testing grid.  
 
4.5.3.3 Electrophysiological studies 
Similar to VA measures, electrophysiology testing demonstrated that patch graft led to a 
general reduction in macular and retinal function.  
Full-field ERG demonstrated vulnerability of the cone and, to a lesser extent, rod 
systems to patch graft surgery. This was the case in both IMD and AMD patients. The 
reduced cone and rod system function is likely to be at the level of photoreceptors since 
a-wave amplitude was also reduced. Significant reduction in full-field ERG has also 
been reported following macular translocation, which is a more complex procedure that 
involves 360º retinectomy and total retinal detachment (Luke et al. 2001). The reasons 
for the decline after graft may include: (1) pre-existing photoreceptor cell dysfunction 
and vulnerability to the insult of surgery, (2) laser and harvesting of autologous RPE-
choroid destroys a significant portion of the retina (Schuurmans et al. 1977), (3) 
prolonged surgery with photic toxicity, (4) prolonged silicone oil tamponade, (5) post-
operative retinal detachment (Hamasaki et al. 1969) and (6) disease progression. None 
of these factor would have made a major contribution to the reduction in ERG based on 
previous animal experiment findings (Wallenten et al. 2008; Mackiewicz et al. 2007). 
Interestingly, 3 patients had a follow-up full-field ERG after the frist post-operative test 
and partial recovery of cone system ERG response abnormalities was noted in 2 of 
these. This peripheral cone system recovery is also mirrored in the change in peripheral 
rings of the multifocal ERG (see below) 
 Page 154  
  Pattern ERG was undetectable in 4 patients pre-operatively and of the remaining 
5 with detectable responses, 2 of these became undetectable after graft (patient 3 and 7) 
probably due to disease progression and iatrogenic damage to the macular 
photoreceptors. Interpretation of multifocal ERG was complicated by the use of 
different preferred retinal loci before and after surgery in most patients and the inability 
of the ERG operator to monitor fixation during testing. Also, the size of central hexagon 
is relative large in comparison to the graft so that functional gain or decline in small 
regions (e.g. 1 disc area) cannot be detected reliably by the multifocal technique. Most 
patients had noisy tracings pre- and pos-operatively in the central and paracentral 
hexagons. However, loss of recordable baseline mfERG waveform in the central 
hexagon is probably related to significant iatrogenic injury to the macular cones. Bleb 
detachment of the macula has been shown not to affect mfERG in a large animal model 
(Kyhn et al. 2008). However, the same cannot be assumed in patients with subclinical 
or clinical atrophic macular disease. Patient 1 had improvement in these central rings 
but it may have been artefactual since the size of his central island of vision was less 
than a third of the disc area. This patient later developed another preferred fixation locus 
temporal to the graft. The improved paracentral response may reflect this shift in 
fixation locus. The delayed recovery of peripheral cone function, as seen on multifocal 
and full-field ERG is difficult to explain. Long-term follow-up ERGs will be needed to 
confirm these findings. 
 Although full-field ERG was feasible to perform in this group of patients, the 
wide inter-individual variation, test-retest variability and lack of robust normative 
database in elderly patients over age of 80 makes its interpretation difficult. Eccentric 
viewing, which occurred in most of these patients, complicates the interpretation of 
mfERG. Therefore, in future studies of patch graft, it will be essential to monitor 
fixation during mfERG. Furthermore, smaller hexagon in the stimulus array will be 
needed to detect changes within a smaller region of the retina. Advances in multimodal 
imaging technique combining smaller mfERG stimulus size, optical coherence 
tomography and scanning laser ophthalmoscope imaging may allow more accurate and 
reliable correlation between graft perfusion, RPE function, intraretinal architecture and 
retinal function after patch graft (Dudgeon et al. 2007).  
 
4.5.3.4 Quality of life questionnaires. 
At baseline, there was a trend for worse quality of vision and vision-related quality of 
life in patients with AMD compared to IMD. Both near and distance tasks were more 
 Page 155  
 difficult for patients with AMD. They also had more role limitations, poorer mental 
health and social functions, and greater dependency on others. This may also be a 
reflection on the lower scores on the general health related quality of life questionnaire.  
In general, the AMD group had a perception of poorer physical health.  
Comparing post- to pre-operative scores, there was a trend for patients to have 
worse peripheral and colour visions following patch graft surgery. This is in keeping 
with the findings from full-field ERG where both scotopic and photopic responses 
declined. The decline in peripheral vision was particularly marked in the AMD group 
probably because 2 of 4 patients developed retinal detachments. Despite overall decline 
in retinal function, there was improvement in mental health in the IMD group and a 
trend for lesser role limitations in the AMD group. These observations highlight the 
importance of having a control group in future trials so that such improvements in 
quality of life are not attributed solely to treatment effect. In the general health 
questionnaires, there were no major changes in the IMD group but patients in the AMD 
group had a trend for declining social functioning, physical and mental health as well as 
emotional well-being.  
Due to the variability of the responses, this pilot study had insufficient power to 
draw conclusions from the questionnaire results (Mangione et al. 2001). Future trials 
using the 25-Item National Eye Institute Visual Function Questionnaire may use the 
results from this study to perform power calculation so that adequate sample sizes are 
used for detection of meaningful change in the subscale scores (Mangione et al. 2001).  
 
4.5.4 Structural assessments 
Functional success of autologous RPE transplantation depends on integration of 
the patch graft with the underlying choroidal bed and survival of the RPE layer. These 
can be demonstrated on fundus angiography and AF imaging. OCT can also 
demonstrate vascular structures within the choroid of the patch graft and rescue of the 
outer nuclear layer over the graft. During the course of the study, the time-domain OCT 
(StratusOCT) was replaced by several types of spectral-domain OCT scanners. Clinical 
trials that report structural outcomes in therapies for macular diseases often use the 
central macular thickness as an endpoint measure. However, this is not a suitable 
endpoint for this trial since some patients do not have clearly identifiable foveal features 
due to severe atrophy and the region of outer nuclear layer rescue is not necessarily 
located at the fovea. In the following paragraphs, the structural outcomes will be 
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 summarised and the limitation of each of the endpoint measure will be discussed 
further. 
 
4.5.4.1 Fundus angiography 
Similar to that observed in the series described by Joussen and colleagues (2007), ICG 
angiography demonstrated perfusion of the patch graft despite clinical evidence of 
choroidal atrophy in the area directly underneath the graft. The evidence of graft 
perfusion came from the differences in the pattern of ICG filling in the macular region 
before and after grafting. 
Intentional and unintentional surgical trauma to the Bruch’s membrane during 
insertion of the graft may have promoted connection of choroidal vessel between 
recipient site and the graft. Damage to the Bruch’s membrane may incite inflammatory 
response which aid proliferation of endothelial cells at the interface, between the 
residual choriocapillaris at the recipient site and the large choroidal vessels of the under 
surface of the patch graft. Experiment in normal pigs has demonstrated bridging vessels 
between the recipient choroidal bed and the choroid graft as early as 1 week, even if the 
Bruch’s was not intentionally damaged and when the graft was placed upside down 
(Maaijwee et al. 2007b). Similarly, transplanted partial thickness autologous RPE-
choroid patch in rabbits were perfused by 1 week after grafting (Hu et al. 2008). 
Unfortunately, angiographies were not performed in patients until 5-12 months after 
grafting. Therefore it is not known how early these grafts became perfused in this cohort 
of patients. 
 
4.5.4.2 Graft autofluorescence 
Fundus AF imaging demonstrated varying patterns and intensities of AF Signal over the 
patch graft. Linear pattern was commonly seen and this is related to the irregular ridges 
on the surface of the graft and the linear RPE hyper-pigmentation. Contraction of the 
elastic patch graft after it is released in the submacular space is likely to contribute to 
the ridges over the surface of the graft. Homogenous AF signal on the portion of the 
graft adjacent to the retinotomy (patients 1, 5 and 8 are good examples) implies that the 
linear patterns of AF may also arise from abrasive trauma during insertion of the patch 
through the retinotomy.  
Absolute intensities of the patch graft are difficult to interpret due to 
confounding factors such as lens and other media opacities. However, significant 
reduction in patch graft AF signal in 3 patients was worth noting. Patient 4 has low AF 
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 signal at the distal portion of the graft which seems to follow the oval shape of the 
original Bull’s eye lesion. The loss of signal is most likely to be related to trauma during 
insertion of the patch rather than absence of outer segment interaction with the graft 
RPE. Patient 7 has large areas of low autofluorescence signal over the patch due to 
masking effect from the ERM. Patient 9 has minimal autofluorescence signal due to 
submacular haemorrhage and trauma to the graft at the time of transplantation. Most 
grafts also had pigmentation at the edge of the graft which masked autofluorescence 
signal.  
The autofluorescence pattern outside the region of the graft did not seem to 
change significantly except for slight enlargement of the hypo-autofluorescent regions 
related to atrophy expansion. Given the limitations of FAF imaging, future studies need 
to explore the use of adaptive optics scanning laser ophthalmoscope (AOSLO) to image 
grafted RPE (Morgan et al. 2009). However, it may not be feasible to use AOSLO in 
these patients due to the irregularity of the RPE monolayer on the graft and the 
frequently observed cystic change within the overlying retina. 
 
4.5.4.3 Optical coherence tomography 
OCT demonstrated that intraretinal architecture was usually abnormal over the graft. 
This is not surprising since most of the macular region was affected by retinal atrophy 
even before patch grafting. Specifically, the most common features were intraretinal 
cystic change and outer nuclear layer and photoreceptor cell segments loss.  
Most patients had some degree of intraretinal cystic change accompanied by 
distortion of retinal surface due to ERM. Another cause of cystic change may be related 
to failure of RPE pump function. In the 2 patients with CNV adjacent to the graft, the 
intraretinal cystic change and subretinal fluid are most likely to be related to leakage 
from the CNV rather than traction from ERM. 
Most scans of retina over the graft showed disorganised outer retinal structures 
with reduced outer nuclear layer thickness and no clear hyper-reflective line that 
correspond to the inner segment/outer segment junction. Occasional areas with intact 
outer retinal structures tended to localise at the portion of the graft closest to the 
retinotomy. Presence of outer nuclear layer and intact inner segment/outer segment 
junction over the graft is consistent with the hypothesis that photoreceptor cells can be 
rescued by RPE transplantation. Histological studies in rabbits also showed that the 
outer segments can regenerate over 3 months when autologous RPE-choroid patch graft 
was used to reconstruct a pre-existing defect in the RPE that was created 2 weeks prior 
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 to transplant (Hu et al. 2008). In the same study, histology demonstrated intact outer 
nuclear layer but absence of outer and inner segments, and choriocapillaris 2 weeks 
after RPE debridement. Without autologous RPE patch graft, the outer nuclear layer 
was lost after 3 months. Unfortunately, spectral domain OCT was not available during 
the early phase of the trial. Therefore it was not possible to study the early rescue effect 
of transplanted RPE on degenerating photoreceptor cells. 
Future clinical studies of RPE transplantation may explore the use of AOSLO to 
image cone mosaic before and after grafting (Liang et al. 1997). However, it should be 
noted that AOSLO imaging will not identify cone photoreceptors cells without inner 
and outer segments since image acquisition depends on the presence of their wave-
guiding properties (Yoon et al. 2008). Therefore, AOSLO may not be able to identify 
cone mosaic during the first few of weeks after RPE cell transplantation.  
 
4.5.5 Future directions in patch graft surgery in atrophic disease  
There are 3 components of the current patch graft approach that require further 
modifications. These areas are: (1) the use of alternative sources of cells such as RPE 
derived from human embryonic stem cell (hESC) or induced pluripotent stem cell 
(iPSC), (2) the use of specialised delivery device that can protect the graft from 
intraocular fluid current and frictional trauma at the sites of sclerostomy and retinotomy, 
and (3) the use of pharmacological adjunct and visco-elastic substances to enable 
atraumatic bleb detachment and maintenance of submacular space during graft 
insertion.  
Alternative RPE sources need to be explored because autologous equatorial RPE 
may be diseased in patients with macular disease and harvesting of autologous RPE-
choroid patch increases the risk of surgical complications. Although this trial excluded 
patients with obvious abnormalities of peripheral fundus AF and ERG evidence of 
severe generalised retinal dysfunction, histological examination of the surplus retina 
removed from 4 of the 5 patients with IMD demonstrated abnormalities in the cone or 
rod photoreceptor inner and outer segments (Wickham et al. 2009). This suggests that 
current clinical tools cannot exclude the possibility of generalised primary 
photoreceptor cell disease and therefore secondary peripheral RPE dysfunction in a 
patient with clinical evidence of isolated macular disease. There are also histological 
evidence of photoreceptor cells degeneration in regions with preserved RPE in patients 
with GA from AMD. Given that some patients with AMD may have the Y420H variant 
of the complement factor H gene (Haines et al. 2005; Edwards et al. 2005; Klein et al. 
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 2005; Zareparsi et al. 2005; Hageman et al. 2005) and that local production of CFH 
may be implicated in the pathogenesis of AMD, autologous source of RPE may not be a 
suitable long-term option for treatment of GA. Alternative sources of RPE derived from 
hESC or iPSC with genetic modification should be explored. 
The current patch delivery device is relatively small and is able to hold and 
release patch grafts through manual control of a fluid-filled syringe. Further 
modifications are required to enable delivery of a larger sized pre-made patch graft. The 
ideal device will be made from disposable material and packaged with the pre-made 
patch graft ready for implant. It will have a protective cover around the patch graft to 
minimise loss of RPE due to fluid current or friction at the sclerostomy and retinotomy. 
The release of the graft will need to be simple and reliable. Such device is currently 
being developed. 
Currently, the macula is detached by infusing the same fluid as the intraocular 
infusion; Hartmann’s solution. Adhesion between atrophic retina and bare Bruch’s 
membrane appeared to be stronger than that between photoreceptor cells and RPE. 
Future studies will need to explore pharmacological agents that may be added to the 
fluid used for bleb detachment to reduce retinal-Bruch or retinal-RPE adhesion. The use 
of sodium hyaluronate (a natural component of vitreous) to maintain bleb detachment 
may enable less traumatic delivery of the graft and more controlled manipulation of the 
patch within the submacular space. Sodium hyaluronate is available commercially as 
Healon® and is approved for use within the eye. It has been used to temporarily detach 
the retina in animal models of retinal detachment and subretinal visual prosthesis 
implant (Cook et al. 1995; Schanze et al. 2006).  
 
4.5.6 Strengths and limitations of the study 
The strengths of the study were its prospective design and the detailed functional and 
structural assessments. Furthermore, the procedure was carried out by a single surgeon 
who already had experience in the technique of autologous patch graft. Therefore, the 
effect of surgical learning curve was unlikely to confound the results of the studies. 
The prospective design of the studies enabled extensive and detailed pre- and 
post-operative examination of retinal function and structure. The use of microperimetry 
provided the most compelling evidence of functional rescue whereas standard visual 
acuity, quality of life questionnaire and electrophysiological testings were not useful for 
demonstrating the rescue effect of RPE transplantation. However, these investigations 
were important for safety assessment.  
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 The main limitation of the study was the use of moderately reduced VA as an 
entry criterion. This resulted in low recruitment rate and enrolment of patients late in the 
disease process. The early termination of the study due to high operative complication 
rates also resulted in a small sample size. Because of these limitations, it was not 
possible to determine the factors that contribute to the varying degrees of functional 
rescue.  
Another limitation of the studies was the evolving technology and the steep 
learning curve in obtaining the various outcome measures during the course of these 
trials. During the course of the autologous RPE graft trials, OCT technology has 
evolved from the time-domain StratusOCT to various SD-OCT scanners. Each of the 
SD-OCT scanners differs in their user interface and quality of image acquired. The 
superior quality of OCT image from the more recently available Spectralis® enabled 
detailed structure function correlation.  
Lastly, an instrinsic limitation of psychophysical outcome measure is test-retest 
variability. Prior to commencement of the clinical trials, there was little information on 
the variability of reading ability test (MNRead) and microperimetry test (Nidek MP1). 
More recently, studies have demonstrated larger variability in reading ability 
measurement among patients with poor vision compared to those with normal vision 
(Subramanian and Pardhan 2006; 2009). Simiarly, there is also evidence to suggest 
significant intra-examiner, intra-session test-retest varaibiltiy in microperimetry among 
patients with macular disease (Chen et al. 2009). 
 
4.5.7 Clinical implications and conclusions 
This study showed that it is possible for retinal function to be maintained over 
autologous RPE-choroid graft for a prolonged period in patients with atrophic macular 
disease. However, the high operative complication rate and poor visual outcomes raise 
concerns regarding the safety of autologous RPE-choroid patch grafts. Based on these 
findings, we postulate that the poor visual outcomes may be due to choice of late cases, 
pre-existing retinal or RPE dysfunction, surgical insult to the remaining macular 
photoreceptors and the transplanted RPE and genetically pre-determined late primary 
photoreceptor cell loss. Therefore, current technique of autologous RPE-choroid graft 




 Page 161  
 4.6 Contribution 
 
Author’s contribution to the works presented in this chapter are summarised in Table 
4.11. As a spin off from the work on RPE patch graft, the author also published a novel 
method of analysing serial microperimetry which will usefull for future clinical trials 
using retinal sensitivity as one of the core outcome measure (see Appendix 1). 
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 Table 4.11 Contribution list for the dry macular degeneration studies 
Contribution cateogory Details of contribution 
1 Conception and 
design 
Author: drafted protocol, patient information and ethics application 
form for the dry AMD study. The author was not involved in setting up 
the inherited macular dystrophy study since study commenced before 
author started the thesis 
GSU: drafted protocol, draft patient information sheet, draft ethics 
application form for the inherited macular dystrophy study 
LDC: approval of all study documents 
 Preoperative data 
acquisition  
Author: examined all 32 potentially eligible patients and performed their 
ETDRS VA, OCT, FAF and microperimetry. Author also performed 
preoperative baseline tests on patients 5 to 9 
GSU: recruited 5 patients for this study and performed their baseline 
reading and microperimetry tests  
LDC: examined all 32 patients referred for patch graft and counselled all 
9 patients prior to enrollment 
MMN: performed all electrodiagnostic tests 
Optometrist: performed all refractions 
 Surgical procedure Author: assisted in patch graft in patient 5 to 9 and removed the silicone 
oil in 3 of these patients  
LDC: performed patch graft in all 9 patients 90%),  
GSU: assisted in patch graft in the patients 1 to 4 
 Postoperative data 
acquisition and 
analysis 
Author: examined all 9 patients post-operatively and performed their 
ETDRS VA, Pelli-Robson CS, reading test, microperimetry, quality of 
life questionnaires, FAF imaging, OCT and interpreted angiography and 
electrodiagnostics tests.  
GSU: examined first 4 patients post-operatively 
LDC: examined all 9 patients post-operatively 
MMN: performed all electrodiagnostic tests 
Optometrist: performed all refractions 
2 Writing  Author: wrote the entire chapter 
 Revising Author: revised the entire chapter  
LDC: read the chapter and made suggestions 
PJC: read the chapter and made suggestions 
3 Statistical analysis Author: performed all statistical analysis 
CB: supervised statistical analysis 
 Funding PJC and LDC: obtained funding for the London Project to Cure 
Blindness 
 Administrative and 
technical support 
Author: arranged all post-operative visits and created all the graphs and 
figure montage from the image database 
TB: arranged correspondence between ethics committee and research 
governance 
CB; Catey Bunce (statistician), CS; contrast sensitivity, ETDRS; Early Treatment Diabetic Retinopathy 
Study, FAF; fundus autofluorescence, GSU; Gurmit S Uppal (research fellow), LDC; Lyndon Da Cruz 
(supervisor), MMN; Magella M Neveu (electrophysiologist), OCT; optical coherence tomography, PJC; 
Peter J Coffey (supervisor), TB; Tina Burman (research co-ordinator), VA; visual acuity. 
 
 





Chapter 5 Autologous RPE Transplantation in Neovascular Macular 
Disease 
Autologous RPE Transplantation in 
Neovascular Macular Disease 
 
 Page 164  
 5.1 Background 
 
Neovascular AMD, characterised by leakage of fluid or haemorrhage from CNV, can 
lead to acute and permanent central visual loss. Recent advances in intravitreal anti-
VEGF therapies have shown promise in the treatment of these lesions with over one 
third of patients gaining 3 or more lines of VA at 12 month and maintained at 2 years 
after initiation of monthly or variable-frequency injections (Brown et al. 2006; 
Rosenfeld et al. 2006; Brown et al. 2009; Lalwani et al. 2009). However, the role of this 
therapeutic modality in patients with large submacular haemorrhage, pigment epithelial 
detachment or retinal pigment epithelial (RPE) rip is uncertain because VEGF blockade 
does not restore or rejuvenate the diseased RPE-choroid. Large surgical case series of 
macular translocation or autologous RPE-choroid graft and a pilot randomised 
controlled trial of translocation versus PDT, have shown visual function rescue in 
patients with neovascular AMD undergoing reconstruction of the submacular RPE 
(Eckardt et al. 1999; van Meurs and Van Den Biesen 2003; Toth et al. 2004; Uppal et 
al. 2007; Gelisken et al. 2007; Maaijwee et al. 2008a).  
Previous reports showed that autologous RPE-choroid grafts harvested from 
within the macular region supported retinal function but this was not maintained after 5 
years (Stanga et al. 2002; MacLaren et al. 2005). Aisenbrey et al. (2007) reported the 
long-term outcomes (mean follow up of 38.2 months) following macular translocation 
with three quarters of eyes not losing 3 or more lines. However, these authors were 
concerned with the ability of extra-macular RPE-choroid in maintaining foveomacular 
function in the long-term. Maaijwee et al. (2007a) reported VA stabilisation and 
improvement after RPE-choroid graft in the 11 patients who were followed for 4 years. 
However, they did not provide perimetric evidence of retinal function rescue by the 
graft. Assumption of long-term rescue cannot be made for several reasons. The source 
of RPE to be positioned under the fovea in full macular translocation is located at the 
vascular arcade (paramacula) if the macula is rotated >45º around the disc. In contrast, 
RPE outside the vascular arcade (equatorial), where it is populated predominantly by 
rods, is chosen for harvesting of autologous RPE-choroid graft. Several studies have 
found topographic differences in the RPE gene expression and Bruch’s membrane 
composition (Ishibashi et al. 2004; Bowes et al. 2006; van Soest et al. 2007; Kociok 
and Joussen 2007; Chong et al. 2005). Therefore, it is likely that there may also be 
topographic differences in RPE function and its ability to maintain the metabolic and 
functional requirements of the cone photoreceptor cells.  
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 In previous studies, VA has been used as a marker for retinal function rescue 
after surgical intervention. However, VA is a measure of retinal function at the fixation 
locus and is therefore not necessarily equivalent to the ability of the patch graft in 
supporting central visual field. Alternative methods of assessing rescue of retinal 
function are (1) to determine the preferred retinal locus in relation to the graft and 
quantify fixation stability, and (2) to measure local retinal sensitivity over the region of 
the graft using a fundus-controlled perimeter (i.e. microperimeter) such as the Nidek 
MP1. Several groups have previously demonstrated, using microperimetry, that retinal 
function over the graft may be preserved for up to 20 months postoperatively (Joussen 
et al. 2006; MacLaren et al. 2007; Treumer et al. 2007b; Heussen et al. 2008). 
However, the long-term outcome of translocation surgery and autologous RPE-choroid 




In this chapter, the results of 3 retrospective studies examining long-term outcomes of 
RPE reconstruction in neovascular AMD are presented to answer the following 
questions:  
 
1.  What is the long-term functional and structural outcomes following full macular 
translocation in neovascular AMD? 
 
2. What is the long-term functional and structural outcomes following autologous 
equatorial RPE-choroid patch graft in neovascular AMD/ 
 
3. How does the long-term functional and structural outcomes in the first 12 
patients of the translocation cohort compare to the outcomes from the first 12 
patients of the RPE-choroid graft cohort? 
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 5.3 Specific Methodology 
 
5.3.1 Peri-operative variables 
The baseline demographic features and duration of symptoms were recorded. Pre-
operative angiographies were retrieved from the electronic image database (ImageNet, 
Topcon, Tokyo, Japan) and graded independently according to the Macular 
Photocoagulation Study criteria (MPS Group 1991) by an experienced observer (Dr P. 
Patel, Locum Medical Retina Consultant). Intra-operative and early post-operative 
courses were reviewed. For macular translocation, the angle of foveal rotation, and the 
degree of cyclotorsion before and after counter-rotation surgery as measured on double 
maddox rod were recorded. For patch graft, intra-operative complication and course 
were scored according to the system described by Maaijwee and colleagues (2008c). 
The outcomes of repair of post-operative retinal detachments and frequency of post-
operative macular pucker due to dense epiretinal membrane (ERM) were also recorded. 
 
5.3.2 Data collection and statistical analysis 
Data were analysed and graphs were constructed using SPSS for Windows, version 14.0 
(SPSS Inc., Chicago, IL, USA). For all statistical comparisons, a p value of less than 
0.05 was considered statistically significant. 
For long-term outcomes, the mean, standard deviation (SD), median, 
interquartile range (IQR) and proportions were used to describe VA and retinal 
sensitivity measures in the subgroups. Wilcoxon signed ranks and McNemar tests were 
used to compare median VA and proportion of patients with a 0.3 logMAR (3 lines) 
gains or VA of 0.7 logMAR (Snellen equivalent of 6/30) or better for each group 
separately at the 1 year time point and the final visit.  
 For the comparison of long-term outcomes, baseline characteristics were 
compared between the macular translocation and patch graft groups using the Fisher’s 
exact test (gender, lesion type) and the Mann-Whitney U test (age, duration of 
symptoms, lesions size, VA and CS). The change in VA and CS at 1, 2, 3 and 4 years 
between the 2 groups were compared using the independent sample t-test. The change in 
VA and CS between preoperative and follow up visits were analysed using the 
Friedman test.  
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 5.4 Results 
 
5.4.1 Full macular translocation long-term outcomes 
 
5.4.1.1 Patient characteristics 
A total of 40 consecutive patients underwent surgery with the intention of full macular 
translocation during a 6 year period from 2003 to 2008. The mean (range) follow-up 
duration was 38 (12-67) months. Thirty-two patients (80%) were followed for 24 
months or longer, 24 patients (60%) for 36 months or longer and 10 patients (25%) for 
48 months or longer. Two patients had died. 
The median age of the cohort at the time of surgery was 77 years and of these, 
24 were female and 21 out of 40 had surgery to the right eye. The median (range) 
duration of symptom was 7 (2 to 32) weeks. Thirteen had predominantly CNV lesion 
and half had submacular haemorrhage. There was a trend for shorter duration of 
symptom and larger predominantly haemorrhagic lesions referred for surgery in recent 
years (see Table 5.1). Half of the patients had predominantly haemorrhagic lesion. An 
overall reduction in the number of cases referred for translocation during 2007 and 2008 
coincided with the years during which anti-VEGF agents became available.  
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 Table 5.1 Macular translocation: demographic data 
 2003-2004 2005 2006 2007-2008 Entire 
cohort 
Number of patients 10 (3, 7) 12 10 8 (5, 3) 40 
Median age 72.0 77.5 81.5 78.0 76.5 
M:F 2:8 6:6 4:6 4:4 16:24 
R:L 4:6 7:5 5:5 5:3 21:19 
Median (range) 
symptom duration in 
weeks 
8.5 
(4 – 32) 
9.0 
(5 – 16) 
7.2 
(2 – 10) 
3.3 




    RPE rip 
    Blood 






















lesion size (DA) 
7 
(4 – 40) 
10 
(2 – 37) 
9 
(3 – 41) 
20 
(9 – 49) 
10 
(2 – 49) 
Previous Rx for 
CNV 
1 had prior 
PDT x 1 
None None None None 
Median VA 
(logMAR) 
0.89 0.70 0.80 1.14 0.80 
% with VA of 1.0 
logMAR or better 
60% 92% 90% 50% 75% 
CNV, choroidal neovascularisation; DA, disc area; F, female; L, left; logMAR, logarithms of 
minimum angle of resolution; M, male; PDT, photodynamic therapy; R, right; RPE, retinal 
pigment epithelium; Rx, treatment. 
† Predominant lesion (lesions with angiographic evidence of tear of the RPE are categorized 
under RPE rip regardless of CNV or blood components). 
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 5.4.1.2 Surgical outcomes 
Translocation was combined with phacoemulsification and intraocular lens (IOL) 
implant in 36 patients. Intra-operative coughing and chorioretinal adhesion at the 
macula precluded translocation of the macula in 1 and 2 patients, respectively. In the 
remaining 37 patients, the fovea was rotated superiorly with the exception of 1 patient 
who had an inferior rotation of the fovea. The median (range) estimated angle of 
rotation was 50º (45-80º). Among these 37 patients, 2 patients did not have excision of 
CNV and subsequently received PDT. Of the other 35, 2 had residual active CNV 
(increasing haemorrhage and subretinal fluid) detected within first 2 months. One of 
these was left to fibrose due to poor visual potential and the other was treated with PDT.  
Postoperative retinal detachment occurred under oil in 6 patients (15%) and 4 of 
these had reattachment surgery prior to counter-rotation. The remaining 2 underwent 
counter-rotation without removal of oil. The median (range) angle of cyclotorsion, as 
measured with double Maddox rod, was 35º (12-80º) prior to counter-rotation. 
Combined removal of oil with counter-rotation was performed in 35 of 37 patients who 
had foveal rotation (see above). Of these 35, 2 (6%) had subsequent retinal detachments 
which were repaired and 4 had further vitreous washout for residual oil (3 patients) or 
vitreous haemorrhage (1 patient). Of the remaining 2 who did not have oil removed at 
the time of counter-rotation, 1 developed total retinal detachment following counter-
rotation and the other had further repair which was successful after subsequent removal 
of oil. Overall, a total of 8 (20%) patients in this cohort developed retinal detachment, 
all within the first 6 months. One patient still had oil in situ at the last follow-up. Dense 
ERM causing macular pucker developed in 9 patients (23%). Among these, 3 had prior 
postoperative retinal detachments, 2 went on to develop total retinal detachments and 2 
underwent ERM peel without improvement in VA. 
Following the initial counter-rotation procedure (37 patients), the median angle 
of torsion was 7.5º of under-correction (ranging from 10º of over correction to 45º of 
under correction). A total of 4 patients had significant diplopia requiring revision of 
counter-rotation surgery and 1 other patient required botulinum toxin injections of the 
contralateral extraocular muscles. One patient developed pan-uveitis at 10 months with 
culture-negative vitreous biopsy. Post-operative complications following translocation 
are summarised in Table 5.2. 
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(N = 10) 
2005 
(N = 12) 
2006 
(N = 10) 
2007-2008 





8 12 9 8 37 (93%) 
Residual CNV  6 0 1 0 7 (18%) 
Retinal 
detachment 
3 0 2 3 8 (20%) 
Dense ERM 
(onset, month) 
5 (at < 12 m) 1 (at < 12 m) 1 (at < 12 m) 2 (at < 12 m) 9 (23%) 
Median residual 
Torsion (number 
of patient needed 


















2 (at 6 and 21 
m) 
3 (at 5, 11 and 
19 m) 
2 (at 10 and 
23 m) 






0 4 (at 3, 3, 8 
and 13 m) 




1 (at 25 m) 1 (at 13 m) 0 0 2 (5%) 
CMO, cystoid macular oedema; CNV, choroidal neovascularisation; ERM, epiretinal 
membrane; CRS, counter-rotation surgery, m; months. 
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 5.4.1.3 Long-term functional outcomes 
 
Visual acuity  
The median (IQR) VA (logMAR) at baseline, 1 year and the final visits (n = 40) were 
0.80 or 6/38 (0.60 to 1.23), 0.70 or 6/30 (0.50 to 1.16) and 0.78 or 6/36 (0.50 to 1.58), 
respectively. There was no significant change in VA from pre-operative to the final visit 
(Wilcoxon signed ranks test, p = 0.71). The number of patients with a VA of 0.70 
logMAR (6/30) or better was 14 (35%) at baseline. This increased to 21 (52%) at 1 year 
and 17 (43%) at the final visit. Similarly, 30 (75%), 29 (72%) and 27 (68%) of eyes had 
a VA of 1.00 logMAR (6/60) or better at baseline, 1 year and the final visit (see Table 
5.3).  
VA improved by a mean (SD) of 0.06 (0.64) logMAR at 1 year and then 
declined by a mean (SD) of 0.05 (0.63) logMAR at the final visit. At 1 year, 12 (30%) 
gained 3 or more lines of VA and 7 (18%) lost 3 or more lines of VA. At the final visit, 
10 (25%) gained 3 or more lines of VA and 13 (33%) lost 3 or more lines of VA (see 
Table 5.4).  
Separate analyses were performed in each of the 4 subgroups within the 
translocation cohort separately over the various time points (see Figure 5.1). There was 
no significant change in postoperative VA from the pre-operative visit in any of the 
cohort except for the 1 year outcome within the earliest cohort (2003-2004) which had a 
overall improvement in VA (mean of 0.35 logMAR or 3.5 lines). This was not 
maintained at 2, 3 and 4 years (see Figure 5.1). 
A subset of the cohort, the first 32 cases (2003-2006), was further examined. 
Their median (IQR) VA (logMAR) at baseline, 1 and 2 years were 0.80 (0.60 to 1.00), 
0.70 (0.50 to 1.00) and 0.78 (0.44 to 1.10), respectively. There was no significant 
change between the baseline and the 2 year BCVA (Wilcoxon signed rank test, p = 
0.530). Among the 32 patients, 24 (75%) achieved a BCVA of 6/60 or better at 1 year. 
At the last observation (mean of 43 months), 6 of these (25%) had 2-line decline in 
BCVA after achieving 6/60 at 12 months. The causes of delayed visual loss in these 
eyes were recurrent CNV (3 patients), CNV complicated by macular hole (1 patient), 
isolated CMO complicated by macular hole (1 patient) and macular pucker (1 patient).  
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 Table 5.3 Macular translocation: frequency distribution of visual acuity 
Visual Acuity At Baseline At 1 Year At Final Visit 
 Visual Acuity (logMAR) 
Mean (95% CI) 0.96 (0.80 to 1.12) 0.90 (0.70 to 1.09) 1.01 (0.79 to 1.23) 
Median (min, max) 0.80 (0.18 to 2.28) 0.70 (0.10 to 2.28) 0.78 (0.12 to 2.28) 
 No. of Patient (%) 
6/12 or better 1 (2%) 5 (12%) 6 (15%) 
6/30 or better, worse than 6/12 13 (33%) 16 (40%) 11 (28%) 
6/60 or better, worse than 6/30 16 (40%) 8 (20%) 10 (25%) 
Worse than 6/60 10 (25%) 11 (28%) 13 (32%) 
CI, confidence interval; max, maximum; min, minimum. 
 
 
Table 5.4 Macular translocation: frequency distribution of change in acuity 
Visual Acuity Baseline to 1 year 1 year to Final Baseline to Final 
 Visual Acuity Change (logMAR) 
Mean (95% CI) 0.06  
(-0.12 to 0.25) 
-0.11  
(-0.20 to -0.02) 
-0.05  
(-0.25 to 0.15) 
Median (min, max) 0.14  
(-1.68 to 1.66) 
-0.02  
(-1.18 to 0.58) 
-0.01  
(-1.68 to 1.60) 
 No. of Patient (%) 
> 6-line improvement 5 (12.5%) 0 (0%) 5 (12.5%) 
> 3-line to < 6-line improvement 7 (17.5%) 1 (2.5%) 5 (12.5%) 
> 1-line to < 3-line improvement 11 (27.5%) 5 (12.5%) 7 (17.5%) 
< 1-line change 6 (15%) 19 (47.5%) 6 (15%) 
> 1-line to < 3-line deterioration 4 (10%) 5 (12.5%) 4 (10%) 
> 3-line to < 6-line deterioration 3 (7.5%) 8 (20%) 8 (20%) 
> 6-line deterioration 4 (10%) 2 (5%) 5 (12.5%) 
CI, confidence interval; max, maximum; min, minimum. 
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 Microperimetry 
From the subset of 21 patients who were followed for 3 or more years, 4 maintained a 
VA of 6/12 or better. Of these, 2 had a microperimetry test within the first year and a 
similar test grid used for follow-up examination at 35 or 41 months. Two other patients 
had their first microperimetry tests performed at 20 and 28 months and follow-up 
microperimetry at 48 and 47 months respectively. For comparison, the change in 
microperimetry 3 patients who developed recurrent CNV was also examined.  
Of the 4 patients who maintained a VA of 6/12 or better, 2 had decline in retinal 
sensitivity in the inferior paracentral macular region which correlated with expansion of 
atrophy from previous CNV excision site. Of the 3 patients with recurrent CNV, 1 had 
stable VA with inferior paracentral retinal sensitivity decline, 1 had decline in VA with 
superior paracentral retinal sensitivity decline, and 1 had decline in VA and retinal 
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 Table 5.5 Macular translocation: microperimetry outcomes 
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 Figure 5.2 Macular translocation: serial microperimetry  
Serial microperimetry, autofluorescence images and optical coherence tomography 
(OCT) scans in patients 9 (A-I) and 21 (J-R) showing long-term rescue of retinal 
function. (A, D, G) Patient 9 presented with a retinal pigment epithelium (RPE) rip with 
subretinal fluid and visual acuity (VA) of 1/60. (B, E, H) At 20 months after 
translocation, VA was approximately 6/9, mean central macular sensitivity was 10.2 dB 
with dense scotoma inferior to the fovea at the site of RPE defect, foveal 
autofluorescence was intact, well-defined hyper-autofluorescence was present in the 
macular region and small intraretinal cysts were noted at the level of inner nuclear layer. 
(C) At 4 years VA remained at around 6/9 and central macular sensitivity increased by 
3.1 dB to 13.3 dB. (F, I) Autofluorescence imaging showed a slight enlargement of the 
RPE defect from CNV excision but no change to the hyper-autofluorescent region in the 
macula and intraretinal cysts in the inner nuclear layer. (J, M, O) Patient 21 presented 
also presented with an RPE rip with subretinal fluid and visual acuity (VA) of 6/24. (K) 
At 5 months after translocation, VA was 6/9 and the mean central macular sensitivity 
was only 3.4 dB with a dense scotoma superior and inferior to the fovea.  (N) The 
scotoma was seen over RPE defect inferiorly but not superior to fovea. (N) 
Autofluorescence image showed foveal hypo-autofluorescence, no autofluorescence at 
the CNV excision site and well-defined hyper-autofluorescence in the macula.  (Q) 
OCT scan showed a small intraretinal cyst at the level of inner nuclear layer. (C) At 
around 3 years, VA was 6/12 and central macular sensitivity remaining at 3.6 dB. (O) 
Autofluorescence image showed slight enlargement of the RPE defect from CNV 
excision but no change to the size of hyper-autofluorescent region in the macula. (R) 
OCT scan showed persistence of intraretinal cysts in the nuclear and ganglion cell 
layers. 
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 5.4.1.4 Long-term structural outcomes 
 
Choroidal neovascularisation 
Recurrent CNV developed in 9 patients; 6 during the first year and 3 during the second 
year (see Table 5.6, Figures 5.3 and 5.4). No recurrent CNV was seen after 2 years in 
the 23 patients who were followed for 3 to 5 years. All CNV recurred at the edge of the 
previous CNV excision site within the macular region except for 1 patient who had de 
novo CNV (unrelated to the excision site) nasal to the fovea. From the onset of CNV, 
these patients were followed for 7 to 43 (mean of 26) months. Recurrent CNV was 
treated in all but one eye using either PDT, anti-VEGF agent, intravitreal triamcinolone 
or a combination of these measures (see Table 5.6). The mean VA (logMAR) at 
baseline and the last observation for these 9 patients were 0.59 (Snellen: 6/24) and 0.73 
(Snellen: 6/33), respectively. Structural outcome after anti-VEGF therapy varied from 
total resolution of the oedema and subretinal fluid to persistent intraretinal cystic 
change, exudates and haemorrhage despite repeated anti-VEGF agent injections (see 
Figure 5.3 and 5.4). 
 
Cystoid macular oedema 
CMO was observed in 38 patients at some stage post-operatively on angiography, SD-
OCT or both. Twenty-one of these were associated with other lesions such as macular 
pucker (7 patients), residual CNV (3 patients), recurrent CNV (9 patients, see Figure 
5.5), pan-uveitis (1 patient) or residual subretinal perfluorocarbon liquid (1 patient). The 
remaining 17 had isolated CMO with varying degrees of severity and duration (see 
Figure 5.6). Twelve of these were only detected on angiography or SD-OCT. These 
subclinical CMO may resolve within a few months or persist for over 4 years. The 
remaining 5 patients had clinical cystoid changes. The mean VA (logMAR) at baseline 
and the last observations for these patients were 0.72 (Snellen: 6/30) and 0.60 (Snellen: 
6/24), respectively. 
Of the 5 patients with clinical cystoid change in the macula, 1 had spontaneous 
partial resolution which led to improvement of VA (logMAR) from 0.8 (at 1 year) to 0.0 
(after 2 years, patient 18), 1 was treated with topical steroid and non-steroidal anti-
inflammatory drops but went on to develop a full-thickness macular hole, and 3 patients 
received 2 or more intravitreal injections of triamcinolone with temporary resolution of 
oedema and transient improvement in VA (median: 0.48 and 0.56 logMAR at 1 and 2 
years respectively, see Figure 5.6).  
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 Follow-up SD-OCT scans at 2 or more years were available in 18 patients. In 
those with clinical CMO within first 2 years, follow-up SD-OCT demonstrated large 
intraretinal cysts for up to 36 months. Follow-up SD-OCT in patients with subclinical 
CMO also demonstrated persistence of the small intraretinal cysts for 36 to 60 months 
(see Figures 5.2).  
 
 

























in months  
7 84, CNV 1.02 (6 m) Excision X 4 (6 m) 3x R (24 m) No 0.78 (32 m) 
 
10 71, CNV 0.20 (21 m) Excision No No MH repair   
(30 m) 
0.56 (49 m) 
13 88, Haem 0.60 (18 m) Excision No 3x B (20 m) No 0.78 (48 m) 
 
15 74, Haem 0.52 (5 m) Excision X 3 (6 m) 4x B (16 m) 3x IVTA  
(29 m) 
1.00 (48 m) 
17 61, CNV 0.60 (11 m) Excision No 3x B (14 m) No 0.46 (43 m) 
 
24 76, CNV 1.00 (23 m) De novo, 
juxtafoveal 
No 4x R (32 m) No 1.00 (41 m) 
 
28 81, Haem 0.30 (10 m) Excision No 3x B (10 m) 
& 12x R 
(17 m) 
No 0.30 (38 m) 
34 70. Haem 0.30 (5 m) Excision No 8x R (16 m) 
 
No 0.70 (28 m) 
38 72, Haem 0.78 (8 m) Excision No 2x R (14m) No 1.00 (15 m) 
 
B; bevacizumab, CNV; predominantly choroidal neovascularisation, Haem; predominantly 
haemorrhagic lesion, IVTA; intravitreal triamcinolone acetonide, m; month(s), MH; macular 
hole, PDT; photodynamic therapy, R; ranibizumab. 
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Figure 5.3 Macular translocation: structural outcome of recurrent CNV 
Patient 28 had juxtafoveal and extrafoveal recurrent choroidal neovascularisations 
(CNV) at 10 months post-translocation. He received 3 intravitreal injections of 
bevacizumab followed by 12 injections of ranibizumab to maintain a visual acuity of 
6/12. (A) Fundus autofluorescence image and (B, C) fluorescein angiography showed 
recurrence of CNV at 10 months. (D) Fundus autofluorescence image and (E) optical 
coherence tomography (OCT) scan at 28 months showed expansion of RPE atrophy at 
the site of recurrence and persistent subfoveal fluid. (F) Fundus autofluorescence image 
and (G) OCT scan at 36 months showed continued expansion of RPE atrophy at new 
sites of CNV recurrence and resolution of subfoveal fluid.  
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 Figure 5.4 Macular translocation: functional outcome of recurrent CNV 
Microperimetry, autofluorescence images and optical coherence tomography (OCT) 
scans in patients 17 (A-I) and 24 (J-R) showing the effect of recurrent choroidal 
neovascularisation (CNV) on retinal structure and function. (A, B, C) Colour fundus 
photographs of patient 17 at around 1, 2 and 3 years showed new CNV at the 
superonasal edge of previous CNV excision site with haemorrhage which resolved into 
a disciform scar after 3 injections of bevacizumab during the second year. (C) 
Microperimetry showed dense scotoma over the area of CNV recurrence. (D, E, F) 
Serial autofluorescence images showed a single small round hyper-autofluorescence at 
the fovea corresponding to cystoid change on OCT. There was also well-defined hyper-
autofluorescent region in the macula and increasing size of the RPE defect superior to 
the fovea which has progressed inferiorly to involve the centre of fovea. (G, H and I) 
Serial OCT scans showed resolution of intraretinal cyst after treatment. (J, K, L) Colour 
fundus photographs of patient 24 at around 2, 2.5 and 3 years showed development of 
retinal haemorrhage and recurrent juxtafoveal CNV which regressed to a disciform scar 
after 3 injections of bevacizumab during the third year. (M, N, O) Serial 
autofluorescence images showed increasing size of the hypo-autofluorescent lesion 
nasal to the fovea, persisting well-defined hyper-autofluorescent region in the macula. 
Note that the recurrent CNV was separated from the RPE defect at the site of old CNV. 
(G, H and I) Serial OCT scans showed development of intraretinal cyst which partially 
resolved after treatment. 
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Figure 5.5 Macular translocation: CMO associated with recurrent CNV 
Patient 18 had extrafoveal recurrent choroidal neovascularisation (CNV) at 12 months 
post-translocation associated with cystoid macular oedema. (A) Fundus 
autofluorescence, (B, C) fluorescein angiography and (D) colour fundus photograph 
showed new haemorrhage and leak at the supra-nasal border of the excision site and 
cystoid macular oedema. Six months later (E) fundus autofluorescence, (F, G) 
fluorescein angiography and (H) colour fundus photograph showed a disciform scar and 
persistence of CMO despite 3 injections of bevacizumab. Small intraretinal cystic 
change remained and RPE atrophy progressed despite inactive CNV at (I, M) 24, (J, N) 
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 Figure 5.6 Macular translocation: isolated CMO responding to IVTA 
Patient 23 had persistent cystoid macular oedema (CMO) from 8 months and received a 
total of 4 intravitreal injections of triamcinolone to maintain a visual acuity of 6/18 at 40 
months after translocation. (A) Late phase angiography and (B) optical coherence 
tomography (OCT) showed CMO at 8 months. After the first injection, (C) cystoid 
changes had partially resolved. However, (D, E) intraretinal cysts re-accumulated at 4 
months after steroid injection. Again, by (F) 4 and (G, H) 20 months, CMO had re-
established after the second injection. Fundus autoflurescence and OCT imaging 
showed increase in retinal thickening, intraretinal cystic change and focal hyper-
autofluorescence at  (I, J) 2 and (K, L) 5 months after the third injection and (M, N) 
rapid anatomical and acuity response to steroid within 1 month of the fourth injection.  
 
 
Fundus autofluorescence features 
Fundus AF images from 5 of the 40 patients were excluded from further analysis 
because the macula was not translocated due to technical issues (3 patients) or post-
operative total retinal detachment which precluded fundus AF imaging (2 patients). 
From the remaining 35 patients, a total of 133 fundus AF images were reviewed. Each 
patient had an average (range) of 4 (1-8) post-operative AF images. These fundus AF 
images were taken between a mean of 13 and 36 months post-operatively; the earliest 
was at 2 months and the latest was at 67 months. 
 Broadly, there were 2 types of changes: (1) decreased fundus AF due RPE 
atrophy or masking by ERM, and (2) increased fundus AF due to RPE lipofuscin 
accumulation or unmasking through reduction of macular or visual pigments.  
 
Decreased AF and expansion of pigment epithelial atrophy 
Among the 35 patients with gradable AF images, 2 patients had extensive RPE atrophy. 
In these 2 patients, there was no typical increased AF at the rim of the extensive atrophy 
as seen in geographic atrophy. Foveal AF was reduced due to masking by dense ERM 
(3 patients), expansion of parafoveal RPE defect (3 patients) and isolated small foveal 
RPE defect (3 patients). Subsequently, in some of the remaining 24 patients, reduced 
foveal AF developed as a result of subfoveal expansion of recurrent CNV or parafoveal 
RPE defect (5 patients), or development of de novo subfoveal CNV or RPE atrophy (3 
patients). Development of postoperative subfoveal RPE atrophy, in association with 
recurrent CNV or expansion of parafoveal atrophy led to a decline in the median VA 
(logMAR) from 0.83 (Snellen: 6/40) at 1 year to 1.07 (Snellen: 6/70) at the last 
observation. However, expansion of RPE atrophy without CNV was not a primary cause 
of delayed loss of VA.  
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 Increased AF and shortening of outer segment  
Fundus AF demonstrated increased AF in parafoveal regions in 33 patients. Increased 
AF change was also noted in parafoveal regions in the 33 patients without extensive 
RPE atrophy (see Figure 5.7). These could be categorized into 3 patterns of change: 
well-delineated homogenous increased AF patches (17 patients, see Figure 5.8), 
curvilinear increased AF bands (4 patients, see Figure 5.9) and poorly demarcated 
speckled increased AF (12 patients) which can be an isolated macular change or 
associated with cystoid macular oedema and recurrent CNV. The location and 
distribution of increased AF did not change at 2 to 5 years of follow-up. 
Among the 21 haemorrhagic lesions, 7 patients had the homogenous increased 
AF regions, 1 had curvilinear increased AF band, 1 had extensive atrophy, 9 had 
speckled AF pattern and 3 were excluded because of total retinal detachment or 
unsuccessful translocation. Among the 19 CNV or RPE rips, 10 had homogenous 
increased AF regions, 3 had curvilinear increased AF band, 1 had extensive atrophy, 3 
had speckled AF pattern and 2 were excluded because of unsuccessful translocation. 
Chi square test showed that the difference in the distribution of the various patterns of 
AF was not statistically significant between the groups of patients with haemorrhagic 
and the CNV/rip subtypes (p = 0.20). 
 Simultaneous fundus AF with SD-OCT was available for review in 20 patients. 
Both homogenous patches and curvilinear bands of increased AF co-registered with 
varying degrees of loss of the outer retinal architecture on SD-OCT. They all shared a 
common feature: loss of the line which corresponds to the so called “interface of the 
inner and outer segment of the photoreceptor cell layer” (IPRL) with or without (1) 
absence of the external limiting membrane and (2) reduction of outer nuclear layer 
thickness (see Figure 5.10). Speckled increased AF lesions co-registered with variable 
features including small intraretinal cystic change at the level of outer nuclear layer, loss 
of IPRL or even intact outer retinal structures. 
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 Figure 5.7 Macular translocation: abnormal patterns of increased fundus AF 
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 Figure 5.8 Macular translocation: well-delineated region of increased fundus AF 
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Figure 5.9 Macular translocation: curvilinear band of increased fundus AF 
(A) Submacular haemorrhage complicating age-related macular degeneration. (B) Same 
patient after macular translocation showed no obvious fundus features in the parafoveal 
region. (C and D) At 4 years post-translocation, bands of increased autofluorescence 
(AF) correlated with loss of the line corresponding to the interface of inner and outer 
segments of the photoreceptor cell layer. The epiretinal membrane seen on optical 
coherence tomography (OCT) was not clinically visible and is unlikely to have masked 
autofluorescence signal from the retinal pigment epithelium. 
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Figure 5.10 Macular translocation: OCT in regions of increased fundus AF 
Six examples from 6 patients showing co-registration between isolated loss of the 
interface of inner and outer segments of the photoreceptor cell layer (IPRL) in the 
optical coherence tomography (OCT) section and region of increased AF supporting the 
hypothesis that increased AF relates to the loss of visual pigment located in the outer 
retina. (A) The (IPRL) dips into the RPE as the fundus AF increased. (B) The IPRL re-
appears as the fundus AF returned to normal intensity. (C) The IPRL dips into RPE at 
the junction of increased AF. (D) Band of increased AF corresponded to region of IPRL 
fusing with the RPE layer. (E) The IPRL re-appears as the fundus AF returned to 
normal intensity. (F) The IPRL and outer nuclear layer re-appears as the fundus AF 
returned to normal. The normal architecture of outer retina on spectral domain OCT 
consists of the following layers: outer nuclear layer (ONL), external limiting membrane 
(ELM), interface of inner and outer segments of the photoreceptor cell layer (IPRL) and 




5.4.2 Autologous RPE patch graft long-term outcomes 
 
5.4.2.1 Patient characteristics 
A total of 12 consecutive patients underwent autologous RPE-choroid patch grafts 
during a 1 year period from between 2004 and 2005. The mean (range) follow-up 
duration was 44 (26-61) months. All patients (100%) were followed for 24 months or 
longer, 11 (92%) patients for 36 months or longer, and 5 patient (42%) for 48 months or 
longer. Two patients had died. 
The median age at the time of surgery was 78 years and of these, 4 were female 
and half had surgery to the right eye. The median (range) duration of symptoms was 5 
(2 to 6) weeks. Eight had predominantly CNV lesion, 2 had submacular haemorrhage 
and 2 had mature or fibrosed CNV. 
 
5.4.2.1 Surgical outcomes 
Patch graft was performed in 11 phakic eyes. Nine of 12 patients had CNV removed in 
1 piece, 11 of 12 had insertion of graft in 1 move, 3 of 12 had no submacular 
manipulation and 5 of 12 had 2 or more manipulations of the graft and none had 
significant submacular choroidal haemorrhage. One patient had intraoperative giant 
retinal tear. Combined phacoemulsification (11 of 12), removal of oil and IOL implant 
was performed at a median of 17 weeks after patch graft. However, in 3 patients, oil 
was re-injected for repair of retinal detachment and then removed at 6 and 22 months 
later in 2 of 3 patients, respectively. 
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 Post-operative retinal detachment occurred in 4 patients and they underwent a 
total of 6 retinal detachment repairs. One other patient had inferotemporal u-tear with 
limited subretinal fluid which was treated with laser retinopexy, No further retinal 
detachment occurred after 1 year although 1 patient still had oil tamponade. Overall, a 
total of 5 (42%) patients in this cohort developed retinal detachment, all within the first 
6 months. 
 
5.4.2.2 Long-term functional outcomes 
 
Visual acuity 
The median (IQR) VA (logMAR) at baseline, 1 year and the final visits (n = 12) were 
0.87 or 6/45 (0.56 to 1.09), 1.46 or 2/60 (0.82 to 1.72) and 1.64 or 1/60 (1.30 to 1.93), 
respectively. There was significant decline in VA from the pre-operative to the final 
visit (Wilcoxon signed ranks test, p = 0.003). The number of patients with a VA of 0.70 
logMAR (6/30) or better was 5 (41%) at baseline. This declined to 2 (16%) at 1 year 
and 1 (8%) at the final visit (McNemar test, p = 0.13). Similarly, 8 (67%), 5 (42%) and 
2 (17%) of eyes had a VA of 1.00 logMAR (6/60) or better at baseline, 1 year and the 
final visit, respectively.  
VA declined by a mean (SD) 0.45 (0.63) logMAR at 1 year and 0.68 (0.50) 
logMAR at the final visit. At 1 year, 1 (8%) patient gained 3 or more lines of VA and 7 
(59%) lost 3 or more lines of VA. At the final visit, none had gained 3 or more lines of 
VA and 8 (67%) lost 3 or more lines of VA (see Figure 5.12).  
 Within the cohort of 12 patients, 5 (42%) achieved  a VA of 1.00 logMAR or 
better at 1 year but 3 of these (60%) had a 2 or more lines (> 0.20 logMAR) decline in 
VA after 1 year. The cause of delayed visual loss in these eyes was macular oedema 
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Figure 5.11 Visual acuity change after patch graft: outcomes at 1 to 4 years 
Scatter plots showing relationship between the baseline and the (A) 1, (B) 2, (C) 3 and 
(D) 4 year visual acuity outcomes following RPE-choroid patch graft. Data loci above 




Six patients (4, 5, 7, 8, 9 and 11) demonstrated fixation over the graft (see Figure 5.12). 
They had the baseline microperimetry tests at various time points ranging from 9 to 31 
months post-operatively. The most recent follow-up microperimetry tests were 
performed between 26 and 48 months post-operatively. Using a small (1-2º) cross 
fixation target, it was found that fixation stability declined in 1 patient (from stable to 
unstable) and improved in another 2 (from unstable to relatively unstable or stable) 
during follow-up (see Table 5.7 and Figure 5.12). However, mean sensitivity over the 
graft declined (loss of 0.1 to 8.4 dB) and dense scotoma over the graft enlarged 
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 (increment of 1 to 13 test loci) in all 6 eyes tested (see Table 5.7, Figures 5.13 and 
5.14). 
All 6 patients with fixation over the graft had postoperative complications (see 
Table 5.7). Decline in fixation stability and VA in patients 4 and 8 were associated with 
the development of atrophic macular cysts or cystoid macular oedema at the locus of 




Figure 5.12 Patch graft: fixation outcomes  
Fixation stability change in 6 patients whose grafts supported fixation. Inserts show 
percentage of fixation locus within 2º and 4º of gravitational centre of all fixation loci 
during a 30 second recording. (A, B) Patient 4 had stable fixation stability despite loss 
of acuity at 48 months. (C, D) Patient 5 had stable fixation for up to 40 months. (E, F) 
Patient 7 had stable fixation for up to 30 months despite recurrent CNV supratemporal 
to the graft. (G, H) Patient 8 had decline in stability due to cystoid macular oedema 
secondary to recurrent CNV temporal to the graft. (I, J) Patient 9 had improvement in 
fixation stability at extrafoveal locus on the patch at 40 months. (K, L) Patient 11 had 
improvement in fixation stability also at extrafoveal locus on the patch at 26 months. 
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  Table 5.7 Patch graft:  microperimetry outcomes 
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 Figure 5.13 Patch graft: serial microperimetry in patients 4 and 5 
Microperimetry tests are displayed as interpolated maps and differential maps on the 
autofluorescence image taken around the time of the most recent microperimetry. 
Borders of the grafts are marked and loci with greater than 6 dB increment (green) or 
decline (pink) are highlighted on the differential map. (A, B, C and D) In patient 4, the 
mean retinal sensitivity (Goldmann V size stimulus) over the graft decline from 5.3 dB 
at 12 months to 1.8, 1.8 and 1.2 dB at 23, 32 and 42 months, respectively. (E) Local 
retinal sensitivity change between 23 and 42 months overlaid on autofluorescence 
image. (F) Visual acuity (VA) at corresponding time points over 4 years showed steady 
decline between 1 and 3 years and rapid decline after 3 years. (G) Optical coherence 
tomography through fixation loci showed foveal cyst which may explain the rapid 
decline in VA after 3 years and intact retinal structure in the nasal macula (region 
marked by white bar) corresponding to regions with retinal sensitivity. (H, I, J and K) In 
patient 5, the mean retinal sensitivity (Goldmann III size stimulus) over the graft 
declined from 1.4 dB at 16 months to 0.2 dB then improved to 2.3 dB and again 
declined to 0.6 dB at 25, 32 and 40 months, respectively. (L) Local retinal sensitivity 
change between 16 and 40 months overlaid on autofluorescence image. (M) VA change 
over 3 years at corresponding time points. (N) Optical coherence tomography through 
fixation locus showed a smooth foveal depression with intact outer retinal structures in 
the foveal region. 
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Figure 5.14 Patch graft: serial microperimetry in patients 7, 8, 9 & 11 
Microperimetry tests are displayed as interpolated maps and differential maps on the 
autofluorescence image taken around the time of the most recent microperimetry. 
Borders of the grafts are marked and loci with greater than 6 dB increment (green) or 
decline (pink) are highlighted on the differential map. (A-E) The graft in patient 7 
supported retinal sensitivity (Goldmann III size stimulus) and stable visual acuity (VA) 
over its nasal region which was associated with presence of autofluorescence signal and 
outer retinal structures (marked by white bar) in the same region at 20 and 30 months. 
(F-J) Patient 8 had marked loss of retinal sensitivity (Goldmann V size stimulus) and 
VA due to cystoid macular oedema between 9 and 29 months. (K-O) Patient 9 had 
retinal sensitivity (Goldmann III size stimulus) over superior half of the graft associated 
with homogenous pattern of autofluorescence signal and intact outer retinal structures in 
the same region at 31 and 40 months. (P-T) Patient 11 had retinal sensitivity (Goldmann 
III size stimulus) over the inferior pole of the graft and stable but poor VA associated 
with faint autofluorescence signal and intact outer retinal structures in the same region 
at 17 and 26 months. 
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 5.4.2.3 Long-term structural outcomes 
 
Recurrent choroidal neovascularisation 
Five patients (42%) had recurrent CNV, extending peripherally from the edge of the 
graft, occurring between 6 and 28 months postoperatively. Although none of these 
invaded the patch graft, some were associated retinal thickening with cystoid macular 
changes over the graft. None of these patients received further treatment for the CNV as 
they were not threatening fixation.  
 
Cystoid macular oedema 
All 12 patients had some degrees of intraretinal cystic change over the patch graft 
accompanied by variable retinal atrophy or thickening (see Figures 5.13 and 5.14). This 
was accompanied by ERM in 8 patients and CNV in 5 patients. None of the patients 
received treatment for their CMO given the poor visual potential in some of these 
patients and mild degree of cystoid change in others. 
SD-OCT through regions over the graft with retinal sensitivity showed intact 
outer plexiform and nuclear layers (see Figures 5.13 and 5.14). In areas without retinal 
sensitivity, retinal thickness was either reduced with loss of the reflective bands 
representing the plexiform layers (retinal atrophy) or thickened accompanied by 
intraretinal cysts (cystoid macular oedema).   
 
Fundus autofluorescence features 
Fundus AF signal was observed over the graft in the 10 patients examined after 1 year 
(18 – 48 months). Patchy areas of reduced autofluorescence over the graft corresponded 
to masking by RPE hyperplasia and subretinal fibrosis. Regions of the graft with 
homogenous AF signal did not necessarily predict retinal sensitivity. Although there 
was no significant loss of graft autofluorescence over time, the surrounding area with 
reduced autofluorescence signal enlarged during follow-up due to either progressive 
RPE atrophy or fibrosis of CNV (see Figure 5.15). 
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Figure 5.15 Patch graft: serial fundus autofluorescence 
(A) Preoperative and (B-F) postoperative serial fundus autofluorescence images through 
5 years deomonstrating enlargement of RPE atrophy surrounding the patch graft. 




5.4.3 Comparison between translocation and patch graft  
 
5.4.3.1 Case-mix matching of baseline features 
Baseline features of the first 12 patients in the translocation cohort and the 12 patients in 
the patch graft cohort were comparable (see Table 5.8).  
The median age for the translocation and patch graft groups were 72 and 78 
respectively (p = 0.05). Distribution of gender was not significantly different between 
the 2 groups (p = 0.1). The duration of symptom prior to surgery in the translocation 
group was longer compared to the RPE graft group, mean of 11 and 5 weeks (p < 
0.001). Six and eight patients in the translocation and patch graft groups, respectively, 
had > 50% of the lesion component comprising of CNV. There was a large variation in 
the size of lesion, ranging from 4 to 46 disc areas with the median size being 8 and 17 
disc areas in the translocation and the graft group respectively (p = 0.4).  
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 There was no significant difference in the baseline median VA (logMAR) 
between the MT (0.90) and the patch graft groups (0.87), p = 0.44. All patients had 
foveal fixation pre-operatively as determined on the slit lamp (Uppal et al. 2007). 
 
5.4.3.2 Visual acuity comparison 
The median (range) follow-up duration was 48 (32-64) and 43 (26-53) months in 
translocation and patch graft groups respectively. A summary of VA over 4 years are 
shown in Table 5.9.  
Figure 5.16 is a series of box plot showing the distribution in VA at the various 
time points for each group. The median VA (logMAR) in the translocation group 
improved from 0.90 at baseline to 0.60, 0.69, 0.69 and 0.58 at 1, 2, 3and 4 years 
respectively (Friedman test, χ2 (df = 4, n = 12) = 10.7, p = 0.03). In contrast, the median 
VA (logMAR) for the patch graft group deteriorated from 0.87 at baseline to 1.46, 1.46, 
1.38 and 1.64 at 1, 2, 3 and 4 years respectively (Friedman test, χ2 (df = 4, n=12) = 19.0, 
p = 0.001).  
 A comparison of change in VA between translocation and patch graft groups at 
1, 2, 3 and 4 years showed significant difference (independent sample t-test) at all time 
points with mean differences of 0.79, 0.63, 0.72 and 0.88 logMAR at the respective 
follow-up visits (see Figure 5.17). 
 
5.4.3.3 Structural outcome comparison 
All 24 patients had postoperative serial OCT and FAF imaging for correlation with 
clinical findings.  
In the translocation group, clinical and OCT assessments of the macula at 1 year 
revealed no retinal thickening, intraretinal cysts, subretinal fluid or subretinal tissue in 6 
of 12 eyes.  However, 1 developed a full-thickness macular hole and 2 showed small 
intraretinal cystic changes on OCT after 2 years. In the other 6 eyes, large intraretinal 
cysts were present. Of which, 2 had insufficient or no foveal rotation, 2 were related to 
CNV detected at 2-3 months following translocation and 2 were associated with dense 
epiretinal membrane which developed at 6-7 months following translocation. In these 
last 2 patients, oedema did not resolve despite peeling of the membranes. Overall, 4 
patients had residual or recurrent CNV; all detected within the first 3 months. 
In the patch graft group, all patients had disruption of outer retinal structure on 
OCT associated with irregular RPE surface of the graft (see Figure 5.13 amd 5.14). 
Although foveal depression was seen in 6 patients, all 12 patients had cystic changes in 
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 the retina over the graft accompanied by varying amount of atrophy and thickening. 
Overall, 5 patients developed recurrent CNV (2 within 1 year and 3 after 1 year). None 
of the recurrent CNV invaded the RPE graft. All grafts also had focal 
hyperpigmentation which became darker over time. Donor sites were free from any 
CNV during follow up. 
The intensity of autofluorescence at the foveal region did not appear to change 
over time but the size of RPE defect (at the inferior arcade after translocation or 
surrounding the entire patch graft) enlarged (see Figure 5.18). Loss of autofluorescence 
around the graft was prominent in all cases of patch graft (see Figure 5.18). 
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Figure 5.16 Translocation versus patch graft: median visual acuity over 4 years 
A box plot showing distribution of visual acuity at baseline, 1, 2, 3 and 4 years 
following macular translocation (blue) and autologous retinal pigment epithelium-
choroid patch graft (green). Thick horizontal line represents the median. The upper and 
lower boundaries of the box represent quartile range and the whiskers represent 
minimum and maximum values.  
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 Table 5.8 Translocation versus patch graft:  baseline features of patients  
Baseline features Translocation Patch graft 
Statistics  
(p-value) 
Number of patients 12 12 - 
Age (years) 
     Median (min, max) 
 
72 (57, 95) 
 











Predominant lesion type 
     CNV (classic, mixed, occult)     
     Non-CNV (blood, fibrosis) 
 
6 (0, 0, 5) 
6 (5, 1) 
 
8 (0, 4, 4) 
4 (2, 2) 
 
0.7 ‡ 
Total lesion size (DA) 
     Median (range) 
 
8.4 (3.6, 40.4) 
 
17.4 (5.1, 46.6) 
 
0.41 † 
Duration of symptoms (weeks) 
     Median (min, max) 
 
10.5 (4, 32) 
 
5.0 (2, 6) 
 
0.00 † 
Baseline VA (logMAR) 
     Median (min, max)  
 
0.90 (0.42, 1.70) 
 




     Range 
 
May 2003 to April 2005 
 
August 2004 to June 2005 
- 
CNV, choroidal neovascularization; CS, contrast sensitivity; DA, disc area; MAR, minimal 
angle of resolution; max, maximum; min, minimum; MT, macular translocation; RPE, retinal 
pigment epithelium; SD, standard deviation; VA, visual acuity. 
† Mann-Whitney U test, ‡ Fisher’s exact test 
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 Table 5.9 Translocation versus patch graft:  visual acuity over 4 years 
 Visual acuity (logMAR)  
Patient Baseline 1 year 2 year 3 year 4 year Follow-up 
(months) 
MT01 1.98 1.36 1.78 1.78 1.78 60 
MT02 1.98 1.98 2.28 1.98 1.98 64 
MT03 0.44 0.10 0.10 0.10 0.10 60 
MT04 0.42 0.60 0.78 0.78 0.60 60 
MT05 1.98 1.78 1.62 1.78 1.78 54 
MT06 0.78 0.60 1.98 2.28 2.28† 43 
MT07 1.00 1.00 1.10 0.78† 0.78† 32 
MT08 0.60 0.34 0.38 0.38 0.38 49 
MT09 1.78 0.12 0.14 0.14 0.12 48 
MT10 0.60 0.20 0.20 0.56 0.56 49 
MT11 1.30 0.60 0.60 0.48 0.48† 38 
MT12 0.80 0.80 0.60 0.60 0.54 48 
PG01 1.12 1.40 1.40 1.32 1.30† 42 
PG02 0.46 0.64 0.60 0.64 0.38 53 
PG03 0.68 1.78 1.78 1.78 1.78† 45 
PG04 0.38 1.98 1.98 1.98 1.98† 40 
PG05 0.86 0.10 0.32 0.52 1.62 48 
PG06 1.00 1.52 1.52 1.98 1.98† 36 
PG07 0.88 1.00 1.00 1.06 1.78 53 
PG08 1.04 0.76 1.06 1.26 1.48† 42 
PG09 0.62 1.00 0.82 0.92 0.90 49 
PG10 0.54 1.54 1.66 1.66† 1.66† 26 
PG11 1.10 1.52 1.56 1.44 1.30 48 
PG12 1.20 1.98 1.68 1.98 1.98† 37 
MT; macular translocation, PG; patch graft 
† Last-observation carried forward 




Figure 5.17 Translocation versus patch graft: mean change in visual acuity 
(A) Line graph showing mean visual acuity (VA) change and error bars representing 
standard error of mean, from baseline to 1, 2, 3 and 4 years following macular 
translocation (red) and autologous retinal pigment epithelium-choroid patch graft (blue). 
(B) Line graph showing median of change in VA at 1, 2, 3 and 4 years following 
translocation (red) and patch graft (blue). (C) Line graph showing mean change in VA 
after diagnosis of neovascular AMD based on meta-analysis of untreated cohort (Wong 
et al. 2008). (D) Line graph showing mean change in VA after monthly injection of 0.5 
mg lucentis in the ANCHOR (green line) and the MARINA (light blue line) trials 
(Brown et al. 2009; Rosenfeld et al. 2006). Positive value on y-axis represents an 
improvement in VA. Note that the y-axis scales are identical in all 4 graphs to aid 
comparison.  
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5.4.3.4 Microperimetry outcome comparison 
Table 5.10 summarises the outcomes from the 3 best cases of each group. Figure 5.19 
shows that after translocation, dense scotoma was present only in the region where CNV 
was removed (dark areas on fundus autofluorescence image) but relative scotoma 
(below 3 standard deviation of the normal retinal sensitivity in NAVIS software 
database of the Nidek MP1) was widespread. In contrast, there was extensive dense 
scotoma after patch graft; even over parts of the graft and the surrounding areas, despite 
intact graft autofluorescence (see Figure 5.19).  
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 Figure 5.18 Translocation versus patch graft: AF and OCT images 
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 Figure 5.19 Translocation versus patch graft: structure-functon corrrelation 
Pre and post-operative images from patients MT03 (a – d), MT09 (e – h), PG04 (h – k) 
and PG08 (l – o). Visual acuity (VA) is shown in bottom right corner and 
microperimetry colour codes are shown at the bottom of the figure. Preoperative 
fluorescein angiography (FA) of patient MT03 at 2 minutes showed subfoveal occult 
choroidal neovascularisation (CNV) with subretinal haemorrhage (a). Postoperative 
microperimetry (using size Goldmann III, 200 ms white stimulus) at 28 months showed 
good retinal sensitivity in the macular region (b). Total deviation plot superimposed on 
autofluorescence (AF) image showed relative scotoma in central macula, dense scotoma 
over area of RPE defect but normal sensitivity (green) superonasally (c). Postoperative 
FA showed normal choroidal flush under the macula at 30 seconds (d). Preoperative FA 
of MT09 at 90 seconds showed subfoveal occult CNV with superior RPE rip (e). 
Postoperative microperimetry at 20 months showed retinal sensitivity present in the 
macular region (f). Total deviation plot superimposed on AF image showed relative 
scotoma in the majority of macular region and dense scotoma over area of RPE defect 
(g). Postoperative FA showed normal choroidal flush under the macula at 15 seconds 
(h). Preoperative FA of PG04 at 1 minute showed subfoveal minimally classic CNV (i). 
Postoperative microperimetry at 12 months showed a central island of sensitivity in the 
region of the graft (j). Total deviation plot superimposed on AF image showed dense 
ring scotoma surrounding an island of relative scotoma over the graft (k). Postoperative 
FA shows uneven choroidal flush in some areas of the graft at 20 seconds (l). 
Preoperative FA of PG08 at 2 minutes showed subfoveal massive subretinal 
haemorrahge (m). Postoperative microperimetry at 9 months showed retinal sensitivity 
in the nasal region of the graft (n). Total deviation plot superimposed on AF image 
showed relative scotoma over the graft but no area with normal sensitivity (o). 
Postoperative FA showed uneven choroidal flush in some areas of the graft at 30 
seconds (p). 
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 Table 5.10 Translocation versus patch graft:  retinal functions from best cases  
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 5.5 Discussions 
 
5.5.1 Long-term outcomes in translocation 
In this series of 40 consecutive patients, the long-term change in VA and its relationship 
to late post-operative complications was examined using detailed macular imaging 
techniques (SD-OCT and fundus AF) and functional assessment (microperimetry). At a 
mean follow-up of 3 years, 25% of patients still had a 3-line gain in VA and the median 
acuity was maintained at 6/36 with 68% of patients achieving 6/60 or better. However, a 
quarter of patients who were able to see 6/60 or better at 1 year, VA declined by greater 
than 2 lines primarily as a result of recurrent CNV.  
 
5.4.1.1 Long-term functional outcomes 
The natural history of neovascular AMD is poor with only about 20% and 30% of the 
eyes being able to see 6/30 and 6/60 or better, respectively, after 3 years (Wong et al. 
2008). the use of anti-VEGF agent has dramatically improved this outcome with up to 
80% of the eyes maintained at VA of better than 6/60 at 2 years (Brown et al. 2006; 
Brown et al. 2009). The contrast between natural histroy of neovascular AMD and 
outcome of lucentis therapy can be seen in Figure 5.17. Previous large series showed 
that full macular translocation can also achieve a VA of 6/60 or better in over 80% of 
eyes at 1 year even in patients with lesion types which may not benefit from anti-VEGF 
therapy (Pertile and Claes 2002; Mruthyunjaya et al. 2004; Gelisken et al. 2007). 
However, recent reports raised concerns over long-term outcomes since (1) subfoveal 
expansion of the RPE atrophy was found in 61% of the eyes accompanied by VA loss 
and (2) recurrent CNV may occur after 1 year to threaten foveal function (Aisenbrey et 
al. 2007; Baer et al. 2008; Luke et al. 2009).  
The 1 year VA outcome in this series is similar to that reported from other seires 
(Pertile and Claes 2002; Mruthyunjaya et al. 2004; Gelisken et al. 2007). The long-term 
follow-up results suggest that VA can be maintained by paracentral RPE-choroid for 2 
to 5 years following macular translocation. More detailed analysis of patients who had 
achieved a VA of 6/60 (25 of 32, 78%) at 1 year showed that the majority (84%) 
remained stable with longer follow-up. This suggests that in most patients, individual 
paramacular RPE cell can adapt to the metabolic demand of over 20 cones even though, 
prior to translocation, it supported only 1 or 2 cones and over 20 rods of the 
paramacular outer retina (Gao and Hollyfield 1992). However, some patients did lose 
VA (16%) or retinal sensitivity due to expansion of atrophy or recurrence of CNV after 
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 1 year. Furthermore, there were persistent intraretinal cystoid changes and increased 
autofluorescence in the parafoveal region which did not seem to affect retinal function. 
Microperimetry in the subset of the cohort (patients 3, 9, 18 and 21) who maintained a 
VA of 6/12 or better beyond 3 years demonstrated stable mean macular sensitivity post-
operatively. However, all 4 patients had improvement in the superior paramcular 
sensitivity and decline in the inferior paramacular sensitivity. This may be related to 
expansion of RPE atrophy at the site of previous CNV excision. During the course of 
this study, it was noted that there was no data on the test-retest variability of retinal 
sensitivity measurement on Nidek MP-1 in patients with macular disease. Therefore, the 
author subsequently conducted a prospective test-retest variability study examining 
intra-session agreement of retinal sensitivity measurements in 50 patients with macular 
disease (Chen et al. 2009). The coefficients of repeatabiltiy for individual test loci and 
the entire test grid (68 loci) were 5.6 and 1.8 dB, respectively. For paramacular region, 
the coefficient of repeatability was 1.9 dB but can be as high as 2.3 dB (upper bound of 
the 95% confidence interval, see Appendix 1).    
 
5.5.1.2 Pigment epithelium atrophy 
A significant proportion (33%) developed subfoveal atrophy after translocation and 
there was a trend for poorer final VA in these patients. A much lower frequency of 
subfoveal RPE atrophy (10%) was reported by Sawa et al. (2008) in a group of myopic 
patients who underwent translocation. The higher rates of RPE atrophy in our series 
(using fundus AF) and the report by Aisenbrey et al. (61% when angiography was used) 
may be related to the older age group (mean of 75 years rather than 60 years) of patients 
and hence more widespread dysfunction in the RPE (Aisenbrey et al. 2007; Sawa et al. 
2008). Expansion of atrophy in AMD has been observed in disciform lesions and after 
laser photocoagulation or submacular surgery to ablate or remove CNV (Dastgheib et 
al. 1993; Castellarin et al. 1998; Sarks et al. 2006). Even with an initially intact RPE 
following removal of type II CNV, RPE atrophy may appear after 18 months 
(MacLaren and Aylward 2005). The cause for delayed atrophy is unknown but may be 
related to changes in choroidal vasculature, primary RPE-Bruch’s membrane disease or 
RPE cell death driven by the neurosensory retina. The latter theory has also been 
proposed as the cause of GA recurrence after translocation in atrophic AMD (Cahill et 
al. 2005a; Khurana et al. 2005). This underlies the importance of large angle rotation to 
move the fovea as far away from the edge of damaged RPE as possible. However, in 
patients with massive submacular haemorrhage or RPE rip, translocation may not be an 
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 option since RPE beyond the arcades may also be damaged. In these cases, the use of 
equatorial autologous RPE-choroid patch graft with or without large retinotomy to 
extract the clot may be another option to restore submacular RPE-photoreceptor 
interaction (van Meurs and Van Den Biesen 2003; Gibran et al. 2009). 
 
5.5.1.3 Recurrent choroidal neovascularisation 
The rate of CNV recurrence following macular translocation ranged from 8 to 56% 
within 1 to 2 years (Pertile and Claes 2002; Abdel-Meguid et al. 2003; Mruthyunjaya et 
al. 2004; Uppal et al. 2007; Gelisken et al. 2007; Gelisken et al. 2007; Baer et al. 2008; 
Luke et al. 2009).  In previous case series of translocation, these lesions were treated by 
re-excision of the CNV, laser photocoagulation or PDT with poor outcome. We showed 
that with anti-VEGF therapy and frequent monitoring, reasonable VA can be maintained 
(median of 6/36). However, microperimetry and AF imaging showed that there was 
enlargement of paracentral scotoma due to RPE cell loss at the site of CNV recurrence. 
This indicates that early recognition and initiation of treatment are critical to limit the 
extent of RPE damage and loss of retinal function. Almost all reported cases of 
recurrent CNV occurred at the foveal edge of the RPE defect created by the CNV 
excision. Baer et al. postulated that the fovea signals the recurrence of CNV. However, 
they did not report any case of CNV arising de novo from under the translocated fovea. 
Our 1 case of de novo occult CNV and the 1 case of de novo classic subfoveal CNV 
described by Pertile et al. are unusual. The rarity of de novo CNV or GA developing at 
the paramacular RPE under the relocated fovea may be related to the thicker and less 
porous elastic layer of Bruch’s membrane or anti-angiogenic factors produced by the 
RPE-choroid outside the macular region (Steele et al. 1993b; Chong et al. 2005; 
Semkova et al. 2006; Bhutto et al. 2006). In order to reduce the recurrent CNV, the 
fovea needs to be rotated as far away from the defect as possible or the submacular 
defect needs to be reconstructed by using healthier RPE such as those derived from stem 
cells (Lund et al. 2006; Vugler et al. 2008).  
 
5.5.1.4 Cystoid macular oedema 
There are 2 groups of patients with post-operative CMO. One group had CMO 
associated with traction (ERM) or leak (CNV). The other had isolated idiopathic CMO 
which tended to be subclinical and may resolve spontaneously or persist for years. This 
higher rate of post-translocation isolated CMO compared to the previous study may be 
related to the longer follow-up in our series and the use of dense raster scan protocol of 
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 SD-OCT to detect small cysts which may be missed by radial scans (Terasaki et al. 
2003). The chronic cystoid change is unlikely to be due to postoperative uveitis alone 
since it persisted for many years in some patients without clinical signs of inflammation. 
Terasaki and colleagues found a 70% incidence rate of CMO and proposed that VEGF, 
carried within the translocated fovea and/or produced by the surrounding RPE, may also 
contribute to persistence perifoveal leakage. However, other mechanisms may also be 
responsible since we observed persistence of cystoid change in the foveal region despite 
resolution of leakage from extrafoveal recurrent CNV following anti-VEGF therapy. 
Another possible mechanism for the development of chronic CMO is non-specific 
vascular or RPE decompensation secondary to severe surgical trauma since macular 
translocation is one of the most invasive vitreoretinal procedures. 
 
5.5.1.5 Increased parafoveal autofluorescence 
Increased AF may be related to increased concentration of fluorophores within the RPE 
resulting from excessive metabolic demand of the foveo-macular photoreceptors on 
paramacular RPE; analogous to that seen in the junctional zones of geographic atrophy. 
This is supported by the rare observation in our study of intact IPRL on SD-OCT, in the 
region of speckled pattern of increased AF surrounding areas of reduced AF. However, 
a much more common observation in this study was the exact co-registration between 
missing IPRL and speckled or homogenous patterns of increased AF on simultaneous 
SD-OCT with AF imaging.  
Increased AF may be an unmasking effect. This phenomenon has been described 
in full-thickness macular holes, cystoid macular oedema and retinal bleaching 
experiments using short-wavelength fundus AF (McBain et al. 2008; Wakabayashi et 
al. 2008; Bessho et al. 2009; Theelen et al. 2008). Masking occurs because of 
absorption of the short-wave excitation light (488 nm) within the neuroretina by luteal 
pigments (i.e. lutein and zeaxanthin within the plexiform and nuclear layers) or visual 
pigments (i.e. blue cone and rod opsins within the outer segments of photoreceptor cell 
layer). Evidence of unmasking effects leading to increased AF were illustrated by the 
following 2 observations; (1) small round lesions within the foveal region co-registered 
with cystic change on SD-OCT (consistent with the findings from 2 previous reports on 
AF features of cystoid macular oedema (McBain et al. 2008; Bessho et al. 2009), and 
(2) well-delineated increased AF patches co-registered with loss of the reflective line 
that corresponds to the so-called IPRL on SD-OCT. Although the precise histological 
correlate of a missing IPRL line is unknown, close examination of the SD-OCT images 
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 showed that IPRL line may have merged with the RPE line. If Drexler was correct in his 
guide to the analysis of the reflective bands in the outer retina and that this 
interpretation can be applied to a post-translocation eye, then the fusion between the 2 
hyper-reflectively lines corresponding to the IPRL and the RPE may be interpreted as 
shortening of the outer segment. Following from this, a corresponding reduction in 
visual pigment in these regions may explain the relatively increased AF. Further 
evidence to support possible unmasking effect is the observation of reduced outer 
nuclear layer thickness in regions of increased AF in some patients and the subnormal 
retinal sensitivity as demonstrated on microperimetry. 
Shortening of the outer segments of photoreceptor cells is a non-specific 
response to various genetic and acquired insults to the outer retina (Marc et al. 2003). 
Animal models have shown that development of CNV can lead to shortening of outer 
segments and loss of outer nuclear layer thickness (Baffi et al. 2000). Similarly, short-
term retinal detachment can also lead to shortening of outer segment which persists 
even after the retina is reattached (Fisher et al. 2005). Detachment, however, cannot 
explain the observed outer segment shortening since the entire retina was detached 
during macular translocation surgery whereas the increased AF changes are limited to 
the parafoveal region. Furthermore, translocation experiment in monkeys showed that 
reattached retina had misaligned but normal length of the outer segment (Fang et al. 
2004). Although we did not specifically examine the degree of matching between the 
distributions of increased AF regions and the pre-operative lesion, the parafoveal 
distribution of increased AF suggest that loss of outer segment is likely to be related to 
its interaction with subretinal fluid, blood and/or CNV tissue prior to translocation. The 
incomplete restoration of outer segment length even after 5 years may be due to 
permanent injury to the mechanisms of outer segment renewal as a result of interaction 
with toxic substances released by the CNV and/or continued unfavourable environment 
provided by paramacular RPE for complete outer segment regeneration. These patchy 
changes in outer segment morphology may explain previous findings of abnormal focal 
electroretinography and microperimetry within the relocated macula (Chieh et al. 2008; 
Terasaki et al. 2004). 
 
5.5.2 Long-term outcomes in patch graft 
Long-term follow-up of the initial cohort of 12 patients who underwent autologous RPE 
patch graft (MacLaren et al. 2007) showed that VA, fixation stability and retinal 
sensitivity can be maintained beyond 4 years. However, there was a gradual decline in 
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 VA and retinal function as measured using microperimetry. At a median follow-up of 
over 3 years, none of these patients gained 3 lines of acuity and only 2 of 12 (18%) had 
a VA of 6/60 or better. The late loss of vision coincided with the appearance of cystic 
retinal changes with or without retinal atrophy, macular oedema, RPE atrophy or CNV 
recurrence from the edge of the graft. 
 
5.5.2.1 Long-term functional outcomes 
Maaijwee et al. (2007a) reported the visual outcomes in a cohort of 83 patients who 
were followed for 2 to 4 years. They found the mean VA (logMAR) improved from 
0.95 at baseline to 0.89 at 1 and 2 years, 0.79 at 3 years and 0.74 at 4 years. (n = 84, 45, 
24 and 11 patients, respectively). They also showed, with a Kaplan-Meier plot that the 
percentage of eyes loosing < 3 ETDRS lines was 70-80% at 1 year and stabilised at 
around 40-50% at 2 to 4 years. Interestingly, the earliest cases of the entire cohort had a 
much better outcome with 82% (2 out of 11) loosing less than 3 lines at 4 years. In their 
series, 19 out of 84 (23%), 6 out of 45 (13%), 4 out of 24 (17%) and 2 out of 11 (18%) 
eyes had VA of 6/24 or better at 1, 2, 3 and 4 years. In comparison, our result showed 
an overall decline in VA with similar percentages of eyes having lost less than 3 lines of 
acuity (50% at 2 years and 33% at 4 years). Although the results of the 12 cases are 
poorer than the earliest cases of van Meurs series, they are similar to the outcome of the 
entire cohort of 84 patients. A comparable result was seen despite higher rates of retinal 
detachment (42% compared to 8%) and recurrent CNV (42% compared to 13%). 
Furthermore, the proportion of patients in this cohort achieving a VA of 6/60 is no 
greater than natural history (Wong et al. 2008). The similarity between outcome of 
patch graft and natural history is shown in Figure 5.17. 
Fixation over graft may be considered a sign of success as it indicates that the 
translocated RPE is able to support central visual function. Using various techniques to 
study fixation, previous studies have also shown 40 to 74% of eyes achieving fixation 
over the graft (van Meurs and Van Den Biesen 2003; Joussen et al. 2006; Treumer et al. 
2007a; Treumer et al. 2007b; Maaijwee et al. 2007a; Heussen et al. 2008). Similar to 
that reported by Maaijwee and colleagues (2007a), it was found that fixation stability 
may worsen or improve during follow-up. The reason for worsening of fixation stability 
may be related to delayed cystic change or atrophy whereas improvement in stability 
may be related to adaptation to eccentric fixation and viewing (Crossland et al. 2005a; 
Crossland et al. 2004a).  
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 Treumer et al. (2007b) reported microperimetry outcome in 5 of 10 patients 
during the first and second year (< 20 months). They found that the mean sensitivity 
improved by 2 or more dB in 2 eyes and lost 2 dB in 1 eye. In the Moorfields series, all 
6 patients had a decline in mean retinal sensitivity but only 1 had significant change (> 
2 dB loss) due to CMO over the graft associated with recurrent CNV (patient 8). 
However, loss of 6 or more dB in local retinal sensitivity at some point over the graft 
was noted in all tested eyes. This loss in local retinal sensitivity may be due to primary 
retinal atrophy, progressive dysfunction of the grafted RPE or test-retest variability in 
microperimetry (Convento and Barbaro 2007). Nevertheless, the results showed that 
some residual retinal sensitivity can be maintained over the graft for more than 3 years 
in some cases. The demonstration of structures which correspond to outer plexiform and 
nuclear layers on SD-OCT in regions over the graft where there is retinal sensitivity is 
consistent with the extensive literature which support photoreceptor cell rescue by RPE 
transplantation (da Cruz et al. 2007). Fundus AF signal, from the fluorophores within 
the RPE, is an indirect measure of outer segments renewal and lipofuscin clearance (von 
Ruckmann et al. 1995; Delori et al. 1995). The loss of retinal sensitivity over regions of 
the graft where AF signals remain may be explained by a combination of (1) prolonged 
retention of lipofuscin within the translocated equatorial RPE, (2) pre- or intra-operative 
loss of photoreceptor cells and (3) postoperative retinal atrophy (patient 4) or oedema 
(patient 8).  
 
5.5.2.2 Long-term structural outcomes 
Late postoperative complications were common. Although retinal detachment did not 
occur after 12 months, some degree of ERM was present in the majority which may 
represent mild forms of proliferative vitreoretinopathy. It is not known if peeling of the 
ERM or ILM may have improved the overall outcome. However, the VA outcome was 
not superior in a previous series where the ILM was frequently peeled at the time of 
removal of oil (Maaijwee et al. 2007a). By using SD-OCT (in 9 patients) or TD-OCT 
(in 3 patients), it was possible to detect retinal atrophy associated with cystic change 
within the retina over all patch grafts. The high rate of cystic change compared to 
previous studies may be related to use of dense raster B-scan instead of the 6 radial B-
scan protocols (Joeres et al. 2008). Intraretinal cysts over the graft may occur as a 
consequence of traction from ERM, leakage from recurrent CNV, compromised RPE, 
leaky perifoveal retinal capillaries, graft ischaemia, retinal atrophy or RPE atrophy 
(causing retinal cysts). Even with fluorescein and indocyanine green angiographies, it 
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 was difficult to determine the contribution of each process to the intraretinal cystic 
change. Patchy loss of autofluorescence signal over the graft was related to 
pigmentation and fibrosis as previously reported (Schmitz-Valckenberg et al. 2008; 
Maaijwee et al. 2007a). The enlarging rim of absent AF signal (due to progressive RPE 
atrophy or fibrosis of recurrent CNV) surrounding the graft is of particular concern as 
this may compromise choice of preferred retinal locus if foveal fixation over the graft is 
lost.  
 
5.5.3 Comparison between translocation and patch graft  
A comparison of outcomes of translocation versus patch graft showed that in the best 
cases, both procedures can restore foveal function in patients with neovascular AMD; 
achieving near-normal levels of VA (0.10 logMAR). However, the long-term visual and 
structural outcomes of translocation surgery appear to be superior compared to patch 
graft. This difference does not appear to be related to the case-mix or the surgical 
learning curves.  
 
5.5.3.1 Case-mix characteristics 
Factors that have been proposed to determine visual outcomes after translocation are 
preoperative features such as fixation stability, VA, duration of symptom and lesion 
composition, and operative variables such as surgical experience and learning curve 
(Oyagi et al. 2004; Wong et al. 2004; Mruthyunjaya et al. 2005; Toth and Freedman 
2001; Abdel-Meguid et al. 2003; Uppal et al. 2007). Similarly, outcomes of patch graft 
have also been shown to be related to lesion composition and intraoperative course 
(Maaijwee et al. 2007a; Maaijwee et al. 2008c). The baseline features of the 2 groups 
are unlikely to explain the superior outcome following translocation in our cohort. 
Regardless of the specific preoperative prognostic factors, timing has been proposed as 
the most critical determinant since both translocation and patch graft are rescue 
procedures that require presence of viable photoreceptors (Uppal et al. 2007). In the 
Moorfields’ cohorts, the baseline VA, fixation and lesion composition were similar 
between the 2 groups; however, the shorter duration of symptoms in the patch graft 
group would have favoured a better outcome. A wide range of total lesion size was 
found in each group and the median lesion size for the patch graft group was larger than 
that of the translocation group. However, this was not statistically significant. 
Furthermore, previous studies have reported that lesion size was not a predictor of VA 
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 outcome in either translocation or patch graft (Mruthyunjaya et al. 2005; Maaijwee et 
al. 2007a).  
 
5.5.3.2 Surgical course and learning curves 
Although only the first 12 cases were chosen, including all intra- and postoperative 
complications arising from surgical learning curves, the surgical outcomes of 
translocation and patch graft are similar to previously reported larger case series of each 
technique.  
Aisenbrey et al. (2007) reported a 75% rate of less than 3 line loss at 3 years 
(similar to results from our group) in a subset of 52 patients from a cohort of 90 
patients. However, they showed a gradual loss of VA from a median of 1.00 logMAR at 
baseline to 1.20 logMAR at final examination after translocation. In contrast, the 
median VA of these first 12 cases improved from 0.90 to 0.69 logMAR at 3 years. The 
difference may be related to the high rate (61%) of secondary geographic atrophy (GA) 
in their study (Aisenbrey et al. 2007). Although secondary GA was not observed within 
the first three years after translocation, the sharp drop in survival (defined as less than 3 
line loss) as shown in the Kapan-Meier plot in their report suggest that GA may occur 
later (Aisenbrey et al. 2007). Early postoperative complication is unlikely to explain the 
difference given the rates of retinal detachment (25%), macular oedema (50%) and 
recurrent CNV (8%) in the 12 cases are similar to those published previously (Eckardt 
et al. 1999; Ohji et al. 2001; Aisenbrey et al. 2002; Pertile and Claes 2002; Abdel-
Meguid et al. 2003; Terasaki et al. 2003; Mruthyunjaya et al. 2004).    
Maaijwee et al. (2007a) reported the 1 to 4 year outcome in a cohort of 83 
patients with slightly poorer pre-operative VA (0.95 logMAR) than our group (0.87 
logMAR). As discussed in previous section, the low post-operative VA in these 12 
patients may be related to the high rates of retinal detachment (42%), graft haemorrhage 
(50%) and macular edema (50%), similar to that reported in previous larger series of 
patch graft (Joussen et al. 2006; Heussen et al. 2008; Joeres et al. 2008). Review of the 
surgical notes, it was found that 5 patients required 2 or more submacular manipulation 
of the graft. It is difficult to compare the scores of intra-operative course in the 12 
patients with that reported by Maaijwee et al. (2008c) because their study was 
prospective and included a larger number of cases. 
Given that the case-mix is similar and the surgical learning curves are matched, 
the difference in outcome may be explained by other factors. As discussed below, 
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 factors related to surgical trauma, source of RPE and choroidal perfusion may explain 
the better outcome in translocation compared to patch graft. 
 
5.5.3.3 Trauma related to surgical approach 
Surgical trauma to macular photoreceptors and donor RPE can occur during 
translocation and patch graft. Both techniques require mechanical retinal detachment 
(by subretinal injection or retinal peeling) at (1) the recipient site to allow removal of 
CNV complex and (2) the donor site, to enable translocation of the macula or the RPE-
choroid patch. Trauma to photoreceptors and RPE occur during induced detachment 
because of disruption to the strong adhesive bond between these two layers. RPE 
damage after harvesting of RPE graft has been demonstrated by electron microscopy 
(MacLaren et al. 2007). Further insult to the RPE and photoreceptor cells is likely to 
occur during insertion and manipulation of the graft in the submacular space (Maaijwee 
et al. 2008c). In contrast, rotation of macula under heavy liquid is a much more 
controlled maneuver and is likely to be less traumatic than graft insertion. The 
microperimetry results showed contrasting patterns of scotoma which may reflect 
differences in the extent of iatrogenic damage to macular photoreceptor cells. After 
translocation, a large scotoma inferior to the fovea was found to correspond to the area 
of RPE defect created by CNV excision. However, in the patch graft patients, the ring 
scotoma in the absence of large areas of RPE defect may be related to surgical trauma to 
the macular photoreceptors during graft insertion and manipulation. Although the 
remaining central island of vision over the graft can maintain stable fixation and high 
spatial resolution, it does not provide the necessary horizontal visual span for reading 
tasks (Sunness et al. 1997). Furthermore, should the central island of vision be lost, the 
alternative retinal fixation locus may be pushed much further away from the fovea since 
there is no adjacent functioning retina. Damage to the RPE and retina may also occur 
during silicone oil tamponade although both had similar duration of oil in situ (Tafoya 
et al. 2003; Gonvers et al. 1986). Overall, the patch graft technique may be more 
traumatic to macular photoreceptor cells and RPE compared to translocation. However, 
surgical trauma alone may not be the only explanation for the difference in outcome.  
 
5.5.3.4 Source of retinal pigment epithelium 
The source of RPE in translocation is located at the vascular arcade (paramacula) when 
the macula is rotated 45º around the disc. In contrast, RPE outside the vascular arcade 
(equatorial) is chosen for harvesting of autologous RPE-choroid graft. Several studies 
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 have found topographic differences in the RPE gene expression and Bruch’s membrane 
composition (Ishibashi et al. 2004; Bowes et al. 2006; van Soest et al. 2007; Kociok 
and Joussen 2007; Chong et al. 2005). Therefore, it is likely that there may also be 
topographic differences in RPE function and that equatorial RPE may not be as suitable 
as paramacular RPE in providing long-term support for foveal cones. This is consistent 
with our findings of the delayed cystic degeneration or cystoid macular edema over the 
RPE graft. However, the late occurrence of de novo GA following translocation 
suggests that even paramacular RPE may not be an ideal substitute for submacular RPE 
in patients with AMD (Aisenbrey et al. 2007).  
 
5.5.3.5 Choroidal and patch graft perfusion 
A major difference between the 2 types of surgical modalities is that in translocation, 
perfused retina is rotated onto perfused choroid whereas in patch graft technique, the 
RPE-choroid patch is a free graft which may not become perfused for several days after 
the procedure. During these first few days, the underlying damaged choroidal bed may 
not provide enough metabolic support for the outer retina through the entire thickness of 
the patch graft. Evidence of first vascular connection between the graft and choroidal 
bed in a pig model is 1 week (Maaijwee et al. 2007b). Clinically, perfusion of the graft 
can be visible on fluorescein or indocyanine green angiography in some patients at 1 
week (Maaijwee et al. 2008d; Treumer et al. 2007a). Although most grafts are perfused 
by 1 month, it may be delayed for as long as 3 months (Joussen et al. 2006). Graft 
reperfusion may depend on (1) the vascularity of the wound bed, which may be 
compromised by prior PDT or during removal of CNV, and (2) the presence of pro-
angiogenic factors, which can be reduced by prior anti-VEGF therapy. Both of these 
factors are not relevant in translocation. While graft perfusion is being established in the 
first few days, ischemic damage to the outer retina is likely to compromise visual 
outcome. Despite this limitation, one advantage of patch graft is that it appears to resist 
invasion by recurrent CNV. This may be related to the thicker and less porous elastic 
layer of equatorial Bruch’s membrane or anti-angiogenic factors produced by the 
equatorial RPE-choroid (Steele et al. 1993a; Chong et al. 2005; Bhutto et al. 2006; 
Semkova et al. 2006). 
 
5.5.4 Strength and limitations of the study  
The strength of the study was the inclusion of consecutive patients undergoing 
translocation or autologous grafts in a single institution. A total of 52 patients with 
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 neovascular AMD were identified to have undergone surgery for translocation or patch 
graft. This is still the largest cohort of patient followed for the longest duration in the 
published literature. All patients were been examined by the author at least once during 
follow-up visits and their ocular status were documented in detail. The availability of 
microperimetry results from many of these patients offered unique opportunity to study 
then long-term function rescue of photoreceptor cells by paramacular or equatorial RPE.  
The main limitation was the retrospective design and therefore various outcome 
measures were not available in all patients. Furthermore, the sample size was not large 
enough for additional statistical analysis of factors that may predict visual outcomes. 
Despite these limitations, the detailed functional tests and macular imaging in 
some patients allowed the relationship between photoreceptor layer structures and 
retinal sensitivity to be explored. In future studies, in vivo cellular imaging using 
AOSLO to visualize RPE and cones mosaic may provide more information on the 
interaction between paramacular RPE and foveal photoreceptors (Liang et al. 1997; 
Roorda et al. 2007).   
The comparison study was also limited by the small sample size (12 versus 12). 
However, it was possible to show that case-mix and learning curves were unlikely to 
contribute to the difference in outcome. The lesser surgical trauma, use of paramacular 
RPE and immediate submacular choroidal perfusion may explain the superior outcome 
following translocation. The difference in outcome was further supported by detailed 
microperimetry which revealed that normal fixation stability (BCEA of <1200 minarc2) 
and a retinal sensitivity of greater than 10 dB within the central 10º can be achieved 
consistently after translocation but not after patch graft (Steinman 1965; Rohrschneider 
et al. 1995; Crossland and Rubin 2002). 
 
5.5.5 Clinical implications and conclusions  
Both translocation and patch graft techniques are options for patients with neovascular 
AMD who are otherwise, ineligible for or non-responders of anti-VEGF therapy. 
Although both types of approaches can rescue foveal function, these data suggest that 
translocation with 360º retinotomy is able to achieve superior long-term visual outcome 
compared to patch graft in the cohort of patients studied. On the whole, the visual 
outcome after patch graft (as described by van Meurs) may not be any different from 
natural history. Furthremore, it seems that the mean VA gain following translocation is 
comparable to that observed after monthly anti-VEGF therapy. Although the patient 
characteristic in the ANCHOR and MARINA studies are very different from those 
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 reported in this chapter, the expected outcome for untreated disease in both groups is 
likely to be similar. This raises an interesting question of whether 2 to 3 operations (day 
procedures) within a 6 month period; a minimal requirement for translocation, is more 
economical than 15-24 anti-VEGF injections over 2 years for the treatment of patients 
presenting with second eye affected by neovascular AMD. However, regardless of 
whether health economics calculation predicts a better cost-benefit ratio for 
translocation surgery compared with anti-VEGF therapy, from the author’s experience 
of counselling patients with acute neovascular AMD, most patients would prefer to have 
a quick intravitreal injection of anti-VEGF agents every month than to undergo 2 or 
more major eye operations which still carry significant risk of blinding complications. 
Therefore, macular translocation would be recommended in preference to patch 
graft as an option for treatment of second eyes with acute neovascular AMD unsuitable 
for anti-VEGF agents. However, expansion of pre-existing RPE atrophy and recurrence 
of CNV within the first 2-3 years may threaten loss of visual function in a minority of 
patients after translocation. Hence, close post-operative monitoring during the first 2 





Author’s contribution to the work presented in this chapter are summarised in Table 
5.11. The author conducted further studies in microperimetry in view of lack of the data 
on repeatability whilst serial microperimetry was analysed. The result of a prospective 
study examining the intra-session test-retest variability of retinal sensitivity 
measurements was published and that of fixation stability is being reviewed. The 
reported coefficients of repeatability for microperimetry will be useful for future clinical 
trials using retinal sensitivity as one of the core outcome measure (see Appendix 1). 
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 Table 5.11 Contribution list for the neovascular macular degeneration studies 
Contribution cateogory Details of contriubtion 
1 Conception and 
design 
Author: drafted protocol and ethics application forms for the 2 
retrospective studies and the comparative study between patch graft and 
macular translocation 
LDC: approval of all study documents 
 Data acquisition  Author: examined all 52 patients who underwent patch graft or macular 
translocation. Also performed all their ETDRS VA, Pelli-Robson CS, 
OCT and FAF imaging. Author performed serial microperimetry on 6 
patch graft patients and 6 translocation patients. All clinical records 
were reviewed by the author 
LDC: performed all surgical procedures 
 Data analysis and 
interpretation 
Author: analysed and interpreted all clinical documentation, fundus 
imaging and microperimetry results 
LDC: supervised interpretation of results 
CB: supervised statistical analysis 
2 Writing  Author: wrote the entire chapter 
 Revising Author: revised the entire chapter  
LDC: read the chapter and made suggestions 
PJC: read the chapter and made suggestions 
3 Statistical analysis Author: performed all statistical analysis 
CB: supervised statistical analysis 
 Funding Author: obtained a scholarship from Bausch & Lomb ($10,000) 
PJC and LDC: obtained funding for the London Project to Cure 
Blindness 
 Administrative and 
technical support 
Author: arranged all post-operative visits and created all the graphs and 
figure montage from the image database 
TB: arranged submission of forms to research governance 
CB; Catey Bunce (statistician), CS; contrast sensitivity, ETDRS; Early Treatment Diabetic Retinopathy 
Study, FAF; fundus autofluorescence, LDC; Lyndon Da Cruz (supervisor), OCT; optical coherence 
tomography, PJC; Peter J Coffey (supervisor), TB; Tina Burman (research co-ordinator), VA; visual 
acuity. 
 




Chapter 6 Human ESC-RPE Transplantation in Porcine Model 
 
Human ESC-RPE Transplantation in 
Porcine Model 
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6.1 Background 
Photoreceptor cell rescue by macular translocation and RPE graft have provided the 
proof of principle in cell replacement therapy for retinal diseases. However, as chapters 
4 and 5 demonstrated, these techniques have not been used widely because of the 
complexity of the surgical procedure and the high postoperative complication rates. For 
RPE reconstruction to become a clinically feasible therapy on a larger scale, a simpler 
and safer surgical technique must be developed. One approach is to deliver a pre-made 
monolayer of healthy RPE on a bio-compatible substrate into the subretinal space. 
Using sources other than autologous RPE to derive the donor cells avoids the extra 
surgical manouvres in harvesting autologous RPE for patch grafting or creation of 360º 
retinotomy and total retinal detachment for translocation. Other advantages of using 
allogeneic cells are that cell lines without known genetic defects that may affect RPE 
cell function can be chosen and there is opportunity to manipulate the donor RPE in 
vitro to enhance its survival and function in vivo.  
  Allotransplantation of adult or fetal RPE has been performed in the past without 
evidence of significant functional rescue (Peyman et al. 1991; Algvere et al. 1994; 
Gouras and Algvere 1996; Algvere et al. 1997; Algvere et al. 1999; Weisz et al. 1999; 
Del Priore et al. 2001; Tezel et al. 2007). This may have been due to (1) anoikis of RPE 
related to cell suspension delivery, or (2) RPE graft rejection characterised by fibrous 
encapsulation of the small RPE sheets delivered into the subretinal space. 
Transplantation of the RPE cells on a substrate has been explored as a way to improve 
its survival in the subretinal space. Many of these substrates were shown to be 
inappropriate as they (1) did not support RPE growth and differentiation, (2) were 
difficult to handle surgically, (3) were insufficiently porous for RPE to exchange 
metabolite with the choroid or (4) induced inflammation and fibrous reaction in the 
subretinal space.  
 To address the two critical issues of (1) donor cell integration and (2) protection 
from immune rejection, this chapter investigates the use of RPE derived from human 
embryonic stem cells (hESC-RPE) in a porcine model.  
 
6.2 Aims 
In this chapter, the results of the 4 porcine experiements are presented to to answer the 
following questions:   
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 1.  Is it feasible to perform subretinal transplantation of hESC-RPE on a polyester 
substrate in the normal porcine eye? 
2. What is the fate of xenografted hESC-RPE, the supporting polyester substrate and 
the photoreceptor cells overlying the graft following transplantation? 
3.  What are the inflammatory and immunological responses to the bleb detachment, 
polyester substrate, matrigel coating and the hESC-RPE? 
 
6.3 Specific Methodology 




6.4.1 Baseline features and surgical intervention 
A total of 21 pigs were operated in 4 separate sessions of experiments (see Table 6.1). 
The age of the pigs ranged from 7 to 9 weeks. These were all female domestic pigs with 
either blue or brown irides. The baseline weight ranged between 20 and 34 kg (median; 
23).  
All pigs had intraocular surgery in the left eye. Amongst the 21 vitrectomies 
performed, 2 had bleb detachment only, 4 had subretinal polyester substrate implant (1 
coated with Matrigel™ and 3 uncoated), 2 had subretinal limbal fibroblast on coated 
polyester substrate and 13 had subretinal hESC-RPE on coated polyester substrate.  
 
6.4.2 Surgical course and outcome 
The surgical steps for hESC-RPE graft are similar to autologous RPE-choroid graft (see 
description in Section 4.4.3) with the exception of the need to harvest autologous RPE. 
The procedure can be divided into the following 5 key steps: (1) induction of posterior 
vitreous detachment and vitrectomy, (2) creation of bleb retinal detachment and 
retinotomy, (3) preparation of the hESC-RPE graft from the modified Transwell® Insert 
at the bench top, (4) transfer and delivery of the graft from the bench top to the 
subretinal space and (5) sealing of the retinotomy / retinal break, and closure of the 
sclerostomies / peritomies.  
Posterior vitreous detachment was induced in all 21 eyes using the vitreous 
cutter at maximum aspiration. During vitrectomy, 1 had lens touch, 1 developed 
suprachoroidal haemorrhage and 1 developed retinal detachment. Bleb detachment was 
achieved consistently using the 41G cannula and the retinotomies were successfully 
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 enlarged using vertical scissors. Two eyes had limited bleeding from the retinotomy 
sites.  
A patch graft was able to be cut out using the customised punch. However, 
several animals required more than 1 patch graft to be cut out from the modified 
Transwell® Insert due to significant loss of the hESC-RPE monolayer during punch of 
the graft, handling of the patch or insertion of the graft into the eye. In 6 of the 12 (50%) 
animals that received hESC-RPE, there was shifting of the hESC-RPE monolayer over 
the substrate when the graft was being pushed into the subretinal space. Of these 6, 4 
had to be explanted due to significant loss of the hESC-RPE. These animals received a 
second graft which was inserted without further complication. All animals had air-fluid 
exchange which allowed the bleb detachment to flatten. Sclerostomies and peritomies 
were closed without any complication. 
Overally, there was no surgical complication in 10 of 21 eyes. All pigs 
recovered from general anaesthesia except for animal numbers 11 (planned euthanasia) 
and 16. Pig number 16 had cardiorespiratory arrest within an hour following surgery 
and therefore was excluded from further analysis. Summaries of operative course and 
postoperative complications are shown in Tables 6.2 and 6.3. 
At the time of termination, fundus examination showed attached retina in 8 of 20 
animals. There was variable amount of pigmentation seen over the graft with some 
depigmentation surrounding the patch. The fundus was not visible in the remaining 12 
animals due to lens opacity (2 eyes), vitreous cavity air bubble (3 eyes) and varying 
degrees of vitreous blood and fibrin strands (7 eyes). The range of intraocular pressure 
was 10 to 28 mmHg across all time points. The choroidal haemorrhage and retinal 
detachment encountered intraoperatively had resolved spontaneously when the animals 
were examined prior to euthanasia.  
Animals were euthanised at the following time points: 2 hours (1 pig), 2 days (2 
pigs), 1 week (4 pigs), 2 weeks (4 pigs), 4 weeks (3 pigs) and 6 weeks (6 pigs).  
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Type of transplant 
received 
CYA given Duration of 
survival 
1 34, 9 12/12/2007 PS + 29 days 
2 34, 9 13/12/2007 PS + MC + hESC (blob) + 28 days 
3 34, 9 13/12/2007 PS + MC + 28 days 
4 20, 7 02//04/2008 PS + MC + hLF - 43 days 
5 23, 7 02//04/2008 PS + MC + hLF + 43 days 
6 22, 7 02//04/2008 PS + MC + hESC (blob) - 43 days 
7 20, 7 03//04/2008 PS + MC + hESC (blob) + 42 days 
8 23, 7 03//04/2008 PS + MC + hESC (blob) - 42 days 
9 24, 7 03//04/2008 PS + MC + hESC (dr-s) + 42 days 
11 32, 9 12/11/2008 PS + MC + hESC (dr-s) - 60-120 min 
12 23, 7 12/11/2008 PS + MC + hESC (dr-s) - 15 days 
13 23, 7 12/11/2008 PS + MC + hESC (dr-s) + 2 days 
14 23, 7 12/11/2008 PS + MC + hESC (dr-s) - 7 days 
15 23, 7 13/11/2008 PS + MC + hESC (dr-s) + 7 days 
16 23, 7 13/11/2008 PS + MC + hESC (dr-s) - deceased 
17 23, 7 13/11/2008 PS + MC + hESC (dr-s) + 14 days 
18 30, 9 04/12/2008 None - 7 days 
19 30, 9 04/12/2008 None - 14 days 
20 30, 9 04/12/2008 PS - 7 days 
21 30, 9 04/12/2008 PS - 14 days 
22 30, 9 04/12/2008 PS + MC + hESC (dr-s) - 2 days 
CYA; cyclosporine A, PS, polyester substrate; dr-s, dissociated then re-seeded; hESC, human 
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 Table 6.2 Pig experiments 1 and 2: Surgical course and complications 
Postoperative examination Pig  Intraoperative 





Lens touch 18 Cataract NV NV 
2 Suprachoroidal 
haemorrhage 
16 Clear Blood, 
Fibirin 
NV 




2 patches required, 1 
removed and analysed 





2 patches required, 1 lost 
and not found 
10 Clear Blood, 
Fibirin 
NV 
6 RPE on patch shifted 17 Clear Clear No RD, Faint pigment 
over graft 
7 RD, retinotomy bleed, 
RPE on patch shifted 
14 Conjunctival 
granuloma 
Clear No RD, Diffuse dense 
pigment over graft 
8 RPE on patch shifted 13 Clear Clear No RD, Diffuse dense 
pigment over graft 
9 None 14 Clear Clear No RD, diffuse pigment 
on graft 
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 Table 6.3 Pig experiments 3 and 4: Surgical course and complications 
Postoperative course Pig  Intraoperative 
complication IOP Anterior 
segment 
Vitreous Fundus 
11 Retinal break, retinotomy 
bleed, loss of hESC-RPE 
- Clear Air NV 
12 2 patches required, 1 
removed and analysed 
12 Clear Blood, 
Fibrin 
NV 




Loss of cell over patch 14 Clear Clear No RD, retinal fold over 




None 15 Clear Blood, 
Fibrin 
NV 
16 None postoperative cardiac arrest on same day (Air in eye) 
Enucleated and fixed 3 hours post-mortem 
17 None 15 Clear Blood NV 
 
18 None 15 Clear Blood No RD 
 
19 None 9, 19 Clear Clear No RD, white punctuate 
mark 
20 None 10 Clear Blood NV 
 
21 None 19, 13 Clear Clear No RD, ERM, pigment 
developed over patch 
22 Loss of cell over patch, 2 
patches used 
19 Clear Air NV 
 
RD; retinal detachment, NV; no view.  
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 6.4.3 Tissue fixation and gross pathology 
Gross pathological features and the type of tissue processings are summarised in Tables 
6.4 and illustrated in Figure 6.1. After removal of the anterior segment, retinal 
detachment was noted in 9 of 20 eyes (see Figure 6.1). However, 8 of these were 
related to fixation artefact. Of the 11 eyes with attached retina, 6 had retinal folds. The 
polyester substrate was found in the subretinal space in 16 of the 18 animals that 
received a patch graft. One of these also had another graft (lost during surgery) in the 
vitreous base, adjacent to the ciliary body. In the remaining 2 animals, the graft was 
found with within the vitreous cavity. Of the 12 animals that had subretinal hESC-RPE 
patch graft on gross examination of the eye cups, 3 had focal, 5 had patchy and 4 had 
diffuse pigmentation on the substrate. Four eyes also had pigmenatry changes in the 
surrounding RPE.  
 Sectioning of the posterior cup induced further retinal detachments in 3 eyes 
which previously had attached retina. Tissue preparation of the eye from pig 22 also led 
to loss of the patch graft precluding further analysis of donor cell survival. A total of 19 




Figure 6.1 Porcine transplantation: gross pathology 
(A) Intra-operative view of the RPE graft during air-fluid exchange in animal number 9. 
(B) The gross appearance of the graft in animal number 9 at 6 weeks (anterior segment 
has been removed). (C) The gross appearance of the graft from animal number 7 at 6 
weeks showing pigmentary alteration around the patch. (D) Rhegmatogenous retinal 
detachment in animal number 15. (E) A large retinal fold across the graft in animal 
number 14. (F) Sectioning of the graft in animal 17 led to artefactual retinal detachment.   
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 Table 6.4 Gross pathology and tissue processing 
 Gross pathological features Tissue processing 
Pig 
No.*  






artefact LM EM 
1 - A - SR - - - + - 
2 - - - SR F - - + - 
3 - - Large SR - - - + - 
4 - A - VC N/A - - - - 
5 - - Large SR + VC F - + + + 
6 - - - SR F - - + - 
7 - - - SR D + - + + 
8 -  - SR D + - + + 
9 - - - SR D - - + + 
11 Air A - SR D + - + + 
12 - A - SR P - - + + 
13 Air A - SR P - - + - 
14 - - Large SR P - + + + 
15 Blood R - VC N/A - - + - 
17 - - Small SR P - + + + 
18 - A - N/A N/A - - + - 
19 - A - N/A N/A - - + - 
20 - - Small SR - - - + - 
21 - - Small SR F - - + - 
22 Air A - SR P + + + + 
A, artefactual retinal detachment; D, diffuse pigmentation; F, focal pigmentation; N/A, not 
applicable; P, patchy pigmentation; R, rhegmatogenoush retinal detachment; RD, retinal 
detachment; RF, retinal fold; SR, subretinal space; VC, vitreous cavity 
* Animal number 10 was not used for transplantation study and animal 16 did not survive 
anaesthesia and are therefore excluded from further analysis. 
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 6.4.4 Donor cell survival and neuroretinal structure 
Human cell was identified in the subretinal space in 50% (6 of 12 eyes) of animals that 
received hESC-RPE (summarised in Table 6.5). At the 2-hour and 2-day time points, 
there was a monolayer of pigmented human cells lining the surface of the substrate (see 
Figure 6.2). On electron microscopy, these cells were polarized; displaying apical 
microvilli and melanosomes (see Figure 6.2). However, between 1 and 2 weeks, there 
was a significant reduction in the number of pigmented human cells. By 6 weeks, only 2 
of 4 animals had surviving human cells. Cell survival was not directly related to 
cyclosporine administration. These surviving cells expressed CRALBP and Bestrophin. 
There was no evidence of uncontrolled donor cell division or tumour formation on Ki67 
staining.  
The outer nuclear layer was intact over the patch at 2 hours, 2 days 1, 2 and 6 
weeks. Inner and outer photoreceptor segments could be identified at the earlier time 
points. In the 3 control eyes that received substrate without cells, there was loss of the 
outer nuclear layer over the graft. Strong GFAP reactivity was present at every time 
point, even at 2 hours postoperatively.  
 
6.4.5 Immunological and inflammatory response 
Inflammatory response was characterized by the predominant presence of macrophages 
adjacent to the patches. At 2 hour post-surgery, macrophage was not detected. By 2 
days, there were occasional small autofluorescent (yellow/red) cells. Some of these 
reacted with anti-porcine macrophage antibody (see Figure 6.2). By 7 days, there were 
some larger, rounded pigment-laden cells on the patches as well as the smaller 
autofluorescent cells. These pigmented cells did not stain with CRALBP or RPE65 and 
were occasionally faintly autofluorescent but did not react with the anti-porcine 
macrophage antibody that is available. Electron microscopy These cells were present at 
all time points from 7 days postoperatively. Small autofluorescent macrophages were 
also present in animals which received the patch implant without hESC-RPE. 
CD8-positive (cytotoxic T) cells were detected in 3 animals; they were present 
in the neural retina in one; at 2 weeks, and in the choroid in another at 6 weeks. This 
animal also had multinucleated giant cells (see Figure 6.3). CD8-positive cells were 
also detected in other animals but did not show evidence of retinal infiltration or 
vascular cuffing. CD4-positive (T helper) cells were also detected in 2 animals both at 
the 2 weeks time point. In the same animals, CD79-positive cells (B lymphocytes) were 
also detected in the neurosensory retina (see Figure 6.4). 
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Table 6.5 Pig experiment: summary of cell survival and immune reaction 
Time Pig No. CYA 
given 
Location of 








2 hours 11 - SR + - - 
2 days 13 + SR + SA CD8 
 22 - SR, Lost N/A N/A N/A 
7 days 18* - No graft - - - 
 20** - SR - SA - 
 15 + VC - LP - 
 14 - SR + SA, LP - 
2 weeks 19* - No graft - N/A N/A 
 21** - SR - N/A N/A 
 17 + SR - SA, M CD4, CD79‡ 
 12 - SR + LP CD4, CD8, CD79‡ 
4 weeks 1** + SR - N/A N/A 
 3** + SR - N/A N/A 
 2 + SR N/A N/A N/A 
6 weeks 4*** + VC N/A N/A N/A 
 5*** - SR N/A SA, M N/A 
 7 + SR + N/A  N/A 
 9 + SR N/A M N/A 
 6 - SR N/A SA, LP, M N/A 
 8 - SR + LP, M CD8† 
SA, small autofluorescent macrophage-like cells; LP, large pigmented macrophage-like cells; 
M, macrophage that reacted with specific macrophage antibodies; N/A, not available; SR; 
subretinal, VC; vitreous cavity, +; yes, -; no.  
* control animals with bleb detachment only; ** control animals with sham patch; *** control 
animals with sham patch with fibroblast; † located in choroid, ‡ located in retina 
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Figure 6.2 Cell survival and inflammatory response 
Pigmented human cells are found (FITC or TRITC) on polyester substrate at (A) 2 
hours, (B) 2 days, (C) 7 days and (D) 14 days. (E) These human pigmented cells appear 
to be polarized with apical microvilli on electron microscopy. Small autofluorescent 
cells (probably host macrophages) are found in eyes which received (F) polyester 
substrate alone and (G) human cells on substrate at 14 days. (H) At 6 weeks, large 
multinucleated giant cells were seen adjacent to the substrate on electron microscopy. 
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Figure 6.3 CD8-positive cells 
CD8-positive (cytotoxic) T cells were detected in (A, B) the retina in one animal at 2 
weeks (FITC) and in (C, D) the choroid (marked with red asterix) in one animal at 6 
weeks (TRITC). There were also occasional CD8-positive cells in other animals 
detected at (E) 2 days and (F) 2 weeks (FITC).  
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Figure 6.4 CD4-positive and CD79-positive cells 
CD4-positive (helper) T cells were detected (FITC) in the retina at 2 weeks in (A) a 
non-immunusoppressed and (B) an immunosuppressed animal. CD79-positive (B) cells 
were detected (FITC) in the retina at 2 weeks in (A) a non-immunusoppressed and (B) 






In animal experimental studies and human clinical trials, replacement of diseased RPE 
or RPE defect by cell transplantation has been shown to restore and maintain visual 
function (Li and Turner 1988a; Machemer and Steinhorst 1993; van Meurs and Van 
Den Biesen 2003). However, the potential benefits of current techniques of RPE 
reconstruction are overshadowed by their complexity, use of aged RPE cells that may 
carry genetic mutation, and the high post-operative complication rates (see Chapters 4 
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 and 5). To enable simpler and safer surgical approach in reconstructing the RPE, 
sources other than autologous RPE need to be explored.  
Previous studies have demonstrated outer nuclear layer and visual function 
rescue with no signs of early graft rejection using hESC-RPE cell suspension in 
immuno-suppressed RCS rats and ELOVL4 mice (Lu et al. 2009; Lund et al. 2006; 
Vugler et al. 2008). However, hESC-RPE cell suspension injection in human will not be 
successful due to poor adhesion and anoikis of the RPE on aged and damaged Bruch’s 
membrane (Del Priore and Tezel 1998; Tezel et al. 1999; Tezel et al. 2004). Therefore, 
a series of experiments was designed to explore feasibility and outcomes of delivering 
hESC-RPE as a monolayer supported by an artificial substrate into the subretinal space 
of a pig eye. The pig eye was chosen because of its anatomical similarity to the human 
eye (large vitreous cavity relative to the lens), thus allowing the use of current standard 
vitreo-retinal surgical instruments.  
The results showed that subretinal transplantation of patch graft is feasible with 
low complication rates. Donor cells can survive for up to 6 weeks although there is 
significant loss of cells at the time of transplantation and 1-2 weeks after surgery. Loss 
of donor cells was accompanied by increasing number of large pigmented cells and 
small autofluorescent host macrophage. 
 
6.5.1 Feasibility and safety of hESC-RPE graft in porcine model 
The pig has been used as a model for subretinal transplantation of allogeneic anterior 
lens capsule (Nicolini et al. 2000; Kiilgaard et al. 2002), allogeneic retinal progenitor 
cells (Warfvinge et al. 2005; Warfvinge et al. 2006; Klassen et al. 2007; Klassen et al. 
2008), allogeneic full-thickness neuroretinal sheet (Ghosh and Arner 2002; Ghosh et al. 
2004; Engelsberg and Ghosh 2007; Ghosh et al. 2007), allogeneic procine RPE sheets 
(Del Priore et al. 2004), autologous porcine RPE-choroid grafts (Lane et al. 1989; 
Maaijwee et al. 2007b), and implantation of retinal prosthesis (Schwahn et al. 2001; 
Montezuma et al. 2006; Gekeler et al. 2007). However, delivery of hESC-RPE into 
porcine eye using modern vitreoretinal surgical instruments has not been reported. 
Therefore, feasibility and safety of patch graft delivery into the subretinal space were 
considered to be important outcome measures. 
 
6.5.1.1 Feasibility of hESC-RPE delivery technique 
The standard vitrectomy technique was feasible in the porcine eye. However, 
canthotomy and tissue retractors were necessary for pars plana access due to the small 
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 palpebral fissure and the stiff eyelids in these 2-3 month old animals. Similar to 
previous reports, the current series of experiments demonstrated the feasibility of pars 
plana vitrectomy, creation of bleb retinal detachment and enlargement of the retinotomy 
in the porcine eye. Future studies will need to explore the use of viscoelastic substance 
to maintain the subretinal space while the graft is inserted through the retinotomy. 
Although these experiments demonstrated the possibility of creating a small 1 x 
3 mm patch graft from a modified Transwell® Insert with a simple punch device and 
delivering the patch into the subretinal space using a pair of commercially available 
intraocular forceps, there was significant loss of pigmented cells during these processes.  
Loss of donor RPE cells may have occurred during the these 6 stages of the 
procedure: (1) removal of the polyester membrane from the Transwell® Insert, (2) 
punching of the graft from the membrane, (3) grasping of the patch graft by forceps, (4) 
insertion of the graft into the eye through a sclerostomy, (5) exposure of the graft to 
fluid current within the vitreous cavity and (6) insertion of the graft into the subretinal 
space through a retinotomy. It is likely that these sequential and cumulative insults to 
the patch graft contributed to the visible movement of the pigmented cells over the graft 
during insertion of the patch into the retinotomy. Furthermore, a third (4 of 12) of these 
grafts lost almost all pigmented cells.  
There are 2 ways to reduce donor cell loss during transfer and delivery of the 
graft. Firstly, the patch can be preloaded on a device (i.e. cells cultured on a substrate 
that is already prepackaged as part of the delivery device) which also protects the hESC-
RPE during passage of the graft through the sclerostomy, vitreous cavity and 
retinotomy. The handle of the delivery device will also need to occlude the sclerostomy 
port to prevent leak and hence fluid current within the vitreous cavity. Secondly, the 
strength of hESC-RPE adhesion to the substrate can be enhanced by coating the 
substrate with adhesion molecules (such as laminin, collagen and fibronectin) in 
optimised concentrations. There are relatively few surgical tools designed for delivery 
of sheets of cells into the subretinal space in comparison to the number of surgical 
instruments described for the purpose of removing subretinal tissue and subretinal 
injection of cell suspensions (Ghosh and Arner 2002; Aramant and Seiler 2002; van 
Meurs and Van Den Biesen 2003; Del Priore et al. 2004; Maaijwee et al. 2008b; 
Thumann et al. 2006). However, none of these devices would be suitable for the 
purpose of patch graft delivery since they do not offer protection of the graft during 
insertion through the sclerostomy and retinotomy and they are unable to deliver large 
grafts which will be necessary in human transplantation. The hESC-RPE used in this 
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 study has been shown to produce essential components of basal lamina such as collagen 
IV, laminin and fibronectin similar to mature RPE in vivo (Vugler et al. 2008). Further 
work is required to determine if modification of substrate coating may enhance adhesion 
of these cells to the polyester substrate. 
 
6.5.1.2 Postoperative complications 
Despite the absence of retinopexy around the retinotomy and the use of air as 
tamponade, only 1 of 20 animals developed a rhegmatogenous retinal detachment. The 
5% rate may be an underestimate since 9 of 21 animals were followed for more than 4 
weeks. In the animal with rhegmatogenous detachment, the retinotomy was open with 
pre-retinal fibrotic reactions simulating proliferative vitreoretinopathy.  
The true rate of detachment following hESC-RPE patch graft is prorably higher 
than previous porcine transplantation studies which reported detachment rates of: 3% (1 
of 38 eyes) in 4-6 months old normal domestic pigs that received allogeneic RPE 
encased in gelatine (Del Priore et al. 2004), 8% (2 of 24 eyes) in 1.5-3 months old 
normal Yorkshire/Hampshire pigs that received nerroretinal sheet (Ghosh and Arner 
2002; Engelsberg and Ghosh 2007) and 0% (none of the 75 eyes) in 3-4 months old 
normal Danish Landrace pigs that received retinal progenitor cell suspensions 
(Warfvinge et al. 2005; Warfvinge et al. 2006; Klassen et al. 2007; Klassen et al. 2008). 
The higher rate of detachment in patch grafting may be related to the large retinotomy 
and could be reduced if retinopexy is applied and longer-acting tamponade is used. 
 
6.5.2 hESC-RPE cell survival and photoreceptor cell rescue 
Similar to a previous study in the RCS rat, this experiment showed that human cells can 
survive for 6 weeks in vivo but they are detected in only 50% of the animals that 
received hESC-RPE (Vugler et al. 2008). Survival was not related to the use of 
cyclosporine. Loss of donor cell in the subretinal space occurred after 1-2 weeks 
coinciding with the onset of macrophage infiltration (see below). There was no evidence 
of continuing cell division to suggest teratoma formation in any of the 20 animals.  
The substrate used to support hESC-RPE remained flat and did not fold in the 
subretinal space unlike other supporting materials used for RPE cell sheet grafts 
(Nicolini et al. 2000; Del Priore et al. 2004). In the majority of animals, the substrate 
was located in the subretinal space, separating the host RPE from the neuroretina. 
Migration of patch out of the retinotomy occurred in 3 animals. This is likely to have 
occurred soon after surgery due to short duration of tamponade by air and lack of 
 Page 242  
 retinopexy at the retinotomy. The polyester substrate used in this study is already 
compliant with the current Good Manufacturing Practices and can be readily used in 
human. 
Photoreceptor rescue was demonstrated over the patch graft that had hESC-RPE 
but not over sham grafts (i.e. without hESC-RPE). It cannot be assumed that this 
observation translates to functional rescue by hESC-RPE. Further studies using 
multifocal ERG recordings to examine localised retinal function (Kyhn M.V. et al. 
2007) or immunohistochemical technique to detect light induced nuclear expression of 
c-Fos in the inner nuclear layer (Carr et al. 2009b) may provide further information on 
whether hESC-RPE transplant and lead to functional rescue in a porcine model. 
 
6.5.3 Inflammatory and immunological response 
At 2 hours and 2 days after graft, there were no signs of inflammatory reaction. 
However, by 1 week, there were small autofluorescent pigmented host macrophages in 
both control/sham patch and hESC-RPE grafted eyes. By 2 weeks, larger pigmented 
host non-RPE cells were present. These are likely to represent macrophages which have 
phagocytosed donor cells since these cells are not seen in eyes which did not receive 
hESC-RPE. Lymphocytic infiltrate was not a prominent feature although in some 
animals, CD8-positive (cytotoxic) and CD4-positive (helper) T cells were seen in the 
neuroretina or choroid of eyes that received hESC-RPE from 2 weeks postoperatively. 
Similarly, CD79-positive (B) cells were also seen within the neuroretina.  
These observations are similar to that reported previously in allo- and xeno-
transplantation into non-immunosuppressed animals. Del Priore et al. (2004) 
demonstrated predominant prepresence of macrophage-like cells in the subretinal space 
from 9 days after porcine allogeneic RPE graft. Grisanti et al. (2002) demonstrated 
large pigmented ED-1 positive cells within the neuroretina of RCS rats at 12 weeks after 
receiving fresh porcine RPE suspension. They also did not detect a prominent 
lymphocytic response unlike the animals which received subcutaneous or anterior 
chamber xenografts. Despite oral cyclosporine, a similar macrophage response was seen 
even in eyes which only received sham patch. The following section describes a 
possible sequence of event that leads rejection of the hESC-RPE. 
 Surgical trauma of vitrectomy and disruption of the blood retinal barrier by 
retinotomy may activate and induce migration of macrophage into the subretinal space. 
These macrophages may be derived from microglial cells residing within the neural 
retina or circulating monocytes from the blood. The former is more likely in the light of 
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 a recent report which showed that autofluorescent perivascular cells in the retina have 
scavenger activity and may be important in maintaining blood retinal barrier (Mendes-
Jorge et al. 2009). The subretinal space display features of immuno-privileged site 
which includes protection of allograft from rejection and induction of systemic immune 
deviation to antigens placed at the site (Streilein et al. 2002). However, this is not 
absolute, particularly in the setting of surgical injury and, more relevant, disease such as 
AMD. Compounding the unfavourable subretinal environment, hESC-RPE itself as a 
tissue may not have absolute immune privilege. Studies on undifferentiated hESC 
showed that they may be relatively immune privileged with no HLA class II expression 
and low levels of HLA class I and co-stimulatory molecules (Drukker et al. 2002; Li et 
al. 2004; Grinnemo et al. 2006; Robertson et al. 2007). However, differentiated hESC-
RPE can express HLA class I and induced to express HLA class II molecules by 
interferon gamma. The combination of subretinal macrophage and activation of hESC-
RPE by cytokines released during surgical trauma may lead to cell-mediated or 
cytotoxic immune reaction, as demonstrated by the presence of CD8-positive T cells, 
and eventual hESC-RPE rejection. 
 The finding of predominantly macrophage response without lymphocytic 
infiltrate is encouraging. This is because inhibition of macrophage response can be 
achieved pharmacologically using glucocorticoid-type agents and antimicrobial drugs 
such as rifampicin or tetracyclines which may directly act on these scavengers 
(Zetterlund et al. 1998; Mlambo and Sigola 2003; Yrjanheikki et al. 1998). Although 
cyclosporine alone did not prevent donor cell loss, it may have a role in enhancing anti-
macrophage effect of glucocorticoid-like agents by suppressing subsequent cell-
mediated immune responses.  
 
6.5.4 Implications for future directions in hESC-RPE graft surgery 
The porcine experiments have provided some evidence of feasibility in using hESC-
RPE to reconstruct submacular RPE in a clinical setting. However, there remain 3 major 
challenges to overcome before the current hESC-RPE grafting technique can be 
translated into clinical practice. These are (1) the low efficiency of producing a pure 
population of mature or well differentiated RPE from hESC, (2) the trauma to the cells 
on the graft during creation of the patch, transfer and implantation of the graft into the 
subretinal space and (3) loss of hESC-RPE associated with macrophage infiltration. In 
order to understand the requirements for further animal studies in refining the technique 
of subretinal hESC-RPE graft, it is critical to take a step back to examine the 
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 translational research route map that has been set out by the various Competent 
Authorities which issue licenses, and monitor and regulate the institutions involved in 
this type of experiment to ensure compliance with the EU Directives. 
Human ESC-derived tissue or cells for clinical use is considered as an Advanced 
Therapy Medicinal Product (ATMP) under the Medicines and Healthcare products 
Regulatory Agency (MHRA) of the British Government. The Regulations that govern 
ATMP came into force on 30th December 2007 and was applied from 30th December 
2008 (EC 1394/2007). The new regulatory framework considers that the Human Tissue 
Authority (HTA) has the role of regulating the donation, procurement and testing of 
tissue and cells that are to be used as ATMP. The MHRA (Competent Authority for 
medicinal products and medical devices), however, is responsible for the subsequent 
stages of ATMP development, including manufacturing, storage, distribution, clinical 
trials and pharmacovigilance. The key requirements for translation of the current use of 
hESC-RPE in animal studies into a phase I clinical trial of hESC-RPE transplantation 
can be broadly classified into 2 areas as suggested by the Gene Therapy Advisory 
Committee (GTAC) of the Department of Health (see Figure 6.5): (1) statutory 
regulatory processes (Section 6.5.4.1) and (2) research or manufacturing activity 
(Section 6.5.4.2).  
 
6.5.4.1 Statutory regulatory processess 
Even before the hESC could be considered to be used for derivation of RPE and 
clinical transplantation, several statutory regulatory processes have already begun. The 
Human Fertilisation and Embryology Authority (HFEA) would have given licence to 
clinics which carry out human embryo research and storage. Once the stem cells are 
harvested from embryo for the intention of human application, a licence from HTA 
would have been required for derivation and storage of the specific tissues or cells.  If 
genetic modifications of these cells are required, the Health & Safety Executive (HSE) 
will also need to be notified. 
When the hESC-RPE is to be considered as a licensed medicinal product, it will be 
treated as an ATMP under the MHRA. The definition of ATMP given by HTA is as 
follows:  
  
“ATMPs are innovative, regenerative therapies which combine aspects of medicine, cell 
biology, science and engineering for the purpose of regenerating, repairing or replacing 
damaged tissue/cells.” 
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Figure 6.5 Interim UK regulatory route map for stem cell research  
This route map is taken from the Gene Therapy Advisory Committee website 
(http://www.dh.gov.uk/ab/GTAC/index.htm) posted in March 2009. This reference tool 
has been developed by the Department of Health with the support of the Gene Therapy 
Advisory Committee, Health & Safety Executive, Home Office, Human Fertilisation & 
Embryology Authority, Human Tissue Authority, Medicines & Healthcare products 
Regulatory Agency, Medical Research Council, NHS Blood & Transplant Authority, 
Scottish National Blood Transfusion Service, Advisory Committee on the Safety of 
Blood, Tissues & Organs, & the UK Stem Cell Bank. Abbreviations: ATMP; Advanced 
Therapy Medicinal Product, EMEA; European Medicines Evaluation Agency, GM; 
genetic modification, GTAC; Gene Therapy Advisory Committee, GLP; Good 
Laboratory Practice, GMP; Good Manufacturing Practice, HSE; Health & Safety 
Executive, HO; Home Office, HTA; Human Tissue Authority, HFEA; Human 
Fertilisation and Embryology Authority, IMP; Investigational Medicinal Product, MCB; 
Master Cell Bank, MP; Medicinal Product, MHRA; Medicines and Healthcare products 
Regulatory Agency, REC; Research Ethics Committee, WCB; Working Cell Bank. 
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 The process of approval for hESC-RPE as an ATMP is likely to involve several parallel 
steps including (1) animal in vivo experiments under conditions of GLP which will also 
require approval from the Home Office of UK, (2) obtaining a GMP Licence to create a 
master cell bank and working cell bank and (3) preparation of clinical trial 
documentation and obtain a clinical trial number.  
 The porcine experiment may be used as a model for the animal in vivo 
experiment if the MHRA requires further animal studies to ensure safety and efficacy. 
It may be sufficient to use the RCS rat model to demonstrate efficacy of hESC-RPE in 
photoreceptor cell rescue since there is currently no known porcine model of RPE 
dystrophy. Laser or chemical ablation of the RPE in the porcine eye is likely to cause 
concurrent photoreceptor cell loss and therefore is not a suitable model. The use of 
sham patch may be adequate to serve as controls providing the host RPE do not grow 
over the substrate. 
 The autologous RPE trials described in Chapter 4 may also form the basis for 
the initial phase I clinical trial. Using similar outcome measures, this initial study can 
determine the safety and efficacy of hESC-RPE transplantation. The additional 
requirements for a phase I hESC-RPE transplantation clinical trial are: (1) MHRA 
application for the use of ATMP, (2) a EudraCT number for the investigation of a 
medicinal product and compliance with EU Directive 2001/20/EC and (3) application to 
GTAC (instead of the local research ethics committee). HSE notification may also be 
required if genetically modified cells are used.  
 
6.5.4.2 Research and manufacturing activity 
In parallel with the statutory regulatory processes, research and manufacturing activities 
need to occur to ensure the success of translating stem cell therapy into the clinics. 
Much work has been done in refining the protocol of generating RPE-like cells from 
various hESC lines.  
Several groups have now reported derivation of cells resembling RPE from 
hESCs (Klimanskaya et al. 2004; Lund et al. 2006; Lu et al. 2009; Vugler et al. 2008; 
Carr et al. 2009a; Gong et al. 2008; Osakada et al. 2009; Idelson et al. 2009). These 
RPE-like cells (hESC-RPE) have been shown to form a pigmented hexagonal 
monolayer, expressing epithelial and junctional markers, enzymes required for visual 
cycle, ion channels, RPE-specific transcriptional and growth factors, and retinaldehyde-
binding and melanosome-associated proteins. They have also been shown to be more 
similar to mature adult RPE than existing RPE cell lines such as ARPE-19 and foetal 
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 RPE cells (Lu et al. 2009; Carr et al. 2009a). In vitro stem cell research is critical but 
alone, is not enough to provide information required for translation into clinical use. 
There are now several publications which have begun to address the issues of safety and 
efficacy of hESC-RPE transplantation in animals. In vivo data are likely to be critical 
for licensing of hESC-RPE as an ATMP by the MHRA.  
Animal studies have shown that hESC-RPE can also phagocytose photoreceptor 
outer segments after subretinal transplantation (Lund et al. 2006; Vugler et al. 2008; 
Carr et al. 2009a; Idelson et al. 2009). Furthermore, visual function was rescued in the 
RCS rat and possibly in the Elovl4 mice (human orthologues are found in retinitis 
pigmentosa and Stargardt’s disease, respectively) after GMP or non-GMP compliant 
hESC-RPE transplantation (Lund et al. 2006; Lu et al. 2009; Vugler et al. 2008; Idelson 
et al. 2009). In animal studies, hESC-RPE has been shown to survive in rats for up to 30 
weeks without tumour formation (Vugler et al. 2008; Lu et al. 2009). The work from 
this thesis also demonstrated that hESC-RPE can also survive in xenogeneic setting 
using a porcine animal model. Importantly, none of the animal studies (including NIH 
III immune deficient mice) to date have reported tumour formation from the 
transplanted hESC-RPE. 
 Despite the various protocols that have been reported to derive RPE from hESC, 
this remains an inefficient process. Some of the hESC may remain in undifferentiated 
state and some differentiated hESC are less pigmented than mature RPE. This variable 
maturation of hESC-RPE poses 2 problems: low yield of well-differentiated RPE 
production and contamination by potentially tumorigenic hESC. Further understanding 
of embryogenesis of the RPE will help to identify nutritional and growth factors (e.g. 
nicotinamide and Activin A) that may enhance the rate and proportion hESC becoming 
pigmented (Idelson et al. 2009). Isolation of pigmented cells from non-pigmented hESC 
derivative is currently performed mechanically. This may lead to contamination of the 
cells chosen for transplantation by undifferentiated hESC. The use of magnetic-
activated or fluorescence activated cell sorting may improve purity of pigmented cell 
harvesting (Fong et al. 2009). Further work in these areas is currently underway. 
 Having produced the hESC-RPE patch graft with high efficiency and minimal 
hESC contamination, the aim will be to deliver this into the subretinal space with 
minimal loss of the donor cell and the least damage to host photoreceptor cells and RPE. 
There are 2 approaches to delivery hESC-RPE: suspension injection or patch graft 
insertion. The use of suspension subretinal injection will only be feasible at an earlier 
stage of macular disease when the BM is not damaged (Francis et al. 2009). This is an 
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 unlikely situation for a phase I clinical trial of hESC-RPE transplantation. The initial 
trial will most likely to involve patients with large RPE tears where there is no 
underlying BM for cell attachment. In this situation, a customised delivery device will 
be needed to protect the graft from damage during insertion through the sclerostomy 
and retinotomy. Results from the porcine experiments demonstrated that a pair of intra-
ocular forceps is inadequate to protect the cells since many of the hESC-RPE were lost 
or shifted when the graft was placed in the subretinal space. A new delivery device 
incorporating a protective covering is currently being developed. Further in vitro and in 
vivo work will be required to validate this new delivery system. 
 Once the graft is placed in the subretinal space with minimal loss of the donor 
cells, survival of hESC-RPE is under threat by the host immune system. The data 
presented in this chapter indicated that macrophage infiltration is likely to be 
responsible for the loss of donor cells. Further in vivo work is required to demonstrate 
that an alternative immunosuppressive and anti-inflammatory regime can stop the 
macrophage activation and allow longer term survival of the grafted cells. There is now 
some evidence that high dose systemic steroid can prolong hESC-RPE survival in the 
RCS rat model (unpublished results). Further studies in the porcine model are currently 
underway. 
 
6.5.5 Strengths and limitations of the study 
The main strength of the animal experiment was its prospective design and the 
consistency in methodology. For example, all surgical procedures were performed by 
the same experienced surgeon (Mr L. Da Cruz) using the same vitrectomy machine and 
surgical instruments. The surgeon has the experience in patch grafting as he has 
previously performed a similar surgical procedure in 18 human subjects with atrophic or 
neovascular macular disease (see Chapters 4 and 5). All animals were cared for by the 
same staff at the same research institution and given the same postoperative eye drops. 
All enucleations were performed by the author using the same technique and all tissue 
processing and staining were performed by Drs Lawrence and Ahmado.  
One of the limitations of this study was the sequential nature of 4 separate 
animal experiments at different times (December 2007, then April, November and 
December 2008). From the outcomes of the initial feasibility study (3 animals 
terminated at 4 weeks), a medium-term (6 animals terminated at 6 week) study was 
designed and conducted 3 months later. However, the low cell survival rate at 6 weeks 
led to 2 other separate studies designed to examine the early (< 2 weeks) cell survival 
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 and immunological reactions to hESC-RPE (8 animals) versus sham (4 animals) 
transplantation. Such study design was necessary due to the the high cost of porcine 
experiment and the unexpected death of one animal. This study design is unlikely to 
significantly confound the outcome of the study since the same methodology was used. 
 The animal studies were also limited by the learning curve involved in tissue 
processing and immunohistochemical staining. Unlike rodent or rabbit eyes, the porcine 
eye is not familiar to most ophthalmic laboratory scientists. It has a thick and tough 
scleral coat making gross dissection difficult. Bisection of the posterior eye-cup induced 
artefactual retinal detachment and shifting of the patch graft. This processing artefact 
may have been minimised if the entire graft was used for either immuno-histochemistry 
or electron microscopy, but not both. The thickness of the sclera also posed difficulty 
during cryosectioning with excessive force required to cut the sclera accompanied by 
crush artefact in the adjacent neuroretina. In eyes which only had bleb detachment 
without graft, it was difficult to determine for certain, the site of detachment after 
fixation. This may have been facilitated by comparing the image from intraoperative 
video clip with vascular features of the posterior eye cup on gross examination.  
Other limitations of the immunological techniques used in this study were (1) 
the restriction to the use of primary antibodies that were raised in mice and (2) the 
limited availability of antibodies against porcine immune cells. It was necessary to use 
the same secondary antibody for restaining RPE markers after human cell marker stain 
in separate sessions by removing and replacing the cover slip. This was necessary 
because both human cell (TRA-1-85) and RPE (CRALBP, Bestrophin and RPE65) 
markers were raised in mice. The same technique was also necessary for concurrently 
staining for Ki-67 (proliferative cells), porcine CD79 (B cells), porcine CD8 (cytotoxic 
T cells) or porcine CD4 (T helper cells) antigens. Inflammatory and immunological 
responses were studied by staining for macrophage and lymphocytes. The primary 
antibodies for these cells have not been used previously and therefore it was not 
possible to determine the specificity and sensitivity of these antibiodies at their 
respective dilutions. The lack of lymphocytic infiltrate and the occasional staining of 
CD4-positive and CD8-positive cells in perivascular and choroidal regions suggest that 
strong immunological reaction was not present. However, such immunohistochemical 
techniques were unable to rule out a specific immune response to human cells. Even if 
immunological response was present in a xenograft model of human cell to porcine 
receipient transplantation, this may not reflect what will happen in a human to human 
allogenic setting. 
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 Functional rescue was not an outcome measure in this study. During the course 
of the experiments, a prototype focal ERG set up was used to record ERG responses to 
flash and flicker ligh stimuli. Due to the internal reflections, it was found that corneal 
ERG recording was unable to distinguish focal white light stimulation on the disc from 
that on the retina using an intraocular light source. Multifocal ERG set up was not 
available and it was not known if c-Fos expression is induced by light stimulation in the 
porcine eye. Further studies are required to confirm anatomical rescue of outer nuclear 
layer translated to functional rescue. 
 
6.5.6 Conclusions 
Using currently available vitreoretinal surgical instruments, it was possible to deliver 
hESC-RPE as a patch graft into the subretinal space. However, significant donor cell 
loss occurred during the process of creating the patch from the Transwell® Insert, 
transfer of the patch to the eye, and delivery of the graft into the subretinal space. 
Human RPE cells derived from Shef-1 can survive in the porcine subretinal space for up 
to 6 weeks. However, loss of donor cell coincided with macrophage response at 1-2 
weeks. There was minimal lymphocytic response and no evidence of tumour formation. 
These results suggest that donor cell survival may be enhance by the use of (1) peri-
operative anti-inflammatory agents such as dexamethasone to prevent macrophage 
activation and migration, and (2) specialised protective delivery device that has been 
preloaded with the correct size of hESC-RPE patch graft.  
6.6 Contribution 
 
Author’s contribution to the work presented in this chapter are summarised in Table 
6.6. During the course of these experiments, the author also collaborated in further 
studies examining the feasibility of focal electro-retinography using intra-ocular probe 
to stimulate the retina in an anaesthetised pig as a way to measure functional rescue by 
hESC-RPE patch graft. In order to analyse immunological response to transplanted 
hESC-RPE, the author also suggested to the research group the use of flow cytometric 
methods to allow multiparametric detection of cell surface antigens and intracellular 
cytokine expression of porcine T cells in response to human antigen stimulus. Thus 
pheripheral blood and vitreous samples were also obtained from all animals for the 
study of adaptive T cell immune response. The author also initially suggested a novel in 
vitro assay for testing phagocytic ability of hESC-RPE by using surplus retina harvested 
during human autologous RPE-choroid patch graft surgery (see Appendix 1). 
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 Table 6.6 Contribution list for the human to porcine xenotransplantation studies 
Contribution cateogory Contributor (details) 
1 Conception and 
design 
Author: contributed to the design of the animal experiment, in particular 
the post-operative care and tissue/blood/vitreous sampling. 
PJC: wrote the animal study ethics protocoal. 
LDC: approval the research protocol. 
 Data acquisition  Author: assisted in all surgical procedures and examined all 21 animals 
following transplant. Also obtained vitreous samples and enucleated all 
globes and transported them to the UCL Institute of Ophthalmology. 
LDC: performed all surgical procedures. 
JML: dissected the globe and performed cryosection, immunostaining. 
and electron microscopy. 
AA: prepared the patch grafts preoperatively and dissected the 
enucleated globe and obtained photographs of the fundus. 
 Data analysis and 
interpretation 
Author: collated, analysed and interpreted the intraoperative, 
postoperative and histological data.  
LDC: supervised interpretation of results. 
PJC: supervised statistical analysis. 
JML: supervised interpretation of results. 
2 Writing  Author: wrote the entire chapter. 
 Revising Author: revised the entire chapter. 
LDC: read the chapter and made suggestions. 
PJC: read the chapter and made suggestions. 
JML: read the chapter and made suggestions. 
3 Statistical analysis Author: performed all statistical analysis. 
 Funding PJC and LDC: obtained funding for the London Project to Cure 
Blindness. 
 Administrative and 
technical support 
Author: arranged delivery of operating microscope and specialised 
vitrectomy surgical equipments, and coordinated availability of 
vitrectomy technician with surgeon and the vet. Also created all the 
figure montage from the images obtained from histology and fundus 
photography. 
PJC: liased with Northwick Park Institute of Medical Research. 
KC: liased with Northwick Park Institute of Medical Research in 
ordering animals and providing anaesthetic support and animal 
husbandary. 
AA; Ahmad Ahmado (PhD student), KC; Karen Cheetham (UCL Business), JML; Jean 
M Lawrence (senior scientist), LDC; Lyndon Da Cruz (supervisor), PJC; Peter J Coffey 
(supervisor). 
 





Chapter 7 Conclusions 
Conclusions 
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 7.1 Original aims 
This thesis aimed to (1) examine whether long-term photoreceptor cell function can be 
rescued by RPE transplantation in atrophic and neovascular macular diseases and (2) to 
determine the feasibility of subretinal transplantation of RPE derived from hESC in a 
porcine model. In the following sections, the key findings from Chapters 4, 5 and 6 are 
described, the strengths and limitations of the studies are summarised and the future 
road map for translational research in RPE transplantation is outlined. 
 
7.2 Summary of key findings and implications 
Chapter 4 of the thesis demonstrated that it is possible to maintain retinal function by 
autologous transplantation of RPE-choroid patch graft in patients with atrophic macular 
disease. However, the choice of patients with advanced disease, the use of diseased 
autologous RPE and the high operative complication rates may explain the overall poor 
visual outcomes. Therefore, autologous RPE-choroid graft as a therapeutic approach for 
these patients cannot be recommended.  
In Chapter 5, the long-term outcomes of RPE reconstruction, using 
translocation and autologous patch graft techniques, in neovascular disease were 
analysed. Although both types of approaches were shown to rescue and maintain high 
quality foveal function, long-term data suggest translocation was able to achieve 
superior quality of vision compared to patch graft in this cohort of patients. However, 
both techniques had significant rates of early post-operative complications and sight 
threatening late recurrence of CNV. In conjunction with the results presented in 
Chapter 4, these findings suggest that a simpler surgical approach using non-
autologous source of RPE need to be developed. This may enable clinical RPE 
transplantation to be performed on a much larger scale. 
Following from the conclusions of Chapters 4 and 5, Chapter 6 examined the 
feasibility, cell survival and inflammatory reactions of subretinal transplantation of 
hESC-RPE on an artificial substrate using the porcine eye as a pre-clinical model. The 
surgical technique described was feasible although significant donor cell loss occurred 
during transfer and delivery of the graft. Human RPE cells survived in the porcine 
subretinal space for up to 6 weeks. However, there was substantial donor cell loss 
accompanied by macrophage infiltration. There was no evidence of tumour formation or 
significant lymphocytic infiltrate. The implications from this study are: (1) 
manufacturing processes needs to be optimised to obtain the highest yield and purity of 
hESC-RPE, (2) a surgical tool that can minimise cell loss during subretinal delivery of 
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 the patch graft will need to be developed and (3) the anti-inflammatory regime will need 
to be optimised to enhance cell survival and prevent macrophage activity against donor 
cells. 
 
7.3 Appraisal of strengths and limitations 
 
7.3.1 Strengths of the Thesis 
The main strength of this work was the prospective design of the human clinical trials 
and the animal experimental studies as described in Chapters 4 and 6. This design 
enabled collection of a wide range of outcome measures and allowed detailed structure-
function correlation in the autologous graft trials. The porcine experiment was initially 
designed as a pilot study of 3 animals. The results from this first study were critical for 
designing of further long-term and short-term animal experiments. The sequential 
experiments helped to reduce the number of animal needed to answer the questions of 
cell survival and immunological reaction. 
The main strength of the work described in Chapter 5 was the inclusion of 
consecutive patients who have undergone surgery for neovascular AMD and the long 
duration of regular follow-up. Furthermore, there was microperimetry data in some 
patients to demonstrate long-term function rescue of photoreceptor cells by paramacular 
or equatorial RPE.  
 
7.3.2 Limitations of the Thesis 
The main limitation of the trials described in Chapter 4 was the inclusion of patients 
with advanced disease. At this late stage of atrophic IMD or AMD, most of the macular 
photoreceptor cells have already degenerated and thus it was difficult to demonstrate 
functional resuce by submacular placement of autologous RPE-choroid patch. Other 
limitations were the evolving technology of fundus imaging and variability of the 
various psychophysical outcome measures as discussed in section 4.5.6. 
 The main limitation of the the studies in Chapter 5 was the restropective design 
and the non-uniform follow-up duration. Despite being one of the largest series of long-
term follow-up study in translocation, the sample size was too small for additional 
statistical analysis of factors that may predict outcomes. 
The animal experimentes described in Chapter 6 also had several limitations. 
These were the sequential experimental design, restricted availability of primary 
antibodies and lack of functional tests to demonstrate photoreceptor cell rescue by 
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 hESC-RPE. There was also a learning curve in the technique of porcine eye processing 
leading to artefactual retinal detachment and loss of patch graft.  
 
7.4 Future work 
The work presented in this Thesis provided the proofs of principle for RPE 
transplantation and the evidence of feasibility in the use of hESC-RPE in clinical 
transplantation. The current protocol of RPE production from hESC is being refined to 
maximise yield. The tool for delivery of hESC-RPE on a substrate is also currently 
being developed. A new prototype delivery device has been used in the porcine eye and 
has demonstrated some promise. Surgical technique has also been modified to reduce 
the rate of retinal detachment following graft in the porcine model. Finally, combined 
intra-ocular and peri-operative oral corticosteroid is currently being investigated as an 
alternative anti-inflammatory regime to reduce donor cell loss.  
In summary, this work has shown that autologous RPE can support macular 
function for prolonged period although the rate of high quality visual function rescue is 
low. This has been shown to be due to high rates of post-operative complications related 
to the complexity of harvesting autologous RPE, damage to the RPE during transplant 
delivery, recurrence of neovascular disease and possibility of transplanting diseased 
autologous RPE. The use of hESC as a source of RPE may be a feasible alternative to 
autologous cells. The short-term outcomes in the porcine experiment offer hope that 
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A. Study Protocol 
 
Retinal Pigment Cell Transplantation for the Treatment of Inherited Macular 
Dystrophies: Protocol version II – 26th June 2005 
Chief Investigator:  Mr Lyndon Da Cruz      
 
Background 
Inherited macular dystrophies are a group of disorders that are due to an intrinsic problem with 
the light-sensitive layer of the eye, known as the retina, specifically with its central portion, 
known as the macula. Persons affected by such a disorder progressively lose their central vision 
causing problems with reading, writing, discriminating colours and other visual tasks such as 
recognising faces. Usually the peripheral vision and thereby the navigational vision remain 
intact. Presently there are no proven methods to either prevent or alleviate these disorders and 
central visual loss is usually inexorable. 
In some patients it is apparent that the defect in the retina is localised. That is, when 
imaging (e.g. autoflourescence imaging of the pigment epithelium) and electrophysiology are 
performed the mid-peripheral and peripheral retina produce normal signals. 
Many patients and families with macular dystrophy have a change in a gene that is 
presently unknown. However, the most common molecular cause of macular dystrophy is 
mutation in a gene, first discovered in 1997, and called ABCA4. Much work has been done on 
the changes that occur in this particular gene and a murine model with retinal degeneration due 
to a mutation in this same gene has been developed. It appears that disease in humans and in 
mice is due to the slow accumulation of toxic molecules within the retinal pigment epithelial 
(RPE) layer of the retina. This takes many years to occur and can be monitored with routine 
retinal imaging. It is likely that other causes of macular dystrophy also cause visual loss by 
primary damage to this layer of the retina, as RPE dysfunction as monitored by retinal imaging 
appears similar. The justification of this surgical approach is the possibility of preserving vision, 
to some degree, by translocating a healthy RPE graft to the macula where it has become 
damaged. In a situation when no other treatments can be recommended to a patient who, for 
instance, reports inexorable deterioration of central vision, any such preservation of vision 
would be of benefit in the patient's management.  
Such surgical techniques are now available to successfully transfer grafts of tissue from 
the periphery of the same eye for transplant to the central vision area and have been applied 
clinically to those persons with macular disease due to advancing age (age-related macular 
degeneration). The proposed study wishes to use these techniques, for the first time, to treat 
younger patients with macular disease due to such an inherent deficiency of a gene. 
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 Recruitment 
1.  Patients will be identified from the inherited disease clinics at Moorfields Eye Hospital based 
on their clinical features. 
2.  Patients will be counselled about the natural history of the disease and the risks and benefits 
associated with surgery and other treatments. The aims of the trial and associated risks will be 
explained in full. This will take place at the initial clinic review at the time of diagnosis.   
3.  Any patient who is interested in taking part in the study will be given a patient information 
sheet to take home when initially referred from the vitreoretinal clinic. The details in this 
information sheet will be discussed in full with the patient (and relatives) at a dedicated research 
session when investigations will also take place.  If eligible for surgery, patients will see Mr 
daCruz and be consented for surgery if they wish to enter the trial. 
 
General Methodology 
Prospective, non-randomised, interventional case series, piloting a new surgical technique. Ten 
patients will be recruited and assessed preoperatively, at 10 days, 6 weeks, 3 months and 6 
months post operatively. At each visit they will undergo assessments as detailed below. 
 
Investigations 
1. Best corrected visual acuity at each visit (full refraction pre-op and at 6 months) 
2. Reading ability with refraction pre-op and at 6 months 
3. Slit lamp bimicroscopic examination and cataract grading pre-op and at 6 months  
4. Colour fundus photography (pre-op, 6 weeks and 6 months) 
5. Fluorescein angiography (pre-op and at 6 months) 
6. Optical coherence tomography - Model 3000 (pre-op and at 6 months) 
7. Scanning laser ophthalmoscope Microperimetry 
    (pre-op, 6 weeks and at 6 months) 
8. Autofluorescence imaging (pre-op, 6 weeks and 6 months). 
9. Indocyanine-green angiography (at 6 weeks and 6 months). 
10.Cataract regarding at 3 months and surgery arranged if necessary. 
11.Patients may undergo further review after 6 months if the surgery has been 
     successful. 





1. Creation of Recipient Site. The patients will undergo a standard three-port pars plana 
vitrectomy.  A small retinotomy will be made temporal to the fovea using a 130° 33 gauge 
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 subretinal cannula (Synergetics 12.01, USA) and a shallow posterior retinal detachment 
overlying the macula will be created by injecting balanced salt solution (BSS) through the 
retinotomy and into the sub-retinal space.  
2. Harvesting of RPE-Choroid Graft. A second shallow retinal detachment will be induced as 
described above, in the superior retina. Retinal diathermy will be applied and the retina cut to 
gain access to the underlying RPE. Vertical scissors will be used to cut a full-thickness RPE-
choroid graft. The infusion pressure will be increased again during this time to reduce the risk of 
choroidal haemorrhage. The patient will be hyperventilated slightly during the procedure to 
induce choroidal vasoconstriction. 
3. Placement of RPE-Choroid Graft. The RPE-choroid graft will be placed (RPE surface up) 
under the fovea. The retina will then flattened by subretinal fluid aspiration through the 
retinotomy. Final adjustments are made during aspiration to ensure the fovea falls onto the 
centre of the RPE bed. In some cases, where a single retinal flap may give access to both the 
fovea and RPE harvest site, perfluorocarbon may be used to roll the retina back into position. 
4. Closure. To reduce the risk of proliferative vitreoretinopathy (PVR), all RPE cells will be 
aspirated with a flute prior to air exchange. Laser retinopexy or cryotherapy will be applied to 
the margins of the RPE-choroid donor site. The vitreous cavity will be drained as much as 
possible before withdrawing instrumentation and exchanging to silicone oil. 
 
Consultation and Informed Consent 
All prospective research participants will be given a Patient Information Sheet describing the 
study in terms that are understandable by non-medical members of the public. We will use our 
own press officer to disseminate results of ongoing research to the public objectively through 
the media and listen to feedback generated from interest groups. 
 
Inclusion Criteria 
1. A diagnosis of inherited macular dystrophy 
2. Visual acuity of 6/36 or less in the treatable eye 
3. Recent visual acuity of 6/12 or better within past 12 months in treatable eye 
4. Over 25 years old 
5.  Fit for surgery and able to consent to surgery 
6. Autofluorescent imaging and full-field ERG results suggestive of a localised macular disorder 




1. Inability to give informed consent  
2. Unfit for general anaesthetic 
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 3. Inability to complete follow-up programme  
4. Corneal opacity or other pathology likely to impair vitreoretinal surgery  
5. Requirement for warfarin or inability to discontinue aspirin peri-operatively 
 
Benefits of Study 
The results of Van Meurs et al (2003) demonstrate that this surgical technique is worth 
exploring. Although the diseases being treated are different they are conceptually both macular 
diseases only with a sudden decrease in vision - implying a window period where the retina 
remains healthy.  The unique combination of medical and surgical retina expertise at Moorfields 
Eye Hospital in London makes this an ideal site to investigate alternative treatment options. If 
successful, the surgery would improve vision in patients recruited for the trial, increase the 
understanding of the pathological mechanisms of the diseases, and develop new surgical 
techniques, applicable to other disorders. 
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 Appendix 3: RPE Transplantation in Geographic Atrophy Study 
Documents 
 
A. Study Protocol 
 
Retinal pigment cell transplantation for the treatment of Dry Age-related Macular 
Degeneration: Protocol version IV – 1st April 2007 
Chief Investigator:  Mr Lyndon Da Cruz      
  
Background 
Dry Age Related Macular Degeneration is a disorder that leads to a progressive loss of the light-
sensitive layer of the eye, known as the retina, as well as the supportive layer under it – the 
retinal pigment epithelium (RPE) – specifically within the central portion, known as the macula. 
Persons affected by such a disorder progressively lose their central vision causing problems 
with reading, writing, discriminating colours and other visual tasks such as recognising faces. 
The peripheral vision and thereby the navigational vision remain intact. Presently there are no 
proven methods to either prevent or treat this disorder. And central visual loss ensues. 
The cause of this degeneration remains unknown. The justification of this surgical approach is 
the possibility of preserving vision, to some degree, by translocating a healthy RPE graft to the 
macula where it has become damaged. In a situation when no other treatments can be 
recommended to a patient who, for instance, reports inexorable deterioration of central vision, 
any such preservation of vision would be a triumph in the patient's management.  
A similar project in this setting has been carried out in Cologne, Germany and has demonstrated 
that the technique is feasible in this setting, that the grafts survive and that the potential for 
visual improvement exists. 
A concurrent project is the development of homologous RPE graft by ex vivo RPE culture on a 
substrate in a media that optimise and maintain differentiated state of the RPE. The substrate on 
which RPE cells are cultured determines the state of differentiation. There are also in vivo and 
ex vivo evidence that RPE cells dedifferentiate if they are not in contact with the sensory retina. 
We are, therefore, interested in the potential of co-culturing human retina with RPE cells in 
inducing further differentiation of the RPE. The combination of using lens capsule and sensory 
retina samples in RPE culture may optimise differentiation of these RPE cells.  
 
Recruitment 
1.  Patients will be identified from the retinal clinics at Moorfields Eye Hospital based on their 
clinical features. 
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 2.  At the time of diagnosis, patients will be counselled about the natural history of the disease 
and the risks and benefits associated with surgery and other treatments. The aims of the trial and 
associated risks will be explained in full.   
3.  Any patient who is interested in taking part in the study will be given a patient information 
sheet to take home when initially assessed at the vitreoretinal research clinic. The details in this 
information sheet will be discussed again in full with the patient (and relatives) at a separate 
research session. Further investigations will also take place to determine if patient is eligible. 
During these research clinics, there are 3 other consultants present sharing adjacent clinics. 
These consultants also specialise in retina but they have no affiliation with this study. This 
provides an opportunity for the patient to discuss the risks of the study with other experts 
unrelated with the study. If the patient agrees to have surgery (during this or subsequent visit), 
Mr daCruz will arrange a date for the patient to come in for the operation. 
 
General Methodology 
Prospective, non-randomised, interventional case series, piloting a new surgical technique. Ten 
patients will be recruited and assessed preoperatively, at 10 days, 6 weeks, 3 months, 6 months 
and 12 months post operatively. At each visit they will undergo assessments as detailed below. 
 
Investigations 
1.  Best corrected visual acuity at each visit (full refraction pre-op and at 6 months) 
2.  Reading ability with refraction pre-op and at 6 months 
3.  Slit lamp bimicroscopic examination and cataract grading pre-op and at 6 months  
4.  Colour fundus photography (pre-op and 6 months) 
5.  Fluorescein angiography (pre-op and at 6 months) 
6.  Optical coherence tomography - Model 3000 (pre-op and at 6 months) 
7.  Nidek MP1 Fixation and Microperimetry (pre-op and at 6 months) 
8.  Autofluorescence imaging (pre-op and at 6 months). 
9.  Indocyanine-green angiography (pre-op and at 6 months). 
10.Cataract re-grading at 3 months and surgery arranged if necessary. 
11.Patients may be reviewed after 6 months if the surgery has been successful. 
12.Quality of life questionnaire (preop and at 12 months). 
13. Surplus retinal tissue obtained will be cultured with human RPE cell lines 
 
Surgical Technique 
1. Creation of Recipient Site. The patients will undergo a standard three-port pars plana 
vitrectomy.  A small retinotomy will be made temporal to the fovea using a 130° 33 gauge 
subretinal cannula (Synergetics 12.01, USA) and a shallow posterior retinal detachment 
 Page 333  
 overlying the macula will be created by injecting balanced salt solution (BSS) through the 
retinotomy and into the sub-retinal space.  
2. Harvesting of RPE-Choroid Graft. Retinal diathermy will be applied and the retina cut to gain 
access to the underlying RPE. Vertical scissors will be used to cut a full-thickness RPE-choroid 
graft. The infusion pressure will be increased again during this time to reduce the risk of 
choroidal haemorrhage. The patient will be hyperventilated slightly during the procedure to 
induce choroidal vasoconstriction. The surplus retina on the donor patch graft is then removed 
from the eye for RPE – retina co-culture experiment. The retinal tissue will be placed in a 
culture medium and transported to the Institute of Ophthalmology within 24 hours. 
3. Placement of RPE-Choroid Graft. The RPE-choroid graft will be placed (RPE surface up) 
under the fovea. The retina will then flattened by subretinal fluid aspiration through the 
retinotomy. Final adjustments are made during aspiration to ensure the fovea falls onto the 
centre of the RPE bed. In some cases, where a single retinal flap may give access to both the 
fovea and RPE harvest site, perfluorocarbon may be used to roll the retina back into position. 
4. Closure. To reduce the risk of proliferative vitreoretinopathy (PVR), all RPE cells will be 
aspirated with a flute prior to air exchange. Laser retinopexy or cryotherapy will be applied to 
the margins of the RPE-choroid donor site. The vitreous cavity will be drained as much as 
possible before withdrawing instrumentation and exchanging to silicone oil. 
 
Laboratory Technique 
1. Transport and storage of retinal tissue. The retinal tissue will be transported in culture 
medium without label to the Institute of Ophthalmology. It will be stored in Professor Pete 
Coffey’s laboratory.  
2. Human RPE cell culture. Human RPE cells are obtained from commercial ARPE19 providers 
or derived from commercial human embryonic stem cells. 
3. Coculturing with human retina. Retinal sample will be placed over these cell lines in a culture 
medium with or without substrate (artificial or human lens capsule) 
4. Methods of analysis for differentiation. Cells will be studied by confocal microscopy with 
immunostaining and electron microscopy. RPE transepithelial resistance will also be studied. 
5. Destruction of human tissue. After completion of experiment, the tissues will be discarded 
according to the protocol set up by the Institute of Ophthalmology.  
 
Consultation and Informed Consent 
All prospective research participants will be given a Patient Information Sheet describing the 
study in terms that are understandable by non-medical members of the public. We will use our 
own press officer to disseminate results of ongoing research to the public objectively through 
the media and listen to feedback generated from interest groups. 
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 Inclusion Criteria 
1. A diagnosis of dry (atrophic) Age Related Macular Degeneration. 
2. Visual acuity of 6/24 or less in the treatable eye 
3. Evidence of recent loss of reading ability in the past 12 months in the study eye 
4. Over 50 years old 
5.  Fit for surgery and able to consent to surgery 
6. Autofluorescent imaging and full-field ERG results suggestive of a localised macular disorder  
  
Exclusion Criteria 
1. Inability to give informed consent  
2. Unfit for local or general anaesthetic  
3. Inability to complete follow-up programme  
4. Any other concurrent corneal, retinal or neurological pathology affecting central vision 
 
Benefits of Study 
The results of van Meurs et al (2003) demonstrate that this surgical technique is worth 
exploring. Although the diseases being treated slightly different, they are conceptually both 
macular diseases due to pigment cell loss. We believe a recent decrease in reading vision - 
implying a window period where the retina remains healthy - is the key in successful 
transplantation. The unique combination of medical and surgical retina expertise at Moorfields 
Eye Hospital in London makes this an ideal site to investigate alternative treatment options. If 
successful, the surgery would improve vision in patients recruited for the trial, increase the 
understanding of the pathological mechanisms of the diseases, and develop new surgical 
techniques, applicable to other disorders. 
 
References 
van Meurs JC, van den Biesen PR Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-
related macular degeneration: short-term follow-up. AJO 2003; 136:668-695 
Kirchhof B, Joeres S, Fawzy N, Heussen FMA, Prinz B, Joussen AM.  Autologous translocation of the choroid and RPE in patients 
with geographic Atrophy. ARVO abstracts 2691, 2006. 
Treumer F, Buse A, Klatt C, Roider J. Autologous RPE-choroid sheet transplantation in AMD: morphological and functional 
results. BJO 2006; E-pub 
Joussen AM, Heussen FMA, Joeres S, Llacer H, Prinz B, Rohrschneider K, Maaijwee KJM, van Meurs JC, Kirchhof B. Autologous 
translocation of the choroid and retinal pigment epithelium in age-related macular degeneration. AJO 2006; 142:17-30 
MacLaren RE, Uppal GS, Balaggan KS, Tufail A, Munro PMG, Milliken AB, Ali RP, Rubin GS, Aylward GW, Da Cruz L. 
Autologou transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular 
degeneration 
Eckardt C, Eckardt U and Conrad HG. Macular rotation with and without counter- rotation of the globe in patients with age -related 
macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999; 237:313-25 
Gass JDM. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal 
neovascular membranes. Am J Ophthalmol 1994; 118:285-98 
Stanga PE, Kychenthal A, Fitzke FW et al. Retinal pigment epithelium translocation after choroidal neovascular membrane removal 
in age-related macular degeneration. Ophthalmology 2002;109:1492-8 
Thomas MA, Dickinson JD, Melberg NS, Ibanez HE and Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal 
neovascular membranes. Ophthalmology 1994; 101: 1384-96 
Wong D, Lois N. Foveal relocation by redistribution of the nuerosensory retina. Br J Ophthalmol 2000; 84: 352-7 
 
 Page 335  




 Page 336  
  
 Page 337  
  
 
 Page 338  
  
 Page 339  





 Page 340  













 Page 342  
 Appendix 4: Long-term Outcomes in Patch Graft Study Documents 
 
A. Study Protocol 
 
A case series reporting the 2-year outcomes of successful autologous RPE-choroid 
transplantation in choroidal neovascularisation (CNV) from age-related macular 
degeneration: Protocol version I - 11/04/ 2007 
Investigator:  Mr Lyndon Da Cruz and Mr Fred K Chen   
 
Introduction 
Age-related macular degeneration (AMD) is a leading cause of blindness in the developed 
world. Exudative AMD, characterised by leakage of fluid or haemorrhage from choroidal 
neovascularisation, can lead to acute and permanent central visual loss. Recent advances in 
intravitreal therapies have shown promise in the treatment of these lesions with over 35% of 
patients gaining 3 lines or more at 2 years after 24 monthly intravitreal injections.1 It has been 
suggested that the mechanism of visual gain is the result of reduction in intra and sub-retinal 
fluid from the anti-permeability effect of these anti-vascular endothelial growth factor (anti-
VEGF) monoclonal antibodies on leaky choroidal neovascular tissue. However, anti-VEGF 
treatment fails to address the diseased retinal pigment epithelium (RPE) – Bruch’s membrane – 
choriocapillaris complex, the initiating pathology. Furthermore, the complex regulatory 
pathways in the interaction between VEGF, choroidal neovascular tissue and normal 
choriocapillaris has raised the concern over the ability of anti-VEGF therapy in inducing 
complete regression of the neovascular tissue and worse still, the possibility of damage the 
existing healthy choriocapillaris, which is essential for both RPE and photoreceptor cell 
function, leading to development of geographic atrophy. 
Surgical removal of choroidal neovascular tissue does not lead to improvement of 
vision due to concomitant removal and damage to the submacular RPE and choriocapillaris.2 
The importance of submacular tissue reconstruction has been reinforced by two surgical 
techniques developed a decade apart. In the early 1990s, Machemer and Steinhorst relocated the 
fovea away from the bare neovascular tissue excision site to an area of healthy, but 
extramacular, RPE by rotating the retina around the optic disc.3 Ten years later, van Meurs and 
van den Biesen relocated a patch of RPE choroid graft from the equatorial region to reconstruct 
the submacular RPE defect after neovascular tissue removal.4 In both reports, foveal functions 
were maintained by extramacular RPE.  
Although several groups have reported the outcomes of autologous RPE-choroid graft, 
there is limited information on whether successful visual function after graft is maintained after 
1 year.4-7 We have reported the 6-12 month follow-up results for the first 12 patients who 
received autologous RPE-choroid graft for treatment of exudative AMD in our institution.8 
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 Among these, three patients were able to see 6/24 or better at the end of the study. We have now 
seen these three patients during routine follow-up visits for over 2 years. Review of case notes 
of these patients will provide insight into the long-term function of the RPE choroid patch graft 
and its interaction with foveal photoreceptor cells. 
 
Materials and Methods 
The medical notes and imaging investigation results will be obtained for the 12 patients who 
underwent autologous RPE choroid transplantation under the study number: MACR1002. 
Patients with 6 months acuity of 6/24 or better will be identified. Some of the patients with poor 
visual outcome will also be chosen to serve as controls. 
Visual acuity, reading acuity and contrast sensitivity measurements in the notes will be 
recorded. Significant patient history and examination findings will be noted. Any new diagnosis 
or treatment received during the period will be recorded. 
  The fundus images performed during and after the study in these three patients will be 
reviewed and described. The images reviewed will include colour fundus photograph, fundus 
autofluorescence image, fluorescein angiography, indocyanine green angiography and optical 
coherence tomography.  
 
Benefits of the study 
This 2-year outcome study will provide more information of the long-term survival of 
peripheral RPE choroid graft and its ability to maintain foveal photoreceptors. We have chosen 
those with successful visual outcome and compare them with those with poor visual outcome. A 
comparison of autofluorescence images and angiographies may shed light on the long-term 
functionality of RPE choroid grafts. 
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 Appendix 5: Translocation vs Patch Graft Study Documents 
 
A. Study Protocol 
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 A. Hospital Research Governance Approval 
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 Appendix 6: Long-term Outcomes in Translocation Study Documents 
 
A. Study Protocol 
 
Two to four year follow-up of macular translocation surgery in neovascular age-related 
macular degeneration: Protocol version I - 26/11/2008 
Investigator:  Mr Fred K Chen      
 
Introduction 
Macular translocation surgery is currently indicated for patients with acute neovascular age-
related macular degeneration (AMD) in their second eye and who are not eligible for intravitreal 
lucentis. The surgical technique involves a vitrectomy, detachment of the retina, 360 degrees of 
retinotomy, removal of choroidal neovascularisation (CNV) and rotation of the fovea away from 
the defect in the retinal pigment epithelium (RPE) onto adjacent healthier paramacular RPE and 
choriocapillaris. Several studies have reported improvement in central visual function following 
translocation at 1 year.1-7 We reported the 12 months outcome in the first 27 patients 
undergoing translocation surgery previously.8 However, there are relatively few studies which 
examined whether functional rescue can be sustained by the para-macular RPE for 2 or more 
years.9,10 The long-term studies raised concerns regarding sustainability of visual acuity due to 
the high rates of recurrent geographic atrophy (GA)9 and CNV10 at the new subfoveal location.  
At Moorfields Eye Hospital, a total of 40 patients have now undergone macular translocation 
surgery. Of these, 30 patients have at least 2 years of follow-up. We wish to examine the clinical 




1. To determine the 2 or more year visual acuity and microperimetry outcomes. 
2. To determine the rate of disease recurrence and other late complications. 
 
Materials and Methods  
Patients who underwent macular translocation and had 2 years or more of follow-up will be 
eligible. We will retrospectively review the medical charts of these patients. Outcome variables 
include visual acuity, retinal sensitivity, fixation locus and stability, postoperative complications 
including intraretinal cystic change, recurrent CNV and de novo atrophy, and response of 
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 Statistical Analysis 
Descriptive analysis will be carried out. Median visual acuity at baseline, 1, 2, 3 and 4 years will 
be reported. Central and paracentral retinal sensitivity on microperimetry will be calculated. 
Late postoperative complications will be described. Proportions patients with certain types of 
complications will be calculated. Change in median visual acuity across different time points 
will be determined by the non-parametric Friedman test. 
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 Appendix 7: ERG outcomes in atrophic macular disease study 
 
 Page 351  
 A: pattern and full-field ERG outcomes 
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Right eye: Rings 1 and 2 tracing morphology fluctuated between 6 – 35 months. Arrows 
shows improvement in ring 2 at 6 months and in ring 1 at 23 months. Rings 3 and 4 had 
mild deterioration. Ring 5 was preserved throughout 35 months. 
 
Left eye: No change in rings 1 to 5 between the 4 test sessions during the 35 months. 
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 Patient 2 
 
 
Right eye: No change in rings 1 to 5 between the 3 test sessions during the 20 months. 
 
Left eye: Noisy waveform tracings in rings 1 and 2 during follow-up period. Ring 3 
remained unchanged. Rings 4 and 5 (arrows) had deterioration at 6 months which 
partially recovered by 20 months. 
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 Patient 3 
 
 
Right eye: No change in rings 1 to 5 between baseline and 8 months. 
 
Left eye: Deterioration was noted in all 6 rings especially in rings 1 to 3 (arrows).
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 Patient 4 
 
 
Right eye: Noisy waveform tracings in rings 1 and 2 at all time points. Deterioration in 
rings 3 to 5 (arrows) at 6 months with partial recovery at 17 months. 
 
Left eye: Some deterioration in ring 5 (arrows) at 17 months.
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Right eye: Improvement of central ring (arrows) at 7 months 
 
Left eye: Deterioration in all rings (arrows) at 7 months
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Right eye: Deterioration in all rings (arrows) at 23 months 
 
Left eye: No significant change at 23 months
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Right eye: Ring 1 had noisy waveforms at baseline and 9 months. Deterioration in rings 
3 to 5 (arrows) at 9 months. 
 
Left eye: No change in rings 1 to 5 between baseline and 9 months. 
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 Patient 8 
 
 
Right eye: Ring 1 response unchanged at 6 months. Marked deterioration of ring 2 
(arrows) at 6 months. Some deterioration in rings 3 to 5 (arrows) at 6 months. 
 
Left eye: No change in rings 1 and 2 but preservation of response in rings 3 to5.
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Patient 9 
 
Right eye: Localised area of dysfunction in ring 1. 
 
Left eye: Localised area of dysfunction in ring 1. 
 
 
